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Summary	  of	  the	  thesis	  “New	  molecular	  scaffolds	  for	  anti-­‐
neurodegenerative	  drug	  discovery”	  
	  
1.	  Introduction	  
Alzheimer’s	  (AD)	  and	  prion	  diseases	  (PrDs)	  are	  characterized	  by	  a	  conformational	  
change	   of	   normally	   expressed	   proteins	   that	   leads	   to	   the	   formation	   of	   fibrillar	  
aggregates,	  causing	  neuronal	  damages.	  In	  both	  maladies,	  amyloid-­‐β	  protein	  (Aβ)	  
or	   cellular	   prion	   protein	   (PrPC),	   respectively,	   are	   converted	   into	   β-­‐sheet	   toxic	  
isoforms	  termed	  β-­‐amyloid	  (Aβ)	  and	  scrapie	  prion	  protein	  (PrPSc)	  that	  represent	  
the	   main	   neuropathological	   hallmarks	   of	   these	   protein-­‐misfolding	   diseases	  
(PMDs)	  for	  diagnosis	  and	  therapy.	  
Despite	  the	  many	  advances	  occurred	  so	  far,	  PrDs	  and	  AD	  remain	  incurable.	  
However,	  in	  the	  context	  of	  PrDs,	  compounds	  consisting	  of	  two	  identical	  moieties	  
joined	   via	   an	   appropriate	   spacer	   (i.e.	   bivalent	   compounds)	   have	   proved	   to	   be	  
effective	   tools	   to	   prevent	   prion	   fibril	   formation.	   Among	   them,	  GN8	   is	   of	   great	  
importance	  because	   for	   the	   first	   time	   the	  mechanism	  of	  action	  of	  an	  antiprion	  
ligand	  was	  clarified.	  
Another	   option	   is	   the	   exploitation	   of	   theranostics,	   i.e.	   single	   agents	   with	  
concomitant	   therapeutic	   and	   diagnostic	   properties,	  with	   the	   aim	   of	   optimizing	  
the	   efficacy	   and	   safety	   of	   therapy.	   In	   the	   field	   of	   neurodegenerative	   diseases,	  
imaging	   of	   fibrillar	   aggregates	   is	   particularly	   suitable	   to	   diagnose	   the	   onset	   of	  
these	  maladies	   in	  their	  early	  stage	  and	  monitor	  their	  progression.	  On	  the	  other	  
hand,	   interference	   with	   amyloid	   fibril	   formation	   is	   well	   known	   to	   have	  
therapeutic	  implications.	  
As	  regard	  bioimaging	  techniques,	  there	  is	  a	  growing	  interest	  in	  fluorescence	  
spectroscopy	   as	   non-­‐invasive	   alternatives	   for	   studying	   fibrillar	   aggregates.	   It	   is	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relevant	  to	  note	  that	  a	  critical	  feature	  for	  an	  ideal	  fluorescent	  tracer	  is	  the	  ability	  
to	  absorb	  and	  emit	   light	   in	   the	  near-­‐infrared	   (NIR)	   region	   (600-­‐900	  nm),	  where	  
tissue	  scattering	  and	  absorption	  is	  lowest.	  
Intriguingly,	   a	   connection	   between	   neurodegenerative	   and	   protozoan	  
diseases	   has	   been	   hypothesized	   due	   to	   the	   fact	   that	   several	   privileged	  
heterocyclic	   motifs,	   most	   notably	   acridine	   and	   quinoline,	   are	   particularly	  
recurrent	  in	  compounds	  active	  against	  these	  quite	  different	  pathologies.	  
2.	  Objectives	  	  
In	   our	   drug	   discovery	   project	   devoted	   to	   the	   identification	   of	   novel	   scaffolds	  
towards	   neurodegenerative	   diseases,	   the	   present	   thesis	   has	   the	   following	  
specific	  objectives:	  
1. Development	  of	  a	  general	  protocol	  for	  the	  amination	  and	  (hetero)arylation	  
of	   halogenated	   nitrogen	   heterocycles	   of	   importance	   in	   the	   field	   of	  
neurodegenerative	  diseases.	  
2. Building	   on	   the	   bivalent	   approach,	   we	   planned	   to	   generate	   a	   chemical	  
library	   of	   bifunctional	   molecules	   focusing	   on	   2,5-­‐diketopiperazine	   as	   the	  
central	  nucleus	  due	  to	  its	  peptidic	  nature.	  
3. Generation	  a	  new	  class	  of	  bifunctional	  carbazole	  and	  fluorene	  GN8-­‐based	  
analogues	   that,	  due	   to	   their	   fluorescent	  properties,	  offer	   the	  potential	   to	  
act	  as	  therapeutic	  tools	  and	  chemical	  sensors	  for	  prion	  protein.	  
4.	   Exploration	   of	   fluorescent	   styrylquinolines	   designed	   with	   the	   aim	   of	  
staining	   amyloid	   fibrils,	   and	   simultaneously	   blocking	   their	   aggregation,	  
acting	  as	  theranostic	  small	  molecules.	  
5	   We	   also	   planned	   to	   explore	   further	   stryrylquinolines	   endowed	   with	  
different	  polyamino	  chains	   to	   face	  AD	  and	  PrDs.	  Based	  on	  the	  concept	  of	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privileged	   structure,	   we	   explored	   this	   new	   series	   of	   compounds	   against	  
protozoan	  diseases.	  
6.	   To	   better	   explore	   the	   theranostic	   field,	   we	   focused	   our	   work	   during	   the	  
three-­‐month	  stay	  required	  for	  the	  European	  Mention	  for	  the	  Ph.	  D.	  title	  on	  
nanomedicine	  and	  nanoparticle	  chemistry.	  
3.	  Results	  and	  discussion	  
The	  main	  results	  obtained	  are	  summarized	  below:	  
• Focused	  MW	  irradiation	  of	  equimolecular	  mixtures	  of	  halogenated	  nitrogen	  
heterocycles	  with	   amines	   in	   the	   presence	   of	   2	   equiv	   of	   phenol	   allows	   the	  
synthesis	  of	  aminated	  compounds.	  Interestingly,	  replacement	  of	  phenol	  with	  
a	  catalytic	  amount	  of	  InCl3	  led	  to	  the	  development	  of	  an	  efficient,	  transition	  
metal-­‐free	  method	  for	  aromatic	  C-­‐N	  and	  C-­‐C	  bond	  generation.	  
 
• A	   library	   of	   bifunctional	   prion	   ligands	   was	   generated	   by	   condensing	   1,4-­‐
diacetyl-­‐2,5-­‐piperazinedione	  with	  aromatic	  aldehydes.	  The	  antiprion	  activity	  
of	  all	  these	  DKPs	  was	  evaluated	  in	  a	  cell-­‐based	  model.	  
 
• Fluorene	  and	  carbazole-­‐based	  analogues	  of	  GN8	  were	  studied	  on	  a	  cellular	  
model	   to	   test	   their	   antiprion	   potency.	   Their	   native	   fluorescence	   and	   their	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• The	  styrylquinoline	  139	   showed	  an	  emission	  maxima	  above	  600	  nm,	   in	  the	  
NIR	  region,	  and	  was	  able	  to	  stain	  both	  Aβ	  and	  prion	  fibrils	  and	  to	  inhibit	  Aβ	  
self-­‐aggregation	  and	  prion	  replication	   in	   infected	  cells.	   In	   the	   light	  of	   these	  
results,	  we	  generated	  a	  large	  library	  of	  styrylquinoline	  derivatives	  to	  detect,	  
and	   potentially	   treat,	   fibrillar	   amyloidogenic	   aggregates.	   A	   preliminary	  
screening	  in	  vitro	  was	  carried	  out	  to	  evaluate	  their	  antiprion	  potential.	  
 
• We	  designed	  two	  new	  chemical	  libraries	  using	  the	  styrylquinoline	  moiety	  as	  
the	   central	   scaffold	   with	   polyamino	   chains	   at	   the	   quinoline	   C-­‐4	   and	   C-­‐8	  
positions.	   We	   tested	   the	   C-­‐4	   functionalized	   compounds	   against	  
leishmaniasis.	  
 
• We	   prepared	   polymer-­‐coated	   magnetite	   (Fe3O4)	   nanoparticles	   and	  
conjugated	  adducts	  between	  a	  peptide	  that	  specifically	  binds	  a	  receptor	  
overexpressed	  on	  the	  melanoma	  cells	  (MC1R)	  and	  PEG.	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4.	  Conclusions	  
1.	   We	  developed	   two	  general	  protocols	   that	   solve	  a	   long-­‐standing	   synthetic	  
problem	   related	   to	   the	   functionalization	   of	   heterocyclic	   frameworks.	  
Besides	  their	  application	  to	  the	  objectives	  of	  this	  thesis,	  these	  methods	  will	  
facilitate	   the	   generation	   of	   compound	   libraries	   of	   great	   significance	   in	  
many	  areas	  of	  medicinal	  chemistry	  and	  drug	  discovery.	  
2.	   We	   identified	   a	   DKP	   compound	   (83)	   that	   is	   able	   to	   perturb	   in	   vitro	   PrP	  
amyloid	  fibril	  formation.	  Moreover,	  it	  has	  also	  been	  shown	  to	  inhibit	  prion	  
replication	  in	  a	  cellular	  context.	  
3.	   Some	   carbazole	   compounds	   turned	   out	   to	   be	  more	   active	   and	   less	   toxic	  
that	   GN8.	   These	   compounds,	   exemplified	   by	   128,	   have	   been	   shown	   to	  
interact	  selectively	  with	  PrPSc,	  which	  represents	  a	  change	  in	  mechanism	  for	  
preventing	  prion	  replication	  with	  regard	  to	  the	  reference	  compound.	  	  
4.	   We	  showed	  that	  the	  styrylquinoline	  compound	  139	  was	  potentially	  useful	  
to	  diagnose,	   treat	  and	  monitor	   response	   to	   therapy	   in	  PMDs.	  Among	   the	  
additional	   styrylquinoline	   derivatives	   generated,	   six	   molecules	   have	   a	  
higher	   antiprion	   activity	   than	   that	   of	   139,	   and	   further	   studies	   on	   these	  
compounds	  are	  in	  progress.	  
5.	   4-­‐(Polyamino)styrylquinolines	   showed	   good	   activity	   as	   anti-­‐leishmanial	  
agents,	   interacting	   with	   the	   parasite	   mitochondrial	   metabolism.	   The	  
polyamino	  chain	  was	  shown	  to	  be	  critical	  for	  their	  activity.	  
6.	   With	   the	   preparation	   of	   coated	   SPIONs,	   we	   paved	   the	   way	   to	   the	   final	  
synthetic	   step	   that	  will	   allow	   their	   combination	  with	   the	   targeting	   ligand	  
(PEG-­‐MSH)	  to	  obtain	  new	  innovative	  tools	  against	  metastatic	  melanoma.	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Resumen	  de	  la	  tesis	  “Nuevos	  esqueletos	  moleculares	  para	  
el	  descubrimiento	  de	  fármacos	  antineurodegenerativos”	  
1.	  Introducción	  
Las	   enfermedades	   de	   Alzheimer	   (AD)	   y	   priónicas	   (PrDs)	   se	   caracterizan	   por	   un	  
cambio	   conformacional	   de	   ciertas	   proteínas	   que	   conduce	   a	   la	   formación	   de	  
agregados	   fibrilares	   y	   causa	   daños	   neuronales.	   En	   estas	   enfermedades,	   la	  
proteína	  β-­‐amiloide	  (Aβ)	  y	  la	  proteína	  priónica	  celular	  (PrPC),	  respectivamente,	  se	  
transforman	  en	   isoformas	  tóxicas,	  con	  un	  gran	  predominio	  de	   lámina	  β,	  que	  se	  
llaman	  proteína	  β-­‐amiloide	  (Aβ)	  proteína	  priónica	  celular	  scrapie	  (PrPSc),	  que	  son	  
las	  principales	  características	  neuropatológicas	  de	  estas	  enfermedades	  asociadas	  
al	   plegamiento	   anómalo	   de	   proteínas	   (PMDs)	   desde	   los	   puntos	   de	   vista	  
diagnóstico	  y	  terapéutico.	  
A	  pesar	  de	  los	  muchos	  avances	  registrados,	  las	  enfermedades	  priónicas	  y	  de	  
Alzheimer	   continúan	   siendo	   incurables.	   En	   el	   contexto	   de	   las	   enfermedades	  
priónicas,	   han	   demostrado	   ser	   prometedores	   los	   llamados	   compuestos	  
divalentes,	  poseedores	  de	  dos	  unidades	   idénticas	  enlazadas	  por	  un	  espaciador.	  
Entre	   ellos,	   es	   especialmente	   importante	   desde	   el	   punto	   de	   vista	   del	  
descubrimiento	  de	   fármacos	  GN8,	  que	   fue	  el	  primer	  compuesto	  para	  el	  que	  se	  
estableció	  un	  mecanismo	  de	  acción	  antipriónica.	  
Otra	   opción	   consiste	   en	   el	   desarrollo	   de	   agentes	   teranósticos,	   es	   decir,	  
compuestos	  que	  poseen	  simultáneamente	  propiedades	  terapéuticas	  y	  capacidad	  
de	   dar	   lugar	   a	   imágenes	   de	   las	   fibrillas	   proteicas	   con	   fines	   diagnósticos.	   En	   el	  
campo	  de	   las	   enfermedades	  neurodegenerativas,	   es	   especialmente	   importante	  
el	  diagnóstico	  temprano.	  	  
En	   relación	   con	   las	   técnicas	   de	   imagen,	   hay	   cada	   vez	   más	   interés	   en	   la	  
fluorimetría	   como	   técnica	   no	   invasiva	   de	   detección	   de	   agregados	   fibrilares.	   El	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marcador	   fluorescente	   ideal	   debería	   emitir	   en	   una	   region	   del	   espectro	  
electromagnético	   en	   la	   que	   sea	   mínima	   la	   absorción	   por	   los	   tejidos,	   siendo	  
prometedor	  en	  ese	  sentido	  el	  infrarrojo	  cercano	  (NIR),	  entre	  600	  y	  900	  nm.	  
2.	  Objetivos	  	  
Dentro	   de	   un	   proyecto	   orientado	   a	   la	   identificación	   de	   nuevos	   esqueletos	  
moleculares	   útiles	   en	   el	   descubrimiento	   de	   fármacos	   para	   enfermedades	  
neurodegenerativas,	  esta	  tesis	  tiene	  los	  siguientes	  objetivos	  concretos:	  	  
1. Desarrollo	   de	   un	  método	   general	   para	   la	   aminación	   y	   (hetero)arilación	   de	  
heterociclos	   halogenados	   nitrogenados	   de	   relevancia	   en	   la	   terapia	   contra	  
enfermedades	  neurodegenerativas.	  
2. Estudio	  como	  agentes	  antipriónicos	  de	  una	  quimioteca	  de	  derivados	  de	  2,5-­‐
dicetopiperazina,	  planificada	  mediante	   la	   combinación	  de	   la	   “aproximación	  
divalente"	  con	  el	  empleo	  de	  un	  espaciador	  peptídico.	  
3. Síntesis	   y	   estudio	   de	   quimiotecas	   de	   análogos	   bifuncionales	   de	   GN8	   con	  
núcleos	   de	   carbazol	   y	   fluoreno,	   capaces	   de	   inhibir	   la	   agregación	   de	   los	  
priones	  y	  cuya	  fluorescencia	  los	  convierte	  en	  marcadores	  potenciales	  de	  los	  
agregados	  fibrilares.	  
4. Estudio	   de	   los	   derivados	   de	   estirilquinolina	   como	   agentes	   teranósticos	  
potenciales	  frente	  a	  proteína	  priónica	  y	  β-­‐amiloide.	  
5. Estudio	   de	   los	   derivados	   de	   (poliamino)estirilquinolina	   frente	   a	  
enfermedades	  asociadas	  a	  plegamientos	  anómalos	  de	  proteínas,	  así	  como	  
su	  estudio	  frente	  a	  enfermedades	  protozoarias,	  basada	  en	  el	  concepto	  de	  
estructuras	  privilegiadas.	  
6. Dentro	  del	  campo	  de	   la	  teranóstica	  y	  durante	   la	  estancia	  conducente	  a	   la	  
Mención	   Europea	   en	   el	   título	   de	   doctor	   se	   ha	   hecho	   un	   estudio	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correspondiente	   al	   campo	   de	   la	   nanomedicina,	   enfocado	   a	   la	   síntesis	   de	  
nanopartículas	  para	  vectorización	  selectiva	  de	  fármacos.	  	  
3.	  Resultados	  y	  discusión	  
Los	  principales	  resultados	  obtenidos	  se	  resumen	  a	  continuación:	  
• La	   irradiación	   con	   microondas	   focalizadas	   de	   mezclas	   equimoleculares	   de	  
heterociclos	   halogenados	   nitrogenados	   y	   aminas	   en	   presencia	   de	   fenol	   (2	  
equiv)	  permite	  la	  síntesis	  de	  productos	  de	  aminación.	  También	  se	  demostró	  
la	   posibilidad	   de	   reemplazar	   el	   fenol	   por	   un	   ácido	   de	   Lewis	   (InCl3),	   lo	   que	  
condujo	   a	   un	  método	   general	   para	   la	   generación	   de	   enlaces	   C-­‐N	   y	   C-­‐C	   en	  
ausencia	  de	  metales	  de	  transición.	  
 
• Se	   sintetizó	  una	  quimioteca	  de	   ligandos	  bifuncionales	   de	  proteína	  priónica	  
por	   doble	   condensación	   aldólica	   de	   1,4-­‐diacetil-­‐2,5-­‐piperazinadiona	   con	  
aldehídos	  aromáticos.	  Estos	  compuestos	  se	  evaluaron	  en	  un	  modelo	  celular.	  	  
 
• Se	   sintetizaron	   quimiotecas	   de	   análogos	   de	   GN8	   derivados	   de	   fluoreno	   y	  
carbazol	   y	   se	   evaluaron	   en	   un	  modelo	   cellular	   para	   investigar	   su	   potencia	  
como	  agentes	  antipriónicos.	  También	  se	  estudiaron	  su	  fluorescencia	  nativa	  y	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• La	   estirilquinolina	   139	   mostró	   un	   máximo	   de	   emisión	   fluorescente	   por	  
encima	  de	  600	  nm.	  Este	  compuesto	  es	  capaz	  de	  marcar	  tanto	  las	  fibrillas	  Aβ	  
como	   las	  priónicas	  y	  de	   inhibir	   la	  autoagregación	  de	  Aβ	   y	   la	   replicación	  de	  
priones.	  A	  la	  vista	  de	  estos	  resultados,	  se	  sintetizó	  una	  quimioteca	  de	  más	  de	  
50	  compuestos	  y	  se	  llevó	  a	  cabo	  un	  ensayo	  preliminar	  in	  vitro	  de	  su	  actividad	  
como	  agentes	  antipriónicos.	  
 
• Se	  han	  diseñado	  quimiotecas	  de	  estirilquinolinas	  portadoras	  de	  cadenas	  de	  
poliamina	   en	   C-­‐4	   y	   C-­‐8.	   Las	   derivados	   sustituidos	   en	   C-­‐4	   se	   han	   estudiado	  
como	  agentes	  anti-­‐leishmania.	  	  
 
• Hemos	  sintetizado	  nanopartículas	  de	  magnetita	  (Fe3O4)	  recubierta	  de	  un	  
polímero,	  así	  como	  sus	  productos	  de	  conjugación	  con	  PEG	  y	  con	  péptidos	  
que	  actúan	  como	  ligandos	  de	  un	  receptor	  sobreexpresado	  en	  células	  de	  
melanoma	  (MC1R).	  	  
4.	  Conclusiones	  
1.	   Hemos	   desarrollado	   dos	   protocolos	   generales	   que	   resuelven	   un	   antiguo	  
problema	   sintético	   relacionado	   con	   la	   funcionalización	   de	   esqueletos	  
heterocíclicos.	  Estos	  métodos,	  además	  de	  su	  aplicación	  a	   los	  objetivos	  de	  
esta	   tesis,	  permitirán	   la	  generación	  de	  quimiotecas	  de	   interés	  en	  muchas	  
áreas	  de	  la	  química	  farmacéutica	  y	  el	  descubrimiento	  de	  fármacos.	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2.	   Hemos	   descubierto	   un	   derivado	   de	   dicetopiperazina	   (compuesto	  83)	   que	  
presenta	   una	   buena	   capacidad	   de	   interferir	   el	   proceso	   de	   formación	   de	  
fibrillas	  amiloides	  priónicas	   in	  vitro.	  Además,	  este	  compuesto	  es	  activo	  en	  
ensayos	  celulares.	  	  
3.	   Algunos	   de	   los	   derivados	   bifuncionales	   portadores	   de	   anillos	   de	   carbazol	  
han	   resultado	   ser	   más	   activos	   y	   menos	   tóxicos	   que	   GN8.	   El	   estudio	  
mecanístico	  de	  estos	  compuestos,	   llevado	  a	  cabo	  en	  128,	  ha	  demostrado	  
que	   interaccionan	  selectivamente	  con	   la	  proteína	  PrPSc,	   lo	  que	  supone	  un	  
cambio	  de	  mecanismo	  respecto	  al	  compuesto	  de	  referencia.	  	  
4.	   Hemos	   descubierto	   un	   derivado	   de	   estirilquinolina	   (compuesto	   139)	   con	  
utilidad	  potencial	   para	   el	   diagnóstico,	   tratamiento	   y	  monitorización	  de	   la	  
respuesta	   a	   la	   terapia	   de	   PMDs.	   De	   entre	   una	   amplia	   quimioteca	   de	  
estirilquinolinas,	   al	   menos	   6	   moléculas	   presentan	   una	   actividad	  
antipriónica	  superior	  a	  la	  de	  139,	  y	  algunos	  de	  estos	  compuestos	  continúan	  
en	  estudio.	  
5.	   Algunos	   derivados	   de	   4-­‐(poliamino)estirilquinolina	   muestran	   buena	  
actividad	  como	  agentes	  anti-­‐leishmania,	  y	  actúan	  por	   interferencia	  con	  el	  
metabolismo	  mitochondrial	  del	  parásito.	  Se	  ha	  demostrado	  que	  la	  cadena	  
de	  poliamina	  es	  crucial	  para	  esta	  actividad.	  
6.	   Se	  ha	  logrado	  la	  preparación	  de	  nanopartículas	  magnéticas	  (SPIONs)	  y	  del	  
conjugado	   PEG-­‐MSH,	   lo	   que	   permitirá	   en	   el	   futuro	   el	   estudio	   de	   nuevos	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1.1.	   Alzheimer’s	   and	   prion	   diseases:	   two	   examples	   of	   protein	  
misfolding	  diseases	  
In	   the	   last	   decades	   protein	   misfolding	   diseases	   (PMDs),	   characterized	   by	   the	  
structural	   change	   of	   normally	   expressed	   proteins	   to	   amyloidogenic	  
conformations,	  have	  come	  to	  public	  and	  scientific	  attention	  due	  to	  the	  fact	  that	  
they	  are	   increasing	  enormously	   in	  developed	  countries	  and	  becoming	  a	  serious	  
problem	  in	  terms	  of	  health	  and	  economic	  costs.1	  Alzheimer’s	  disease	  (AD),	  prion	  
diseases	   (PrDs),	   Parkinson’s	   disease	   (PD)	   and	   amyotrophic	   lateral	   sclerosis	   are	  
prominent	  examples	  of	   PMDs,	   in	  which	   the	  misfolded	  proteins	   are	   responsible	  
for	  the	  neurodegeneration.	  
Among	  them,	  AD	  is	  the	  most	  common	  type	  of	  dementia,	  characterized	  by	  a	  
progressive	   cognitive	   decline	   and	   loss	   of	   the	   ability	   to	   learn,	   reason	   and	  
communicate.	   One	   of	   the	   main	   hallmarks	   of	   AD	   is	   the	   formation	   and	  
accumulation	  of	   fibrillar	  aggregates	  known	  as	  β-­‐amyloid	   (Aβ)	  plaques	   that	   lead	  
to	   neuronal	   death	   and	   to	   the	   disruption	   of	   memory.	   These	   amyloidogenic	  
deposits	   consist	   mainly	   of	   two	   peptides,	   Aβ40	   and	   Aβ42,	   resulting	   from	   the	  
proteolytic	   cleavage	   of	   the	   transmembrane	   glycoprotein	   amyloid	   precursor	  
protein	   (APP).	   Aβ	   peptides	   are	   rich	   in	   β-­‐sheet	   secondary	   structures,	  which	   are	  
insoluble	   and	   resistant	   to	   proteolytic	   digestion	   and	   tend	   to	   aggregate	   in	  
plaques.2	  
On	   the	   other	   hand,	   prion	   diseases	   (PrDs)	   or	   transmissible	   spongiform	  
encephalopathies	   (TSEs),	   are	   a	   family	   of	   neurological	   disorders	   that	   include	  
Creutzfeldt-­‐Jakob	   disease	   (CJD)	   and	   Gerstmann-­‐Sträussler-­‐Scheinker	   disease	  
(GSS)	   in	   humans,	   chronic	   wasting	   disease	   in	   deer,	   and	   scrapie	   in	   sheep.3,4	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	   Chiti,	  F.;	  Dobson,	  C.	  M.	  Annu.	  Rev.	  Biochem.	  2006,	  75,	  333.	  
2	   Mucke,	  L.;	  Selkoe,	  D.	  J.	  Cold	  Spring	  Harb.	  Perspect.	  Med.	  2012,	  2,	  a006338.	  
3	   Aguzzi,	  A.	  J.	  Neurochem.	  2006,	  97,	  1726.	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Although	  CJD	  is	  a	  rare	  human	  malady,	  it	  affects	  approximately	  one	  in	  one	  million	  
people	  worldwide	  and	  invariably	  proves	  fatal.4	  
Scientific	   and	   public	   interest	   in	   PrDs	   has	   increased	   dramatically	   in	   recent	  
years,	   transforming	   them	   from	   rare,	   enigmatic	   infectious	   diseases	   to	   a	   sort	   of	  
emblem	   of	   neurodegeneration.5	   Initially,	   what	   made	   them	   so	   unique	   and	  
fascinating	  to	  scientists	  was	  the	  growing	  understanding	  that	  the	  infectious	  agent	  
responsible	  for	  PrDs	  was	  different	  from	  conventional	  microorganisms.6	  Over	  the	  
years,	   many	   discoveries	   provided	   compelling	   evidence	   in	   favor	   of	   Prusiner’s	  
revolutionary	  prion	  only	  hypothesis,	  i.e.	  that	  a	  misfolded	  protein	  is	  the	  main	  (and	  
perhaps	   the	   sole)	   component	   of	   the	   prion	   infectious	   agent.7	   In	   PrDs,	   the	   key	  
pathological	  event	  is	  a	  conformational	  change	  of	  the	  normally	  expressed	  protein,	  
known	  as	  cellular	  prion	  protein	  (PrPC),	  into	  its	  abnormal	  amyloidogenic	  isoform,	  
the	   scrapie	   prion	   protein	   (PrPSc)	   which	   features	   the	   same	   characteristics	   of	  
Aβ including	  insolubility,	  resistance	  to	  proteolytic	  digestion	  and	  a	  high	  content	  of	  
β-­‐sheet	   secondary	   structures.8,9	   Through	   an	   autocatalytic	   replication	   process,	  
PrPSc	  accumulates	  in	  proteinaceous	  aggregates,	  resulting	  in	  the	  diffuse	  neuronal	  
degeneration	  and	  the	  spongiform	  brain	  lesions	  typical	  of	  the	  disease.10	  Although	  
the	  exact	  molecular	  mechanism	  of	  PrPC	  to	  PrPSc	  conversion	  is	  still	  not	  clear,	  it	  has	  
been	   proposed	   that	   the	   misfolded	   PrPSc	   acts	   as	   a	   template	   that	   induces	   the	  
normally	  folded	  proteins	  to	  change	  their	  conformation	  (Figure	  1.1).11	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4	   Collinge	  J.	  Annu.	  Rev.	  Neurosci.	  2001,	  24,	  519.	  
5	   Legname,	  G.;	  Bolognesi,	  M.	  L.Curr.	  Top.	  Med.	  Chem.	  2013,	  13,	  2395.	  
6	   Soto	  C.	  Trends	  Biochem.	  Sci.	  2011,	  36,	  151.	  
7	   Prusiner,	  S.	  B.	  Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A.	  1998,	  95,	  13363.	  
8	   Kovacs,	  G.	  G.;	  Budka,	  H.Am.	  J.	  Pathol.	  2008,	  172,	  555.	  
9	   Lloyd,	  S.;	  Mead,	  S.;	  Collinge,	  J.	  Top.	  Curr.	  Chem.	  2011,	  305,	  1.	  
10	   Aguzzi,	  A.;	  Calella,	  A.	  M.	  Physiol.	  Rev.	  2009,	  89,	  1105.	  
11	   Aguzzi,	  A.;	  Steele,	  A.	  D.	  Cell	  2009,	  137,	  994.	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Figure	  1.1.	  The	  scrapie	  prion	  protein	  (PrPSc)	  acts	  as	  a	  template	  for	  the	  misfolding	  of	  the	  
normal	  cellular	  PrPC	  	  
	  
Recent	  studies	  suggest	  that	  Aβ	  and	  α-­‐synuclein	  proteins,	  involved	  in	  AD	  and	  
PD,	  respectively,	  could	  also	  have	  a	  prion-­‐like	  mechanism	  of	  propagation.12,13	  On	  
the	   basis	   of	   these	   findings,	   Prusiner	   claimed	   that	   proteins	   causing	  
neurodegeneration	   are	   all	   prions,	   in	   the	   sense	   that	   folded	   and	   aggregated	  
molecules	  are	  able	   to	   catalyze	   the	   transformation	  of	  normal	  proteins	  and	   thus	  
propagate	   the	   disease.14	   If	   confirmed,	   this	   hypothesis	   would	   profoundly	  
influence	   the	   development	   of	   therapeutic	   tools.	   Nevertheless,	   Prusiner’s	  
hypothesis	  seems	  to	  be	  somewhat	  premature	  and	  it	  has	  been	  pointed	  out	  that,	  
at	  least	  in	  the	  case	  of	  AD,	  it	  ignores	  a	  great	  deal	  of	  evidence	  about	  the	  etiology	  of	  
this	  disorder.15	  
	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
12	   Frost,	  B.;	  Diamond,	  M.	  I.	  Nat.	  Rev.	  Neurosci.	  2010,	  11,	  155.	  
13	   Miller,	  G.	  Science	  2009,	  326,	  1137.	  
14	   Prusiner,	  S.	  B.	  Science	  2012,	  336,	  1511.	  
15	   Lahiri,	  D.	  K.	  Science	  2012,	  337,	  1172.	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1.2.	  Modulation	  of	  prion	  by	  small	  molecules:	  from	  monovalent	  to	  
bivalent	  ligands	  
As	  mentioned	  above,	  PrPSc	  plays	  a	  pivotal	   role	   in	   the	  onset	  and	  propagation	  of	  
PrDs.6	  	  
Several	  reports	  have	  suggested	  that	  small	  molecules	  that	  directly	  target	  the	  
proteins	   involved	   in	   the	   fibrillization	   process	   represent	   valid	   therapeutic	   tools	  
against	  prion	   replication.16	   In	   this	   regard,	  drug	  discovery	   approaches	   that	  have	  
been	  widely	  employed	  consisted	   in	  developing	  molecules	  able	  to	   interfere	  with	  
protein-­‐protein	   interactions	   (PPIs)	   between	   PrPSc	   and	   PrPC,	   to	   avoid	   prion	  
propagation,	   or	   to	   directly	   prevent	   fibril	   formation.17	   On	   the	   other	   hand,	   the	  
modulation	   of	   these	   PPIs	   using	   small	   molecules	   is	   currently	   regarded	   as	   very	  
challenging,	  for	  several	  reasons:	  	  
(i)	  	   It	  does	  not	  present	  defined	  active	  sites	  or	  pockets	  as	  in	  the	  case	  of	  enzymes	  
and	  receptors,	  since	  in	  PPIs	  large	  and	  extended	  surfaces	  are	  involved,	  and	  a	  
complex	  network	  of	  weak	  interactions	  takes	  place.18	  	  
(ii)	  	   High-­‐resolution	   structural	   information	   on	   amyloid	   fibrils	   and	   aggregates	   is	  
very	  scarce.	  This	  is	  mostly	  due	  to	  the	  inability	  of	  crystallography	  and	  NMR	  to	  
address	   proteins	   that	   are	   by	   nature	   insoluble	   and	   non-­‐crystalline.	  
Furthermore,	   characterization	   of	   the	   transient	   states	   of	   such	   proteins	  
remains	   challenging	   because	   these	   techniques	   are	   not	   even	   suitable	   for	  
studying	  short-­‐lived	  protein	  states.17	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
16	   Trevitt,	  C.	  R.;	  Collinge,	  J.	  Brain	  2006,	  129,	  2241.	  
17	   Gavrin,	  L.	  K.;	  Denny,	  R.	  A.;	  Saiah,	  E.	  J.	  Med.	  Chem.	  2012,	  55,	  10823.	  
18	   Kranjc,	  A.;	  Bongarzone,	  S.;	  Rossetti,	  G.;	  Biarnés,	  X.;	  Cavalli,	  A.;	  Bolognesi,	  M.	  L.;	  Roberti,	  M.;	  
Legname,	  G.;	  Carloni,	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Based	  on	  these	  considerations,	  it	  clearly	  emerges	  that	  the	  rational	  design	  of	  
antiprion	   compounds	   represents	   a	   big	   challenge	   for	   medicinal	   chemists.	  
However,	   considering	   the	   oligomeric	   and	   repetitive	   structure	   of	   fibrillar	  
aggregates,	   it	   has	   been	   deemed	   convincible	   that	   bivalent	  molecules,	   endowed	  
with	   two	   identical	   protein	   recognition	   motifs	   (PRMs)	   connected	   by	   a	   spacer,	  
could	  interact	  simultaneously	  with	  two	  prion	  binding	  surfaces	  (hot	  spots),	  which	  
are	  regions	  of	  the	  protein	  that	  contribute	  a	  disproportionate	  percentage	  of	  the	  
binding	   energy	   and	   can	   serve	   as	   crucial	   point	   for	   chemical	   intervention.19	   The	  
protein	  recognition	  motifs	  can,	  at	   least	   initially,	  be	  designed	  from	  the	  structure	  
of	  known	  prion	  inhibitors	  (Figure	  1.2).	  
	  
	  
Figure	  1.2.	  Design	  strategy	  leading	  to	  bifunctional	  derivatives	  able	  to	  modulate	  PPIs	  in	  
PrDs	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  







24	   	   1.	  Introduction	  
The	  synergy	  between	  two	  PRMs	  connected	  by	  a	  spacer	  is	  due	  to	  two	  factors:	  	  
(i)	  An	  increase	  in	  the	  local	  concentration	  of	  the	  active	  moiety.	  
(ii)	   Since	   a	   bivalent	   ligand	  must	   first	   undergo	   univalent	   binding,	   in	   this	   bound-­‐
state	  the	  binding	  of	  the	  second	  pharmacophore	  to	  a	  neighboring	  recognition	  site	  
is	  favored	  owing	  to	  entropic	  factors.20	  
This	   type	   of	   binding	   allows	   achieving	   a	   higher	   potency	   and	   enhancing	  
significantly	  the	  recognition	  process.21	  In	  the	  light	  of	  the	  considerations	  outlined	  
above,	   many	   libraries	   of	   bifunctional	   molecules	   have	   been	   generated	   by	  
synthetic	  approaches	  in	  order	  to	  identify	  novel	  ligands	  to	  combat	  PrDs.	  The	  most	  
relevant	  ones	  will	  be	  reviewed	  in	  the	  following	  Sections.	  
	  
1.2.1.	  Modulators	  of	  PPIs:	  benzoquinone	  derivatives	  
Several	   lines	  of	  evidences	   suggest	   that	   lipophilic	   and	  aromatic	   residues	  able	   to	  
provide	   van	   der	   Waals	   and	   π−π stacking	   interactions,	   connected	   by	   a	   central	  
core,	  might	  modulate	  PPIs.	  With	  this	  in	  mind,	  Bolognesi	  et	  al.	  developed	  a	  small	  
library	  of	  bivalent	   ligands	  by	  attaching	  seven	  amino	  acids	  methyl	  esters	   to	   two	  
different	  2,5-­‐bis-­‐diaminobenzoquinone	  (BQ,	  Figure	  1.2).22,	  The	  choice	  of	  the	  BQ	  
system	  as	  the	  central	  spacer	  was	  motivated	  by	  the	  fact	  that	  it	  is	  a	  planar	  system	  
that	   should	   be	   able	   to	   interfere,	   through	   hydrophobic	   interactions,	   with	   the	  
aromatic	   residues	   involved	   in	   the	   fibril	   formation.	   Furthermore,	   BQ	  derivatives	  
have	   been	   demonstrated	   to	   be	   able	   to	   bind	   Aβ	   and	   interfere	   with	   the	   native	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
20	   Portoghese,	  P.	  S.	  J.	  Med.	  Chem.2001,	  44,	  2259.	  
21	   Staderini,	  M.;	  Legname,	  G.;	  Bolognesi,	  M.	  L.;	  Menéndez,	  J.	  C.	  Curr.	  Top.	  Med.	  Chem.	  2013,	  
13,	  2491.	  
22	   Tran,	  H.	  N.	  A.;	  Bongarzone,	  S.;	  Carloni,	  P.;	  Legname,	  G.;	  Bolognesi,	  M.	  L.	  Bioorg.	  Med.	  Chem.	  
Lett.	  2010,	  20,	  1866.	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ability	  of	  Aβ	   to	  self-­‐assemble	  by	  disrupting	  PPIs.23	  On	  the	  other	  hand,	  aromatic	  
amino	  acid	  fragments,	  such	  as	  Trp,	  Phe	  and	  Tyr,	  could	  act	  as	  PRMs	  and	  promote	  
the	  molecular	  recognition	  process	  providing	  hydrogen	  bonds,	  van	  der	  Waals	  and	  
π-­‐π	   stacking	   interactions.	   As	   expected,	   in	   a	   prion	   cell	   culture	   model	   the	  
phenylalanine	  derivatives	  BQ-­‐1	  and	  BQ-­‐2	  (Figure	  1.3)	  showed	  the	  best	  anti-­‐prion	  
activity,	   displaying	   EC50	   values	   of	   0.9	   and	   3.6	   μM,	   respectively.	   In	   addition,	   a	  
chemoinformatic	  analysis	  confirmed	  that	  a	  BQ	  central	  scaffold	  connected	  to	  two	  
aromatic	  rings	  is	  a	  suitable	  motif	  for	  designing	  novel	  antiprion	  compounds.	  
Considering	   the	  BQ	  nucleus	  as	  particularly	   suitable	   for	  perturbing	  PPIs,	   the	  
same	  authors	  developed	  a	   further	   series	  of	  bivalent	   ligands.24	  Thus,	   two	  active	  
terminal	  moieties	  were	  attached	  at	  the	  positions	  2	  and	  5	  of	  the	  central	  BQ	  core	  
through	   proper	   linkers.	   As	   PRMs	   acridine,	   quinoline,	   and	   1,2,3,4-­‐	  
tetrahydroacridine	   systems	   were	   chosen	   due	   to	   the	   fact	   that	   these	   aromatic	  
heterocycles	  had	  been	  shown	  to	  have	  anti-­‐prion	  potential.25	  On	  the	  other	  hand,	  
three	   different	   polyamine	   chains	   linkers	   were	   selected	   to	   explore	   different	  
lengths	   and	   chemical	   compositions.24	   Compounds	   BQ-­‐3	   –	   BQ-­‐6	   (Figure	   1.2)	  
showed	   remarkably	   potency	   against	   prion	   replication	   in	   cell	   culture,	   with	   EC50	  
values	  ranging	  from	  0.2	  to	  0.7	  μM.	  The	  obtained	  results	  suggested	  that	  a	  specific	  
length	  of	  the	  linker	  and	  the	  presence	  of	  a	  chlorine	  atom	  on	  the	  terminal	  residues	  
are	  critical	   for	  the	  anti-­‐prion	  activity.	  Furthermore,	  to	  elucidate	  the	  mechanism	  
of	  action	  of	   these	   ligands,	   the	  capability	  of	   inhibiting	  prion	   fibril	   formation	  was	  
studied	  in	  vitro	  by	  using	  an	  amyloid	  seeding	  assay	  (ASA).26	  Interestingly,	  only	  BQ-­‐
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   Bartolini,	   M.;	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   C.;	   Bolognesi,	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   C.;	   Andrisano,	   V.	  
ChemBioChem	  2007,	  8,	  2152.	  
24	   Bongarzone,	  S.;	  Tran,	  H.	  N.	  A.;	  Cavalli,	  A.;	  Roberti,	  M.;	  Carloni,	  P.;	  Legname,	  G.;	  Bolognesi,	  
M.	  L.	  J.	  Med.	  Chem.	  2010,	  53,	  8197.	  
25	   Bongarzone,	  S.;	  Bolognesi	  M.	  L.	  Expert	  Opin.	  Drug	  Discov.	  2011,	  6,	  251.	  
26	   Colby,	  D.	  W.;	  Zhang,	  Q.;	  Wang,	  S.;	  Groth,	  D.;	  Legname,	  G.;	  Riesner,	  D.;	  Prusiner,	  S.	  B.	  Proc.	  
Natl.	  Acad.	  Sci.	  USA	  2007,	  104,	  20914.	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4	   and	   BQ-­‐6	   delayed	   fibril	   formation,	   and	   it	   was	   proposed	   that	   the	   active	  





Figure	  1.3.	  Chemical	  structure	  of	  benzoquinone-­‐based	  (BQ-­‐1	  -­‐BQ-­‐6)	  bivalent	  ligands.	  
1.2.2.	  Dimeric	  acridine	  and	  quinoline	  compounds	  
Quinacrine,	   an	   acridine-­‐based	   compound,	   is	   a	   well-­‐known	   antimalarial	   drug.	  
Interestingly,	  quinacrine	  and	  its	  analogues	  were	  found	  to	  inhibit	  PrPSc	  formation	  
in	  cell	  cultures.27,28	  In	  addition,	  due	  to	  its	  good	  pharmacokinetic	  properties,	   low	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  2001,	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toxicity	   and	   ability	   to	   cross	   the	   BBB,	   its	   efficacy	   and	   safety	   were	   explored	   in	  
vivo.29	   In	   an	   effort	   to	   shed	   some	   light	   on	   the	   mechanism	   of	   action	   of	   these	  
derivatives,	  Vogtherr	  et	  al.	  used	  nuclear	  magnetic	  resonance	  (NMR)	  to	  map	  the	  
binding	   site	   of	   quinacrine	   to	   recombinant	   human	   prion	   protein.	   Although	   the	  
precise	  mechanism	  by	  which	  quinacrine	  hinders	  the	  conversion	  of	  PrPC	   into	  the	  
scrapie	   pathogenic	   form	   remains	   unclear,	   the	   identification	   of	   its	   binding	   site	  
influenced	  profoundly	  the	  development	  of	  new	  strategies	  to	  combat	  PrDs.30	  
Considering	  the	  propensity	  of	  PrPSc	  to	  assemble	  into	  multimers,	  May	  and	  co-­‐
workers	  envisaged	  that	  dimers	  of	  quinacrine	  could	  be	  more	  potent	  inhibitors	  of	  
prion	   replication	   by	   increasing	   the	   local	   concentration	   of	   the	   active	   moiety.31	  
Thus,	  bis-­‐acridine	  compounds	  were	  generated	  and,	  as	  expected,	  they	  turned	  out	  
to	   be	   ten-­‐fold	   more	   active	   than	   quinacrine	   in	   cell	   models.	   For	   instance,	  
compound	  ACR-­‐1,	  consisting	  of	   two	  quinacrine	  nucleus	   linked	  by	  an	  alkyl	  ether	  
chain,	  showed	  activity	   in	  a	  nanomolar	  range	  (Figure	  1.4	  A).	   In	  the	  literature	  are	  
reported	   other	   examples	   of	   bis-­‐acridines,	   i.e.	   compound	   ACR-­‐2	   (Figure	   1.4A),	  
that	   exhibited	   higher	   antiprion	   potency	   than	   monomeric	   acridines	   in	   infected	  
neuroblastoma	   cells	   offering	   a	   valid	   starting	   point	   to	   study	   the	  mechanism	   of	  
prion	  replication.32	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Quinine,	   chloroquine	   and	   other	   antimalarial	   drugs	   were	   found	   to	   be	  
effective	  for	   inhibition	  of	  PrPSc	   formation	   in	  scrapie-­‐infected	  cells.33	  Since	  these	  
compounds	   have	   a	   quinoline	   ring	   in	   their	   structures,	   Mukarami-­‐Kubo	   et	   al.	  
decided	  to	  focus	  on	  quinoline	  derivatives	  to	  explore	  the	  structure-­‐activity	  
	  
	  
Figure	  1.4.	  (A)	  Quinacrine	  and	  bis-­‐acridine	  compounds	  (ACR-­‐1	  and	  ACR-­‐2)	  with	  high	  
inhibitory	  effect	  against	  PrPSc	  formation.	  (B)	  2,2’-­‐Biquinoline	  was	  1000	  times	  more	  
effective	  than	  quinine	  in	  inhibiting	  PrPSc	  formation	  in	  infected	  cell	  cultures.	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relationships	  involved	  in	  prion	  replication	  process.	  Interestingly,	  the	  symmetrical	  
bisquinoline	   (Figure	   1.4B)	   inhibited	   PrPSc	   formation	  with	   an	   impressive	   EC50	   of	  
0.003	  µM,	  being	  1000	  times	  more	  effective	  than	  quinine.34	  
As	  regards	  the	  mechanism	  behind	  the	  inhibitory	  action	  of	  2,2’-­‐bis-­‐quinoline,	  
the	   authors	   demonstrated	   that	   no	   alterations	   in	   the	   protein	   biosynthesis	   or	   in	  
the	  metabolic	  labeling	  of	  PrPC	  were	  involved,	  whereas	  2,2’-­‐bis-­‐quinoline	  was	  able	  
to	  exert	  a	  strong	  binding	  with	  recombinant	  cellular	  prion	  protein.	  In	  the	  light	  of	  
these	   evidences,	   the	   authors	   suggested	   that	   bisquinoline	   might	   inhibit	   the	  
conversion	   of	   PrPC	   to	   PrPSc	   interacting	   directly	  with	   PrPC	  molecule,	   even	   if	   the	  
binding	   site	   remains	   to	   be	   determined.	   Furthermore,	   it	   also	   prolonged	   the	  
incubation	  periods	  in	  infected	  mice.34	  
	  
1.2.3.	  GN8,	  a	  chemical	  chaperone	  
In	  2007,	  a	  Japanese	  group	  headed	  by	  K.	  Kuwata	  used	  a	  virtual	  screening	  protocol	  
based	  on	  the	  NMR-­‐elucidated	  structure	  of	  PrPC	  to	  discover	  a	  compound	  named	  
GN8,	   able	   to	   inhibit	   PrPSc	   formation	   in	   cell-­‐based	  models	   and	   prolong	   survival	  
time	  of	  TSE-­‐infected	  mice.35	  Furthermore,	  the	  toxicological	  and	  pharmacological	  
profile	  of	  GN8	  was	  characterized	  in	  rats	  and	  dogs,	  and	  no	  severe	  adverse	  effects	  
were	   found	   at	   doses	   sufficient	   for	   antiprion	   activity.36	   On	   its	   own,	   this	   finding	  
was	   important	   although	  not	   exceptional,	   but	  what	  made	   this	   discovery	  unique	  
was	   that	   for	   the	   first	   time	   the	  mechanism	  of	   action	  of	   an	  antiprion	   compound	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   Murakami-­‐Kubo,	   I.;	   Doh-­‐ura,	   K.;	   Ishikawa,	   K.;	   Kawatake,	   S.;	   Sasaki,	   K.;	   Kira,	   J.	   I.;	   Ohta,	   S.;	  
Iwaki,	  T.	  J.	  Virol.	  2004,	  78,	  1281.	  
35	   Kuwata,	   K.;	   Nishida,	   N.;	  Matsumoto,	   T.;	   Kamatari,	   Y.	   O.;	   Hosokawa-­‐Muto,	   J.;	   Kodama,	   K.;	  
Nakamura,	  H.	  K.;	  Kimura,	  K.;	  Kawasaki,	  M.;	  Takakura,	  Y.;	  Shirabe,	  S.;	  Takata,	  J.;	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  Y.;	  
Katamine,	  S.	  Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A.	  2007,	  104,	  11921.	  
36	   Hosokawa-­‐Muto,	  J.;	  Kimura,	  T.;	  Kuwata,	  K.	  Drug.	  Chem.	  Toxicol.	  2012,	  35,	  264.	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was	   clarified.	   Thus,	   it	   was	   proposed	   that	   GN8	   acts	   as	   chemical	   chaperone	  
interacting	  with	  hot	  spot	  regions	  at	  the	  helix	  B	  of	  PrPC	  forming	  a	  stable	  complex	  
PrPC-­‐GN8	  that	  blocks	  its	  conformational	  change	  into	  PrPSc	  (Figure	  1.5).	  
	  
	  
Figure	  1.5.	  GN8	  interacts	  with	  a	  hot	  spot	  region	  of	  PrPC	  forming	  a	  stable	  complex	  PrPC-­‐
GN8	  that	  blocks	  its	  conformational	  change	  into	  PrPSc	  
	  
GN8	  is	  composed	  of	  two	  2-­‐(1-­‐pyrrolidinyl)acetylamino	  groups	  attached	  to	  a	  
diphenylmethane	   scaffold.	   In	   an	  effort	   to	   study	   the	   SAR	  and	  optimize	   the	   lead	  
compound,	  a	   large	   library	  of	  GN8	  derivatives	  was	  generated.	  The	  evaluation	  of	  
the	  antiprion	  activity	   in	   infected	  cell	   culture	  across	   the	  synthetized	  compounds	  
showed	  that	  the	  bivalent	  character	  of	  GN8	  is	  essential	  for	  its	  action	  against	  prion	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replication.37	  Indeed,	  truncation	  of	  one	  or	  two	  tetramethylene	  units,	  pyrrolidine	  
units,	  or	  2-­‐(1-­‐pyrrolidinyl)acetyl	  units	  resulted	   in	  a	  significant	  decrease	   in	  terms	  
of	  activity.	  Furthermore,	  other	  chemical	  manipulations	  suggested	   that,	  more	   in	  
general,	   the	   overall	   structure	   of	   GN8	   contributes	   to	   the	   activity	   including	   the	  
amide	  N–H	  and	  nitrogen	  atoms	  of	  the	  pyrrolidine	  rings	  that	  act	  as	  H-­‐bond	  donors	  
and	   acceptors,	   respectively.	   The	   hydrophobicity	   of	   the	   substituents	   on	   the	  
nitrogen	   atoms	   of	   both	   terminal	   amino	   groups	   also	   plays	   a	   crucial	   role	   in	   the	  
ligand–protein	   interaction.	   Moreover,	   the	   introduction	   of	   one	   or	   two	  
substituents	   at	   the	   benzylic	   position	   of	   GN8	   restricts	   the	   conformational	  
variability	   of	   the	   diphenylmethane	   unit	   leading	   to	   an	   increased	   stability	   of	   the	  
prion	   protein	   upon	  binding,	   and	   consequently	   to	   an	   improvement	   of	   antiprion	  
activity	  (Figure	  1.6).	  
	  
Figure	  1.6.	  From	  a	  large	  library	  of	  GN8	  derivatives	  the	  SAR	  was	  studied	  highlighting	  the	  
chemical	  properties	  of	  the	  molecules	  critical	  for	  the	  antiprion	  activity	  
	  
	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
37	   Kimura,	  T.;	  Hosokawa-­‐Muto,	  J.;	  Kamatari,	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  Kuwata,	  K.	  Bioorg.	  Med.	  Chem.	  Lett.	  2011,	  
21,	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1.3.	  Theranostics	  in	  neurodegenerative	  diseases	  
Despite	  the	  great	  advances	  achieved	  so	  far	  and	  their	  potential	   impact	   in	  future	  
therapies,	  PrDs,	  AD	  and	  other	  neurodegenerative	  diseases,	  remain	  incurable	  and	  
are	   extremely	   challenging	   for	   medicinal	   chemists.5,38	   Paradoxically,	   in	   the	   last	  
decades	   we	   seem	   to	   have	   witnessed	   an	   inverse	   relationship	   between	  
investments	   in	   research	   on	   CNS	   drug	   discovery	   and	   the	   development	   of	  
successful	  new	  drugs.	  As	  a	  result,	  treatments	  able	  to	  definitely	  arrest	  the	  course	  
of	  disease	  do	  not	  yet	  exist	   for	  any	  of	   these	  disorders.39	  This	  situation	  has	  been	  
attributed	   to	   several	   hurdles	   that	   apply	   to	   neurodegenerative	   diseases	   in	  
general:	  	  
(i)	  Their	  etiology	  is	  not	  well	  understood	  and	  consequently	  no	  therapeutic	  target	  
has	  been	   truly	   validated.	   Furthermore,	  drug	  discovery	   in	   this	  area	  appears	   less	  
amenable	   to	   target-­‐based	   approaches	   than	   it	   seems	   for	   other	   types	   of	  
therapeutics.40	  	  
(ii)	  Another	  reason	  for	  the	  high	  attrition	  rate	  of	  drugs	  in	  the	  clinic	  has	  been	  the	  
poor	  predictive	  power	  of	  animal	  models	  for	  efficacy	  in	  humans.41	  	  
(iii)	  Furthermore,	  the	  failure	  of	  many	  drug	  candidates	  has	  been	  related	  to	  their	  
late	  administration	  when	  the	  pathology	  is	  too	  advanced.42	  
All	   these	   inherent	   difficulties	   have	   somehow	   led	   medicinal	   chemists	   to	  
neglect	  rational	  approaches	  and	  consider	  screening	  approaches	  as	  the	  method	  of	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  M.;	  Louth,	  J.;	  Guo,	  K.	  Curr.	  Top.	  Med.	  Chem.	  2013,	  13,	  2441.	  
39	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  M.	  N.;	  Schechter,	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  2009,	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   Markou,	   A.;	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Neuropsychopharmacology	  2009,	  34,	  74.	  
42	   Becker,	  R.	  E.;	  Greig,	  N.	  H.	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  Drug	  Discov.	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  7,	  367.	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election	  when	   looking	   for	  new	  drugs.	  Nevertheless,	   there	   is	   still	   a	  multitude	  of	  
intriguing	  ideas	  in	  the	  med-­‐chem	  toolbox	  on	  how	  to	  potentially	  target	  PrDs	  and	  
AD	  and	  eventually	  overcome	  the	  challenges	  summarized	  above.	  One	  such	  option	  
is	  the	  exploitation	  of	  theranostics,	  i.e.	  the	  use	  of	  single	  agents	  with	  concomitant	  
therapeutic	  and	  diagnostic	  properties	  in	  order	  to	  optimize	  the	  efficacy	  and	  safety	  
of	   therapy,	   as	   well	   as	   to	   streamline	   the	   whole	   drug	   discovery	   process	   (Figure	  
1.7.).43,44	   Theranostic	   agents	   seem	   particularly	   suitable	   towards	  
neurodegenerative	  diseases45,46	  because	  in	  the	  case	  of	  both	  PrDs	  and	  AD,	  brain	  
amyloidogenic	  deposition	  is	  the	  main	  pathological	  hallmark,	  which	  is	  believed	  to	  




Figure	  1.7.	  The	  concept	  of	  theranostic	  in	  biomedicine:	  a	  single	  agent	  that	  can	  be	  used	  as	  
diagnostic	  and	  for	  therapeutic	  intervention	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aggregates	  is	  particularly	  suitable	  to	  diagnose	  the	  onset	  of	  the	  disease	  in	  its	  early	  
stage	  and	  monitor	  its	  progression.49	  
Theranostics	   raises	   fascinating	   questions	   about	   the	   possibility	   to	   devise	  
common	  strategies	   for	  monitoring	   the	  aggregation	  process	  and	   for	   therapeutic	  
intervention.46	   These	   agents,	   if	   properly	   designed,	   would	   have	   the	   ability	   to	  
simultaneously	  allow	  the	  real	  time	  assessment	  of	  the	  amount	  of	  drug	  reaching	  a	  
pathological	   district	   and	   the	   visualization	   of	   molecular	   changes	   due	   to	   the	  
therapeutic	  effects	  of	  the	  drug	  itself.	  	  
Although	  research	  in	  the	  theranostic	  area	  poses	  many	  difficulties	  because	  of	  
the	   sophisticated	   technology	   and	   the	   novel	   challenges	   involved,	   it	   offers	  
concrete	  alternatives	   to	   the	  current	  paradigm	  of	  drug	  discovery.	   In	   this	   regard,	  
examples	   of	   nanoparticles	   (NPs)	   for	   improving	   diagnosis	   and	   therapy	   of	   AD	  
already	  exist	  and	  have	  been	  recently	  reviewed	  by	  Andrieux	  and	  Couvreur.50	  NPs	  
seem	   particularly	   suitable	   for	   the	   development	   of	   theranostic	   agents	   by	  
combining	   diagnostic	   and	   therapeutic	   components	   in	   a	   unique	   particle.	  
Furthermore,	   NPs	   are	   currently	   used	   as	   drug	   delivery	   systems	   to	   improve	   the	  
pharmacokinetic	  and	  pharmacodynamic	  properties	  of	  existing	  drugs,51	  although	  
they	   do	   pose	   a	   number	   of	   health	   risks.52	   For	   this	   reason,	   the	   use	   of	   small	  
molecules	   as	   theranostics	   is	   an	   attractive	   alternative.	   In	   the	   context	   of	   PrDs,	  
many	  molecules	   staining	   scrapie	   fibrils	  with	   high	   affinity	   turned	  out	   to	   be	   also	  
capable	   of	   blocking	   their	   aggregation.	   Ishikawa	   et	   al.	   provided	   two	  
representative	   examples:	   a	   thioflavin	   (BTA-­‐1)	   and	   a	   styrylbenzene	   (BSB)	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derivative	   (Figure	  1.8).53	   Both	   fluorescent	  probes,	   known	   to	   image	  Aβ	   plaques,	  
were	  shown	  to	  stain	  prion	  fibrils	  ex	  vivo	  and	  to	  prevent	  abnormal	  PrP	  formation	  
in	   a	   cellular	   model.	   In	   addition,	   the	   incubation	   time	   of	   an	   experimental	   prion	  
mouse	  model	  was	  prolonged	  when	  BSB	  was	  injected	  intravenously.53	  In	  the	  same	  
vein,	   amyloid	   ligands	   that	   showed	   the	   concomitant	   capability	   of	   staining	  
abnormal	   prion	   deposits	   and	   inhibiting	   prion	   replication	   were	   recently	  
reviewed.49,54	   Thus,	   it	   seems	   conceivable	   that	   PrPSc	   binding	   compounds	  
represent	   attractive	   candidates	   for	  monitoring	   the	   aggregation	   process	   and	   at	  
the	  same	  time	  for	  therapeutic	  intervention.	  
	  
	  
Figure	  1.8.	  Chemical	  structures	  of	  BTA-­‐1	  and	  BSB	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1.4.	  Imaging	  of	  amyloid	  plaques	  by	  near	  infrared	  fluorescent	  tracers	  
In	   the	   last	   decade,	   great	   strides	   forward	   have	   been	   made	   in	   the	   field	   of	  
molecular	  imaging	  with	  the	  aim	  of	  detecting	  abnormal	  proteinaceous	  deposits	  in	  
vivo.	   Generally	   speaking,	  MRI	   (magnetic	   resonance	   imaging)	   and	   PET	   (positron	  
emission	   tomography)	   are	   the	   most	   used	   imaging	   techniques	   in	   clinical	  
settings.55	  However,	  MRI	  has	  too	  low	  a	  sensitivity	  for	  amyloid	  imaging,	  and	  PET	  
has	   some	   serious	   limitations	   due	   to	   its	   high	   cost,	   the	   scarcity	   of	   the	   required	  
isotopes	  and	  practical	  limitations	  in	  their	  use	  associated	  to	  the	  need	  to	  prepare	  
and	  use	  them	  within	  the	  short	  half-­‐lives	  of	  the	  radioactive	  atomic	  species	  (20	  min	  
in	  the	  case	  of	  14C	  and	  110	  min	  for	  18F).56	  In	  addition,	  PET	  has	  not	  found	  practical	  
application	  for	  monitoring	  drug	  effectiveness	  in	  mice	  because	  of	  the	  complexity	  
of	   the	   experimental	   procedure	   and	   data	   analysis	   protocols	   required	   for	   small	  
animals.	  On	   the	  other	  hand,	   fluorescence	   spectroscopy	  has	  proven	  suitable	   for	  
studying	  fibrillar	  aggregates.	  
There	   is	   a	   growing	   interest	   in	   fluorescence	   spectroscopy	   as	   a	   non-­‐invasive	  
alternative	   for	   early	   diagnosis	   that	   enables	   the	   real-­‐time	   visualization	   of	  
biomolecules	  in	  living	  systems.	  It	  is	  a	  versatile	  and	  sensitive	  method	  that	  leads	  to	  
a	   rapid,	   inexpensive	   and	   non-­‐radioactive	   imaging	   system.57	   It	   is	   important	   to	  
remark	   that	   for	   their	   in	   vivo	   application,	   fluorescent	   probes	   have	   to	   possess	  
proper	  features	  including	  the	  ability	  to	  emit	  fluorescence	  in	  the	  far-­‐red	  or	  near-­‐
infrared	  (NIR)	  region	  (600-­‐900	  nm).	  In	  fact,	  NIR	  light	  is	  particularly	  suitable	  to	  be	  
used	   for	   in	   vivo	   imaging	   of	   molecular	   processes	   due	   its	   acceptable	   depth	   of	  
penetration,	   non-­‐invasive	   operation,	   minimal	   interferences	   from	   the	   auto-­‐
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fluorescence	   of	   biological	   matter	   and	   minimal	   photo-­‐damage	   to	   biological	  
samples.58	   Furthermore,	   in	   this	   spectral	   range	   the	   absorption	   of	   fluorescence	  
signals	  by	  body	  tissues	  are	  minimal.	  
Although,	   so	   far,	   NIR	   fluorescent	   probes	   have	   been	   mainly	   used	   in	   the	  
oncology	   field	   for	   imaging	   tumors,	   both	   in	   vivo	   and	   in	   vitro,	   they	   are	   also	  
extremely	   useful	   to	   visualize	   and	   monitor	   amyloid	   plaque	   formation	   and	   to	  
evaluate	   the	   effectiveness	   of	   drug	   treatment	   in	   animal	   models	   and	   they	   are	  
therefore	  considered	  an	  attractive	  and	  promising	  tool	  for	  the	  early	  diagnosis	  of	  
AD	  and	  PrDs	  (Figure	  1.9).52	  
	  
Figure	  1.9.	  Near	  infrared	  fluorescent	  tracers	  have	  shown	  to	  be	  suitable	  to	  image	  amyloid	  
aggregates	  in	  vivo	  
	  
The	  application	  of	  NIR	  imaging	  in	  neurodegenerative	  diseases	  is	  challenging	  
due	   to	   the	   fact	   that	   Aβ	   plaques	   are	   located	   inside	   the	   skull-­‐shielded	   brain.	  
Indeed,	   fluorescence-­‐based	   optical	   imaging	   of	   the	   brain	   of	   small	   animals	   in	  
traditional	   near-­‐infrared	   regions	   has	   previously	   relied	   on	   craniotomy,	   cranial	  
windows	   and	   skull-­‐thinning	   techniques.	   Since	   the	   resolution	   of	   optical	   imaging	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decreases	  with	  increasing	  depth	  of	  the	  source	  of	  fluorescence	  emission	  because	  
of	   fluorescence	   scattering	   in	   the	   biological	   environment,	   quantification	   of	   the	  
amyloid	  load	  by	  NIR	  imaging	  is	  limited	  to	  the	  surface	  area	  of	  the	  brain.	  	  
The	  development	  of	  modern	  and	  efficient	  optical	   imaging	  systems,	  such	  as	  
fluorescent	   molecular	   tomographic	   (FMT)	   imaging	   and	   the	   hybrid	   technique	  
known	  as	  FMT-­‐CT	  (X-­‐ray	  computed	  tomography)	  imaging,	  has	  enabled	  the	  in	  vivo	  
visualization	   of	   Aβ	   plaque	   distribution	   in	   AD	   mice	   with	   an	   intact	   cranium.	  
Nevertheless,	   mice	   do	   not	   develop	   the	   same	   neuropathological	   or	   clinical	  
characteristics	   seen	   in	  humans,	  and	   therefore	  amyloid	  aggregates	   in	   transgenic	  
mouse	   models	   are	   different	   to	   those	   observed	   in	   AD	   patients,	   thereby	  
hampering	  the	  translation	  into	  clinics	  of	  diagnostic	  or	  therapeutic	  findings	  done	  
in	  these	  models.59	  Although	  further	  technological	  improvements	  are	  needed	  and	  
it	   is	   not	   likely	   that	   the	   entire	   human	   brain	   can	   be	   visualized	   using	   optical	  
methods,	  it	  has	  been	  proposed	  that	  it	  will	  be	  feasible	  in	  the	  near	  future	  to	  probe	  
the	  brain	  cortex	  at	  depths	  up	  to	  3–5	  cm.60	  This	  should	  be	  sufficient	  for	  obtaining	  
diagnostic	   information	   on	   AD	   patients,	   taking	   into	   account	   that	   most	   of	   the	  
amyloid	   depositions	   are	   placed	   on	   the	   neo-­‐cortical	   surface,	   although	   the	  
problem	  of	  non-­‐specific	  binding	  to	  white	  matter	  has	  to	  be	  taken	  into	  account	  as	  
well.61	  
Another	  possible	  approach	  to	  NIR	  AD	  imaging	  could	  be	  based	  on	  the	  use	  of	  
parts	  of	  the	  central	  nervous	  system	  (CNS)	  that	  are	  not	  shielded	  by	  the	  skull	  and	  
can	  therefore	  be	  considered	  physiological	  skull	  windows.	  For	  instance,	  the	  retina,	  
which	   is	   easily	   accessible	   for	   direct	   and	   non-­‐invasive	   imaging,	   could	   provide	   a	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unique	  opportunity	   for	   early	  diagnosis	  of	  AD	   in	   animal	  models	   and	  humans	  by	  
exploiting	  NIR	   imaging.	  Thus,	   recent	   findings	  demonstrated	   the	  presence	  of	  Aβ	  
plaques	  in	  the	  retina,	  of	  AD	  patients	  with	  similar	  biochemical	  properties	  of	  those	  
observed	   in	   their	  brains,62	  and	  curcumin	  was	  shown	  to	  bind	   these	  plaques	  and	  
allow	  their	  visualization	   in	  vivo	  at	  high	   resolution.62	  Unfortunately,	  Schon	  et	  al.	  
could	   not	   find	   any	   evidence	   for	   the	   presence	   of	   Aβ	   plaques	   in	   retina	   of	  
transgenic	  mice	  or	  AD	  patients,	  challenging	  the	  results	  of	  the	  previous	  work.63	  On	  
the	   other	   hand,	   they	   were	   able	   to	   detect	   fibrillar	   tau	   aggregates	   in	   vivo	   in	  
transgenic	  mice	  retina,	  whereas	  only	  hyperphosphorylated	  (but	  not	  fibrillar)	  tau	  
was	   observed	   in	   AD	   human	   retina.63	   The	   olfactory	   epithelium,	   being	   also	   an	  
extension	  of	  the	  brain,	  can	  be	  viewed	  as	  an	  optimum	  target	  for	  NIR	  imaging.	  It	  is	  
interesting	  to	  note	  that	  the	  presence	  of	  neurofibrillary	  tangles	  was	  confirmed	  by	  
staining,	  whereas	  no	  Aβ	  deposits	  could	  be	  observed	  in	  this	  region.64	  
Since	  the	  discovery	  of	  amyloid	  depositions	  more	  than	  a	  century	  ago,	  several	  
fluorescent	  dyes	  with	  high	  affinity	  for	  the	  amyloid	  species	  have	  been	  generated	  
for	   the	   post-­‐mortem	   diagnosis	   of	   PrDs,	   AD	   and	   other	   PMDs.65,66	   Nevertheless,	  
most	  conventional	  dyes	  cannot	  translate	  into	  clinical	  diagnostic	  tools	  because	  of	  
their	   low	   specificity,	   poor	   sensitivity,	   inability	   to	   cross	   the	   blood	   brain	   barrier	  
(BBB)	   and	  marked	   toxicity.67	  Many	   efforts	   have	   been	   done	   to	   overcome	   these	  
drawbacks	  with	  the	  purpose	  of	  obtaining	  an	  optical	  marker	  to	  be	  used	  for	  in	  vivo	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imaging	  of	  amyloid	  plaques.	  To	  this	  end,	  NIR	  probes	  have	  been	  proposed	  as	  ideal	  
candidates.	  Apart	  from	  the	  ability	  to	  emit	  fluorescence	  in	  the	  NIR	  region,68	  these	  
probes	   must	   possess	   additional	   features	   including:	   (1)	   specificity	   to	   amyloid	  
plaques,	  (2)	  ability	  to	  change	  fluorescence	  properties	  upon	  binding	  to	  fibrils,	  (3)	  
high-­‐affinity	  binding,	  (4)	  high	  fluorescence	  quantum	  yield,	  (5)	   large	  Stokes	  shift,	  
(6)	  minimum	  interference	  from	  human	  serum	  albumin	  (HSA)	  binding,	  (7)	  a	  small	  
molecular	   size	   and	   a	   suitable	   lipophilicity,	   enabling	   the	   molecule	   to	   cross	   the	  
BBB,	  and	  (8)	  low	  toxicity.69	  
	  
1.4.1.	  Molecular	  design	  for	  emission	  in	  the	  NIR	  region	  
If	   the	   suitable	   amount	   of	   energy	   is	   given	   to	   a	   molecule,	   electrons	   can	   be	  
promoted	  from	  an	  occupied,	   low-­‐energy	  molecular	  orbital	  to	  an	  empty,	  higher-­‐
energy	   one,	   giving	   rise	   to	   an	   absorption	   transition	   that	   corresponds	   to	   an	  
absorption	   band	   in	   the	   spectrum.	   For	   a	   large	   number	   of	   organic	   compounds,	  
energy	   is	   then	   dissipated	   by	   collision	  with	   solvent	  molecules.	   However,	   in	   the	  
case	   of	   fluorescent	   compounds,	   electrons	   from	   the	   excited	   state	   return	   to	   the	  
ground	   state	   by	   emission	   of	   photons,	   the	   latter	   phenomenon	   being	   known	   as	  
fluorescence,	  because	  the	  electrons	  of	  the	  excited	  and	  ground	  states	  are	  paired	  
(singlet	  state).	  The	  smallest	  possible	  difference	  in	  energy	  between	  a	  full	  and	  an	  
empty	  orbital	  is	  the	  one	  existing	  between	  the	  highest	  occupied	  molecular	  orbital	  
(HOMO)	   and	   lowest	   unoccupied	   molecular	   orbital	   (LUMO),	   called	   the	   HOMO-­‐
LUMO	   gap,	   which	   is	   closely	   correlated	   to	   the	   absorption	   and	   emission	  
wavelengths.	  In	  fact,	  for	  a	  low	  energy	  gap	  a	  red	  shift	  in	  absorption	  and	  emission	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spectra	  would	  be	  expected.	   In	   line	  with	   these	   considerations,	  NIR	  probes	  have	  
been	  designed	  and	  engineered	  with	  the	  aim	  of	  reducing	  the	  HOMO-­‐LUMO	  gap	  of	  
existing	  amyloid	  dyes.	  
It	  is	  well	  known	  that	  two	  double	  bonds	  connected	  by	  one	  single	  bond	  form	  a	  
conjugated	  system	  in	  which	  electrons	  are	  delocalized	  over	  the	  entire	  molecule	  	  
	  
	  
Figure	   1.10.	   Schematic	   representation	   of	   the	   HOMO-­‐LUMO	   gap	   of	   an	  
isolated	   double	   bond	   and	   an	   extended	   conjugated	   system.	   The	   more	  
conjugated	   a	   molecule	   is,	   the	   smaller	   the	   energy	   transition	   between	   its	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through	  π-­‐molecular	   orbitals	   that	   result	   from	   combining	   the	   2p	   orbitals	   of	   the	  
separate	  atoms.	  In	  this	  simple	  conjugated	  system	  model,	  fluorescent	  emission	  is	  
due	  to	  the	  transition	  of	  electrons	  from	  the	  antibonding	  π*	  LUMO	  orbital	  to	  the	  
bonding	  π	  HOMO	  orbital	   (π*	  →	  π	   transition),	  whose	  energy	  difference	   is	   lower	  
than	   the	   HOMO-­‐LUMO	   gap	   of	   an	   isolated	   double	   bond.	   Therefore,	   the	  
conjugated	  system	  absorbs	  and	  emits	   light	  of	  a	   longer	  wavelength	   than	  a	  non-­‐
conjugated	   system.	   In	   addition,	   if	   the	   conjugation	   is	   extended	   further,	   the	   gap	  
between	   HOMO	   and	   LUMO	   will	   decrease	   and	   consequently	   the	   fluorescent	  
emission	  will	  be	  red-­‐shifted	  (Figure	  1.10).70	  Therefore,	  a	  conjugated	  π	  system	  is	  
the	   ideal	   scaffold	   for	   the	   construction	   of	   NIR	   probes	   and	   a	   change	   of	   the	  
conjugation	  length	  represents	  an	  effective	  way	  to	  tune	  the	  energy	  gap	  level.	  
Achieving	  NIR	  emission	  by	  conjugation	  alone	  would	  require	  the	  construction	  
of	   prohibitively	   big	   molecules.	   A	   very	   common	   strategy	   used	   to	   lower	   the	  
HOMO-­‐LUMO	   gap	   of	   a	   conjugated	   π	   system	   is	   based	   upon	   the	   presence	   of	  
electron-­‐donor	   (D)	   and	   electron-­‐acceptor	   (A)	   groups	   as	   terminal	   moieties	   in	  
order	   to	   generate	   a	   “push-­‐pull	  molecule”.	   In	   its	   ground	   state,	   such	   a	  molecule	  
can	  be	  described	  by	  two	  resonance	  forms,	  one	  of	  which	  is	  neutral	  and	  the	  other	  
one	   is	   zwitterionic	   (Figure	   1.11),	   with	   the	   latter	   form	   being	   a	   better	  
representation	  of	  the	  excited	  state.	  Due	  to	  the	  presence	  of	  the	  A	  and	  D	  groups,	  
the	   whole	   conjugated	   system	   is	   more	   polarized	   and,	   in	   terms	   of	   energy,	   the	  
ground	   state	   is	   closer	   to	   the	  excited	   state.	   Therefore,	   less	  energy	   is	  needed	   to	  
absorption	  and	  emission	  transitions	  and	  thus	  a	  longer	  wavelength	  (bathochromic	  
shift)	   is	   observed.	   It	   is	   important	   to	   remark	   that	   obtaining	   the	   desired	   shift	  
depends	  on	  the	  electronic	   features	  of	  D	  and	  A.	  The	  electron	  donor	  group	  must	  
possess	   a	   lone	   pair	   of	   electrons	   in	   a	   π	   orbital	   able	   to	   interact	   with	   the	   π-­‐
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molecular	   orbitals	   of	   the	   conjugated	   system	   increasing	   the	   HOMO	   energy.	   On	  
the	  other	  hand,	  the	  LUMO	  orbitals	  are	  made	  more	  stable	  by	  the	  interaction	  with	  
the	  antibonding	  orbitals	  of	  the	  π	  electron-­‐withdrawing	  group.	  Both	  concomitant	  
effects	  lead	  to	  reduction	  of	  the	  HOMO-­‐LUMO	  gap.	  Among	  the	  π-­‐electron	  donor	  
groups,	   dimethylamino	   (NMe2)	   is	   widely	   regarded	   as	   the	   best	   red-­‐shift	  
absorption-­‐pushing	   group,	  whereas	   the	   formyl	   (CHO)	   and	   cyano	   (CN)	  moieties	  
are	   considered	   optimum	   acceptors.	   Moreover,	   pH	   can	   also	   influence	   the	  
bathochromic	  shift	  of	  push-­‐pull	  molecules.	  In	  fact,	  in	  a	  medium	  with	  pH	  around	  7	  
the	  neutral	  form	  is	  generally	  dominant,	  often	  showing	  short	  absorption/emission	  
wavelengths	  due	  to	  the	  weak	  push-­‐pull	  system.	  In	  acid	  conditions,	  an	  ionic	  form	  
having	   a	   strong	   push-­‐pull	   system	   becomes	   dominant	   and	   a	   red-­‐shift	   in	  
absorption/emission	  is	  observed.71	  
A	  donor-­‐acceptor-­‐donor	  (D-­‐A-­‐D)	  architecture	  (Figure	  1.11)	  is	  preferred	  when	  
two	  photon	  microscopy	  (TPM)	  bioimaging	  is	  applied.72	  TPM	  has	  some	  advantages	  
compared	   to	  one	  photon	  microscopy	   including	   increased	  depth	  penetration	  by	  
exciting	   at	   a	   longer	   wavelength,	   enhanced	   3D	   resolution	   and	   reduced	  
photodamage.	   Unfortunately,	   the	   technique	   is	   invasive	   in	   vivo	   and	   cannot	   be	  
used	   in	   the	   clinic.73	   TPM	   features	   a	   nonlinear	   dependence	   between	   absorbed	  
light	  and	  incident	  light	  intensity,	  since	  in	  two-­‐photon	  absorption	  (TPA)	  processes	  
two	  photons	  are	  absorbed	  with	  a	  probability	  that	  is	  proportional	  to	  the	  square	  of	  
the	   incident	   light	   intensity.72	   Considering	   that	   TPA	   efficiency	   depends	   on	   the	  
conjugation	  length	  and	  D/A	  strength,	  a	  D-­‐A-­‐D	  system	  furnishes	  higher	  TPA	  cross	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sections	   (a	   measure	   for	   the	   probability	   of	   an	   absorption	   process)	   than	   a	   D-­‐A	  
molecule.72	  
	  
Figure	  1.11.	  A	  push-­‐pull	  molecule	  and	  a	  donor-­‐acceptor-­‐donor	  molecule,	  showing	  their	  
neutral	  and	  zwitterionic	  forms.	  
	  
Another	   important	   factor	   that	  must	   be	   considered	   for	   the	   reduction	   of	   the	  
energy	   gap	   is	   the	   bond	   length	   alternation	   (BLA).	   BLA	   is	   the	   length	   difference	  
between	   consecutive	   single	   and	   double	   bonds	   and	   its	   value	   quantifies	   the	  
delocalization	  of	  electrons	  across	  the	  whole	  molecule.74	   In	  fact,	   in	  a	  conjugated	  
system	  a	  single	  C-­‐C	  bond	  has	  a	  partial	  double	  bond	  character	  due	  to	  the	  overlap	  
of	   the	  π	  orbitals,	  and	  hence	   its	   length	   is	   slightly	   shorter	   than	  a	   standard	   single	  
bond	   (154	  pm)	  and	   closer	   to	  a	  double	  one	   (134	  pm).	   Furthermore,	  because	  of	  
this	   overlap	   such	   “formal	   single	   bond”	   becomes	   harder	   to	   rotate	   and	   the	  
molecular	   structure	   tends	   to	   adopt	   a	   planar	   conformation.	   Based	   on	   these	  
considerations,	   if	  the	  BLA	  is	  close	  to	  zero	   it	  means	  that	  there	   is	  a	  great	  overlap	  
among	  the	  π	  orbitals	  and	  consequently	  the	  system	  is	  highly	  conjugated	  and	  the	  
electrons	   very	   delocalized,	   leading	   to	   a	   reduction	   of	   the	   HOMO-­‐LUMO	   gap.	   In	  
push-­‐pull	  molecules,	  the	  presence	  of	  D	  and	  A	  leads	  to	  an	  increase	  of	  the	  double-­‐
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bond	  character	  of	  the	  C-­‐C	  bonds,	  resulting	  in	  a	  reduction	  of	  the	  BLA	  value	  as	  well	  
as	  the	  energy	  gap.	  
As	  mentioned	  above,	  π	  orbitals	  overlap	  and	  combine	  better	  if	  the	  molecule	  
is	   planar.	   In	   this	   way,	   a	   big	   molecular	   orbital	   over	   the	   whole	   molecule	   is	  
generated	   that	   allows	   a	   strong	  π	   conjugation	   and	   a	   great	   delocalization	  of	   the	  
electrons.	   This	   effect	   explains	   why	   the	   fluorescent	   emission	   maximum	   of	  
compounds	  in	  their	  solid	  state	  is	  observed	  at	  longer	  wavelengths	  with	  regard	  to	  
those	  obtained	   in	   solution.	   Indeed,	   in	   the	   solid	   state	   the	   free	  movements	  of	   a	  
molecule	   are	   restricted	   resulting	   in	   a	   more	   rigid	   conformation,	   whereas	   in	  
solution	  it	  possesses	  a	  substantial	  degree	  of	  conformational	  freedom.	  	  
Planarity	   is	  a	   common	  structural	   feature	  of	   fluorescent	  molecules,	  but	   it	   is	  
not	   a	   requirement,	   and	   excited	   states	   have	   been	   proved	   to	   be	   non-­‐planar	   in	  
many	   cases,	   such	   as	   thioflavin	   T,	   and	   to	   have	   a	   different	   geometry	   from	   the	  
ground	   state.75	   In	   the	   case	   of	   molecules	   containing	   aromatic	   rings	   linked	   by	  
ethylene	   chains,	   which	   is	   the	   most	   common	   structure	   for	   amyloid	   probes,	   a	  
change	  in	  the	  geometry	  of	  the	  molecule	  from	  the	  ground	  to	  the	  excited	  state	  is	  
accompanied	   by	   a	   red	   shift	   in	   the	   fluorescent	   emission,	   together	   with	   a	  
broadening	   of	   the	   spectrum.	   Furthermore,	   the	   donor-­‐acceptor	   energy	   transfer	  
effects	  may	  be	  enhanced	  by	  such	  changes	  in	  the	  excited	  state	  geometry.	  
Upon	  binding	  to	  aggregated	  Aβ	  proteins,	  fluorescent	  probes	  normally	  show	  
shifts	  of	  their	  emission	  maxima	  and	  an	  increase	  in	  the	  fluorescent	  quantum	  yield.	  
These	   effects	   are	   similar	   to	   those	   found	   upon	   an	   increase	   of	   viscosity	   of	   the	  
medium	  and	  are	  due	  to	  conformational	  changes,	  since	  when	  the	  molecule	   is	   in	  
unbound	   condition,	   e.g.	   in	   solution,	   free	   rotation	   around	   the	   single	   bonds	   is	  
allowed,	  whereas	  upon	  binding	  to	  fibrils,	  where	  these	  movements	  are	  restricted	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and	  its	  rings	  are	  held	  rigidly,	  it	  becomes	  more	  planar,	  triggering	  a	  change	  in	  the	  
HOMO-­‐LUMO	   gap	   reduction	   and	   a	   concomitant	   red-­‐shift	   in	   the	   absorption	  
maximum.	  In	  addition,	  in	  such	  a	  rigid	  system	  the	  vibrational-­‐rotational	  processes	  
that	   couple	   the	   excited	   and	   the	   ground	   state	   are	   reduced	   and	   therefore	   the	  
radiationless	   decay	   rate	   decreases,	   giving	   rise	   to	   an	   enhancement	   of	   the	  
fluorescent	   yield.	   As	   previously	   mentioned,	   fluorescence	   quantum	   yield	  
enhancement	  upon	  binding	  to	  fibrils	   is	  a	  desirable	  feature	  for	  a	  probe,	   in	  order	  
for	  its	  fluorescence	  to	  be	  clearly	  distinguished	  from	  that	  of	  the	  background.	  	  
In	   summary,	  different	   factors	   influence	   the	  π*	  →	  π	   transition	   reducing	   the	  
energy	   gap	   between	   HOMO-­‐LUMO	   including	   the	   extension	   of	   the	   conjugated	  
system,	   the	   introduction	   of	   electron	   donor	   and	   acceptor	   moieties,	   the	   bond	  
length	   alternation	   and	   the	   degree	   of	   planarity.	   Building	   on	   this	   knowledge,	  
several	  fluorescent	  NIR	  probes	  have	  been	  designed	  to	  stain	  amyloid	  plaques.	  
	  
1.4.2.	  NIR	  tracers	  imaging	  amyloid	  plaques	  in	  vivo	  
NIAD-­‐4	   is	  considered	  a	  milestone,	  as	   it	  was	  one	  of	   the	   first	  NIR	  probes	  used	  to	  
image	  Aβ	  plaques	   in	  vivo.76	  NIAD-­‐4	  presents	  the	  classical	  push-­‐pull	  architecture	  
in	   which	   a	   p-­‐hydroxyphenyl	   group	   (D)	   and	   a	   dicyanomethylene	   group	   (A)	   are	  
connected	  by	  a	  dithienylethenyl	  π-­‐conjugated	  bridge	  making	  the	  whole	  molecule	  
highly	   polarizable.	   Interestingly,	   this	   biomarker	   changes	   its	   fluorescent	  
properties	   upon	   binding	   to	   fibrils.	   Indeed,	   in	   the	   presence	   of	   synthetic	  
aggregated	   Aβ	   proteins,	   the	   dye	   showed	   a	   noteworthy	   red	   shift	   (absorption	  
above	  600	  nm)	  and	  the	  binding	  was	  accompanied	  by	  a	  strong	  enhancement	  (400	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fold)	   of	   the	   fluorescent	   intensity	   (Figure	   1.12).	   Furthermore,	   NIAD-­‐4	   showed	  
higha	  ffinity	  (Ki	  =	  580	  nM)	  to	  Aβ,	   thereby	   it	  was	  tested	   in	  vivo	   in	  transgenic	  AD	  
mice	  with	   a	   cranial	  window	   to	   allow	  direct	  monitoring	   of	   the	   brain	   surface	   by	  
multiphoton	  microscopy.	  The	  biomarker	  turned	  out	  to	  be	  able	  to	  cross	  the	  blood	  
brain	  barrier	  (BBB)	  after	  intravenous	  injection	  and	  bound	  with	  high	  specificity	  to	  
Aβ	  plaques	  in	  the	  living	  brain,	  allowing	  their	  easy	  detection	  due	  to	  its	  intense	  red	  
fluorescence,	  even	  if	  the	  method	  used	  was	  invasive.	  
	  
Figure	  1.12.	  NIAD-­‐4	  features	  a	  push-­‐pull	  architecture.	  A	  strong	  enhancement	  of	  the	  
fluorescent	  signal	  is	  observed	  when	  it	  binds	  the	  Aβ	  fibrillar	  aggregates.	  
In	   an	  effort	   to	  overcome	   this	   limit,	   other	  NIR	   tracers	  were	  generated	  with	  
improved	  optical	  properties.	  For	  example,	  AOI-­‐987	  (see	  its	  chemical	  structure	  in	  
Figure	   1.13)	   allowed	   the	   visualization	   of	   Aβ	   plaques	   in	   vivo	   in	   a	   non-­‐invasive	  
way.77	   AOI-­‐987	   is	   an	   oxazine	   dye	   characterized	   by	   its	   relatively	   low	  molecular	  
weight	   (427	  Da)	   and	  high	   lipophilicity	   that	   enables	   the	   compound	   to	   cross	   the	  
BBB.	   Due	   to	   its	   conjugated	   structure,	   it	   showed	   good	   spectral	   properties	  with	  
both	  absorption	  and	  emission	  maximum	   in	   the	  NIR	   region,	  at	  650	  and	  670	  nm	  
respectively.	   Because	   its	   good	   spectroscopic	   characteristics	   and	   ability	   to	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specifically	  bind	  Aβ	  fibrils,	  AOI-­‐987	  was	  used	  to	  visualize	  amyloid	  plaques	  in	  living	  
APP23	  transgenic	  mice	  that	  overexpressed	  amyloidogenic	  deposits.	  Following	  i.v.	  
administration	  of	  AOI-­‐987	   into	  APP23	  mice,	  an	   intense	   fluorescence	   signal	  was	  
detected	   in	   the	  brain,	   significantly	  higher	   than	   that	  observed	   in	  wild	   type	  mice	  
validating	   the	   feasibility	   of	   specific	   plaque	   labeling	   in	   vivo	   (Figure	   1.13).	   It	   is	  
important	  to	  note	  that	  amyloid	  plaques	  were	  observed	  without	  the	  need	  for	  any	  
cranial	  windows.	  	  
The	   NIR	   technique	   used	   to	   capture	   mice	   images	   is	   known	   as	   reflectance	  
fluorescence	   imaging	   (RFI),	   a	   system	   that	   has	   been	   shown	   to	   be	   particularly	  
suitable	  for	  fast	  imaging	  but	  has	  limited	  depth	  resolution	  beyond	  (3–5	  mm	  from	  
the	  surface)	  and	  is	  not	  quantitative.60	  Despite	  these	  limitations,	  AOI-­‐987	  was	  the	  
first	   successful	   NIR	   probe	   for	   non-­‐invasive	   in	   vivo	   detection	   of	   Aβ	   plaque	  
formation	   in	   AD	   animal	  models.	   Using	   a	  NIR	   device,	   it	  was	   demonstrated	   that	  
this	   compound	  was	  able	   to	  distinguish	   transgenic	  mice	   from	  wild	   type	  mice	  as	  
well	  as	  monitor	  disease	  progression.	  
 
Figure	  1.13.	  AOI-­‐987	  allowed	  the	  in	  vivo	  visualization	  of	  Aβ	  plaques	  in	  transgenic	  mice	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Another	   important	   achievement	   in	   this	   field	   was	   the	   generation	   of	   a	  
curcumin	   derivative	   named	   CRANAD-­‐2	   (Figure	   1.14).69 This	   compound	   was	  
prepared	  by	  introducing	  a	  difluoroboronate	  moiety	  into	  curcumin	  that	  provided	  
a	  favorable	  bathochromic	  shift	  of	  the	  absorption	  and	  emission	  wavelength.	  This	  
effect	   was	   further	   reinforced	   by	   replacing	   the	   phenolic	   hydroxyl	   groups	   of	  
curcumin	  with	  an	  N,N’-­‐dimethylamino	  group	  that	  is	  regarded	  as	  one	  of	  the	  best	  
groups	   for	   red-­‐shifting	   the	  absorption.	  As	  expected,	  both	  absorption	   (λex	  =	  640	  
nm)	  and	  emission	  (λem	  =	  805	  nm)	  maxima,	  measured	  in	  PBS,	  fell	  in	  the	  NIR	  region	  
(Figure	   1.14).	   Remarkably,	   the	   molecule	   “turned	   on”	   in	   presence	   of	   amyloid	  
fibrils	  showing	  a	  significant	  enhancement	  of	  its	  fluorescent	  intensity	  (70-­‐fold),	  a	  
 
Figure	   1.14.	   (A)	   Chemical	   structure	   and	   fluorescent	   properties	   of	   curcumin	   and	  
CRANAD-­‐2.	   It	   exhibited	   excitation	   and	   emission	   maximum	   in	   the	   ideal	   NIR	   spectral	  
region.	   (B)	   CRANAD-­‐2	   was	   used	   to	   stain	   brain	   sections	   from	   transgenic	   mice.	  
Amplification	  from	  left	  to	  right:	  2x,	  10x,	  40x.	  Reprinted	  (adapted)	  with	  permission	  from	  
Ran,	   C.;	   Xu,	   X.;	   Raymond,	   S.	   B.;	   Ferrara,	   B.	   J.;	   Neal,	   K.;	   Bacskai,	   B.	   J.;	   Medarova,	   Z.;	  
Moore,	   A.	   J.	   Am.	   Chem.	   Soc.	   2009,	   131,	   15257.	   Copyright	   (2009)	   American	   Chemical	  
Society.	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critical	  requirement	  for	  an	  ideal	  NIR	  tracer.	  On	  the	  other	  hand,	  its	  binding	  affinity	  
to	  Aβ aggregates	  was	  much	  higher	   than	   that	   of	  AOI-­‐987	   and	   similar	   to	   that	   of	  
NIAD-­‐4.	  Then,	  CRANAD-­‐2	  was	  finally	  investigated	  in	  vivo	  and	  it	  was	  injected	  into	  
transgenic	   mice	   that	   expressed	   significant	   concentration	   of	   Aβ fibrils.	   More	  
intense	   fluorescent	  signals	  were	  observed	   in	   these	  transgenic	  mice	  with	  regard	  
of	  those	  found	  in	  control	  mice.	  These	  data	  were	  confirmed	  by	  ex	  vivo	  staining	  of	  
transgenic	  mice	  brain	  slices	  (Figure	  1.14).	  	  Nevertheless,	  also	  in	  this	  case	  the	  NIR	  
imaging	   technique	   employed	   was	   fluorescence	   reflectance,	   which	   is	  
characterized	  by	  a	  low	  penetrating	  depth	  (<	  1	  cm)	  and	  a	  low	  resolution.	  
Another	   important	   breakthrough	   in	   the	   search	   for	   novel	  NIR	   tracers	   to	   be	  
used	   in	  vivo	  was	  achieved	  with	  the	  discovery	  of	  THK-­‐265.78	  This	  compound	  was	  
identified	  through	  a	  virtual	  screening	  of	  NIR	  candidates	  and	  has	  the	  advantage	  of	  
being	   commercially	   available.	   THK-­‐265	   (see	   its	   chemical	   structure	   in	   Figure	  
1.15A)	   is	   formed	   by	   two	   thiobarbituric	   acid	   units	   connected	   by	   a	  
pentadienylidene	  chain,	   forming	  an	  extended	  conjugated	  system	  after	  oxo-­‐enol	  
tautomerism	   at	   one	   of	   the	   lactam	   groups.	   It	   showed	   suitable	   spectroscopic	  
properties,	   with	   an	   emission	   maximum	   at	   λ >	   650	   nm	   and	   a	   high	   fluorescent	  
quantum	   yield	   (38.5%	   in	   methanol).	   Importantly,	   a	   fluorescent	   binding	   assay	  
revealed	   a	   strong	   affinity	   to	   Aβ	   aggregates,	   higher	   than	   that	   of	   ThT	   and	   AOI-­‐
1987,	  which	  was	  confirmed	  by	  a	  fluorescent	  staining	  on	  AD	  brain	  slices.	  Since	  the	  
dye	  THK-­‐265	  also	  exhibited	  a	  low	  toxicity	  and	  a	  good	  brain	  uptake,	  its	  capability	  
of	   visualizing	   Aβ	   plaques	   was	   explored	   in	   vivo.	   Thus,	   the	   compound	   was	  
intravenously	   injected	   into	   AβPP-­‐transgenic	   mice	   that	   overexpressed	   senile	  
plaques	   and	   the	   fluorescent	   signal	   intensity	   observed	   was	   significantly	   higher	  
than	  that	  detected	  in	  wild	  type	  mice.	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In	  the	  light	  of	  these	  findings,	  Schmidt	  et	  al.	  developed	  a	  systematic	  protocol	  
to	   image	   and	   quantify	   amyloid	   fibrils	   in	   transgenic	   mice	   at	   different	   disease	  
stages	   using	   THK-­‐265	   as	   NIR	   probe.79	   All	   the	   experiments	   were	   carried	   out	  
involving	  AβPP-­‐transgenic	  mice	  that	  started	  to	  show	  senile	  plaques	  after	  50	  days.	  
Considering	  that	  the	  number	  and	  size	  of	  the	  Aβ	  plaques	  increased	  with	  age,	  the	  
mice	   were	   scanned	   at	   different	   ages:	   50,	   75,	   100	   and	   older	   than	   200	   days	   in	  
order	   to	   monitor	   the	   amyloid	   accumulation.	   Importantly,	   in	   vivo	   results	  
confirmed	   a	   direct	   correlation	   between	   the	   enhancement	   of	   the	   fluorescence	  
intensity	  signal	  and	  the	  increasing	  age	  of	  the	  mice	  (Figure	  1.15B).	  As	  expected,	  ex	  
vivo	   experiments	   proved	   that	   fluorescent	   signal	   changes	   were	   due	   to	   the	  
different	  Aβ	  loads.	  Nevertheless,	  higher	  sensitivity	  is	  needed	  to	  real-­‐time	  	  
	  
	  
Figure	  1.15.	  (A)	  Chemical	  structure	  of	  THK-­‐265.	  (B)	  The	  fluorescence	  intensity	  signal	  of	  
THK-­‐265	  enhances	  with	  the	  increasing	  age	  of	  the	  mice.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
79 Schmidt	  A.;	  Pahnke,	  J.	  J.	  Alzh.	  Dis.	  2012,	  30,	  651.	  
	  
52	   	   1.	  Introduction	  
monitor	  cerebral	  amyloid	  deposits	  by	  using	  NIR	   imaging,	  even	   if	  THK-­‐265	  could	  
represent	  a	  possible	  candidate	  to	  track	  AD	  progression	  and	  evaluate	  the	  efficacy	  
of	  anti-­‐AD	  drug.	  
Although	  all	  the	  NIR	  tracers	  for	  Aβ	  imaging	  discussed	  so	  far	  are	  able	  to	  cross	  
the	  BBB	  and	  label	  selectively	  the	  amyloid	  plaques,	  they	  still	  show	  limitations	  that	  
need	  to	  be	  overcome.	  For	  example,	  NIAD-­‐4	  could	  not	  be	  detected	  in	  mice	  with	  
an	   intact	   cranium,	   AOI-­‐1987	   showed	   only	  moderate	   affinity	   for	   Aβ	   aggregates	  
and	  CRANAD-­‐2	  displayed	   a	   low	  washout	   from	   the	  brain.	   In	   an	   effort	   to	   design	  
improved	   NIR	   probes,	   Cui	   et	   al.	   developed	   a	   new	   series	   of	   fluorescent	   small	  
molecules	  for	  in	  vivo	  detection	  of	  amyloid	  plaques.80	  The	  authors	  used	  the	  push-­‐
pull	   architecture	   to	   generate	   new	   compounds	   that	   consisted	   of	   a	   donor	   and	  
acceptor	   connected	  by	  a	   conjugated	  π	   electron	   chain.	   The	  N,N’-­‐dimethylamino	  
group	  was	  selected	  as	  the	  electron	  donor	  because	  of	  its	  known	  ability	  to	  redshift	  
light	   absorption,	   and	   a	   dicyanomethylene	   group	   was	   chosen	   as	   acceptor.	   The	  
donor-­‐acceptor	   system	   was	   separated	   by	   a	   polymethine	   moiety	   that	   was	  
expected	  to	  further	  push	  both	  absorption	  and	  emission	  wavelength	  toward	  the	  
NIR	   spectral	   region.	   Compound	   DANIR	   showed	   a	   red-­‐shifted	   emission	  
wavelength	   at	   665	   nm	   (Figure	   1.16A).	   This	   biomarker	   was	   able	   to	   bind	   Aβ	  
plaques	  with	  great	  affinity,	  cross	  the	  BBB	  and	  could	  be	  quickly	  washed	  out	  from	  
the	   brain.	   Thus,	   following	   administration	   of	   DANIR	   to	   APPswe/PSEN1	   double	  
transgenic	  mice,	  the	  fluorescent	  signal	  detected	  was	  remarkably	  higher	  than	  that	  
for	   the	   wild-­‐type	   control.	   Importantly,	   this	   specific	   labelling	   was	   confirmed	   ex	  
vivo	  (Fig.	  1.16B).	  Taken	  in	  the	  aggregate,	  these	  results	  confirmed	  that	  compound	  
DANIR	  is	  close	  to	  meeting	  the	  requirements	  for	  an	  ideal	  NIR	  probe.	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Figure	   1.16.	   (A)	   Chemical	   structure	   and	   optical	   properties	   of	   DANIR.	   Due	   to	   its	  
favourable	   florescent	   features	   and	   high	   affinity	   to	   amyloid	   fibrils,	   DANIR	  was	   selected	  
for	   in	  vivo	  NIR	   imaging.	   (B)	  Fluorescence	  staining	  with	  DANIR	  of	  a	  brain	  section	  from	  a	  
transgenic	  mouse	  compared	  with	   that	   from	  a	  wild	   type	  one.	  Reprinted	   (adapted)	  with	  
permission	  from	  Cui,	  M.;	  Ono,	  M.;	  Watanabe,	  H.;	  Kimura,	  H.;	  Liu,	  B.	  and	  Saji,	  H.	  J.	  Am.	  
Chem.	  Soc.	  2014,	  136,	  3388.	  Copyright	  (2014)	  American	  Chemical	  Society.	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1.5.	   Privileged	   structures	   common	   to	   neurodegenerative	   and	  
protozoan	  disease	  drugss	  
From	   a	  medicinal	   chemistry	   point	   of	   view,	   a	   privileged	   structure	   consists	   in	   a	  
single	   molecular	   fragment	   that	   can	   provide	   ligands	   for	   different	   targets.81	  
Privileged	  structures	  have	  been	  widely	  used	  in	  drug	  discovery	  as	  they	  represent	  
an	  ideal	  source	  of	  scaffolds	  and	  capping	  fragments	  to	  be	  used	  for	  the	  design	  of	  
combinatorial	   libraries	   addressed	   to	   explore	   a	   broad	   spectrum	   of	  
pharmacological	  targets.	  In	  few	  words,	  the	  privileged	  structure	  is	  supposed	  to	  be	  
responsible	   for	   the	  affinity	   to	  a	   receptor,	  meanwhile	  structure	  modifications	  of	  
the	  whole	  molecule	  provide	  the	  selectivity.82	  	  
Antimalarial	   quinolines83	   are	   represented	   by	   the	   4-­‐aminoquinoline	  
derivatives	  amodiaquine,	  mefloquine	  and	  chloroquine	  and	  by	   the	  8-­‐substituted	  
quinolines	   primaquine,	   pamaquine	   and	   sitamaquine.84	   Interestingly,	   some	  
quinoline-­‐derived	  antimalarial	  drugs	  including	  chloroquine,	  mefloquine	  and	  2,2’-­‐
bis-­‐quinoline	   were	   found	   to	   be	   also	   active	   against	   prion	   replication.33	   In	   this	  
context,	  Klingenstein	  et	  al.	  reported	  a	  further	  4-­‐aminoquinoline	  compound	  that	  
exhibited	  concomitant	  inhibitory	  potency	  in	  scrapie	  infected	  cells	  and	  against	  P.	  
falciparum	   growth	   (Figure	   1.17).33b	   Similarity,	   the	   acridine	   motif	   has	   been	  
observed	   in	  many	  antiprion,	  antimalarial	  and	  antileishmanial	   ligands.85	  Acridine	  
quinacrine	  is	  one	  of	  the	  earliest	  antimalarial	  drug	  that	  was	  found	  to	  inhibit	  PrPSc	  
fibril	   formation.27	   Starting	   from	   this	   finding,	   many	   9-­‐aminoacridines	   were	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generated	  and	  evaluated	  in	  scrapie	  infected	  cells	  revealing	  nanomolar	  actvity.28	  
In	  particular,	  bis-­‐acridines	  exhibited	  very	  high	  potency	  against	  prion	   replication	  
as	   well	   as	   Leishmania,	   such	   as	   compound	   BiCappa	   (Figure	   1.17).24,31,86	   In	  
summary,	   it	   can	   be	   concluded	   that	   some	   molecular	   targets	   of	   antiprion	   and	  
antiprotozoal	   ligands,	   including	   the	   acidic	   organelles	   or	   endosomal/lysosomal	  
compartments	   and	   downstream	   molecular	   targets	   of	   lipid	   metabolism,	   could	  
overlap.25,33b	  
	  
Figure	  1.17.	  Quinoline	  and	  acridine	  cores	  are	  particularly	  recurrent	  in	  compounds	  active	  
against	  two	  different	  pathologies,	  neurodegenerative	  and	  protozoan	  diseases	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In	   the	   light	   of	   these	   considerations,	   acridine,	   quinoline	   and	   other	   kinds	   of	  
privileged	  structures	  represent	  a	  unique	  opportunity	  to	  improve	  the	  productivity	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In	  the	  context	  of	  our	  drug	  discovery	  project	  devoted	  to	  the	  identification	  of	  novel	  
scaffolds	   towards	   neurodegenerative	   diseases,	   the	   present	   thesis	   has	   the	  
following	  specific	  objectives:	  
1.	   We	   started	   our	   work	   with	   the	   development	   of	   synthetic	   methodology	  
required	   for	   some	  parts	  of	   the	  project.	  More	   specifically,	  we	  needed	  a	  general	  
and	   green	   protocol	   for	   the	   amination	   and	   (hetero)arylation	   of	   halogenated	  
nitrogen	   heterocycles.	   We	   focused	   in	   particular	   on	   quinoline	   and	   acridine	  
substrates,	  by	  exploiting	  focused	  microwave	  (MW)	  irradiation	  in	  order	  to	  provide	  
a	   rapid	   access	   to	   molecular	   frameworks	   of	   relevance	   in	   the	   field	   of	  
neurodegenerative	  diseases	  (Figure	  2.1).	  
 
Figure	  2.1.	  Generation	  of	  carbon-­‐carbon	  (C-­‐C)	  and	  carbon-­‐nitrogen	  (C-­‐N)	  bonds	  on	  
heterocyclic	  substrates	  
	  
2.	   Building	   on	   the	   bivalent	   approach,	   we	   planned	   to	   generate	   a	   chemical	  
library	   of	   bifunctional	   molecules,	   consisting	   of	   two	   prion	   recognition	   moieties	  
joined	   via	   an	   appropriate	   spacer.21	   In	   an	   effort	   to	   employ	   a	   spacer	   that	  might	  
have	   an	   active	   role	   in	   the	   molecular	   recognition	   process,	   we	   focused	   on	   2,5-­‐
diketopiperazine	  (DKP)	  due	  to	  its	  peptidic	  nature.	  Thus,	  a	  library	  was	  generated	  
by	   condensing	   DKP	  with	   aromatic	   aldehydes	   (structure	   I,	   Scheme	   2.1)	   bearing	  
side	  chains	  that	  have	  been	  shown	  to	  be	  critical	  for	  the	  molecular	  recognition	  and	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study	   the	   importance	   of	   an	   appropriate	   planar	   conformation,	   some	  
monoreduced	  (structure	  II,	  Scheme	  2.1)	  and	  a	  saturated	  derivative	  (structure	  III,	  
Scheme	  2.1)	  were	  also	  synthesized.	  
 
Scheme	  2.1.Chemical	  structure	  of	  planned	  DKP	  derivatives	  
	  
3. In	  our	  search	  for	  novel	  symmetrical	  small	  molecules	  to	  diagnose	  and	  treat	  
PrDs,	   we	   focused	   on	   GN8,	   an	   antiprion	   compound,	   which	   acts	   as	   a	   chemical	  
chaperone	  by	  binding	  PrPC.	  We	  modified	   the	  diphenylmethane	  core	  of	  GN8	  by	  
linking	   its	   two	   phenyl	   rings	   in	   order	   to	   generate	   a	   new	   class	   of	   carbazole	   and	  
fluorene	   derivatives	   (Scheme	   2.2).	   Furthermore,	   additional	  modifications	   were	  
carried	  out,	  such	  as	  the	  replacement	  of	  the	  pyrrolidine	  group	  on	  the	  side	  chains	  
with	  several	  secondary	  amino	  moieties	  (cyclic,	  acyclic	  and	  heterocyclic	  amines).	  
Such	  structural	  changes	  made	  the	  new	  compounds	  more	  planar	  and	  fluorescent,	  
offering	   the	  opportunity	   to	  use	   them	  as	   therapeutic	   tools	  and	  also	  as	  chemical	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Scheme	  2.2.	  Chemical	  modifications	  of	  GN8	  to	  generate	  new	  libraries	  of	  fluorene	  and	  
carbazole	  derivatives.	  
	  
4.	   In	  an	  effort	  to	   identify	  novel	  fluorescent	  compounds	  capable	  of	  marking	  
amyloid	   fibrils,	   and,	   ideally,	   of	   simultaneously	   blocking	   their	   aggregation,	   we	  
turned	   our	   attention	   on	   styryl	   heterocycles.	   They	   have	   been	   widely	   used	   for	  
amyloid	  staining,	  and	  some	  of	   them	  were	  also	   found	  to	  be	  active	  against	  prion	  
replication.	  Therefore,	  it	  seemed	  conceivable	  that	  the	  styryl	  moiety	  is	  critical	  to	  
recognize	  and	  interfere	  with	  the	  amyloidogenic	  processes.	  With	  this	  in	  mind,	  we	  
generated	   some	   styrylquinoline	   derivatives	   by	   linking	   the	   styryl	   moiety	   to	   a	  
quinoline	   nucleus,	   to	   detect,	   and	   potentially	   treat,	   fibrillar	   amyloidogenic	  
aggregates.	  The	  synthesis	  was	  achieved	  via	  a	  vinylogous	  variation	  of	  the	  Povarov	  
reaction	   to	   afford	   2-­‐styryl-­‐1,2,3,4-­‐tetrahydroquinolines	   followed	   by	   their	  
dehydrogenation	   or,	   alternatively,	   by	   microwave-­‐assisted	   aldol	   condensation	  
between	  substituted	  quinaldines	  and	  aromatic	  aldehydes	  (Scheme	  2.3).	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Scheme	  2.3.	  Synthetic	  approach	  to	  substituted	  styrylquinolines	  
	  
5.	   Several	  lines	  of	  evidence	  suggest	  that	  polyamines	  play	  a	  fundamental	  role	  
in	  many	  biological	  processes.	   Indeed,	  they	  are	   involved	   in	  cell	  proliferation	  and	  
have	   both	   pro-­‐	   and	   antiapoptotic	   effects	   and	   in	   many	   signaling	   pathways	  
through	   their	   effects	   on	   G	   proteins,	   protein	   kinases,	   nucleotide	   cyclases,	   and	  
receptors.87	   Interestingly,	   in	   the	   context	   of	   central	   nervous	   system	   (CNS)	  
diseases,	   it	  has	  been	  postulated	  that	  polyamines	  act	  as	  neuromodulators88	  and	  
influence	   the	   properties	   of	   several	   neurotransmitter	   pathways,	   including	  
catecholamines,	  γ-­‐aminobutyric	  acid,	  nitric	  oxide,	  and	  glutamate.89	  Furthermore,	  
polyamines	   that	   function	   as	   neuroprotectants,90	   and	   as	   antiprion	  
chemotherapeutics91	  have	  been	  described.	  
With	   these	   concepts	   in	   mind,	   we	   planned	   to	   introduce	   diverse	   types	   of	  
polyamino	  chains	  at	  C-­‐4	  position	  of	  the	  styrylquinoline	  moiety	  in	  order	  to	  provide	  
novel	   molecules	   to	   treat	   PrDs	   and	   AD.	   The	   preparation	   of	   these	   4-­‐
polyaminostyrylquinolines	  was	  planned	  via	  a	  seven-­‐step	  synthetic	  route	  involving	  
the	  amination	  of	  4-­‐chlorostyrylquinoline	  (Scheme	  2.4).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
87	   Melchiorre,	  C.;	  Bolognesi,	  M.	  L.;	  Minarini,	  A.;	  Rosini,	  M.;	  Tumiatti,	  V.	  J.	  Med.	  Chem.	  2010,	  53,	  
5906.	  
88	   Masuko,	  T.;	  Kusama-­‐Eguchi,	  K.;	  Sakata,	  K.	  et	  al.	  J.	  Neurochem.	  2003,	  84,	  610.	  
89	   Fiori,	  L.	  M.;	  Turecki,	  G.	  J.	  Psychiatry	  Neurosci.	  2008,	  33,	  102.	  
90	   Li,	  J.;	  Doyle,	  K.	  M.;	  Tatlisumak,	  T.	  Curr.	  Med.	  Chem.	  2007,	  14,	  1807.	  
91	   Supattapone,	  S.;	  Piro,	  J.	  R.;	  Rees,	  J.	  R.	  CNS	  Neurol.	  Disord.	  Drug	  Targets	  2009,	  8,	  323.	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Scheme	  2.4.	  Synthetic	  approach	  to	  4-­‐aminostyrylquinoline	  derivatives	  
	  
6.	   Based	   on	   the	   concept	   of	   privileged	   structure	   and	   on	   the	   parallelism	  
between	  neurodegenerative	  and	  protozoan	  diseases,	  we	  planned	  to	  screen	  our	  
4-­‐aminostrylquinoline	   derivatives	   against	   trypanosomatid	   diseases.	   Thus,	   their	  
anti-­‐leishmanial	   and	   antitrypanosomal	   activities	   were	   preliminary	   evaluated	   in	  
vitro,	  revealing	  good	  efficacies.	  
In	  the	  light	  of	  these	  results,	  we	  designed	  a	  further	  series	  of	  styrylquinolines	  
introducing	  different	  polyamino	  chains	  at	  the	  quinoline	  C-­‐8	  position,	   in	  analogy	  
to	  sitamaquine,	  a	  potent	  anti-­‐leishmanial	  agent.	  The	  plan	  for	  the	  preparation	  of	  
these	  8-­‐aminostyrylquinolines	  involved	  the	  alkylation	  of	  8-­‐aminostyrylquinoline,	  
which	  in	  turn	  would	  be	  obtained	  from	  8-­‐nitroquinaldine	  (Scheme	  2.5).	  	  
	  
Scheme	  2.5.	  Synthetic	  strategy	  for	  the	  preparation	  of	  8-­‐aminostyrylquinoline	  derivatives	  
 
7.	   In	   the	   course	   of	   the	   three-­‐month	   stay	   abroad	   that	   is	   part	   of	   the	  
requirements	   for	   the	   European	   Ph.	   D.	   Mention,	   we	   turned	   our	   attention	   to	  
nanomedicine	  as	  another	  entry	  to	  the	  field	  of	  theranostics.	  The	  work	  developed	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superparamagnetic	  iron	  oxide	  nanoparticles	  (SPIONs),	  which	  are	  good	  candidates	  
as	  theranostic	  agents.	  Due	  to	  their	  paramagnetic	  properties,	  these	  nanoparticles	  
are	   particularly	   suitable	   for	   diagnostic	   techniques	   such	   as	  magnetic	   resonance	  
imaging	  (MRI),	  acting	  as	  imaging	  tools	  complementary	  to	  optical	  probes,	  and	  at	  
the	  same	  time	  they	  can	  transport	  a	  drug	  with	  the	  aid	  of	  a	  targeting	  moiety.	  This	  
project	   involved	  an	  anticancer	  drug	  and	  the	  use	  of	  NDP-­‐MSH,	  a	  peptide	  able	  to	  
address	   the	   nanocarrier	   towards	   the	   melanocortin	   type-­‐1	   receptor	   (MC1R),	  
which	  is	  overexpressed	  in	  many	  melanoma	  cells	  at	  high	  levels	  (Figure	  2.2).	  	  
	  
	  
Figure	  2.2.	  SPIONs	  can	  be	  functionalized	  with	  a	  targeting	  moiety	  (NDP-­‐MSH),	  a	  drug	  and	  







3.	  Development	  of	  general	  methods	  for	  the	  
functionalization	  of	  π-­‐defficient	  heterocyclic	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3.1.	  Introduction	  
Nitrogen	  heterocycles	  constitute	  the	  central	  core	  of	  many	  drugs	  and	  are	  crucial	  
for	  the	  pharmaceutical	  and	  agrochemical	  industries.25,92	  Cross-­‐coupling	  reactions	  
able	   to	   generate	   carbon-­‐carbon	   (C-­‐C)	   and	   carbon-­‐nitrogen	   (C-­‐N)	   bonds	   on	   π-­‐
deficient	   heterocyclic	   substrates	   are	   of	   great	   importance	   in	   the	   synthesis	   of	   a	  
large	   variety	   of	   bioactive	   agents93	   such	   as	   the	   antimalarials	   chloroquine,	  
amodiaquine	   and	   quinacrine	   (see	   Chapter	   1).	   Other	   examples	   include	  
indolylquinolines,	   which	   are	   crucial	   in	   several	   biological	   processes	   and	   have	  
shown	   to	   possess	   antileishmanial	   and	   antibacterial	   activities94	   and	   amino	  
derivatives	  of	  the	  acridine	  and	  quinazoline	  nuclei	  with	  anticancer	  (amsacrine	  and	  
gefitinib)95,96	  and	  anti-­‐Alzheimer	  (bistacrine)	  activity.97	  Other	  related	  compounds	  
of	   considerable	   biomedical	   interest	   are	   the	   amino	   derivatives	   of	   quinoxaline,98	  
purine,99	   pyridine100	   and	   benzimidazole.101	   Some	   representative	   examples	   are	  
shown	  in	  Figure	  3.1.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
92	   Pozharskii,	  A.	  F.;	  Soldartenkov,	  A.	  T.;	  Katrizky,	  A.	  R.	  Heterocycles	  in	  Life	  and	  Society,	  2nd	  Ed.	  
John	   Wiley	   &	   Sons,	   Weinheim,	   Germany,	   2011;	   b)	   Pitt,	   W.	   R.;	   Parry,	   D.	   M.;Perry,	   B.	  
G.;Groom,	  C.	  R.	  J.	  Med.	  Chem.	  2009,	  52,	  2952.	  
93	   Tracy,	   J.	   W.;	   Webster	   Jr.,	   L.	   T.	   in	   Goodman	   and	   Gilman’sThe	   Pharmacological	   Basis	   of	  
Therapeutics	  (Eds.:	  J.	  G.	  Hardman,	  L.	  E.	  Limbird),	  McGraw	  Hill,	  New	  York,	  2001,	  1111.	  
94	   a)	   Ray,	   S.;	   Sadhukhan,	   P.;	   Mandal,	   N.;	   Mahato,	   S.;	   Majumder,	   H.	   Biochem.	   Biophys.	   Res.	  
Commun.	  1997,	  230,	  171;	  b)	  Chakrabarti,	  G.;	  Basu,	  A.;	  Manna,	  P.;	  Mahato,	  S.;	  Mandal,	  N.;	  
Bandyopadhyay,	  S.	  J.	  Antimicrob.	  Chemother.	  1999,	  43,	  359.	  
95	   a)	   Demeunynck,	   M.;	   Charmantray,	   F.;	   Martelli,	   A.	   Curr.	   Pharm.	   Design	   2001,	   7,	   1703;	   b)	  
Denny,	  W.	  A.	  Curr.	  Med.	  Chem.	  2002,	  9,	  1655.	  
96	   Marzaro,	  G.;	  Guiotto,	  A.;	  Chilin,	  A.	  Expert	  Opin.	  Ther.	  Patents	  2012,	  22,	  223.	  
97	   Tumiatti,	  V.;	  Minarini,	  A.;	  Bolognesi,	  M.	  L.;	  Milelli,	  A.;	  Rosini,	  M.;	  Melchiorre,	  C.	  Curr.	  Med.	  
Chem.	  2010,	  17,	  1825.	  
98	   For	  a	  review,	  see:	  González,	  M.;	  Cerecetto,	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Figure	  3.1.	  Examples	  of	  pharmacologically	  relevant	  compounds	  arising	  from	  the	  
generation	  of	  C-­‐C	  or	  C-­‐N	  bonds	  on	  a	  π-­‐deficient	  heterocyclic	  substrate	  
	  
As	   highlighted	   in	   the	   Introduction,	   6-­‐chloro-­‐2-­‐methoxyacridine	   and	   7-­‐
chloroquinoline	  are	  well-­‐known	  prion	  recognition	  motifs	  as	  their	  derivatives	  have	  
been	   shown	   to	   inhibit	   PrPSc	   formation	   in	   infected	   cells	   and	   to	   bind	   PrP.25	  
Furthermore,	  the	  quinazoline	  fragment	  is	  also	  present	  in	  many	  compounds	  that	  
have	   been	   evaluated	   against	   prion	   replication.102	   Therefore,	   we	   deemed	  
reasonable	   that	   the	   functionalization	   of	   such	   nitrogen	   heterocycles	   could	  
represent	  a	  valid	  strategy	  in	  our	  search	  for	  novel	  anti-­‐prion	  agents.	  
Transition	   metal-­‐catalyzed	   cross-­‐coupling	   has	   been	   the	   most	   widely	  
employed	  method	  for	  the	  generation	  of	  both	  C-­‐N	  and	  C-­‐C	  bonds	  on	  heterocyclic	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substrates.	   However,	   Buchwald-­‐Hartwig,	   Suzuki-­‐Miyaura	   and	   related	   reactions	  
require	   the	   use	   of	   expensive	   and	   cumbersome	   catalysts	   and	   phosphine	  
ligands.103	  In	  the	  particular	  case	  of	  C-­‐C	  bond	  formation,	  substantial	  efforts	  have	  
been	   made	   to	   achieve	   the	   coupling	   between	   heteroarenes	   and	   aza-­‐aromatic	  
compounds,	  and	  several	  methods	  have	  been	  described	  that	  include:	  (1)	  the	  use	  
of	  organolithium	  or	  organomagnesium	  reagents,	  which	  are	  problematic	  owing	  to	  
their	  pyrophoric	  nature	  and	  the	  need	  for	  low	  temperatures	  in	  many	  cases;104	  (2)	  
the	   multistep	   construction	   of	   the	   chemical	   moiety	   to	   be	   attached	   to	   the	  
heterocycle;105	   (3)	   the	   use	   of	   more	   contrived	   protocols	   requiring	   specialized	  
equipment	   such	   as	   photochemical106	   and	   electrochemical107	   reactions.	  
Unfortunately,	   these	   methods	   are	   far	   from	   being	   general	   and	   are	   only	  
appropriate	  for	  the	  preparation	  of	  specific	  compounds.	  	  
Another	   approach	   involves	   addition-­‐elimination	   reactions	   between	   a	  
halogenated	  nitrogen	  heterocycle	  and	  heteroarenes	   in	   the	  presence	  at	   least	  of	  
one	  equivalent	  of	  the	  corrosive	  and	  irritating	  AlCl3	  in	  dichloroethane.	  Also	  in	  this	  
case	  such	  protocol	  is	  not	  general	  because	  it	  works	  only	  if	  the	  carbon	  bearing	  the	  
halogen	  is	  strongly	  activated	  by	  electron-­‐withdrawing	  substituents,	  as	  in	  the	  case	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
103	   a)	  Payack,	  J.;	  Vázquez,	  E.;	  Matty,	  L.;	  Kress,	  M.;	  McNamara,	  J.	  J.	  Org.	  Chem.	  2005,	  70,	  175;	  b)	  
Nishida,	  A.;	  Miyashita,	  N.;	  Fuwa,	  M.;	  Nakagawa,	  M.	  Heterocycles,	  2003,	  59,	  473;	  c)	  Iglesias,	  
M.	  J.;	  Prieto,	  A.;	  Nicasio,	  M.	  C.	  Adv.	  Synth.	  Catal.	  2010,	  352,	  1949;	  d)	  Chen,	  L.;	  Yu,	  G.	  A.;	  Li,	  
F.;	  Zhu,	  X.;	  Zhang,	  B.;	  Guo,	  R.;	  Li,	  X.;	  Yang,	  Q.;	  Jin,	  S.;	  Liu,	  C.;	  Liu,	  S.	  H.	  J.	  Organomet.	  Chem.	  
2010,	  695,	  1768;	  e)	  Seregin,	  V.	  I.;	  Gevorgyan,	  V.	  Chem.	  Soc.	  Rev.	  2007,	  36,	  1173;	  f)	  Wagaw,	  
S.;	  Buchwald,	  S.	  L.	  J.	  Org.	  Chem.	  1996,	  61,	  7240.	  
104	   a)	  Yamaguchi,	  M.;	  Kamei,	  K.;	  Koga,	  T.;	  Akima,	  M.;	  Maruyama,	  A.;	  Kuroki,	  T.;	  Ohi,	  N.	  J.	  Med.	  
Chem.	  1993,	  36,	  4052;	  b)	  Luth,	  A.;	  Lowe,	  W.	  Eur.	  J.	  Med.	  Chem.	  2008,	  43,	  1478.	  
105	   a)	  Kuethe,	  J.;	  Wong,	  A.;	  Davies,	  I.	  Org.	  Lett.	  2003,	  5,	  3975;	  b)	  Zhu,	  S.;	  Ji,	  S.;	  Zhao,	  K.;	  Liu,	  Y.	  
Tetrahedron	   Lett.	  2008,	  49,	   2578;	   c)	   Lian,	  M.;	   Li,	   Q.;	   Zhu,	   Y.;	   Yin,	   G.;	  Wu,	   A.	  Tetrahedron	  
2012,	  68,	  9598;	  d)	  Kamila,	  S.;	  Ankati,	  H.;	  Biehl,	  E.	  R.	  Arkivoc,	  2011,	  9,	  94.	  
106	   Ohkura,	  K.;	  Seki,	  K.;	  Terashima,	  M.;	  Kanaoka,	  Y.	  Heterocycles	  1990,	  30,	  957.	  
107	   Chahma,	  M.;	  Combellas,	  C.;	  Thiébault,	  A.	  Synthesis	  1994,	  366.	  
70	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.	  Functionalization	  of	  π-­‐defficient	  N	  heterocycles	  
of	   1,4-­‐dichlorophthalazine,	   2,4-­‐dichloroquinazoline	   and	   3-­‐nitro(cyano)-­‐2-­‐
chloropyridine.108	  
The	  addition-­‐elimination	  reaction	  between	  a	  halogenated	  heterocycle	  and	  an	  
amine	   is	   the	   most	   common	   approach	   for	   the	   generation	   of	   the	   C-­‐N	   bond.	   It	  
requires	  very	  harsh	  and	  unsafe	  conditions,	  such	  as	  heating	  at	  high	  temperatures	  
in	  sealed	  tubes109	  or	  using	   large	  amounts	  of	  phenol	  as	   the	  reaction	  medium.110	  
Also	   importantly	   from	   the	  point	  of	   view	  of	  waste	  generation,	   the	   conventional	  
conditions	   often	   involve	   the	   use	   of	   a	   large	   excess	   of	   toxic	   reagents,	   such	   as	  
amines,24	  or	  necessitate	  the	  use	  of	  extraction	  and	  chromatographic	  purification	  
steps	   that	   involve	   the	   generation	   of	   waste	   from	   organic	   solvents	   and	  
chromatographic	  stationary	  phases.111	  
In	   an	   effort	   to	   develop	   a	   general	   and	   green	   protocol	   useful	   for	   both	   the	  
amination	  and	  (hetero)arylation	  of	  nitrogen	  heterocycles,	  we	  explored	  the	  use	  of	  
different	   catalysts,	   phenol	   and	   InCl3,	   carrying	   out	   the	   reactions	   under	   focused	  
microwave	  (MW)	  irradiation	  that	  is	  able	  to	  heat	  the	  reactants	  without	  the	  need	  
to	  heat	   the	  entire	   furnace	  or	  oil	  bath,	   leading	   to	  decreased	   reaction	   times	  and	  
energy	  savings.	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3.2	   Amination	   of	   π-­‐deficient	   nitrogen	   heterocycles	   under	   MW	  
irradiation	  in	  the	  presence	  of	  phenol	  	  
As	   mentioned	   in	   the	   Introduction,	   the	   acridine	   moiety	   constitutes	   the	   central	  
core	   of	   many	   antiprion	   and	   antiprotozoan	   compounds	   (see	   Chapter	   1.2).28,30	  
Thus,	  we	  started	  our	  study	  with	  the	  amination	  of	  acridine	  derivatives,	  and	  to	  this	  
end	  we	  examined	  the	  reactions	  between	  a	  variety	  of	  amines	  and	  6,9-­‐dichloro-­‐2-­‐
methoxyacridine.	  In	  an	  effort	  to	  find	  out	  a	  general	  and	  green	  method,	  we	  sought	  
conditions	  that	  avoided	  the	  use	  of	  solvents	  and	  excess	  of	  amine	  and	  that	  led	  to	  
crude	  materials	  that	  were	  sufficiently	  pure	  to	  allow	  isolation	  of	  the	  final	  products	  
without	   the	   need	   for	   extraction	   or	   chromatography.	   With	   this	   in	   mind,	   after	  
some	  experimentation	  we	   found	   that	   the	  desired	  amination	  could	  be	  achieved	  
very	   efficiently	   by	   irradiating	   equimolecular	   amounts	   of	   6,9-­‐dichloro-­‐2-­‐
methoxyacridine,	  the	  suitable	  amine	  in	  presence	  of	  2	  equiv.	  of	  phenol	  that	  acts	  
as	   the	   reaction	  medium	   and	   acid	   catalyst.	   The	   reaction	  was	   carried	   out	   under	  
focalized	  MW	  irradiation	  at	  150	  W	  and	  120	  °C	  for	  30-­‐45	  min	  achieving	  compound	  
1-­‐12	  (Scheme	  3.1	  and	  Table	  3.1).112	  A	  control	  experiment	  using	  ethylenediamine	  
under	   conventional	   conditions113	   (large	   excess	   of	   phenol,	   reflux	   overnight)	  
afforded	  only	  a	  small	  amount	  of	  the	  desired	  compound,	  the	  major	  product	  being	  
an	  acridin-­‐9-­‐one	  arising	  from	  the	  hydrolysis	  of	  the	  starting	  acridine.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
112	   Staderini,	  M.;	  Cabezas,	  N.;	  Bolognesi	  M.	  L.;	  Menéndez	  J.	  C.	  Tetrahedron	  2013,	  69,	  1024.	  
113	   a)	  de	  Souza,	  M.	  V.	  N.;	  Pais,	  K.	  C.;	  Kaiser,	  C.	  R.;	  Peralta,	  M.	  A.;	  de	  L.	  Ferreira,	  M.;	  Lourenço,	  M.	  
C.	  S.	  Bioorg.	  Med.	  Chem.	  2009,	  17,	  1474;	  b)	  Ressurreição,	  A.	  S.;	  Gonçalves,	  D.;	  Sitoe,	  A.	  R.;	  
Albuquerque,	  I.	  S.;	  Gut,	  J.;	  Góis,	  A.;	  Gonçalves,	  L.	  M.;	  Bronze,	  M.	  R.;	  Hanscheid,	  T.;	  Biagini,	  G.	  
A.;	  Rosenthal,	  P.	   J.;	  Prudêncio,	  M.;	  O’Neill,	  P.;	  Mota,	  M.	  M.;	   Lopes,	  F.;	  Moreira,	  R.	   J.	  Med.	  
Chem.	  2013,	  56,	  7679.	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Scheme	  3.1.	  General	  conditions	  for	  the	  amination	  of	  6,9-­‐dichloro-­‐2-­‐methoxyacridine	  
Phenol	  presumably	  acts	  by	  protonating	  the	  acridine	  nitrogen	  and	  thus	  increasing	  
the	   electrophilicity	   of	   the	   halogenated	   C-­‐9	   position	   and	   promoting	   the	   attack	  
from	   the	   nucleophile.	   The	   mechanism	   proposed	   for	   this	   transformation	   is	  
represented	  in	  Scheme	  3.2.	  
	  
Scheme	  3.2.	  Mechanism	  of	  action	  for	  the	  addition-­‐elimination	  reaction	  in	  presence	  of	  
phenol	  as	  acid	  catalyst.	  
This	   protocol	   worked	   equally	   well	   for	   aromatic	   (Table	   3.1,	   entries	   1-­‐5),	  
primary	   aliphatic	   (entries	   6,	   7),	   α-­‐branched	   primary	   aliphatic	   (entry	   8)	   and	  
secondary	  aliphatic	  (entry	  9)	  amines.	  A	  four-­‐fold	  excess	  of	  ethylenediamine	  was	  
needed	  in	  order	  to	  avoid	  products	  arising	  from	  double	  amination	  (entry	  10),	  but	  
it	  is	  noteworthy	  that	  similar	  reactions	  carried	  out	  under	  conventional	  conditions	  
typically	  require	  an	  excess	  of	  up	  to	  27	  equiv.	  of	  the	  diamine.24	  In	  the	  case	  of	  less	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reactive	  nitrogen	  nucleophiles,	  such	  as	  imidazole	  and	  benzimidazole,	  2	  equiv.	  of	  
the	  nucleophile	  were	  needed	  (entries	  11	  and	  12).	  Comparison	  of	  our	  results	   to	  
those	   obtained	   using	   conventional	   conditions	   revealed	   consistent	   increases	   (7-­‐
53%)	  in	  the	  product	  yields	  together	  with	  dramatic	  shortening	  of	  reaction	  times	  in	  
most	  cases.	  Most	  importantly,	  unlike	  the	  conventional	  method,	  compound	  	  
Table	  3.1.	  Scope	  and	  yields	  of	  the	  synthesis	  of	  9-­‐aminoacridines	  
	  
Entry	   Cmpd.	   R1	   R2	  
MW-­‐assisted	  conditions	  








	   Eqs.	  of	  
amine	  
Time	   Yield	  
%	  
Ref.	  





88	   102	  
2	   2	   4-­‐MeO-­‐C6H4	   H	   1	   30	   90	  
	  
1	   24	  h	   37	   102	  
3	   3	   4-­‐Me2N-­‐C6H4	   H	   1	   45	   94	  
	  
2	   24	  h	   70	   28a	  
4	   4	  
	  
H	   1	   45	   89	  
	  
2	   24	  h	   65	   28a	  
5	   5	  
	  
H	   1	   45	   85	  
	  
2	   24	  h	   69	   28a	  
6	   6	   n-­‐Hex	   H	   1	   30	   88	  
	  
40	   4	  h	   61	   114	  
7	   7	   C6H5-­‐CH2	   H	   1	   30	   98	  
	  
-­‐-­‐	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	  
8	   8	  
	  
H	   1	   45	   93	  
	  
1.1	   5	  h	   45	   28	  
9	   9	  
	  
1	   45	   96	  
	  
-­‐-­‐	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	  
10	   10	   H2N-­‐CH2-­‐CH2	   H	   4	   30	   82
a	  
	  
27	   5	  h	   38	   24	  
11	   11	   	   2	   30	   64	  
	  
-­‐-­‐	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	  
12	   12	  
	  
2	   30	   87	  
	  
-­‐-­‐	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	  
a	  Phenol	  was	  not	  necessary	  in	  this	  case.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
114	   Guetzoyan,	   L.;	   Yu,	   X.	  M.;	   Ramiandrasoa,	   F.;	   Pethe,	   S.;	   Rogier,	   C.;	   Pradines,	   B.;	   Cresteil,	   T.;	  
Fauvet,	  M.	  P.;	  Mahy,	  J.	  P.	  Bioorg.	  Med.	  Chem.	  2009,	  17,	  8032.	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purification	   required	   simple	   washing	   of	   the	   crude	   with	   water	   followed	   by	  
recrystallization,	  avoiding	  the	  use	  of	  volatile	  organic	  solvents.	  
As	  outlined	  in	  the	  Introduction,	  the	  bivalent	  strategy	  is	  a	  validated	  approach	  
to	  design	  chemical	  entities	  to	  combat	  PrDs.21	  Since	  bivalent	  compounds	  could	  be	  
accessible	  via	  the	  double	  amination	  of	  diamines,	  we	  also	  examined	  the	  possibility	  
of	   achieving	   this	   transformation	   under	   our	   conditions.	   Indeed,	   as	   shown	   in	  
Scheme	   3.3,	   we	   found	   that	   treatment	   of	   a	   1:2	  mixture	   of	   piperazine	   and	   6,9-­‐
dichloro-­‐2-­‐methoxyacridine	   under	   our	   usual	   conditions	   cleanly	   afforded	  
compound	  13	  in	  78%	  yield.	  
	  
	  
Scheme	  3.3.	  Double	  amination	  of	  a	  9-­‐chloroacridine	  
7-­‐Chloroquinoline	  derivatives	  are	  also	  effective	  against	  prion	  replication	  and	  
protozoan	   diseases.33	   Therefore,	   we	   studied	   the	   coupling	   of	   4,7-­‐
dichloroquinoline	   and	   amines	   by	   applying	   our	   protocol.	   As	   in	   the	   case	   of	   the	  
acridines,	   the	   reaction	   tolerated	  well	   the	   use	   of	   all	   structural	   types	   of	   amines	  
affording	   compounds	   14-­‐21	   (Scheme	   3.4	   and	   Table	   3.2).	   Again,	   the	   use	   of	  
diamines	  was	  possible	  (entries	  4	  and	  5)	  affording	  compounds	  17	  and	  18,	  which	  
have	   a	   functional	   group	   in	   their	   side	   chains	   that	   allows	   further	   structural	  
manipulation.	  As	  shown	  in	  Table	  3.2,	  our	  method	  required	  short	  reaction	  times	  
and	  the	  yields	  were	  again	  excellent,	  generally	  speaking,	  and	  greatly	  improved	  the	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results	   obtained	   under	   conventional	   conditions.	   Some	   of	   these	   reactions	   had	  
been	   previously	   carried	   out	   under	   focused	   MW	   irradiation,	   albeit	   in	   different	  
conditions	  involving	  the	  use	  of	  DMSO	  as	  solvent,	  and	  in	  slightly	  lower	  yields.111	  
	  
Scheme	  3.4.	  Amination	  of	  4-­‐chloroquinolines	  
Table	  3.2.	  Scope	  and	  yields	  in	  the	  synthesis	  of	  4-­‐aminoquinolines	  
	  
Entry	  Cmpd.	   R1	   R2	  














1	   14	   4-­‐MeO-­‐C6H4	   H	   1	   30	   98	   	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	  
2	   15	  
	  
H	   1	   45	   94a	   	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	  
3	   16	   C6H5-­‐CH2	   H	   1	   30	   91	   	   2.1	   10	  h	   80	   115	  
4	   17	   H2N-­‐CH2-­‐CH2	   H	   4	   30	   90
a	   	   5	   7	  h	   75	   115	  
5	   18	   H3C-­‐HN-­‐CH2-­‐CH2	   CH3	   4	   30	   87	   	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	  
6	   19	  
	  
1	   45	   85a	   	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	  
7	   20	  
	  
1	   45	   89	   	   “excess”	   4	  h	   80	   116	  
8	   21	  
	  
2	   30	   85	   	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	  
aThese	   compounds	   have	   also	   been	   prepared	   under	   microwave-­‐assisted	   conditions,	   in	   DMSO	   solution,	   in	  
yields	  of	  85%	  (15),	  94%	  (17),	  and	  80%	  (19).111	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
115	   Rojas	  Ruiz,	  F.	  A.;	  García-­‐Sánchez,	  R.	  N.;	  Estupiñán,	  S.	  V.;	  Gómez-­‐Barrio,	  A.;	  Torres	  Amado,	  D.	  
F.;	   Pérez-­‐Solórzano,	   B.	  M.;	   Nogal-­‐Ruiz,	   J.	   J.;	  Martínez-­‐Fernández,	   A.	   R.;	   Kouznetsov,	   V.	   V.	  
Bioorg.	  Med.	  Chem.	  2011,	  19,	  4562.	  
116	   Warhurst,	  D.	  C.;	  Craig,	  J.	  C.;	  Adagu,	  I.	  S.;	  Guy,	  R.	  K.;	  Madrid,	  P.	  B.;	  Fivelman,	  Q.	  L.	  Biochem.	  
Pharmacol.	  2007,	  73,	  1910.	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Because	  some	  4-­‐aminoquinazoline	  compounds	  have	  also	  been	  found	  active	  
against	  prion	  amplification	  in	  a	  cell-­‐based	  model,102	  we	  also	  examined	  briefly	  the	  
amination	   reactions	   starting	   from	   4-­‐chloro-­‐2-­‐phenylquinazoline,	   which	  
proceeded	   uneventfully	   under	   the	   previously	   established	   protocol	   to	   provide	  
compounds	   22-­‐26	   (Scheme	   3.5	   and	   Table	   3.3).	   It	   is	   noteworthy	   that	   typical	  
conventional	  conditions	  for	  similar	  transformations	  involve	  reflux	  in	  1,4-­‐dioxane	  
for	  24	  h	  in	  the	  presence	  of	  17	  equiv.	  of	  amine.117	  Besides	  the	  drastically	  shorter	  
reaction	  time,	  an	  improvement	  of	  up	  to	  38%	  in	  the	  yields	  was	  again	  observed.	  
	  
Scheme	  3.5.	  Amination	  of	  4-­‐chloro-­‐2-­‐phenylquinazoline	  
Table	  3.3.Scope	  and	  yields	  in	  the	  synthesis	  of4-­‐chloro-­‐2-­‐phenylquinazoline	  
	  
Entry	   Cmpd.	   R1	   R2	  














1	   22	   4-­‐Cl-­‐C6H4	   H	   1	   30	   98	   	   2	   18	  h	   50	   117	  
2	   23	   C6H5-­‐CH2	   H	   1	   30	   94	   	   17	   24	  h	   84	   117	  
3	   24	   (H3C)2N-­‐CH2-­‐CH2	   H	   1	   30	   91	   	   2	   18	  h	   83	   102	  
4	   25	  
	  
1	   45	   90	   	   17	   24	  h	   88	   117	  
5	   26	   	   2	   30	   87	   	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	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   Nguyen,	  L.	  T.;	  Yang,	  S.	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  Khadka,	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  H.	  T.	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  Cho,	  S.	  H.;	  Kwon,	  Y.	  J.;	  Lee,	  E.	  S.;	  Lee,	  
K.	  T.;	  Cho,	  W.	  J.	  Bioorg.	  Med.	  Chem.	  2011,	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  4399.	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In	  order	   to	   confirm	   the	  versatility	  of	  our	  protocol,	  we	  decided	   to	   study	   its	  
application	   to	   the	   synthesis	   of	   two	   representative	   target	  molecules	   with	   well-­‐
established	  pharmacological	  activity.	  Thus,	  as	  shown	  in	  Scheme	  3.6,	  the	  reaction	  
between	   9-­‐chloroacridine	   and	   the	   commercially	   available	   N-­‐(4-­‐amino-­‐3-­‐
methoxy)methanesulfonamide	   under	   our	   standard	   conditions	   afforded	   a	   78%	  
yield	   of	   the	   topoisomerase	   II	   inhibitor	   amsacrine	   (27),	   a	   currently	   marketed	  
antileukemic	  drug.	  
	  
Scheme	  3.6.	  Synthesis	  of	  amsacrine	  
The	   synthesis	   of	   bis(7)-­‐tacrine	   using	   our	   methodology,	   providing	   a	   new	  
example	   of	   a	   double	   amination	   via	   a	   pseudo-­‐three-­‐component	   reaction,	   is	  
summarized	  in	  Scheme	  3.7.	  The	  starting	  9-­‐chloro-­‐1,2,3,4-­‐tetrahydroacridine	  was	  
prepared	  by	  a	  literature	  method,118	  refluxing	  anthranilic	  acid	  and	  cyclohexanone	  
in	   a	   large	   excess	   of	   POCl3.	   Afterwards,	   compound	  28	  was	   treated	  with	   half	   an	  
equivalent	  of	  1,7-­‐heptanediamine	  under	  our	  microwave	  conditions	  to	  give	  bis(7)-­‐
tacrine	   (29)	   in	   98%	   yield,	   which	   compares	   very	   favourably	   with	   the	   literature	  
yield	  for	  this	  reaction	  under	  conventional	  heating	  conditions	  (47%	  yield	  after	  2	  h	  
at	  180	  °C	  in	  a	  sealed	  tube	  containing	  phenol).110	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   Szymanski,	  P.;	  Karpiński,	  A.;	  Mikiciuk-­‐Olasik,	  E.	  Eur.	  J.	  Med.	  Chem.	  2011,	  46,	  3250.	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Scheme	  3.7.	  Synthesis	  of	  bistacrine	  
	  
Finally,	   we	   studied	   the	   application	   of	   our	   method	   to	   the	   generation	   of	  
carbon-­‐carbon	   bonds	   by	   treating	   4,7-­‐dichloroquinoline	   with	   indole.	   This	  
heterocycle	  acted	  as	  enamine-­‐like	  nucleophile	  and	  the	  reaction	  proceeded	  at	  the	  
C-­‐3	  position	  to	  provide	  compound	  30	  together	  with	  a	  side	  product	  derived	  from	  
4-­‐phenoxyquinoline	   in	   a	   3:1	   ratio.	  Unfortunately,	   in	   the	   case	   of	   a	   less	   reactive	  
nucleophile	   such	   as	   ethyl	   3-­‐aminocrotonate,	   the	   phenoxy	   derivative	   was	   the	  
main	  reaction	  product	  and	  the	  desired	  product	  31	  was	  obtained	  only	  in	  29%	  yield	  
(Scheme	  3.8). 
	  
Scheme	  3.8.	  Coupling	  reaction	  in	  the	  presence	  of	  phenol	  between	  4,7-­‐dichloroquinoline	  




















1:3 with respect to 30
2:1 with respect to 31
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3.3.	   Lewis	   acid–catalyzed	   generation	   of	   C-­‐C	   and	   C-­‐N	   bonds	   on	  
nitrogen	  heterocycles	  
In	  an	  effort	  to	  avoid	  the	  generation	  of	  the	  undesired	  phenoxy	  side	  product,	  we	  
planned	   to	   replace	   phenol	   by	   a	   non-­‐nucleophilic	   catalyst.	   Because	   of	   the	   near	  
absence	   of	   precedent	   for	   the	   use	   of	   Lewis	   acids	   for	   this	   purpose,	   we	   were	  
attracted	  to	  the	  study	  of	  this	  type	  of	  catalysts.	  
Due	   to	   the	   importance	  of	   the	  7-­‐chloroquinoline	  moiety	  as	  antiprion	  agent,	  
we	  focused	  again	  on	  this	  fragment.	  In	  our	  first	  experiments,	  several	  Lewis	  acids,	  
including	   CAN	   (cerium	   ammonium	   nitrate)	   and	   ytterbium	   (III)	   triflate,	   were	  
assayed	   unsuccessfully.	   Subsequent	   work	   gave	   positive	   results	   with	   indium	  
triflate,	  gallium	  trichloride,	  boron	  trifluoride	  etherate	  and	  indium	  chloride.	  After	  
discarding	   the	  highly	  hygroscopic	   In(OTf)3	  and	  GaCl3,	  we	  chose	   InCl3	   for	   further	  
experiments	   because	   this	   catalyst	   is	   inexpensive,	   relatively	   stable	   and	   gave	   a	  
slightly	  higher	  yield	  than	  BF3.Et2O	  (Table	  3.4).	  The	  best	  conditions	  were	  found	  to	  
involve	   the	   reaction	   between	   equimolecular	   amounts	   of	   4,7-­‐dichloroquinoline	  
and	  indole	  and	  10%	  mol	  of	  InCl3	  in	  acetonitrile	  under	  focused	  MW	  irradiation	  at	  
150	  W	  and	  120	  °C	  for	  2	  h	  to	  furnish	  30	  as	  the	  only	  product	  in	  89%	  yield	  (Scheme	  
3.11	  and	  Figure	  3.2).119	   Since	  we	  did	  not	  employ	   rigorously	  dried	   solvents,	   it	   is	  
likely	   that	   the	   catalyst	   experiences	   some	   hydrolysis	   under	   the	   reaction	  
conditions.	  We	  therefore	  examined	  the	  catalytic	  effect	  of	  In(OH)3	  and	  In2O3,	  the	  
likely	   hydrolysis	   products,	   but	   found	   them	   to	   be	   inactive	   (Table	   3.4).	   This	  
protocol	  worked	  equally	  well	  for	  other	  nucleophilic	  heterocycles	  such	  as	  pyrrole	  
(32)	   and	   4-­‐hydroxycoumarin	   (33),	   for	   which	   only	   one	   hour	   was	   needed	   after	  
increasing	   the	   temperature	   to	   140	   °C.	   In	   the	   case	   of	   2-­‐methylfuran	   (34),	   the	  
reaction	  was	  carried	  during	  3	  h	  in	  dichloromethane	  (Figure	  3.2).	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Table	  3.4.	  Catalyst	  optimizationa	  
Catalyst	  (10	  mol%)	   Yield,	  %	  
CAN	   0	  
Yb(OTf)3	   0	  
In(OTf)3	   83	  
GaCl3	   84	  
BF3.Et2O	   82	  
InCl3	   89	  
In2O	   0	  
In(OH)3	   0	  
aReaction	   conditions:	   acetonitrile,	   MW,	   150	   W,	  
120	  °C,	  180	  psi,	  2	  h	  
	  
Figure	  3.2.	  C-­‐C	  bond	  forming	  reactions	  with	  heterocycles	  at	  the	  quinoline	  C-­‐4	  position	  
In	   view	  of	   the	   synthetic	   importance	  of	  β-­‐enaminones	  and	   the	  poor	   results	  
obtained	  in	  the	  preparation	  of	  compound	  31	  with	  the	  phenol-­‐promoted	  method,	  
we	   attempted	   the	   application	   of	   the	   new	   conditions	   to	   this	   case,	   achieving	   a	  
good	  75%	  yield.	  In	  order	  to	  examine	  the	  generality	  of	  this	  protocol,	  we	  prepared	  
a	  series	  of	  β-­‐enamino	  esters	  via	  the	  CAN-­‐catalyzed	  reaction	  between	  the	  suitable	  
primary	   amine	   and	   ethyl	   acetoacetate	   (Scheme	   3.9	   and	   Table	   3.5),120	  whereas	  
pyrrolidine,	   a	   secondary	   amine,	   was	   treated	   with	   ethyl	   acetoacetate	   in	   the	  
absence	  of	  catalyst	  and	  solvent.121	  We	  noted	  that	  the	  primary	  amines	  lead	  to	  the	  
formation	  of	   the	  desired	  product	  exclusively	  as	  Z-­‐isomers,	  presumably	  because	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
120	   Sridharan,	  V.;	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  2007,	  6,	  881.	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   Vohra,	  R.	  K.;	  Renaud,	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  5,	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30 (2 h, 89%)
NCl
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32 (2 h, 90%)
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34 (3 h, CH2Cl2, 82%)
H3C
3.	  Functionalization	  of	  π-­‐defficient	  N	  heterocycles	   	   81	   	   	  
of	   the	   hydrogen	   bonding	   interaction	   between	   the	   amino	   and	   carbonyl	   groups,	  
whereas	   in	   the	   case	   of	   a	   secondary	   amine	   only	   the	   E-­‐isomer	   was	   isolated	  
(compound	  40).	  	  
 
Scheme	  3.9.	  General	  procedure	  for	  the	  synthesis	  of	  β-­‐enamino	  esters	  	  
Table	  3.5.	  Scope	  and	  yields	  of	  the	  synthesis	  of	  β-­‐enamino	  esters	  
from	  primary	  amines	  
Entry	   Cmpd.	   R	   Yield,	  %	  
1	   35	   CH3	   71	  
2	   36	   n-­‐But	   77	  
3	   37	   sec-­‐But	   82	  
4	   38	  
	  
85	  
5	   39	   C6H5-­‐CH2	   81	  
	  
The	   Z-­‐β-­‐enaminones	   35-­‐39	   reacted	   with	   quinoline	   to	   give	   the	   novel	  
vinylation	   products	   41-­‐45	   (Figure	   3.3),	   which	   are	   of	   interest	   in	   view	   of	   the	  
important	  role	  of	  β-­‐enaminones	  as	  starting	  materials	  for	  synthesis.122	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Figure	  3.3.	  C-­‐C	  bond	  forming	  reactions	  with	  β-­‐enaminones	  at	  the	  quinoline	  C-­‐4	  position	  
To	  the	  contrary,	  the	  attempted	  reaction	  between	  4,7-­‐dichloroquinoline	  and	  
compound	   40	   as	   E-­‐isomer	   failed,	   probably	   due	   to	   the	   steric	   hindrance	   of	   the	  
pyrrolidino	   group	   that	   hampers	   the	   nucleophilic	   attack	   to	   the	   heterocycle	  
(Scheme	  3.10).	  	  
 
Scheme	  3.10.	  An	  E-­‐β-­‐aminoester	  was	  not	  able	  to	  react	  with	  quinoline	  
Because	   the	   importance	  of	  β-­‐amino	  acids	  and	   their	   related	  esters	   for	   their	  
biological	  and	  pharmacological	  activities,123	  we	  studied	  the	  reduction	  of	  the	  C=C	  
double	   bond	   in	   compounds	   31	   and	   42.	   Unfortunately,	   all	   our	   attempts	   using	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sodium	   triacetoxyborohydride,124	   generated	   in	   situ	   from	   sodium	   borohydride	  
and	   acetic	   acid,	   LiAlH4	   and	  hydrogen	   in	   the	   presence	   of	   several	   catalysts	  were	  
unsuccessful.	  
For	  comparison	  purposes,	  we	  carried	  out	  a	  few	  of	  our	  reactions	  under	  reflux	  
conditions	  and	  also	  by	  heating	  in	  a	  sealed	  tube	  at	  120	  °C,	  which	  mimicked	  more	  
closely	   the	   temperature	   conditions	  existing	   in	   the	  microwave	  experiments.	  We	  
found	  dramatic	  differences	  in	  favor	  of	  the	  MW-­‐assisted	  protocol	  in	  terms	  of	  both	  
yields	  and	  decreased	  reaction	  times	  (Table	  3.6).	  
	  
Table	  3.6.	  Comparison	  between	  reflux,	  heating	  in	  a	  sealed	  tube	  and	  microwave	  
heating	  in	  the	  C-­‐C	  coupling	  reactions	  of	  4,7-­‐dichloroquinoline	  
Cmpd.	   Reflux	  
Sealed	  tube	  heating	  
(120	  °C)	  
MW	  
30	   -­‐-­‐-­‐	   15	  h,	  69%	   2	  h,	  89%	  
31	   3	  d,	  45%	   24	  h,	  25%	   3	  h,	  82%	  
32	   1	  d,	  50%	   15	  h,	  72%	   2	  h,	  90%	  
33	   1	  d,	  62%	   -­‐-­‐-­‐	   1	  h,	  84%a	  
44	   1	  d,	  27%	   15	  h,	  45%	   3	  h,	  87%	  
a	  This	  experiment	  was	  performed	  at	  140	  °C	  
	  
These	   encouraging	   results	   prompted	   us	   to	   extend	   the	   InCl3–catalyzed	  
method	   to	   other	   heterocyclic	   substrates,	   starting	   with	   6,9-­‐dichloro-­‐2-­‐
methoxyacridine.	   These	   new	   reactions	   showed	   a	   similar	   scope	   to	   the	   ones	  
starting	  from	  4,7-­‐dichloroquinoline,	  and	  afforded	  the	  target	  acridine	  derivatives	  
46-­‐50	  in	  excellent	  84-­‐93%	  isolated	  yields	  (Figure	  3.4).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
124	   Sridharan,	  V.;	  Menéndez,	  J.	  C.	  Org.	  Lett.	  2008,	  10,	  4303.	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Figure	  3.4.	  C-­‐C	  bond	  forming	  reactions	  at	  the	  acridine	  C-­‐9	  position.	  
Finally,	   we	   also	   investigated	   the	   formation	   of	   C-­‐C	   bonds	   at	   two	   other	  
pharmaceutically	   relevant	   heterocyclic	   substrates,	   such	   as	   quinazoline	   and	  
quinoxaline.98	   As	   shown	   in	   Figure	   3.5,	   the	   results	   obtained	   were	   again	  
satisfactory,	  and	   these	   reactions	  allowed	   the	  preparation	  of	   compounds	  51-­‐57.	  
2-­‐(3-­‐Indolyl)quinoxaline	  56	  had	  been	  previously	  obtained	  in	  47%	  overall	  yield	  via	  
a	  multistep	  sequence	  based	  on	  the	  construction	  of	  the	  quinoxaline	  ring	  from	  an	  
indole	  ketoaldehyde	  precursor,105d	  or	  in	  two	  steps	  and	  58%	  overall	  yield	  from	  3-­‐
acetylindole.105c	   Rather	   surprisingly,	   the	   reaction	   between	   4-­‐hydroxycoumarin	  
and	  2-­‐chloroquinoxaline	  afforded	  the	  O-­‐arylation	  product	  58,	  while	  its	  treatment	  
with	   ethyl	   3-­‐aminocrotonate	   generated	   a	   C-­‐C	   bond	   at	   the	   quinoxaline	   C-­‐3	  
position	  to	  give	  59,	  as	  expected.	  Some	  of	  the	  reactions	  (i.e.	  those	  leading	  to	  54,	  
58	   and	   59)	   gave	   comparatively	   low	   yields,	   which	   was	   due	   to	   the	   recovery	   of	  
unreacted	   starting	  material.	   These	   results	   could	  not	  be	   improved	  by	   increasing	  
the	  reaction	  times.	  The	  regioselective	  formation	  of	  compound	  59	   is	  noteworthy	  
in	   that	   it	   must	   involve	   an	   addition	   to	   the	   position	   α	   to	   the	   halogen	   atom,	  
followed	  by	  air	  oxidation	  of	  the	  initial	  adduct,	  instead	  of	  the	  usual	  addition	  to	  the	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position	   ipso	   to	   the	   halogen	   followed	   by	   elimination	   of	   hydrogen	   halide.	   This	  
behavior	  is	  relatively	  common	  in	  reactions	  involving	  hindered	  C-­‐nucleophiles	  and	  
ambivalent,	   monohalogenated	   electrophiles	   such	   as	   haloquinones,125	   and	   is	  
probably	  due	  to	  steric	  effects.	  	  
	  
Figure	  3.5.	  C-­‐C	  bond	  forming	  reactions	  at	  the	  quinazoline	  C-­‐4	  and	  quinoxaline	  C-­‐2	  
positions.	  
To	   summarize,	   our	   protocol	   allows	   the	   efficient	   CH	   functionalization	   of	  
several	   heterocycles	   and	   Z-­‐β-­‐enaminones	   and	   their	   coupling	   to	   a	   variety	   of	   p-­‐
deficient	   heterocyclic	   substrates.	   The	   isolated	   yields	   obtained	  were	   in	   the	   71–
96%	  range,	  and	  the	  method	  was	  more	  general	  and	  efficient	  than	  the	  previously	  
mentioned	   one	   based	   on	   the	   use	   of	   AlCl3108c	   in	   that	   only	   catalytic	   amounts	   of	  
InCl3	   were	   required	   and,	   furthermore,	   the	   activation	   of	   the	   substrate	   by	   the	  
introduction	  of	  strong	  electron-­‐withdrawing	  groups	  was	  not	  necessary	  (Scheme	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
125	   For	   representative	   examples,	   see:	   a)	   Alonso,	   M.	   A.;	   López-­‐Alvarado,	   P.;	   Avendaño,	   C.;	  
Menéndez,	  J.	  C.	  Tetrahedron	  2003,	  59,	  2821;	  b)	  Manzanaro,	  S.;	  Vicent,	  M.	  J.;	  Martín,	  M.	  J.;	  
Salvador-­‐Tormo,	  N.;	  Pérez,	  J.	  M.;	  Blanco,	  M.	  M.;	  Avendaño,C.;	  Menéndez,	  J.	  C.;	  de	  la	  Fuente,	  
J.	  A.	  Bioorg.	  Med.	  Chem.	  2004,	  12,	  6505.	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3.11).	   Unfortunately,	   the	   coupling	   reaction	   with	   heteroarenes	   or	   β-­‐enamino	  
esters	  failed	  in	  the	  cases	  of	  purine,	  benzimidazole	  and	  pyridine	  substrates.	  
	  
Scheme	  3.11.	  General	  scheme	  illustrating	  the	  formation	  of	  C-­‐C	  carbon	  bonds	  at	  π-­‐
deficient	  heterocyclic	  substrates	  	  
At	  this	  stage,	  we	  decided	  to	  study	  the	  extension	  of	  the	  new	  conditions	  to	  the	  
SNAr	   displacement	   of	   halogen	   atoms	   by	   amines	   in	   π-­‐deficient	   heterocyclic	  
substrates.	   While	   the	   previously	   developed	   phenol-­‐catalyzed	   conditions	  
overcame	   many	   drawbacks	   found	   using	   conventional	   procedures,	   only	   three	  
heterocyclic	  nuclei	  were	  explored,	  namely	  acridine,	  quinoline	  and	  quinazoline.	  In	  
addition,	   the	   toxicity	   and	   corrosive	   nature	   of	   phenol	   detracted	   from	   the	   user-­‐
friendliness	   and	   sustainability	   of	   the	   method.	   When	   tested	   on	   the	   4,7-­‐
dichloroquinoline	   substrate,	   InCl3	   catalysis	   turned	  out	   to	  be	  extremely	  efficient	  
for	  the	  reaction	  with	  aromatic,	  primary	  aliphatic	  and	  secondary	  aliphatic	  amines,	  
and	  was	  also	  useful	  for	  the	  N-­‐arylation	  of	  benzimidazole	  (Scheme	  3.12	  and	  Figure	  
3.6).	  Furthermore,	  compound	  isolation	  required	  simple	  filtration	  and	  no	  further	  
purification	   was	   needed,	   and	   hence	   the	   use	   of	   volatile	   organic	   solvents	   in	  
extraction	  and	  chromatographic	  purification	  steps	  was	  unnecessary.	  
MW	  irradiation	  was	  essential	  for	  success,	  as	  shown	  by	  the	  comparison	  of	  the	  
conditions	  required	  and	  the	  yields	  obtained	  for	  the	  synthesis	  of	  60	  and	  61	  under	  
reflux	   (Figure	   3.7).	   This	   new	   method	   was	   also	   compared	   with	   our	   previous	  
described	   protocol	   involving	   MW	   irradiation	   of	   the	   starting	   materials	   in	   the	  
presence	  of	  two	  equivalents	  of	  phenol.112	  Reaction	  times	  and	  yields	  were	  similar	  
but,	  since	  the	  new	  protocol	  avoided	  the	  use	  of	  the	  toxic	  and	  corrosive	  phenol,	  it	  
RH
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can	   be	   regarded	   as	   meeting	   more	   stringent	   green	   chemistry	   requirements.	  
Furthermore,	  for	  the	  first	  time	  a	  Lewis	  acid	  was	  shown	  to	  be	  an	  effective	  catalyst	  
for	  this	  type	  of	  amination	  reactions.	  
	  
Scheme	  3.12.	  C-­‐N	  coupling	  reactions	  of	  4,7-­‐dichloroquinoline	  
	  
Figure	  3.6.	  C-­‐N	  bond	  forming	  reactions	  at	  the	  quinoline	  C-­‐4	  position	  
The	  coupling	  of	  6,9-­‐dichloro-­‐2-­‐methoxyacridine	  with	  representative	  amines	  
was	   also	   carried	   out,	   affording	   compounds	  5-­‐7,	  9	   and	  11	   in	   excellent	   yields	   as	  
precipitates	  that,	  after	  filtration,	  did	  not	  require	  further	  purification	  (Figure	  3.7).	  
As	   in	   the	   case	   of	   quinoline,	   the	   reaction	   tolerated	   well	   the	   use	   of	   different	  
structural	   types	   of	   amines.	   Similar	   results	   were	   obtained	   for	   quinazoline	  
derivatives	  23-­‐25	  and	  62-­‐63	  (Figure	  3.7).	  A	  comparison	  with	  the	  results	  obtained	  
for	   these	   compounds	   employing	   our	   first-­‐generation	   method	   revealed	   similar	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yields,	   although	   the	   previously	   mentioned	   advantages	   associated	   to	   the	  
avoidance	  of	  phenol	  are	  noteworthy.	  A	  considerable	  improvement	  of	  the	  yield	  of	  
the	   imidazolyl	  derivative	  11	  was	  observed	  with	  regard	  to	  our	  previous	  method,	  
and	  comparison	  with	  the	  literature	  revealed	  our	  protocol	  to	  give	  improved	  yields	  
in	   the	  cases	  when	  a	  comparison	  was	  possible,126	  avoiding	   the	  use	  of	  phenol	  or	  
bulky	  phosphonium	  ligands.127	  
	  
Figure	  3.7.	  C-­‐N	  bond	  forming	  reactions	  at	  the	  acridine	  and	  quinazoline	  C-­‐9	  and	  C-­‐4	  
positions,	  respectively.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
126	   Xing,	  Z.	  Y.;	  Fu,	  Y.;	  Ye,	  F.	  J.	  Heterocycl.	  Chem.	  2012,	  49,	  1210.	  
127	   Wan,	  Z.	  K.;	  Wacharasindhu,	  S.;	  Levins,	  C.	  G.;Lin,	  M.;Tabei,	  K.;	  Mansour,	  T.	  S.	   J.	  Org.	  Chem.	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In	   order	   to	   confirm	   the	   generality	   of	   our	   new	   protocol,	   we	   examined	   the	  
reactivity	   towards	   amines	   of	   several	   additional	   halogenated	   nitrogen	  
heterocycles,	   namely	   2-­‐chloroquinoxaline,128	   4-­‐chloropurine,129	   2-­‐chloro-­‐
benzimidazole101b,130	   and	   2-­‐chloropyridine131	   and	   obtained	   excellent	   yields	   of	  
compounds	   64-­‐78,	   for	   which	   no	   general	   method	   of	   synthesis	   was	   available	  
(Figure	  3.8).	  	  
 
Figure	  3.8.	  C-­‐N	  bond	  forming	  reactions	  at	  the	  quinoxaline	  C-­‐2,	  purine	  C-­‐6,	  benzimidazole	  
C-­‐2	  and	  pyridine	  C-­‐2	  positions.	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  Med.	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  2011,	  19,	  939;	  b)	  Smits,	  R.	  A.;	  
Lim,	  H.	  D.;	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  Zuiderveld,	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  Guaita,	  E.;	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  M.;	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  R.;	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I.	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  2008,	  51,	  2457;	  c)	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  T.	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  Bulletin	  1989,	  37,	  618.	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  Cheng,	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  J.	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  Y.	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2007,	  63,	  5323;	  b)	  Qu,	  G.;	  Han,	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  Zhang,	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  Geng,	  M.;	  Xue,	  F.	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  Braz.	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  Soc.	  2006,	  17,	  
915;	   c)	   Adamska,	   E.;	   Barciszewski,	   J.;	   Markiewicz,	   W.	   T.	  Nucleosides,	   Nucleotides	   Nucleic	  
Acids,	  2012,	  31,	  861.	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   a)	   Yella,	   R.;	   Patel,	   B.	   K.	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   2010,	   12,	   754;	   b)	   Verma,	   S.	   K.;	   Acharya,	   B.	   N.;	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  M.	  P.	  Org.	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  2011,	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As	   a	   final	   refinement,	   we	   applied	   our	   method	   to	   the	   synthesis	   of	   several	  
representative	   drugs	   having	   both	   antimalarial	   and	   antiprion	   activities,132	  
including	  amodiaquine,	  chloroquine	  and	  quinacrine.	  Thus,	  the	  reaction	  under	  our	  
standard	   conditions	   between	   4,7-­‐dichloroquinoline	   and	   the	   commercially	  
available	   5-­‐diethylaminopentan-­‐2-­‐amine	   afforded	   chloroquine	   (79),	   while	   the	  
use	   of	   4-­‐amino-­‐2-­‐(diethylaminomethyl)-­‐o-­‐cresol	   furnished	   amodiaquine	   (80)	   in	  
73%	  and	   71%	   yields,	   respectively	   (Scheme	  3.13).	   Similarly,	   quinacrine	   (81)	  was	  
prepared	   in	   good	   yield	   (75%)	   by	   reaction	   between	   6,9-­‐dichloro-­‐2-­‐
methoxyacridine	  and	  5-­‐diethylaminopentan-­‐2-­‐amine	  (Scheme	  3.14).	  
	  
Scheme	  3.13	  Synthesis	  of	  chloroquine	  and	  amodiaquine.	  
	  
Scheme	  3.14.	  Synthesis	  of	  quinacrine	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The	  last	  proof	  of	  the	  versatility	  of	  our	  protocol	  came	  from	  an	  example	  of	  a	  
double	   amination,	   in	   which	   we	   carried	   out	   again	   the	   synthesis	   of	   the	   anti-­‐
Alzheimer	  drug	  bis(7)-­‐tacrine	  29.	  To	  this	  end,	  9-­‐chloro-­‐1,2,3,4-­‐tetrahydroacridine	  
28	  was	  treated	  with	  half	  an	  equivalent	  of	  1,7-­‐heptanediamine	  in	  the	  presence	  of	  
InCl3	  under	  our	  usual	  MW	  conditions	  to	  give	  the	  target	  compound	  in	  88%	  yield	  
(Scheme	  3.15).	  
	  
Scheme	  3.15.	  Synthesis	  of	  the	  anti-­‐Alzheimer	  drug	  bistacrine	  
	  
Besides	   using	   this	  methodology	   for	   other	   parts	   of	   our	  work,	   the	   library	   of	  
heterocycles	   described	   in	   this	   chapter	   is	   currently	   being	   studied	   by	   virtual	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4.1.	  Design	  rationale	  
As	   outlined	   in	   the	   Introduction,	   most	   of	   the	   anti-­‐prion	   compounds	   possess	   a	  
symmetrical	   bifunctional	   structure,	   consisting	   of	   two	   moieties	   joined	   via	   an	  
appropriate	   spacer.	   In	   general,	   for	   all	   these	   compounds	   the	   role	   of	   the	   spacer	  
has	   been	   demonstrated	   to	   be	   critical	   in	   the	   molecular	   recognition	   process.21	  
Therefore,	  in	  our	  search	  for	  novel	  bifunctional	  molecules,	  we	  initially	  focused	  on	  
a	  nucleus	  that	  could	  provide	  the	  ideal	  features	  to	  interact	  with	  protein	  surfaces	  
by	   behaving	   as	   a	   peptidomimetic.	   In	   this	   connection,	   the	   peptidic	   nature	   of	  
diketopiperazines	   (DPKs)	   and	   their	   occurrence	   in	   biologically	   active	   natural	  
products	   has	   inspired	   the	   use	   of	   DKP	   scaffolds	   as	   privileged	   structures.	  
Furthermore,	   DKPs	   are	   able	   to	   modulate	   PPIs,133	   are	   synthetically	   readily	  
accessible,134	  have	  neuroprotective	  activity,135	  can	  cross	  the	  blood	  brain	  barrier	  
(BBB)136	  and	  have	  been	  extensively	  explored	  in	  medicinal	  chemistry.137	  
Therefore,	   it	   seemed	   conceivable	   that	   DKPs	   carrying	   (Z)-­‐alkene	   units	   of	  
general	   structure	   I	   (Figure	  4.1)	   could	   serve	  as	   a	   template	   supporting	  a	  diverse	  
array	   of	   pharmacophores	   towards	   the	   identification	   of	   novel	   bifunctional	  
structures	  for	  prion	  diseases.	  Building	  on	  this	  concept,	  a	  compound	  library	  was	  
generated	  by	  appending	  several	  aromatic	  and	  heteroaromatic	  rings	  at	  C-­‐3	  and	  C-­‐
6	  of	  the	  3,6-­‐dimethylenepiperazine-­‐2,5-­‐dione	  scaffold	  (Figure	  4.1).138	  The	  role	  of	  
aromatic	  residues	  in	  molecular	  recognition	  and	  self-­‐assembly	  processes	  leading	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  Tanigaki,	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  Sasaki,	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  S.;	  Ohno,	  H.;	  Tamamura,	  H.;	  Wang,	  Z.;	  
Peiper,	  S.	  C;.	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  K.;	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  A.;Fujii,	  N.	  J.	  Org.	  Chem.	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  3942.	  
134	   Horton,	  D.	  A.;	  Bourne,	  G.	  T.;Smythe,	  M.	  L.	  J.	  Comput.	  Aided	  Mol.	  Des.	  2002,	  16,	  415.	  
135	   Faden,	  A.I.;	  Knoblach,	  S.M.;	  Movsesyan,	  V.A.;	  Cernak,	  I.	  J.	  Alzheimers	  Dis.	  2004,	  6,	  S93.	  
136	   Teixido,	  M.;	  Zurita,	  E.;	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  M.;	  Tárrago,	  T.;	  Giralt,	  E.	  J.	  Am.	  Chem.	  Soc.	  2007,	  129,	  
11802.	  
137	   O'Neill,	  J.	  C.;Blackwell,	  H.	  E.	  Comb.	  Chem.	  High	  Throughput	  Screen	  2007,	  10,	  857.	  
138	   Bolognesi,	  M.	  L.;	  Tran,	  H.	  N.	  A.;	  Staderini,	  M.;	  Monaco,	  A.;	  Lopez-­‐Cobeñas,	  A.;	  Bongarzone,	  
S.;	  Biarnes,	  X.;	  López-­‐Alvarado,	  P.;	  Cabezas,	  N.;	  Caramelli,	  M.;	  Carloni,	  P.;	  Menéndez,	   J.	  C.;	  
Legname,	  G.	  ChemMedChem	  2010,	  5,	  1324.	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to	   various	   fibrillar	   aggregates	   has	   been	   recognized	   as	   critical.	   Targeting	   these	  
aromatic	  residues	  has	  been	  consequently	  proposed	  as	  an	  important	  strategy	  to	  
inhibit	   amyloid	   formation.139	   The	   choice	   of	   pyridine140	   and	   quinoline141,34	   was	  
dictated	  by	  the	  fact	  that	  these	  nuclei	  are	  quite	  frequent	  in	  antiprion	  compounds.	  
Furan,	  thiophene	  and	  benzene	  derivatives	  were	  then	  also	  synthesized	  to	  enlarge	  
the	   library	   chemical	   diversity.	   Heteroaromatic	   β-­‐carboline	   derivatives	   were	  
purposely	  designed	  with	  the	  aim	  to	  obtain	  potential	   fluorescent	  probes,	  owing	  
to	  the	  excellent	  native	  fluorescence	  found	  in	  carboline	  systems142	  that	  has	  led	  to	  
their	  use	  as	  probes	   for	  biomolecules.143	  To	   study	   the	   importance,	   if	   any,	  of	  an	  
appropriate	   planar	   conformation,	   some	  monoreduced	   (structure	   II,	   Figure	   4.1)	  
and	  a	  saturated	  derivative	  (structure	  III,	  Figure	  4.1)	  were	  also	  synthesized.	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Figure	  4.1.	  Chemical	  structure	  of	  the	  DKPs	  described	  in	  this	  chapter	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4.2	  Library	  synthesis	  
The	   preparation	   of	   3,6-­‐bis(arylmethylene)-­‐2,5-­‐piperazinedione	   compounds	   was	  
achieved	   in	   a	   single	   step	   by	   using	   a	   pseudo-­‐three-­‐component	   reaction	   that	  
involves	   a	   double	   condensation	   of	   1,4-­‐diacetylpiperazine-­‐2,5-­‐dione	   with	   two	  
molecules	  of	  an	  aromatic	  aldehyde.	  Piperazine-­‐2,5-­‐dione	   is	   the	   result	  of	  a	   self-­‐
condensation	  of	  glycine	  and	  was	  available	  in	  the	  laboratory	  as	  glycine	  anhydride.	  
The	   first	   step	   of	   our	   route	   consisted	   of	   the	   acetylation	   of	   the	   piperazine-­‐2,5-­‐
dione	  nitrogen	  atoms	   in	  order	  to	  avoid	  the	   interference	  of	  their	  acidic	  protons.	  
Furthermore,	   nitrogen	   acetylation	   promotes	   the	   subsequent	   condensation	  
reaction	  by	  increasing	  the	  acidity	  of	  protons	  in	  α	  to	  carbonyl	  groups,	  due	  to	  the	  
electron-­‐withdrawing	   effect	   of	   the	   acetate	   group.	   For	   the	   preparation	   of	   the	  
starting	   compound,	   the	   commercial	   glicyne	   anhydride	   was	   refluxed	   in	   acetic	  
anhydride	  during	  three	  hours,	  affording	  compound	  82	  in	  97%	  yield	  (scheme	  4.1).	  
 
Scheme	  4.1.	  Synthesis	  of	  1,4-­‐diacetylpiperazine-­‐2,5-­‐dione	  
	  
For	   the	   double	   condensation	   reactions,	  we	   employed	   conditions	   based	   on	  
those	   described	   by	   Katritzky,144	   which	   involve	   treatment	   of	   1,4-­‐
diacetylpiperazine-­‐2,5-­‐dione	   (82)	  with	   two	  equivalents	  of	   the	   suitable	  aromatic	  
aldehydes	   in	   dimethylformamide	   as	   solvent,	   using	   two	   equivalents	   of	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
144	   Katritzky,	  A.	  R.;	  Fan,	  W.	  Q.;	  Szajda,	  M.;	  Li,	  Q.	  L.;	  Caster,	  K.	  C.	  J.	  Heterocycl.	  Chem.	  1988,	  25,	  
591.	  
4.	  Diketopiperazine	  based-­‐ligands	  of	  prion	  protein	   	   99	   	   	  
triethylamine	   as	   base.	   In	   our	   initial	   experiments	   involving	   pyridine-­‐2-­‐
carbaldehyde,	   pyridine-­‐3-­‐carbaldehyde	   and	   pyridine-­‐4-­‐carbaldehyde,	   the	  
reactions	   were	   carried	   out	   at	   room	   temperature	   and	   afforded	   the	   double	  
condensation	   products	   83-­‐85	   in	   acceptable	   or	   good	   yields.	   Similar	   conditions	  
were	   also	   applied	   to	   the	   case	   of	   quinoline-­‐4-­‐carbaldehyde,	   which	   furnished	  
compound	   86	   in	   84%	   yield.	   However,	   when	   the	   same	   room	   temperature	  
conditions	   were	   applied	   to	   quinoline-­‐2-­‐carbaldehyde	   and	   quinoline-­‐3-­‐
carbaldehyde,	   the	   only	   products	   that	   could	   be	   isolated,	   even	   after	   very	   long	  
reaction	   times	   (4	   days),	   were	   the	  monocondensation	   derivatives	  87	   and	  88.	   A	  
similar	   result	   was	   obtained	   for	   benzaldehyde,	   studied	   as	   a	  model	   case,	   which	  
gave	  compound	  89.	  The	  preparation	  of	  the	  double	  condensation	  products	  90,	  91	  
and	   92	   required	   the	   use	   of	   harsher	   reaction	   conditions	   (refluxing	   DMF,	   larger	  
excess	   of	   triethylamine,	   more	   concentrated	   solutions	   where	   Et3N/DMF	   =	   4:1	  
v/v).	   The	   lower	   reactivity	   generally	   observed	   for	   the	   quinoline	   aldehydes	  with	  
regard	   to	   their	  pyridine	  counterparts	   can	  be	  attributed	   to	  delocalization	  of	   the	  
electron-­‐withdrawing	  effect	  of	  the	  nitrogen	  atom	  throughout	  the	  more	  extended	  
aromatic	   system,	   while	   the	   different	   reactivity	   of	   the	   quinoline-­‐2-­‐	   and	   -­‐3-­‐
carbaldehydes	  can	  be	  attributed	  to	  the	  steric	  effect	  of	  the	  nitrogen	  lone	  pair	   in	  
the	   former	   case.	   These	  harsh	   conditions	  were	   also	   employed	   for	   the	   reactions	  
involving	   other	   aromatic	   aldehydes	   such	   as	   terephtaldeyde,	   furan-­‐2-­‐
carbaldehyde	  and	   thiophene-­‐2-­‐carbaldehyde,	   to	   furnish	  compounds	  93,	  94	   and	  
95	  in	  good	  yields	  (Scheme	  4.2).	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  based-­‐ligands	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Scheme	  4.2.	  Scope	  and	  yields	  of	  the	  syntheses	  of	  mono	  and	  double	  condensation	  
products	  
	  
The	   reaction	  mechanism	   for	   the	   double	   condensation	   reaction	   is	   complex	  
and	  involves	  anchimeric	  assistance	  from	  the	  N-­‐acetyl	  substituents,	  which	  are	  lost	  
in	   the	  course	  of	   the	  reaction.145	  Thus,	   the	   initial	  addition	  reaction	   involving	  the	  
active	   methylene	   and	   the	   aldehyde	   molecule	   is	   followed	   by	   intramolecular	  
transfer	  of	  the	  acyl	  group	  to	  the	  oxygen	  atom	  belonging	  initially	  to	  the	  aldehyde	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
145	   (a)	  Gallina,	  C.;	  Liberatori,	  A.	  Tetrahedron	  Lett,	  1973,	  14,	  1135.	   (b)	  Gallina,	  C.;	  Liberatori,	  A.	  
Tetrahedron,	  1974,	  30,	  667.	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4.	  Diketopiperazine	  based-­‐ligands	  of	  prion	  protein	   	   101	   	   	  
and	   a	   final	   elimination	   of	   acetate.	   These	   reactions	   lead	   exclusively	   to	   the	   Z	  
isomer,	   probably	   because	   the	   E	   compound	   is	   de-­‐stabilized	   by	   repulsive	  
interactions	   between	   the	   aryl	   substituents	   and	   the	   carbonyl	   groups.	   The	  
proposed	  mechanism	  is	  depicted	  in	  Scheme	  4.	  3.	  
	  
	  
Scheme	  4.3.	  The	  reaction	  mechanism	  for	  the	  double	  condensation	  reaction	  
	  
All	   the	   aromatic	   aldehydes	   employed	   so	   far	   were	   commercially	   available.	  
However,	   as	   previously	   mentioned,	   in	   order	   to	   obtain	   potential	   fluorescent	  
probes	  we	  designed	  heteroaromatic	  β-­‐carboline	  derivatives.	  The	  preparation	  of	  
the	   corresponding	   β-­‐carboline-­‐derived	   aldehydes	   was	   accomplished	   via	   the	  
Pictet-­‐Spengler	   reaction,146	   utilizing	   the	   appropriate	   3-­‐(aminoethyl)indole	   and	  
aldehyde	  derivatives.	  As	  shown	   in	  Scheme	  4.4,	  we	  prepared	  β-­‐carboline-­‐1-­‐	  and	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  4.	  Diketopiperazine	  based-­‐ligands	  of	  prion	  protein	  
3-­‐carbaldehyde	  on	  the	  basis	  of	  the	  method	  described	  by	  Snyder	  et	  al.,147	  starting	  
by	   the	   condensation	   between	   or	   tryptophan	   and	   formaldehyde	   or	   tryptamine	  
and	   glyoxylic	   acid,148	   to	   give	   compounds	   96	   and	   97,	   respectively.	   These	   acid	  
derivatives	  were	  subsequently	  transformed	  into	  the	  corresponding	  methyl	  esters	  
98	  and	  99	  by	  heating	  in	  methanolic	  hydrogen	  chloride	  solution.	  
	  
 
Scheme	  4.4.	  Synthesis	  of	  the	  β-­‐carboline-­‐derived	  methyl	  esters	  
As	  summarized	  in	  Scheme	  4.5,	  compound	  99	  was	  aromatized	  by	  exposure	  to	  
30%	   Pd/C	   in	   refluxing	   methanol	   for	   four	   days	   to	   afford	   101.	   In	   the	   case	   of	  
compound	   98,	   these	   conditions	   failed	   and	   we	   needed	   to	   resort	   to	   the	   use	   of	  
sulfur149	  to	  carry	  out	  its	  oxidation	  to	  100,	  suggesting	  that	  the	  different	  positions	  
of	  ester	  group	  decreases	  the	  reactivity	  of	  the	  ring.	  Finally,	  the	  desired	  aldehydes	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
147	   Snyder,	  H.	  R.;	  Walker,	  H.	  G.;	  Werber,	  F.	  X.	  J.	  Am.	  Chem.	  Soc.	  1949,	  71,	  527.	  
148	   Ho,	  B.	  T.;	  Walker,	  K.	  E.	  Org.	  Synth.	  1988,	  6	  ,965.	  
149	   Cain,	  M.;	  Weber,	  R.	  W.;	  Guzman,	  F.;	  Cook,	  J.	  M.;	  Barker,	  S.	  A.;	  Rice,	  K.	  C.;	  Crawley,	  J.	  N.;	  Paul	  
S.	  M.;Skolnick,	  P.	  J.	  Med.	  Chem.1983,	  25,	  1081.	  
4.	  Diketopiperazine	  based-­‐ligands	  of	  prion	  protein	   	   103	   	   	  
were	   obtained	   by	   careful	   reduction	   of	   the	   ester	   groups	   of	   100	   and	   101	   with	  
DIBALH	  to	  give	  102	  and	  103,	  respectively.150	  Condensation	  of	  these	  compounds	  
with	   1,4-­‐diacetylpiperazine-­‐2,5-­‐dione	   required	   rather	   harsh	   conditions	   that	  
involved	  heating	  of	  the	  starting	  materials	  with	  2.5	  equivalents	  of	  triethylamine	  in	  
refluxing	  DMF	  and	  afforded	  compounds	  104	  and	  105,	  respectively.	  
 
Scheme	  4.5.	  Synthesis	  of	  the	  β-­‐carboline-­‐derived	  aldehydes	  and	  the	  corresponding	  
double	  condensation	  products	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
150	   Suzuky,	   H.;	   Adachi,	   M.;	   Ebihara,	   Y.;	   Gyoutoku,	   H.;	   Furuya,	   H.;	   Murakami,	   Y.;Okuno,	   H.	  
Synthesis	  2005,	  1,	  28.	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In	   order	   to	   explore	   the	   importance	   of	   the	   planarity	   of	   our	   ligands,	   we	  
planned	   the	   reduction	   of	   one	   or	   both	   double	   bonds	   of	   the	   condensation	  
products.	  To	  this	  end,	  we	  treated	  compound	  83	  with	  Zn	  in	  refluxing	  acetic	  acid151	  
for	   1	   hour	   and	   obtained	   the	   partially	   reduced	   compound	   106	   in	   54%	   yield.	  
Catalytic	  hydrogenation	  of	  106	   in	   the	  presence	  of	  30%	  Pd-­‐C	  at	  30	  psi	   afforded	  
compound	   107,	   albeit	   in	   a	  moderate	   34%	   yield.	   This	   compound	   could	   also	   be	  
prepared	   in	  one	  step	  and	   in	  58%	  yield	  by	   increasing	  the	  reaction	  time	  with	  the	  
Zn/AcOH	  reagent	  to	  24	  h	  (Scheme	  4.6).	  The	  conditions	  for	  the	  reduction	  of	  83	  to	  
106	   were	   much	   milder	   than	   those	   found	   in	   the	   literature	   for	   a	   related	   case	  
where	  Ar	  =	  Ph.	  This	  can	  be	  explained	  by	  taking	  into	  account	  that	  the	  mechanism	  
of	   the	   reaction	   (Scheme	   4.7)	   involves	   the	   generation	   of	   a	   carbanion	   in	   the	  
benzylic	   position,	   which	   would	   be	   stabilized	   by	   the	   electron-­‐withdrawing	  
pyridine	  nitrogen.	  
	  
Scheme	  4.6.	  Reduction	  methods	  of	  compound	  83	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
151	   Marcuccio,	  S.	  M.;	  Elix,	  J.	  A.	  Aust.	  J.	  Chem.	  1984,	  37,	  1791.	  
4.	  Diketopiperazine	  based-­‐ligands	  of	  prion	  protein	   	   105	   	   	  
	  
Scheme	  4.7.	  Mechanism	  of	  the	  reaction	  of	  reduction	  in	  presence	  of	  Zn	  	  
With	  this	  precedent	  in	  hand,	  we	  also	  undertook	  the	  reduction	  of	  compound	  
93	   in	  the	  presence	  of	  zinc	   in	  acetic	  acid.	  As	  shown	   in	  Scheme	  4.9,	   this	  reaction	  
afforded	  compound	  108,	  where	  one	  of	  the	  C=C	  double	  bonds	  and	  both	  aldehyde	  
groups	   were	   reduced.	   Although	   the	   unoptimized	   yield	   for	   this	   reaction	   was	  
modest,	   we	   consider	   this	   result	   to	   be	   of	   interest	   since	   compound	   108	   can	   be	  
easily	  functionalized	  by	  exploiting	  the	  reactivity	  of	  its	  hydroxymethyl	  groups.	  
	  
Scheme	  4.9.	  Reduction	  of	  compound	  93	  to	  108.	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4.3.	  Screening	  methodology	  
The	   biological	   study	   of	   our	   compound	   library	  was	   performed	   by	   H.	   N.	   Ai	   Tran	  
under	   the	   supervision	   of	   Prof.	   G.	   Legname	   at	   the	   International	   School	   of	  
Advanced	  Studies	   (SISSA),	  Trieste,	   Italy.	  A	  cell-­‐screening	  assay	  was	  used	   to	   test	  
antiprion	  activity	  across	  our	  library.	  The	  ability	  to	  reduce	  PrPSc	  concentrations	  in	  
scrapie-­‐infected	   mouse	   hypothalamus	   (ScGT1)	   cells	   was	   determined	   from	  
Western	  blot	  densitometry	  of	  the	  proteinase	  K	  (PK)-­‐resistant	  PrPSc.	  Compounds	  
were	   initially	   screened	   at	   10	   μM	   and	   their	   effects	   in	   reducing	   PrPSc	   levels	   in	  
comparison	  with	   the	   untreated	   control	   after	   5-­‐day	   exposure	  were	   considered.	  
Prior,	  effects	  of	  library	  members	  on	  ScGT1	  cells	  viability	  were	  determined	  (Tables	  
4.1	  and	  4.2).	  Compound	  toxicity	  is	  expressed	  as	  an	  average	  percent	  of	  viable	  cells	  
when	   treated	   with	   a	   compound	   concentration	   of	   10	   μM,	   versus	   control	   cells	  
treated	   with	   no	   compound.	   Anti-­‐prion	   activity	   is	   expressed	   as	   the	   average	  
percent	   of	   PK-­‐resistant	   PrP	   reduction	   after	   incubation	   with	   compound	   at	   the	  
given	   concentration,	   versus	   control	   cells	   incubated	   with	   no	   compound.	   For	  
entries	  83	  and	  105	  the	  EC50	  values,	  which	  represent	  the	  effective	  concentrations	  
for	   half-­‐maximal	   inhibition,	   were	   also	   calculated.	   Two	   well	   documented	   anti-­‐
prion	  agents,	  quinacrine	  and	  imipramine,	  were	   investigated	  as	  positive	  controls	  
exhibiting	  an	  EC50	  value	  of	  6.2	  ±	  0.4	  and	  0.4	  ±	  0.1	  μM,	  respectively.	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4.4.	  Biological	  activity	  results	  and	  SAR	  
As	   a	   first	   step,	   the	   cytotoxic	   effects	   of	   all	   compounds	   were	   determined	   by	  
calcein-­‐AM	   assay	   in	   ScGT1	   cell	   line.	   As	   summarized	   in	   Tables	   4.1	   and	   4.2,	  
treatment	  of	  ScGT1	  (10	  μM)	  did	  not	   lead	  to	  major	  modifications	   in	  cell	  viability	  
for	  most	   compounds,	  with	   the	   exception	  of	  104	  where	   cell	   viability	  was	   lower	  
than	   50%.	   Therefore,	   the	   latter	   compound	   was	   not	   screened	   for	   prion	  
replication,	  whereas	  the	  other	  library	  members	  were	  assayed	  at	  a	  concentration	  
of	  10	  µM.	  From	  an	  analysis	  of	  the	  results,	   it	   is	  possible	  to	  conclude	  that	  at	  this	  
concentration	   not	   all	   the	   tested	   DKPs	   displayed	   activity.	   In	   fact,	   among	   the	  
selected	  aromatic	  rings,	  we	  observed	  null	  or	  very	   low	  activity	  for	  benzene	  (92),	  
furan	   (94),	   thiophene	   (95)	   and	  quinoline	   (86,	  90	   and	  91)	   derivatives.	   The	  most	  
striking	  result	  of	  this	   investigation	  was	  the	  remarkable	  activity	  displayed	  by	  the	  
2-­‐pyridyl	   derivative	   83,	   which	   at	   10	   µM	   is	   able	   to	   completely	   inhibit	   prion	  
replication	  (100.8	  ±	  2.5	  %	  of	  inhibition).	  Intriguingly,	  when	  the	  pyridine	  nitrogen	  
was	  moved	  to	  positions	  3	  (84)	  and	  4	  (85),	  the	  activity	  decreased	  to	  percentages	  
of	  12.4	  and	  11.5,	  respectively.	  Similarly,	  the	  potent	  activity	  of	  83	  was	  reduced	  by	  
fusing	  additional	  aromatic	  groups,	  as	  in	  the	  cases	  of	  the	  2-­‐quinolinyl	  (86)	  and	  β-­‐
carbolin-­‐3-­‐yl	  (105)	  compounds	  (Table	  4.1).	  
Significant	  preliminary	  structure-­‐activity	  relationships	  can	  be	  gathered	  from	  
this	   first	   set	   of	   tested	   compounds.	   A	   DKP	   bearing	   a	   2-­‐pyridyl	   substituent	   was	  
revealed	   as	   a	   strict	   requirement	   for	   potency	   in	   the	   cell	   line	   assay.	   The	   only	  
exception	   to	   this	   trend	   was	   the	   4-­‐quinolyl	   derivative	   86,	   which	   was	   the	   only 
compound	   devoid	   of	   the	   apparently	   key	   molecular	   feature	   and	   displaying	   an	  
activity	  higher	  than	  20%.	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Table	  4.1.	  Screening	  results	  for	  the	  DKP	  double	  condensation	  products	  
	  
Cmpd.	   R	  
%	  of	  viable	  cells	  at	  10	  
μM	  




50.9	  ±	  2.1	   100.8	  ±	  2.5	  
84	  
	  
102.7	  ±	  3.7	   12.4	  ±	  0.5	  
85	  
	  
108.5	  ±	  4.2	   11.5	  ±	  0.5	  
90	  
	  
71.7	  ±	  3.1	   5.1	  ±	  0.1	  
91	  
	  
63.7	  ±	  2.8	   3.5	  ±	  0.1	  
86	  
	  
94.8	  ±	  4.1	   20.6	  ±	  0.8	  
92	  
	  
85.6	  ±	  3.1	   0.11	  ±	  0.01	  
94	  
	  
83.0	  ±	  2.9	   0.14	  ±	  0.02	  
95	  
	  
73.6	  ±	  3.5	   1.8	  ±	  0.1	  
104	  
	  
37.3	  ±	  2.6	   NDa	  
105	  
	  
77.0	  ±	  3.2	   10.4	  ±	  1.2	  
a	  Not	  determinated	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The	   results	  obtained	  could	   imply	   that	  a	  planar	   conformation,	  as	   in	  83,	   is	   a	  
basic	   requirement	   for	  activity.	  Starting	   from	  this	  assumption,	  we	  examined	   the	  
effects	  of	  the	  reduction	  on	  the	  double	  bonds	  at	  the	  positions	  3	  and	  6	  of	  the	  DKP	  
system.	  Thus,	   the	  partially	   saturated	   (106	  and	  108)	  and	   fully	  unsaturated	   (107)	  
derivatives	   were	   also	   tested	   against	   prion	   replication	   in	   the	   same	   cell-­‐based	  
model	  (Table	  4.2).	  Even	  in	  this	  series,	  the	  most	  active	  compound	  was	  again	  the	  2-­‐
pyridyl	  derivative	  106.	  Again,	  this	  can	  be	  rationalized	  by	  the	  assumption	  that	  at	  
least	  one	  half	  of	  the	  molecule	  is	  able	  to	  assume	  the	  planar	  conformation	  critical	  
for	   activity.	   In	   line	   with	   this	   speculation,	   the	   doubly	   saturated	   compound	   108	  
showed	  lower	  potency.	  
Table	  4.2.	  Screening	  results	  for	  mono	  and	  fully	  reduced	  DKP	  products	  106-­‐108	  
Cmpd.	   %	  of	  viable	  cells	  at	  10	  μM	  
%	  PrPSc	  inhibition	  at	  
10	  μM	  
	  
100.1	  ±	  4.4	   18.1	  ±	  0.7	  
	  
107.4	  ±	  4.6	   12.2	  ±	  0.2	  
	  
110.5	  ±	  5.3	   13.8	  ±	  0.4	  
	  
Given	   the	   high	   inhibitory	   activity	   of	   83	   and	   the	   possible	   use	   of	   105	   as	   a	  
fluorescent	   probe,	   their	   antiprion	   potential	   was	   studied	   in	   more	   detail	   by	  
calculating	   their	   EC50	   values.	   For	  83,	   a	   remarkable	   single-­‐digit	  micromolar	   EC50	  
value	  (4.1	  ±	  0.2	  µm,	  Table	  4.3)	  was	  observed,	  comparable	  to	  that	  of	  imipramine	  
(6.2	  ±	  0.4	  µm),	  a	  reference	  antiprion	  compound.	  Notably,	  105	  (EC50	  =	  15.8	  ±	  0.9	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µm)	  was	  only	   fourfold	   less	  active	  than	  83,	  emerging	  as	  a	  promising	   fluorescent	  
probe.	  
Table	  4.3.	  EC50	  was	  calculated	  for	  83	  and	  105
a	  






4.1	  ±	  0.2	   75.2	  ±	  2.1	  
	  
	  
15.8	  ±	  0.9	   60.4	  ±	  4.	  
	  
aValues	   given	   are	   the	   mean	   ±	   the	   standard	   deviation	   (SD)	   of	   three	   experiments.	   bThe	  
concentration	   of	   test	   compound	   required	   to	   reduce	   the	   PrPSc	   level	   in	   cells	   to	   50%	   versus	  
untreated	  cells	   (EC50).	  
cCell	  viability	  at	   the	  EC50	  concentration	  was	  determined	  by	  calcein-­‐AM	  
cytotoxicity	   assay	   and	   expressed	   as	   an	   average	   percentage	   of	   viable	   cells	   versus	   untreated	  
control	  cells.	  
	  
	   	  
4.	  Diketopiperazine	  based-­‐ligands	  of	  prion	  protein	   	   111	   	   	  
4.5.	  Modeling	  studies	  
To	   better	   elucidate	   the	   putative	   relationships	   between	   bioactivity	   and	   the	  
planarity	  of	  tested	  compounds,	  their	  structural	  conformations	  were	  studied.	  To	  
this	  end,	  three-­‐dimensional	  low-­‐energy	  geometries	  were	  computed	  by	  Salvatore	  
Bongarzone	  at	  SISSA,	  Trieste.	  These	  studies	  showed	  that	  all	  doubly	  unsaturated	  
DKP	   derivatives	   bearing	   an	   α	   heteroatom	   are	   fully	   planar,	   while	   the	   others	  
display	  rotated	  aromatic	  rings	  (e.g.	  92	  is	  rotated	  by	  33.6°	  with	  respect	  to	  the	  DKP	  
plane,	   Figure	   4.2).	   The	   difference	   between	   planar	   and	   non-­‐planar	  molecules	   is	  
due	   to	   the	   presence	   or	   absence	   of	   an	   intramolecular	   hydrogen	   bond	   between	  
the	  aromatic	  substituents	  and	  the	  DKP	  ring.	  	  
	  
Figure	  4.2.	  Three-­‐dimensional	  structure	  of	  a	  planar	  (83)	  and	  a	  non-­‐planar	  (92)	  DKP;	  the	  
difference	  in	  geometry	  is	  due	  to	  the	  presence	  or	  absence	  of	  intramolecular	  hydrogen	  
bonds	  
Molecular	   planarity	   may	   be	   a	   necessary,	   but	   not	   sufficient,	   condition	   for	  
antiprion	  activity.	  In	  fact,	  modeling	  results	  predicted	  that	  compounds	  90,	  94,	  95	  
and	  105	   are	   equally	   planar	   as	  83,	   but	   possessed	   lower	   activity	   (Table	   4.1).	   To	  
explain	  this	  result,	  the	  planarity	  strength,	  in	  terms	  of	  the	  barrier	  for	  the	  rotation	  
of	   the	   arylmethylene	   side	   chains,	   was	   calculated	   (Table	   4.4).	   The	   planar	  
geometry	   of	   83	   was	   found	   to	   the	   most	   stable	   one,	   confirming	   that	   antiprion	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activity	  of	  this	  subset	  of	  molecules	  is	  directly	  related	  to	  their	  capability	  to	  retain	  
a	  planar	  conformation.	  
Table	  4.4.	  Planarity	  degrees	  and	  planar	  stability	  of	  83,	  90,	  92,	  94,	  95,	  105	  
	  
Cmpd.	   R	  






0.02	   18.02	  
90	  
	  
0.01	   15.06	  
92	  
	  
33.60	   0.0	  
94	  
	  
0.00	   7.3	  
95	  
	  
0.00	   1.8	  
105	  
	  
0.07	   17.2	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4.6.	  Mechanism	  of	  action	  
Based	  on	  the	  consideration	  that	  planar	  aromatic	  molecules	  are	  reported	  as	  good	  
inhibitors	  of	  fibril	  formation	  in	  several	  neuronal	  amyloidosis,	  we	  decided	  to	  study	  
the	   behavior	   of	   83	   by	   a	   known	   amyloid	   seeding	   assay	   (ASA).26 N.	   H.	   Ai	   Tran	  
performed	  this	  experiment	  using	  as	  templates	  recombinant	  (rec)	  mouse	  (recMo)	  
full-­‐length	   PrP(23–230)	   and	   truncated	   recMoPrP(89–230),	   which	   both	   form	  
amyloid	   fibers.	   The	   antiaggregation	   potential	   of	  83	   (50	  µm)	  was	   quantitatively	  
detected	   by	   observing	   the	   decrease	   in	   the	   mean	   lag	   phase	   of	   the	   fibrillation	  
reaction,	  compared	  with	  control	  samples.	  Compound	  83	   (50	  mm)	  exhibited	  PrP	  
amyloid	   fibril	   forming	   inhibitory	   activity,	   showing	   a	  much	   slower	   kinetics	   than	  
the	  control,	  in	  which	  the	  lag	  phase	  was	  57	  h	  and	  15	  h	  for	  recMoPrP(23–230)	  and	  
recMoPrP(89–230),	   respectively.	   In	   particular,	  83	   significantly	   extended	   the	   lag	  
phase	   to	   72	   h	   in	   recMoPrP(23–230)	   and	   48	   h	   in	   recMoPrP(89–230)	   fibrillation	  
assays.	  Given	  the	  potency	  of	  83	  at	  inhibiting	  recPrP	  fibril	  formation,	  we	  suggest	  
that	  the	  compound	  might	  interact	  directly	  with	  recPrP	  to	  prevent	  its	  conversion	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5.1.	   Synthesis	   of	   GN8	   and	   their	   fluorene	   and	   carbazole	   based	  
analogues	  
The	   experimental	   work	   reported	   in	   this	   chapter	   was	   carried	   out	   with	  
collaboration	  from	  three	  undergraduate	  students:	  Lucia	  Morelli,	  Alice	  D’Onofrio	  
and	  Giulia	  Bianchini,	  who	  worked	  under	  my	  supervision.	  Our	  study	  started	  with	  
the	   preparation	   of	  GN8	   (110)	   in	   order	   to	   have	   a	   reference	   compound,	   using	   a	  
variation	  of	   the	  published	  method.37	  To	   this	  end,	  we	  coupled	  the	  commercially	  
available	  4,4'-­‐methylenedianiline	  with	  bromoacetic	  acid	   in	  the	  presence	  of	  Et3N	  
and	   1-­‐ethyl-­‐3-­‐(3-­‐dimethylaminopropyl)carbodiimide	   hydrochloride	   (EDC·∙HCl),	  
that	  was	  used	  to	  activate	  the	  carboxylic	  group.	  Afterwards,	  compound	  109	  was	  
treated	  with	  pyrrolidine,	  carrying	  out	  the	  reaction	  in	  DMF	  at	  80°C	  during	  24	  h,	  to	  
afford	  GN8	  110	  (Scheme	  5.1).	  
Scheme	  5.1.	  Synthesis	  of	  GN8	  
Then,	  a	   series	  of	   fluorene	  based	  analogues	  was	  generated	  by	   transforming	  
the	  commercially	  available	  9H-­‐fluorene-­‐2,7-­‐diamine	  into	  the	  bis-­‐halide	  111	  via	  a	  
coupling	  reaction	  with	  bromoacetylbromide	  in	  the	  presence	  of	  EDC.	  Because	  the	  
product	   was	   obtained	   in	   very	   low	   yield	   (24%),	   we	   experimented	   with	   other	  
catalysts,	   obtaining	   good	   results	   with	   4-­‐dimethylaminopyridine	   (DMAP)	   in	   THF	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(Scheme	  5.2).	  DMAP	  is	  often	  used	  as	  a	  catalyst	  for	  acyl	  transfer	  reactions	  and	  can	  
be	  easily	  washed	  off	  with	  aqueous	  acid	  as	  a	  bromide	  salt.	  The	  mechanism	  of	  the	  
activation	  of	  bromoacetyl	  bromide	  by	  DMAP	  is	  depicted	  in	  Scheme	  5.3.	  
 
Scheme	  5.2.	  Transformation	  of	  9H-­‐fluorene-­‐2,7-­‐diamine	  into	  the	  bis-­‐halide	  111	  
 
Scheme	  5.3.	  Mechanism	  of	  the	  activation	  of	  bromoacetylbromide	  by	  DMAP.	  
Finally,	   intermediate	   111	   was	   treated	   with	   different	   amines	   to	   afford	  
compounds	  112-­‐120	  by	  double	  nucleophilic	  displacement	  of	  bromide	  anions	  by	  
the	  N-­‐nucleophiles	  (Table	  5.1).	  These	  reactions	  were	  carried	  under	  the	  standard	  
conditions	  previously	  developed	  for	  GN8	  (Scheme	  5.4).	  
 
Scheme	  5.4.	  Synthesis	  of	  the	  amino	  fluorene	  derivatives	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Table	  5.1.	  Scope	  and	  yield	  of	  the	  amino-­‐fluorene	  derivatives	  
Entry	   Cmpd.	   NHR2	   Yield,	  %	  	  
1	   112	  
	  
90	  
2	   113	  
	  
34	  
3	   114	  
	  
64	  
4	   115	  
	  
80	  
5	   116	  
	  
57	  
6	   117	  
	  
73	  
7	   118	  
 
64	  
8	   119	  
 
72	  




Another	  class	  of	  GN8-­‐based	  ligands	  was	  generated	  by	  replacing	  the	  fluorene	  
central	   core	   by	   carbazole,	   due	   to	   the	   intrinsic	   fluorescence	   of	   this	   ring	   system	  
and	   its	  antioxidant	  properties.	  Our	  synthetic	  route	  started	  with	  the	  nitration	  of	  
carbazole	  with	  a	  mixture	  of	  acetic	  and	  nitric	  acid	  (1:1)	  to	  give	  a	  mixture	  of	  3,6-­‐
dinitrocarbazole	   121	   and	   3-­‐nitrocarbazole	   122	   in	   modest	   yields,	   using	   a	  
published	  method.152	  (Scheme	  5.5).	  	  
 
Scheme	  5.5.	  Nitration	  of	  carbazole	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The	   reduction	   of	   compound	   121	   also	   posed	   some	   problems,	   and	   several	  
literature	  methods	  for	  nitro	  reduction152,153	  failed.	  Eventually,	  we	  found	  that	  121	  
was	  reduced	  quantitatively	  to	  3,6-­‐diaminocarbazole	  123	  by	  using	  iron	  powder	  in	  
a	   refluxing	  mixture	   of	   ethanol,	   water	   and	   acetic	   acid	   containing	   37%	   aqueous	  
hydrochloric	  acid	  (Scheme	  5.6).154	  
 
Scheme	  5.6.	  Reduction	  of	  compound	  121	  to	  123	  
Then,	   compound	   123	   was	   transformed	   into	   bis-­‐halide	   124	   by	   double	  
acylation	  with	  bromoacetyl	  bromide	  by	  using	  DMPA	  under	  the	  same	  conditions	  
applied	  in	  the	  case	  of	  fluorene	  (Scheme	  5.7).	  
 
Scheme	  5.7.	  Synthesis	  of	  the	  bis-­‐halide	  derivative	  124	  
With	   compound	   124	   in	   hand,	   we	   carried	   out	   the	   coupling	   reaction	   with	  
different	   amines	   in	   DMF,	   following	   the	   protocol	   established	   for	   the	   fluorene	  
derivative,	  to	  afford	  compounds	  125-­‐133	  (Scheme	  5.8	  and	  Table	  5.2).	  In	  the	  case	  
of	  the	  carbazole	  derivatives,	  the	  yields	  were	  generally	  only	  moderate,	  owing	  to	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difficulties	   found	   in	   isolating	   the	   products	   from	   DMF	   and	   in	   their	   purification,	  
which	  was	  hampered	  by	  their	  very	  low	  solubility	  in	  all	  media.	  
 
Scheme	  5.8.	  General	  conditions	  to	  achieve	  carbazole	  products	  
Table	  5.2.	  Scope	  and	  yield	  of	  the	  amino-­‐carabazole	  derivatives	  
Entry	   Cmpd.	   NHR2	   Yield,	  %	  	  
1	   125	  
	  
58	  
2	   126	  
	  
60	  
3	   127	  
	  
47	  
4	   128	  
	  
40	  
5	   129	  
	  
38	  
6	   130	  
	  
55	  
7	   131	  
 
48	  
8	   132	  
 
30	  




In	   order	   to	   verify	   the	   proposed	   relationship	   between	  molecular	   symmetry	  
and	  anti-­‐prion	  action,	  we	  also	  decided	  to	  synthesize	  a	  non-­‐symmetric	  carbazole	  
derivative.	   To	   this	   end,	   we	   treated	   3-­‐nitrocarbazole	   122	   with	   iron	   powder	   to	  
obtain	   its	   reduced	  derivative	  134	   (Scheme	  5.9).	  We	   then	   treated	  134	  with	  one	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equivalent	   of	   bromoacetyl	   bromide	   to	   afford	   the	   halide	   135,	   which	   was	  
subsequently	   treated	   with	   pyrrolidine	   to	   finally	   achieve	   compound	   136,	  
containing	  a	  single	  side	  chain	  (Scheme	  5.10).	  
 
Scheme	  5.9.	  Synthesis	  of	  compound	  134	  
 
Scheme	  5.10.	  Synthesis	  of	  the	  asymmetric	  carbazole	  derivative	  136	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5.2.	  Fluorescence	  studies	  
As	  mentioned	  above,	   the	  fluorene	  and	  carbazole	  moieties	  were	  employed	  with	  
the	  aim	  to	  obtain	   fluorescent	  probes	  potentially	  useful	   to	   trace	  PrP.	  Therefore,	  
the	   native	   fluorescence	   of	   a	   series	   of	   selected	   compounds	  was	   studied	   by	   Dr.	  
Víctor	   González-­‐Ruiz	   under	   the	   supervision	   of	   Prof.	   Maria	   Antonia	   Martín	   at	  
Sección	  Departamental	  de	  Química	  Analítica,	  Facultad	  de	  Farmacia,	  Universidad	  
Complutense	  de	  Madrid.	  
Fluorescence	   emission	   can	   be	   affected	   by	   the	   polarity	   properties	   of	   the	  
microenvironment.	   For	   this	   reason,	   the	   native	   fluorescence	   of	   some	  
representative	   compounds,	   including	   the	   pyrrolidine	   derivatives	   115	   and	   128,	  
closely	   related	   to	   GN8,	   and	   compounds	   112	   and	   116	   were	   investigated	   in	  
different	   solvents:	  water,	  ethanol,	   cyclohexane	  and	  acetonitrile.	  Figures	  5.1-­‐5.5	  
show	  the	  fluorescence	  spectra	  obtained	  for	  these	  derivatives	  and	  fluorene,	  used	  
as	   reference,	   and	   Table	   5.3	   summarizes	   the	   position	   of	   the	   corresponding	  
maxima.	   As	   regards	   the	   fluorene	   derivatives,	   compounds	   112,	   115	   and	   116	  
exhibited	   good	   fluorescent	   intensities	   although	   they	   are	   lower	   than	   those	  
observed	  for	  fluorene	  in	  all	  solvents.	  In	  cyclohexane	  and	  ethanol,	  whose	  polarity	  
mimics	   the	   protein	   environment,	   the	   fluorescence	   emission	   maxima	   were	  
observed	  in	  the	  spectral	  range	  between	  340	  and	  360	  nm,	  far	  away	  from	  the	  NIR	  
region,	   and	   was	   ca.	   10	   times	   higher	   than	   in	   water.	   This	   behavior	   led	   to	   the	  
reasonable	  expectation	  that	  compounds	  112,	  115	  and	  116	  will	  probably	  show	  an	  
increase	   in	   the	   fluorescence	   emission	   intensity	   upon	   binding	   to	   fibrils	   as	   a	  
consequence	   of	   the	   resulting	   change	   in	   polarity	   associated	   to	   this	  
microenvironment.	  With	  regard	  to	  the	  carbazole	  derivative	  128,	  interestingly,	  an	  
emission	   maximum	   above	   600	   nm	   was	   observed,	   facilitating	   its	   use	   as	   a	   NIR	  
tracer. 	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Figure	  5.1.	  Corrected	  fluorescence	  excitation	  and	  emission	  spectra	  of	  compound	  112	  in	  
different	  solvents	  at	  concentration	  5.0	  x	  10-­‐6	  M	  
	  
	  
Figure	  5.2.	  Corrected	  fluorescence	  excitation	  and	  emission	  spectra	  of	  compound	  115	  in	  
different	  solvents	  at	  concentration	  5.0	  x	  10-­‐6	  M	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Figure	  5.3.	  Corrected	  fluorescence	  excitation	  and	  emission	  spectra	  of	  compound	  116	  in	  
different	  solvents	  at	  concentration	  5.0	  x	  10-­‐6	  M	  
	  
Figure	  5.4.	  Corrected	  fluorescence	  excitation	  and	  emission	  spectra	  of	  fluorene	  in	  
different	  solvents	  at	  concentration	  5.0	  x	  10-­‐6	  M	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Figure	  5.5.	  Fluorescence	  emission	  spectra	  of	  128	  in	  different	  solvents	  showing	  maxima	  
above	  600	  nm,	  just	  in	  the	  NIR	  region	  
Table	  5.3.	  Excitation	  and	  emission	  maxima	  of	  compounds	  112,	  115,	  116,	  128	  in	  different	  
solvents	  
Cmpd.	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5.3.	  Antiprion	  activity	  evaluation	  in	  a	  cell-­‐based	  model	  
The	  antiprion	  potential	  of	  of	  the	  synthetized	  compounds	  was	  assessed	  in	  ScGT1	  
infected	  cells	  by	  Dr.	  H.	  N.	  Ai	  Tran	  and	  Sivia	  Vanni	  under	  the	  supervision	  of	  Prof.	  
Giuseppe	  Legname	  at	  SISSA,	  Trieste.	  A	  preliminary	  screening	  assay	  was	  used	  to	  
test	  an	  initial	  selection	  of	  the	  fluorene	  derivatives	  112,	  115,	  116.	  Compound	  116	  
was	  not	  assayed	  for	  prion	  replication	  since	  cell	  viability	  was	  lower	  than	  50%.	  On	  
the	   other	   hand,	  112	   and	  115	   showed	   activity	   at	   a	   concentration	   of	   in	   the	   low	  
micromolar	   range	  against	  prion	   replication	  with	  EC50	  values	  of	  4.6	  and	  1.9	  µM,	  
which	  are	  similar	  to	  that	  of	  GN8	  and,	  encouragingly,	  they	  displayed	  low	  toxicities	  
(Table	   5.4).	   Furthermore,	   they	   were	   found	   to	   delay	   fibril	   formation	   with	  
efficacies	  similar	  to	  that	  of	  GN8,	  using	  the	  previously	  described	  amyloid	  seeding	  
assay	  (ASA,	  Figure	  5.6).	  
Table	  5.4.	  EC50	  and	  the	  cell	  viability	  at	  this	  concentration	  was	  calculated	  for	  
compounds	  112,	  115	  and	  116	  
	  
Cmpd.	   NR2	   EC50	  (µM)	  
%	  of	  viable	  cells	  at	  
EC50	  
GN8	   - 1.5	  ±	  0.1	   93.4	  ±	  7.3	  
112	  
	  
4.6	  	  ±	  0.1	   92.1	  ±	  5.7	  
115	  
	  
1.9	  	  ±	  0.1	   68.2	  ±	  3.8	  
116	  
	  
-­‐-­‐	   -­‐-­‐	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Figure	  5.6.	  In	  vitro	  inhibitory	  activity	  of	  prion	  fibril	  formation	  for	  compounds	  112,	  115-­‐
116	  (50	  µM)	  compared	  with	  GN8	  
	  
As	   regards	   carbazole	   derivatives,	   the	   data	   concerning	   their	   toxicity	   and	  
ability	  to	  inhibit	  the	  prion	  replication	  at	  different	  concentrations	  are	  summarized	  
in	  Table	  5.5.	  Most	  of	  the	  tested	  compounds	  (except	  125	  and	  126)	  showed	  some	  
toxicity	   at	   10	   μM	   concentration,	   and	   compounds	   125-­‐128,	   132	   and	   136	   were	  
able	   to	   reduce	   the	   PrPSc	   levels	   and	   their	   efficacy	  was	   comparable	  with	   that	   of	  
GN8.	   On	   the	   other	   hand,	   at	   1	   µM	   concentration	   compounds	   125	   and	   126	  
exhibited	  a	  very	   low	  toxicity,	  with	  cell	  viability	  above	  90%,	  and	  continued	  to	  be	  
active	  against	  prion	   replication,	  even	  more	   that	  GN8,	  with	  a	  %PrPSc	   level	  of	  44	  
and	  33.	  Compounds	  127	   and	  132	  were	  able	   to	   inhibit	   scrapie	  propagation	  at	  1	  
µM	  concentration,	   but	  unfortunately	   they	  were	   toxic.	   Importantly,	   at	   a	   10	  μM	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Table	  5.5.	  Screening	  results	  for	  GN8	  and	  carbazole	  derivatives	  
 
Cmpd.	   NR2	  


















 50	   17	   69	   79	   85	   104	  
125	  
	  
95	   21	   99	   44	   111	   103	  
126	  
	  
103	   19	   99	   33	   108	   71	  
127	  
	  
61	   24	   75	   39	   92	   73	  
128	  
	  
71	   27	   85	   103	   118	   148	  
129	  
	  
77	   74	   89	   98	   100	   120	  
130	  
	  
69	   44	   76	   105	   81	   109	  
131	  
 
84	   59	   86	   102	   101	   96	  
132	  
 
47	   28	   70	   46	   99	   85	  
133	  
 
63	   134	   73	   136	   71	   124	  
136	   -- 29	   26	   72	   75	   83	   78	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5.4.	  Fluorescent	  staining	  in	  ScN2A	  cells	  
In	   an	   effort	   to	   shed	   light	   on	   the	   molecular	   mechanism	   of	   action	   of	   our	  
compounds,	   fluorescent	  staining	  with	  compound	  128	  was	  carried	  out	  using	  the	  
ScN2A	  cell	  model,	  infected	  by	  scrapie.	  This	  experiment	  was	  performed	  by	  Suzana	  
Aulić	   under	   the	   supervision	   of	   Prof.	   Giuseppe	   Legname	   at	   SISSA,	   Trieste.	   The	  
choice	   of	   128	   was	   dictated	   by	   the	   fact	   that	   it	   emits	   fluorescence	   in	   the	   NIR	  
region.	  It	  was	  found	  that	  a	  small	  amount	  of	  128	  was	  sufficient	  to	  observe	  many	  
fluorescent	   spots	   in	   the	   treated	   cells	   examined	   by	   fluorescent	   microscopy,	  
before	   and	  after	  denaturation	  with	  6	  M	  guanidinium	  chloride	   (GndHCl)	   (Figure	  
5.7A).	  The	  fact	  that	  fluorescent	  spots	  were	  still	  observed	  after	  the	  denaturation	  
of	   the	   PrPC	   means	   that	   128	   interacts	   only	   with	   PrPSc	   instead	   of	   PrPC	   as	   GN8.	  
Furthermore,	   the	   staining	   pattern	   was	   consistent	   with	   that	   observed	   with	  
Thioflavin	   S	   (ThS),	   a	   common	   PrPSc	   dye	   (Figure	   5.7B).	   In	   order	   to	   confirm	   the	  
selective	  binding	  of	  128	  for	  the	  scrapie	  fibrils,	  the	  same	  experiment	  was	  carried	  
in	   uninfected	   cells.	   As	   expected,	   no	   spots	   were	   observed	   confirming	   the	  
selectivity	  of	  the	  biomarker	  for	  PrPSc	  (Figure	  5.8).	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Figure	  5.7.	  (A)	  Detection	  of	  PrPSc	  aggregates	  with	  128	  in	  ScN2A	  (scrapie	  prion-­‐infected	  
cells)	  by	  intensity	  fluorescence	  (IF)	  before	  and	  after	  denaturation	  with	  6M	  GndHCl.	  (B)	  
Comparison	  of	  the	  fluorescent	  staining	  with	  128	  (red)	  and	  Thioflavin-­‐S	  (green),	  a	  dye	  
that	  specifically	  binds	  to	  aggregates,	  in	  ScN2A	  cells	  before	  and	  after	  denaturation	  with	  
6M	  guanidinium	  hydrochloride	  (GndHCl).	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Figure	  5.8.	  Uninfected	  N2A	  cells	  with	  or	  without	  denaturation	  step	  with	  6	  M	  GndHCl	  did	  
not	  show	  staining	  in	  the	  presence	  of	  128	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5.5.	  Proposed	  mechanism	  of	  action	  
In	   the	   light	   of	   these	   results,	   we	   propose	   for	   our	   compounds	   an	   antiprion	  
mechanism	   of	   action	   alternative	   to	   that	   described	   for	   GN8.	   The	   previously	  
summarized	  data	  demonstrate	  that	  compound	  128	  binds	  selectively	  prion	  fibrils,	  
and	   therefore	   that	   its	   antiprion	   activity	   is	   due	   to	   the	   interaction	   with	   PrPSc	  
instead	   of	   PrPC	   as	   in	   the	   case	   of	   GN8.	   This	   would	   prevent	   prion	   propagation	  
either	  by	   interfering	  with	  protein-­‐protein	   interactions	   (PPIs)	  between	  PrPSc	  and	  
PrPC	   or	   by	   directly	   preventing	   fibril	   formation	   from	   PrPSc.	   On	   the	   other	   hand,	  
Kuwata’s	   group	   suggested	   that	   a	   restricted	   conformation	  of	   the	  GN8	  molecule	  
led	   to	   its	   antiprion	   activity	   by	   stabilizing	   PrPC	   upon	   binding.37	   It	   emerges	   that	  
modifying	  the	  structure	  of	  GN8	  by	  generating	  a	  more	  planar	  and	  rigid	  molecule	  
leads	  to	  a	  change	  in	  the	  biological	  target	  (Figure	  5.9).	  
 
Figure	  5.9.	  Rigidification	  of	  the	  structure	  of	  GN8	  influenced	  the	  mechanism	  of	  action	  
against	  the	  prion	  replication.	  Our	  data	  show	  that	  128	  exerts	  its	  antiprion	  activity	  by	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6.1.	  Styryl	  compounds	  to	  detect	  and	  treat	  amyloid	  aggregates	  
As	  highlighted	   in	   the	   Introduction,	   one	  of	   the	  main	   goal	   of	   this	   thesis	  was	   the	  
identification	  of	  novel	  fluorescent	  compounds	  capable	  of	  staining	  amyloid	  fibrils,	  
and,	  ideally,	  of	  simultaneously	  blocking	  their	  aggregation.46	  
As	  a	  starting	  point,	  we	  noticed	  that	  several	  styryl	  derivatives,	  designed	  by	  Li	  
et	  al.	  to	  improve	  the	  pharmacokinetic	  properties	  of	  CR	  and	  ThT,	  were	  employed	  
as	  AD	  imaging	  agents	   in	  vivo.155	  Interestingly,	  some	  of	  them	  were	  also	  found	  to	  
be	  active	  against	  prion	  replication	   in	   infected	  cells.156	  Furthermore,	   Ishikawa	  et	  
al.	   reported	   that	   a	   styrylbenzene	   derivative	   (BSB)	   was	   useful	   to	   detect	   PrPSc	  
aggregates	  ex	  vivo	  and	  showed	  effectiveness	   in	  cellular	  assays.53	  Therefore,	  we	  
reasoned	  that	  the	  styryl	  moiety	  was	  important	  to	  the	  ability	  of	  small	  molecules	  
to	  label	  and	  interfere	  with	  pathological	  fibrillar	  aggregates,	  both	  in	  PrD	  and	  AD.	  
We	   first	   reported	   a	   preliminary	   exploration	   of	   three	   styrylquinoline	  
derivatives	  as	  Aβ/PrPSc	  diagnostic	  and	  therapeutic	  small	  molecules.	  We	  focused	  
on	   a	   quinoline	   moiety	   because	   it	   constitutes	   the	   core	   of	   many	   anti-­‐prion	  
compounds,	  while	  displaying	  good	  pharmacokinetic	  properties	  and	  a	  high	  degree	  
of	   drug-­‐likeness.25 In	   one	   of	   the	   compounds,	   an	   amino	   group	   was	   purposely	  
introduced	   (139)	   to	  have	  an	  electron-­‐releasing	  substituent	  conjugated	  with	   the	  
quinoline	   nitrogen	   to	   shift	   the	   fluorescence	   emission	   toward	   the	   NIR	   spectral	  
region.	   In	   order	   to	   reinforce	   this	   effect	   by	   increasing	   the	   electron-­‐withdrawing	  
character	   of	   the	   quinoline	   nitrogen,	   the	   hydrochloride	   salt	   of	   139	   was	   also	  
prepared.	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   Li,	  Q.;	  Min,	  J.;	  Ahn,	  Y.	  H.;	  Namm,	  J.;	  Kim,	  E.	  M.;	  Lui,	  R.;	  Kim,	  H.	  Y.;	  Ji,	  Y.;	  Wu,	  H.;	  Wisniewski,	  
T.;	  Chang,	  Y.	  T.	  ChemBioChem	  2007,	  8,	  1679.	  
156	   Chung,	  E.;	  Prelli,	   F.;	  Dealler,	   S.;	   Lee,	  W.	  S.;	  Chang,	  Y.	   T.;	  Wisniewski,	   T.	  PLoS	  ONE	  2011,	  6,	  
24844.	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In	   the	   light	   of	   the	   encouraging	   results	   obtained	   from	   these	  molecules,	  we	  
developed	  a	  new	  series	  of	  styryquinolines.	  Accordingly,	  we	  designed	  a	  library	  of	  
54	   compounds,	   which	   aims	   to	   explore	   structure	   activity	   relationships	   (SARs)	  
around	   the	   2-­‐styrylquinoline	   scaffold	   and	   optimize	   its	   profile.	   Most	   of	   the	  
compounds	   were	   purposely	   designed	   with	   the	   aim	   of	   pushing	   their	   emission	  
wavelength	  into	  the	  ideal	  NIR	  region	  by	  introducing	  electron	  donor	  and	  electron-­‐
acceptor	  groups	  as	  terminal	  moieties	  in	  order	  to	  generate	  a	  “push-­‐pull”	  molecule	  
and	   at	   the	   same	   time	   improving	   the	   antiprion	   activity.	   Methoxy	   and	   chlorine	  
substituents	   were	   introduced	   because	   they	   are	   present	   in	   many	   quinoline-­‐
derived	  antiprion	  compounds,	  while	   the	  dimethylamino	  group	   is	  well	  known	  as	  
the	   best	   red-­‐shift	   absorption-­‐pushing	   group.	   In	   addition,	   we	   obtained	   some	  
compounds	  in	  which	  the	  phenyl	  moiety	  was	  replaced	  by	  a	  pyridine	  or	  quinoline	  
ring	   in	   order	   to	   have	   a	   further	   atom	   capable	   of	   hydrogen	  bonding	   interaction.	  
Finally,	   methyl	   and	   fluorine	   substituents	   were	   also	   introduced	   to	   increase	   the	  
library	  diversity	  (Figure	  6.1).	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6.2.	   A	   fluorescent	   styrylquinoline	   with	   combined	   therapeutic	   and	  
diagnostic	  activities	  against	  Alzheimer’s	  and	  prion	  diseases	  
6.2.1.	  Synthesis	  of	  2-­‐styrylquinolines	  
Our	   investigation	   started	   with	   the	   synthesis	   of	   2-­‐functionalized	  
tetrahydroquinolines	   followed	  by	   their	  aromatization	   to	  2-­‐styrylquinolines.	  This	  
methodology	  has	  been	  well	   studied	  by	  our	  research	  group	  and	   it	   is	  based	  on	  a	  
three-­‐component	   reaction	   between	   arylamines,	   alkyl	   vinyl	   ether	   and	  
cinnamaldehydes	   catalyzed	   by	   cerium(IV)	   ammonium	   nitrate	   (CAN)	   (Scheme	  
6.1).157	   Starting	   from	   the	   suitable	   anilines	   (toluidine	   and	   anisidine),	  we	   carried	  
out	  the	  reaction	  in	  acetonitrile	  at	  r.t.	  during	  2	  h	  to	  obtain	  the	  corresponding	  2-­‐
styryl-­‐1,2,3,4-­‐tetrahydroquinoline	  derivatives	  that	  were	  directly	  dehydrogenated	  
in	   the	  presence	  of	  DDQ	   to	  give	   compounds	  137	   and	  138	   in	  good	  overall	   yields	  
(Scheme	  6.2).	   
Scheme	  6.1.	  Retrosynthesis	  of	  the	  styrylquinoline	  derivatives.	  
 
Scheme	  6.2.	  Synthesis	  of	  2-­‐styrylquinolines	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   Sridharan,	  V.;	  Avendaño,	  C.;	  Menéndez	  J.	  C.	  Tetrahedron	  2009,	  65,	  2087.	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The	   mechanism	   that	   leads	   to	   the	   generation	   of	   2-­‐styryl-­‐1,2,3,4-­‐
tetrahydroquinolines	  is	  depicted	  in	  Scheme	  6.3.	  The	  first	  step	  consists	  of	  a	  type-­‐II	  
vinylogous	   Povarov	   reaction	   between	   an	   arylamine	   and	   cinnamaldehyde	  
promoted	  by	  CAN,	  acting	  as	  a	  Lewis	  acid.	  This	  reaction	  involves	  the	  formation	  of	  
an	   α,β-­‐unsaturated	   derivative,	   as	   intermediate	   product,	   followed	   by	   a	  
nucleophilic	   1,2-­‐additions	   from	   alkyl	   vinyl	   ether	   to	   afford	   the	   2-­‐styryl-­‐1,2,3,4-­‐
tetrahidroquinoline	  compound.	  It	   is	   interesting	  to	  note	  that	  the	  reaction	  is	  fully	  
diastereoselective	  and	  gives	  only	  2-­‐styryl-­‐1,2,3,4-­‐tetrahydroquinolines	  with	  a	  cis	  
arrangement.	  This	  complete	  diastereoselectivity	  can	  be	  explained	  by	  assuming	  a	  
stepwise	   mechanism	   for	   the	   vinylogous	   Povarov	   reaction,	   where	   a	   cis	  
arrangement	   between	   the	   alkoxy	   and	   styryl	   groups	   leads	   to	   minimum	  
interactions	  between	  these	  bulky	  substituents	  and	  the	  axial	  protons	  in	  the	  chair-­‐
like	   transition	   state	   of	   the	   cyclization	   step	   leading	   to	   the	   tetrahydroquinoline	  
system. 
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In	   order	   to	   improve	   the	   optical	   properties	   of	   our	   compounds,	   an	   amino	  
group	  was	  purposely	  introduced	  on	  the	  styryl	  moiety	  of	  compound	  137.	  To	  this	  
end,	  we	  treated	  this	  compound	  with	  a	  mixture	  of	  fuming	  and	  concentrated	  nitric	  
acids,	  followed	  by	  reduction	  of	  the	  crude	  nitration	  product	  with	  iron	  powder	  and	  
concentrated	  HCl.154	   This	   protocol	   afforded	   compound	  139,	   bearing	   the	   amino	  
group	   at	   para	   position	   on	   the	   phenyl	   ring	   in	   68%	   yield	   after	   chromatography	  
together	  with	  a	  small	  amount	  of	  the	  corresponding	  ortho	  derivative,	  compound	  
140	  (Scheme	  6.4).	  Furthermore,	  in	  order	  to	  reinforce	  this	  effect	  by	  increasing	  the	  
electron-­‐withdrawing	  character	  of	  the	  quinoline	  nitrogen,	  the	  hydrochloride	  salt	  
(compound	   139·∙HCl)	   was	   also	   prepared	   by	   treating	   compound	   139	   with	   a	  
solution	   of	   methanol	   saturated	   with	   HCl.	   The	   protonation	   of	   the	   quinoline	  
nitrogen	  was	  confirmed	  by	  1H-­‐NMR	  studies	  of	  139·∙HCl,	  which	  showed	  	  
 
Scheme	  6.4.	  Synthesis	  of	  compound	  139	  and	  its	  hydrochloride	  salt	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significative	   displacements	   of	   the	   protons	   adjacent	   to	   the	   quinoline	   nitrogen,	  
namely	   H-­‐8	   and	   the	   olefinic	   protons	   with	   regard	   to	   139,	   whereas	   the	   o-­‐NH2	  
protons	   remained	  almost	  unaltered.	   Similar	   changes	  were	  observed	   in	   the	   13C-­‐
NMR	  spectra.	  
6.2.2.	  Native	  fluorescence	  study	  of	  styrylquinolines	  
The	  fluorescence	  study	  of	  our	  molecules	  was	  performed	  by	  Dr.	  Víctor	  González-­‐
Ruiz	   under	   the	   supervision	   of	   Prof.	   María	   Antonia	   Martín	   at	   Sección	  
Departamental	   de	   Química	   Analítica,	   Facultad	   de	   Farmacia,	   Universidad	  
Complutense	  de	  Madrid.	   Thus,	   the	  native	   fluorescence	  of	   styrylquinolines	  137-­‐
139	   and	   139·∙HCl	   was	   investigated	   in	   several	   solvents,	   including	   phosphate	  
buffered	   saline	   (PBS)	   at	   physiological	   pH	   (Table	   6.1).	   In	   the	   case	   of	   139,	   the	  
fluorescence	  emission	  greatly	  depended	  on	  solvent	  polarity	  (Figure	  6.2A,B	  and	  
	  
Table	  6.1.	  Excitation	  and	  emission	  maxima	  of	  compounds	  137-­‐139	  and	  139·∙HCl	  in	  
different	  solvents 
Cmpd.	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Table	   1).	   It	   is	   interesting	   to	   note	   that	   the	   fluorescence	   emission	   of	   the	  
protonated	   form	   of	   139	   (Figure	   6.2B)	   in	   ethanol,	   whose	   polarity	   mimics	   the	  
protein	   environment,	   was	   red-­‐shifted	   with	   regard	   to	   the	   more	   polar	   water	  
solvent.	  Since	  compound	  139	  would	  be	  adsorbed	  onto	  protein	  aggregates	  where	  
its	   free	  movement	  would	  be	   restricted,	   the	   fluorescence	  emission	   spectrum	  of	  
139·∙HCl	  in	  the	  solid	  state	  was	  also	  obtained	  (Figure	  6.2C),	  showing	  an	  interesting	  
emission	  maximum	  above	  600	  nm.	  On	  this	  basis,	  we	  consider	  139	  as	  a	  potential	  a	  
NIR	  tracer.158	  An	  additional	  advantageous	  feature	  of	  139	  is	  its	  large	  Stokes	  shift	  
	  
Figure.	  6.2.	  Fluorescence	  spectra	  for	  139	  in	  its	  neutral	  (A)	  and	  protonated	  form	  (B)	  in	  
solution,	  and	  for	  139·∙HCl	  in	  the	  solid	  state	  (C)	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(>	   150	   nm),	   which	   minimizes	   interference	   from	   the	   exciting	   radiation.	  
Furthermore,	  the	  structure	  of	  139	  allows	  its	  easy	  manipulation	  by	  increasing	  the	  
electron-­‐donating/accepting	   ability	   of	   the	   molecule	   to	   enhance	   the	   spectral	  
bathochromic	   shift,	   facilitating	   its	   use	   as	   a	   lead	   in	   the	   generation	   of	   a	   second	  
generation	  of	  improved	  fluorescent	  probes.	  
	  
6.2.3.	  Prediction	  of	  brain	  penetration	  
To	   assess	   the	   potential	   value	   of	   our	   compounds	   as	   CNS	   directed	   ligands,	   the	  
capability	  of	  137-­‐139	   to	  cross	   the	  blood	  brain	  barrier	   (BBB)	  was	  studied	  by	   the	  
parallel	   artificial	   membrane	   permeability	   assay	   (PAMPA).159	   The	   experiments	  
were	   carried	   out	   by	   Dr.	   Daniel	   I.	   Pérez	   under	   the	   supervision	   of	   Prof.	   Ana	  
Martínez	   at	   Instituto	   de	   Química	   Médica-­‐CSIC,	   Madrid.	   The	   PAMPA	   test	   is	   a	  
method	   that	   allows	   evaluating	   the	   permeability	   of	   a	   compound	   from	   a	   donor	  
compartment,	   through	   a	   porcine	   brain	   lipid	   membrane,	   into	   an	   acceptor	  
compartment.	   The	   donor	   plate	   is	   put	   on	   the	   acceptor	   plate	   to	   form	   a	  
“sandwich”,	  which	   is	   left	  undisturbed	   for	   a	   couple	  of	  hours.	  During	   this	   time	  a	  
compound	  diffuses	  from	  the	  donor	  plate	  through	  the	  brain	  lipid	  membrane	  into	  
the	  acceptor	  plate	  where	  its	  concentration	  is	  determined	  by	  an	  UV	  plate	  reader.	  
The	  data	  obtained	  for	  our	  compounds	  are	  summarized	  in	  Table	  6.2,	  and	  allowed	  	  
Table	  6.2.	  BBB	  permeation	  prediction	  for	  137-­‐139	  
Cmpd.	   Pe	  (10-­‐6	  cm	  s-­‐1)a	   Predictionb	  
137	   3.0	  ±	  0.6	   CNS	  +/−	  
138	   8.5	  +	  1.1	   CNS	  +	  
139	   23.1	  ±	  1.9	   CNS	  +	  
aMean	  ±	  standard	  deviation	  (SD)	  of	  two	  experiments.	  bCNS	  +	  means	  Pe	  >	  3.74	  ×	  
10−6	  cm	  s−1,	  and	  CNS	  ±	  means	  Pe	  between	  3.74	  ×	  10−6	  and	  1.50	  ×	  10−6	  cm	  s−1	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us	  to	  predict	  optimal	  BBB	  permeation	  for	  138	  and	  139,	  although	  the	  result	  was	  
not	  so	  clear-­‐cut	  in	  the	  case	  of	  137.	  
6.2.4.	  Antiaggregating	  potency	  towards	  Aβ 	  
In	  vitro	  activities	  of	  compounds	  137-­‐139	  on	  Aβ were	  investigated	  by	  Dr.	  Manuela	  
Bartolini	  under	  the	  supervision	  of	  Prof.	  Vincenza	  Andrisano	  at	  the	  University	  of	  
Bologna,	   Italy.	   The	   inhibitory	   potency	   of	   137-­‐139	   as	   antiaggregating	   agents	  
toward	  Aβ42	  was	  determined	  by	  a	  ThT	  based	  fluorometric	  assay.
160	  When	  tested	  
at	   a	   1:1	   ratio	   with	   Aβ42,	   137	   and	   138	   did	   not	   significantly	   alter	   amyloid	   fibril	  
formation,	   while	   139	   decreased	   the	   fluorescence	   signal	   by	   42.4	   ±	   2.6%,	   thus	  
behaving	  as	   an	   inhibitor	  of	   fibrilization	  and	  an	  amyloid	  binder.	  On	   the	  basis	  of	  
data	  available	  in	  the	  literature,	  139	  can	  be	  ranked	  as	  a	  moderate	  inhibitor,	  with	  
potency	   slightly	   lower	   than	   that	   of	   the	  well-­‐known	   antiaggregating	   compound	  
curcumin,161	   which,	   in	   the	   same	   assay	   conditions,	   was	   able	   to	   inhibit	   fibril	  
formation	   by	   73%.	   Furthermore,	   no	   negative	   or	   positive	   interference	   in	   the	  
fluorescence	   signal	   of	   ThT	   was	   observed	   under	   the	   experimental	   conditions	  
(Figure	   6.3C).	   In	   the	   light	   of	   these	   findings,	   compound	   139	   was	   regarded	   as	  
sufficiently	  interesting	  to	  warrant	  further	  study.	  
Due	  to	  its	  potential	  application	  as	  an	  amyloid	  sensor,	  the	  emission	  spectra	  of	  
compound	  139	   in	  the	  absence	  and	  presence	  of	  aggregated	  Aβ42	  were	  recorded.	  
While	   the	  excitation	  maxima	   for	   the	  bound	  and	  unbound	   forms	  of	  139	  did	  not	  
significantly	  differ,	  a	  strong	  hypsochromic	  shift	  of	  the	  emission	  maximum	  (from	  
528	   to	   490	   nm),	   concomitant	   with	   a	   hyperchromic	   effect	   upon	   binding,	   was	  
observed	   (Figure	  6.3A).	   In	  agreement	  with	   the	  previously	  mentioned	  studies	   in	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solvents	  with	  decreasing	  polarity,	  this	  behavior	  seems	  related	  to	  a	  change	  in	  the	  
environmental	  conditions,	  as	  the	  binding	  of	  139	  to	  the	  amyloid	  fibrils	  takes	  place	  
in	   a	   lower	   dielectric	   constant	   environment.	   Indeed,	   adopting	   the	   β-­‐sheet	  
secondary	   structure	   in	   the	   Aβ42	   self-­‐assembly	   process	   is	   likely	   to	   expose	  
hydrophobic	   regions	   that	  are	  accessible	   to	  139.	   The	   spectral	   shift	  observed	   for	  
139	  is	  similar	  to	  that	  reported	  for	  the	  Aβ42	  fluorescent	  sensor	  1-­‐anilinophthalene-­‐
8-­‐sulfonic	   acid.162	   Furthermore,	   the	   fluorescence	   emission	   intensity	   at	   450	   nm	  
linearly	   correlated	  with	   the	   concentration	   of	   preaggregated	   Aβ42	   (R
2	   =	   0.9992)	  
(Figure	  6.4).	  	  
Finally,	   to	   gain	   further	   insights	   into	   the	   binding	   mode	   of	   139	   to	   Aβ,	  
displacement	  studies	  in	  the	  presence	  of	  aggregated	  Aβ42	  were	  carried	  out	  using	  a	  
fixed	   concentration	   of	   Aβ42	   and	   ThT	   and	   an	   increasing	   concentration	   of	   139.	  
Overlaid	   excitation	   spectra	   showed	   that	   139	   binds	   amyloid	   fibrils	   with	   a	   high	  
affinity.	  At	  a	  low	  concentration	  (25	  nM)	  and	  in	  the	  presence	  of	  Aβ42,	  139	  showed	  
a	   significant	   emission	   signal	   (Figure	   6.3B)	   without	   affecting	   the	   ThT	   excitation	  
and	   emission	   profile	   (Figure	   6.3C).	   Conversely,	   at	   higher	   concentrations,	   139	  
progressively	  displaced	  ThT	  from	  its	  binding	  site(s)	  (Figure	  6.5).163	  This	  behavior	  
led	   us	   to	   hypothesize	   that	   139	   may	   have	   a	   primary	   high	   affinity	   binding	   site	  
distinct	  from	  ThT	  and	  a	  secondary	  low-­‐affinity	  binding	  site	  in	  common	  with	  ThT.	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Figure.6.3.	   (A)	   Fluorescence	   emission	   spectra	   of	   139	   (5	   μM)	   in	   aqueous	   phosphate	  
buffer	   (10	  mM,	  pH	  7.4)	   in	  the	  absence	  (dotted	   line)	  and	   in	  the	  presence	  (solid	   line)	  of	  
aggregated	   Aβ42	   (3	   μM).	   (B)	   Fluorescence	   emission	   spectra	   of	   a	   solution	   containing	  
aggregated	   Aβ42	   protein	   and	   139	   [25	   nM]	   in	   glycine−NaOH	   buffer	   (50	   mM,	   pH	   8.5)	  
recorded	   at	   the	   excitation	   maximum	   of	   ThT	   (λex	   =	   446	   nm,	   dotted	   line)	   and	   at	   the	  
excitation	  maximum	  of	  139	  (λexc	  =	  375	  nm,	  solid	  line).(C)	  Excitation	  (λem	  =	  490	  nm)	  and	  
emission	  (λexc	  =	  446	  nm)	  spectra	  of	  a	  solution	  containing	  aggregated	  Aβ42	  protein	  in	  1.5	  
µM	  ThT	  buffered	  solution	  (glycine-­‐NaOH	  buffer,	  50	  mM	  pH	  8.5)	  in	  the	  presence	  (dotted	  
line)	  and	  absence	  (solid	  line)	  of	  139	  [25	  nM]	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Figure	   6.4.	   Linear	   dependence	   of	   the	   fluorescence	   emission	   intensity	   from	   the	  




Figure	   6.5.	  Overlaid	   excitation	   spectra	   of	   Aβ42	   protein	   diluted	   in	   1.5	  µM	  ThT	  buffered	  
solution	   (glycine-­‐NaOH	   buffer	   50	   mM,	   pH	   8.5)	   in	   the	   presence	   of	   increasing	  
concentrations	  of	  139;	  λem	  =	  490	  nm.	  
6.	  Fluorescent	  styrylquinolines	  as	  theranostics	   	   149	   	   	  
In	  order	   to	  discard	   the	  possible	   interference	  of	  human	  serum	  albumin	   (HSA)	   in	  
future	   in	   vivo	   studies,	   a	   comparison	   between	   the	   changes	   in	   the	   fluorescence	  
intensity	   in	   the	   presence	   of	   HSA	   and	   Aβ42	   was	   carried	   out.	   It	   evidenced	   a	  
stronger	   fluorescence	  change	   for	   the	   latter,	  as	  deduced	   from	  the	  slopes	  of	   the	  
titration	  plots	  (Figure	  6.6).	  
	   	  
Figure	  6.6.	  Left:	  Emission	  spectra	  of	  139	  in	  PBS	  in	  the	  presence	  of	  increasing	  amounts	  of	  
human	  serum	  albumin	  (HSA).	  Right:	  Selective	  increase	  in	  the	  fluorescence	  of	  139	  in	  the	  
presence	  of	  Aβ42	  protein	  with	  regard	  to	  HSA;	  Aβ42:	  y	  =	  9.27x	  +	  1.04,	  R
2	  =	  0.9935;	  HSA:	  y	  =	  
1.08x	  +	  0.97,	  R2	  =	  0.9959.	  
	  
6.2.5.	  Antiprion	  evaluation	  
The	  study	  on	  the	  antiprion	  activity	  of	  our	  molecules	  were	  conducted	  again	  by	  H.	  
N.	  Ai	  Tran	  under	  the	  supervision	  of	  Prof.	  G.	  Legname	  at	  the	  Trieste	  International	  
School	   of	   Advanced	   Studies	   (SISSA)	   employing	   the	   same	   protocol	   described	  
above	  for	  diketopiperazines.	  First,	  the	  capability	  to	   inhibit	  prion	  fibril	   formation	  
in	  vitro	  was	  studied,	  using	  the	  amyloid	  seeding	  assay	  (ASA).	  At	  a	  concentration	  of	  
50	   μM,	   137-­‐139	   delayed	   fibril	   formation,	   extending	   the	   lag	   phase	   to	   ≥70	   h	  
(control:	   59	   h)	   (Figure	   6.7).	   A	   similar	   profile	  was	   found	   for	   GN8,	   the	   antiprion	  
drug	   candidate	   that	   was	   described	   in	   the	   previous	   chapter.	   Taken	   together,	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these	   results	   showed	   that	   compound	   139	   is	   indeed	   able	   to	   recognize	   and	  
modulate	  Aβ42	  and	  PrP
Sc	  fibril	  aggregation	  in	  vitro.	  
	  
Figure	  6.7.	  Prion	  fibril	  formation	  inhibitory	  activity	  in	  vitro	  for	  compounds	  137-­‐139	  (50	  
µM)	  compared	  with	  GN8.	  
Next,	   the	   therapeutic	   antiprion	   potential	   (toxicity	   and	   activity)	   of	   137-­‐139	  
was	  preliminarily	  assessed	  in	  a	  cell-­‐based	  model	  of	  PrD	  (ScGT1	  cells).	  At	  a	  1	  μM	  
concentration,	  137	  and	  139	  showed	  a	  very	  low	  toxicity,	  with	  cell	  viability	  above	  
90%,	  while	   138	   caused	   viability	   to	   decrease	   to	   60%.	   Interestingly,	   at	   a	   10	   μM	  
concentration	   139	   still	   showed	   a	   tolerable	   toxicity,	   with	   a	   residual	   60%	   cell	  
viability	  similar	  to	  that	  of	  drug	  candidate	  GN8	  (Figure	  6.8).	  The	  three	  compounds	  	  
	  
Figure	  6.8.	  Cell	  viability	  profiles	  of	  137-­‐139	  in	  comparison	  with	  GN8	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were	   studied	   for	   their	   antiprion	   activity	   in	   a	   non-­‐toxic	   range	  of	   concentrations	  
(Table	  6.3).	   They	  all	   showed	   remarkable	  activities	   (submicromolar	  EC50	   values),	  
which	  make	   them	  more	  potent	   than	  GN8	  and	  equipotent	   to	   the	  gold	   standard	  
quinacrine.	   Cell	   viability	   at	   the	   concentration	   corresponding	   to	   EC50	   was	  
particularly	  high	  for	  139	  (94.6%).	  
Table	  6.3.	  Antiprion	  activity	  and	  cell	  viability	  of	  137-­‐139	  on	  ScGT1	  cells	  
Cmpd.	   EC50	  (mM)
a	   %	  of	  viable	  cells	  at	  
EC50
a	  
Quinacrine	   0.4	  ±	  0.1	   100.0	  ±	  4.3	  
GN8	   1.5	  ±	  0.1	   93.4	  ±	  7.3	  
137	   0.5	  ±	  0.1	   90.5	  ±	  6.8	  
138	   0.7	  ±	  0.1	   74.9	  ±	  4.1	  
139	   0.5	  ±	  0.1	   94.6	  ±	  4.9	  
	  
6.2.6.	  Fluorescent	  staining	  of	  PrPSc	  in	  ScGT1	  cells	  
To	   confirm	   the	   labeling	   of	   PrPSc	   aggregates	   in	   living	   cells,	   fluorescent	   staining	  
with	  139·∙HCl	  was	  carried	  out	  using	   the	  previously	  mentioned	  ScGT1	  cell	  model	  
by	   Suzana	   Aulić	   under	   the	   supervision	   of	   Prof.	   Giuseppe	   Legname	   at	   SISSA,	  
Trieste.	  It	  was	  found	  that	  0.025%	  of	  139·∙HCl	  (0.84	  mM)	  was	  sufficient	  to	  observe	  
many	   fluorescent	   spots	   in	   the	   treated	   cells	  before	  and	  after	  denaturation	  with	  
6M	   GndHCl	   examined	   by	   fluorescent	   microscopy	   (Figure	   6.9A,B).	   The	   green	  
colour	  of	   the	  spots	   is	  arbitrary	  and	  was	  manually	   selected;	   in	  other	  words,	   the	  
fluorescent	   emission	   of	   our	   compound	   is	   not	   properly	   green.	   Importantly,	   no	  
spots	  were	  observed	  in	  the	  uninfected	  cells	  (Figure	  6.9D−F),	  confirming	  a	  specific	  
binding	   for	   scrapie	   fibrils.	   Furthermore,	   139·∙HCl	   distinguished	   the	   abnormal,	  
proteinase	   K	   (PK)	   aggregated	   and	   resistant	   PrPSc	   isoform	   from	   the	   normal,	   PK-­‐
sensitive	  PrPC	   isoform.	  Thus,	  after	  eliminating	  PrPC	  through	  a	  PK	  digestion	  step,	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the	   previous	   fluorescence-­‐staining	   pattern	   was	   observed	   (Figure	   6.9C).	   ).	   A	  
further	   experiment	   proved	   that	   the	   staining	   pattern	   was	   consistent	   with	   that	  
observed	  with	  0.025%	  Thioflavin	  S	  (ThS),	  a	  common	  PrPSc	  dye	  (Figure	  6.10).	   
	  
	  
Figure	  6.9.	  Detection	  of	  PrPSc	  aggregates	  with	  139·∙HCl	  in	  ScGT1	  cells	  by	  IF	  before	  (A)	  and	  
after	  (B)	  denaturation	  with	  6M	  GndHCl.	  After	  PK	  digestion,	  PK	  resistant	  PrP	  (PrPSc)	  was	  
observed	  with	  139·∙HCl	  (C).	  Uninfected	  GT1	  cells	  with	  or	  without	  denaturation	  step	  with	  
6M	  GndHCl	   (D,	  E)	   and	   after	   PK	   digestion	   (F)	   did	   not	   show	   staining	   in	   the	   presence	   of	  
0.025%	  of	  139·∙HCl	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A	   B	  
	   	  
Figure.	  6.10.	  Comparison	  of	  the	  methods	  used	  to	  visualize	  PrPSc	  in	  ScGT1	  (scrapie	  prion-­‐
infected	   cells,	   panel	   A)	   and	   non-­‐infected	   GT1	   cells	   (panel	   B)	   before	   and	   after	  
denaturation	  with	   6M	  GndHCl,	   and	   after	   proteinase	   K	   digestion	   (PK)	   prior	   to	   staining	  
with	   Thioflavin-­‐S	   (yellow),	   a	   dye	   that	   specifically	   binds	   to	   aggregates,	   and	   counter	  
staining	  with	  DAPI	  (blue).	  Scale	  bar	  20μm	  
We	   primarily	   used	   the	   FITC	   filter	   set	   for	   these	   studies,	   but	   we	   confirmed	   the	  
staining	   by	   employing	   the	   ThS	   one,	   which	   is	   within	   the	   NIR	   optical	   window	  
(Figure	  6.11).	  
	  
Figure	  6.11.	  ScGT1	  cell	  line	  treated	  with	  6M	  GndHCl	  and	  stained	  with	  compound	  
139·∙HCl.	  (A)	  FITC	  filter.	  (B)	  ThS	  filter.	  Nuclei	  stained	  with	  DAPI	  (blue).	  Scale	  bar	  20μm	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6.3.	  Second	  styrylquinoline	  library	  	  
6.3.1	  Synthetic	  approaches	  
As	  anticipated,	  and	  in	  the	  light	  of	  the	  good	  results	  obtained	  for	  compound	  139,	  
we	  decided	  to	  develop	  a	  larger,	  focused	  library	  of	  styrylquinoline	  derivatives.	  Our	  
investigation	  started	  again	  with	  the	  application	  of	  the	  vinylogous	  variation	  of	  the	  
Povarov	  reaction.	  In	  order	  to	  introduce	  varied	  substituents	  on	  the	  phenyl	  moiety,	  
we	  needed	  suitable	  functionalized	  cinnamaldehydes,	  which	  we	  prepared	  using	  a	  
literature	  method.164	   Thus,	   a	   Heck	   reaction	   between	   aryl	   iodides	   and	   acrolein	  
diethyl	  acetal	  in	  the	  presence	  of	  Pd(OAc)2,	  nBu4NOAc,	  K2CO3,	  KCl,	  in	  DMF	  at	  90	  °C	  
was	  followed	  by	  in	  situ	  hydrolytic	  deprotection	  to	  give	  the	  desired	  products	  141-­‐
145	  in	  high	  yields	  (Scheme	  6.5). 
 
Scheme	  6.5.	  Scope	  and	  yields	  of	  the	  synthesis	  of	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With	   these	   cinnamaldehydes	   in	   hand,	  we	   carried	   out	   the	  multicomponent	  
reaction	  with	   arylamines	   and	   alkyl	   vinyl	   catalyzed	   by	   CAN	   under	   our	   standard	  
conditions	   to	   obtain	   the	   corresponding	   2-­‐styryl-­‐1,2,3,4-­‐tetrahydroquinolines.	  
This	  was	  followed	  by	  their	  dehydrogenation	  in	  the	  crude	  state	  in	  the	  presence	  of	  
DDQ	  to	  give	  the	  2-­‐styryquinoline	  compounds	  146-­‐160	  in	  moderate	  overall	  yields	  
(Scheme	  6.6	  and	  Table	  6.4).	  
	  
Scheme	  6.6.	  Synthesis	  of	  2-­‐styrylquinolines	  
Table	  6.4.	  Scope	  and	  yields	  of	  the	  synthesis	  of	  2-­‐styrlquinolines	  
 
Unexpectedly,	   the	   reaction	   starting	   from	   cinnamaldehyde	   derivatives	  
bearing	  a	  methoxy	  group	  at	  the	  meta	  and	  para	  positions	  failed	  or	  provided	  the	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desired	  product	  only	   in	   trace	  amounts.	  Probably,	   this	  was	  due	   to	   the	  electron-­‐
releasing	  effect	  of	  the	  methoxy	  group,	  which	  reduces	  the	  electrophilicity	  of	  the	  
aldehyde	   carbonyl	   group	   (Scheme	   6.7).	   Steric	   hindrance	   to	   resonance	   was	  
probably	  responsible	  for	  the	  isolation	  of	  compounds	  159	  and	  160,	  albeit	  in	  small	  
yields,	  in	  the	  reactions	  starting	  from	  o-­‐methoxycinnamaldehyde.	  
	  
 
Scheme	  6.7.	  Electron	  donor	  groups	  on	  the	  cinnamaldehyde	  moiety	  hamper	  the	  Povarov	  
reaction	  
In	  an	  effort	   to	  overcome	  this	  problem,	  we	  sought	  another	   strategy	   for	   the	  
synthesis	  of	  2-­‐styrylquinolines.	  It	  is	  well	  known	  that	  the	  most	  common	  method	  is	  
based	   on	   acid-­‐	   or	   base-­‐catalyzed	   condensation	   of	   2-­‐methyquinolines	  
(quinaldines)	  with	  aromatic	  aldehydes.165	  	  
As	   the	   first	   step,	   we	   prepared	   several	   substituted	   quinaldines	   exploiting	  
again	   a	   CAN-­‐catalyzed	   ABB’	   chemodifferentiating	   three-­‐component	   reaction	  
between	  anilines	  and	  vinyl	  ethers.166	  As	  shown	  in	  Scheme	  6.8,	  the	  treatment	  of	  
aniline	  derivatives	  with	  vinyl	  ethers	  in	  the	  presence	  of	  5%	  CAN	  in	  acetonitrile	  at	  
r.t.	   led	   to	   the	   corresponding	   2-­‐methyl-­‐1,2,3,4-­‐tetrahydroquinolines	   with	   about	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  M.;	  Salehi,	  P.;	  Baghbanzadeh,	  M.;	  Nikcheh,	  M.	  S.	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  Lett.	  2008,	  49,	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  J.	  T.;	  Roy,	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  2008,	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  F.;	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9:1	   cis/trans	   diastereoselectivity.	   Since	   we	   were	   interested	   in	   their	  
dehydrogenated	  derivatives,	  these	  two	  diastereoisomers	  were	  not	  separated	  by	  
chromatography;	   instead,	   the	   crude	   products	  were	   directly	   dehydrogenated	   in	  
the	   presence	   of	   palladium	   in	   refluxing	   toluene	   to	   give	   compounds	   161-­‐167	  
(Scheme	  6.8	  and	  Table	  6.5).	  The	  yields	  were	  generally	  good,	  with	  the	  exception	  
of	  the	  reactions	  starting	  from	  m-­‐substituted	  anilines,	  which	  were	  complicated	  by	  
the	  possibility	  to	  obtain	  two	  products,	  since	  the	  starting	  aniline	  is	  not	  symmetric.	  
	  
 
Scheme	  6.8.	  Synthesis	  of	  2-­‐methylquinolines	  (quinaldines)	  
Table	  6.5.	  Scope	  and	  yields	  of	  the	  synthesis	  of	  2-­‐methylquinolines	  
Entry	   Cmpd.	   R1	   R2	   Overall	  yield,	  %	  	  
1	   161	   H	   H	   78	  
2	   162	   CH3	   H	   82	  
3	   163	   Cl	   H	   67	  
4	   164	   OMe	   H	   70	  
5	   165	   H	   CH3	   40	  
6	   166	   H	   Cl	   45	  
7	   167	   H	   OMe	   Trace	  
	  
The	   domino	  mechanism	   of	   the	   reaction	   that	   leads	   to	   the	   formation	   of	   2-­‐
methyl-­‐1,2,3,4-­‐tetrahydroquinolines	   is	   summarized	   in	   Scheme	   6.9	   and	   involves	  
five	   individual	   steps.	   First,	   a	   condensation	   reaction	   between	   aniline	   and	   one	  
molecule	   of	   ethyl	   vinyl	   ether,	  which	   can	  be	   regarded	   as	   an	   enol	   ether	   derived	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from	  acetaldehyde,	  takes	  place	  catalyzed	  by	  CAN	  that	  acts	  as	  Lewis	  acid	  to	  afford	  
the	  imine	  intermediated	  product.	  Then,	  the	  latter	  compound	  undergoes	  a	  CAN-­‐
catalyzed	  imino	  Diels–Alder	  reaction	  (Povarov	  reaction)	  with	  a	  second	  molecule	  
of	   ethyl	   vinyl	   ether,	   now	   acting	   as	   an	   electron-­‐rich	   dienophile,	   to	   give	   the	  
observed	  tetrahydroquinolines	  after	  the	  final	  cyclization	  step.	  	  
 
Scheme	  6.9.	  Mechanism	  of	  the	  CAN-­‐catalyzed	  three-­‐component	  reaction	  between	  
anilines	  and	  ethyl	  vinyl	  ether	  
Because	   this	   protocol	   turned	   out	   to	   be	   unsuitable	   for	   the	   synthesis	   of	  
compound	   167,	   we	   looked	   for	   a	   more	   efficient	   method.	   Thus,	   we	   applied	  
conditions	   found	   in	   literature	  based	  on	   the	  preparation	  of	  7-­‐hydroxyquinaldine	  
followed	  by	   its	  transformation	   into	  the	  methoxy	  derivative	  (Scheme	  6.10).167	  7-­‐
hydroxyquinaldine	   (compound	   168)	   was	   obtained	   via	   the	   Skraup	   reaction	   by	  
treating	  m-­‐aminophenol	   with	   crotonaldehyde	   in	   the	   presence	   of	   concentrated	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hydrochloric	  acid	  and	  tetrachloro-­‐1,4-­‐benzoquinone	  (p-­‐chloranil),	  with	  1-­‐butanol	  
as	  solvent.168	  Afterwards,	   the	  hydroxyl	  group	  was	   transformed	   into	   the	  desired	  
methoxy	  by	  methylation	  in	  the	  presence	  of	  CH3I	  and	  K2CO3	  in	  DMF.	  
	  
 
Scheme	  6.10.	  Synthesis	  of	  compound	  167	  via	  Skraup	  reaction	  
With	   all	   the	   quinaldines	   in	   hand,	   we	   needed	   to	   study	   their	   reaction	   with	  
aromatic	   aldehydes.	   Using	   common	   literature	   methods,	   this	   aldol-­‐type	  
condensation	   requires	   high	   temperatures	   and	   gives	   only	   moderate	   yields	   in	  
many	  cases.	  An	  attempt	  to	   improve	  this	  reaction	  by	  applying	  MW	  irradiation	   is	  
described	   in	  the	   literature,169	  but	   it	   involves	  the	  use	  of	  a	  domestic	  oven,	  which	  
leads	  to	  well-­‐known	  safety	  concerns	  and	  serious	  reproducibility	  issues	  related	  to	  
the	   generation	   of	   an	   uneven	   pattern	   of	   hot	   and	   cold	   spots	   inside	   the	   oven	  
cavity.170	  Even	  more	  importantly,	  the	  method	  was	  not	  general,	  allowing	  only	  the	  
preparation	   of	   carboxyquinolines	   and	   little	   structural	   variation	   on	   the	   styryl	  
chain.	  	  
With	  this	  precedent	  in	  mind,	  in	  an	  effort	  to	  circumvent	  these	  limitations,	  we	  
investigated	   the	   condensation	   reaction	   under	   focused	   MW	   irradiation.	   After	  
some	   experimentation,	   we	   found	   that	   microwave	   irradiation	   of	   a	   solvent-­‐free	  
mixture	   of	   quinaldine	   derivatives,	   aromatic	   aldehydes	   and	   acetic	   anhydride	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
168	   Fedoryak,	  O.	  D.;	  Dore,	  T.	  M.	  Org.	  Lett.	  2002,	  4,	  3419.	  
169	   Musiol,	  R.;	  Podeszwa,	  B.;	  Finster,	  J.;	  Niedbala,	  H.;	  Polansli,	  J.	  Monatsh.	  Chem.	  2006,	  137,	  
1211.	  
170	   Kappe,	  A.	  O.	  Angew.	  Chem.	  Int.	  Ed.	  2004,	  43,	  6250.	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afforded	  excellent	  yields	  of	   styrylquinolines	   in	  a	   single	   synthetic	  operation	   that	  
leads	   to	   the	   generation	   of	   a	   carbon-­‐carbon	   double	   bond	   in	   a	   very	   efficient	  
diastereoselective	  fashion,	  with	  water	  and	  acetic	  acid	  as	  the	  only	  side	  products	  
(Scheme	  6.11).171	  	  
	  
 
Scheme	  6.11.	  General	  conditions	  for	  the	  synthesis	  of	  2-­‐styrylquinolines	  
	  
This	  protocol	  was	  applied	  to	  different	  aromatic	  aldehydes	  such	  as	  pyridine-­‐
2-­‐carbaldehyde,	   pyridine-­‐3-­‐carbaldehyde,	   pyridine-­‐4-­‐carbaldehyde,	   3	   and	   4-­‐
methoxybenzaldehyde,	  4-­‐fluorobenzaldehyde,	  and	  substituted	  cinnamaldehydes	  
including	   (E)-­‐3-­‐(4-­‐chlorophenyl)acrylaldehyde	   and	   (E)-­‐3-­‐(2-­‐nitrophenyl)-­‐
acrylaldehyde	  to	  obtain	  compounds	  169-­‐199	  (Table	  6.6).	  
	  
	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
171	   Staderini,	  M.;	  Cabezas,	  N.;	  Bolognesi,	  M.	  L.;	  Menéndez,	  J.	  C.	  Synlett	  2011,	  17,	  2577.	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As	  summarized	  in	  Scheme	  6.12,	  we	  propose	  this	  transformation	  to	  proceed	  
through	   a	   domino	   sequence	   comprising	   an	   initial	   aldol	   addition,	   followed	   by	  
intramolecular	  O-­‐acetylation	  and	  elimination.	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Scheme	  6.12.	  Proposed	  mechanism	  for	  the	  Ac2O-­‐promoted	  aldol	  reaction 
	  
Unexpectedly,	   in	   the	   case	   of	   4-­‐(dimethylamino)benzaldehyde	   the	  
microwave-­‐enhanced	   aldol	   reaction	   failed.	   As	   an	   alternative,	  we	   resorted	   to	   a	  
protocol	   that	   involved	   the	  use	  of	  potassium	   t-­‐butoxide	  as	  base	   to	   catalyze	   the	  
condensation	  reaction	  with	  quinladines.172	  The	  reaction	  was	  carried	  at	  r.t.	  during	  
24	  h	  in	  DMF	  in	  the	  presence	  of	  LiH	  to	  ensure	  a	  dry	  non-­‐protic	  reaction	  medium	  
to	  give	  compounds	  200-­‐203	  (Scheme	  6.13	  and	  Table	  6.7).	  The	  same	  method	  was	  
used	  for	  quinoline-­‐2-­‐carbaldehyde	  to	  obtain	  compound	  204.	  
	  
 
Scheme	  6.13.	  Synthesis	  of	  compounds	  200-­‐204	  in	  the	  presence	  of	  potassium	  t-­‐butoxide	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   De,	  C.;	  Samuels,	  T.	  A.;	  Haywood,	  T.	  L.;	  Anderson,	  G.	  A.;	  Campbell,	  K.;	  Fletcher,	  K.;	  Murray,	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Table	  6.7.	  Scope	  and	  yields	  of	  the	  synthesis	  of	  compounds	  200-­‐204	  
 
 
Since	  compound	  139	  had	  shown	  excellent	  optical	  and	  biological	  properties,	  
we	  decided	  to	  explore	  the	  role	  of	  the	  amino	  moiety	  at	  different	  positions	  of	  the	  
styrylquinoline	   fragment.	  We	   first	   decided	   to	   introduce	   an	   amino	   group	  at	   the	  
quinoline	  C-­‐4	  position,	  and	  to	  this	  end	  we	  planned	  the	  use	  the	  Conrad-­‐Limpach	  
reaction	  to	  prepare	  the	  suitable	  quinolin-­‐4-­‐ones,	  which	  would	  then	  be	  submitted	  
to	  aldol	  condensations	  and	  a	  hydroxy-­‐amino	  exchange	  (Scheme	  6.14).	  	  
	  
Scheme	  6.14.	  Retrosynthetic	  scheme	  for	  the	  preparation	  of	  4-­‐aminostyrylquinolines.	  
We	   started	   with	   the	   reaction	   between	   the	   suitable	   aniline	   and	   ethyl	  
acetoacetate	   to	   obtain	   the	   corresponding	   β-­‐enaminones.	   This	   reaction	   is	   well	  
described	  in	  the	  literature,	  and	  it	  is	  often	  carried	  out	  in	  the	  presence	  of	  a	  Lewis	  
acid	  as	  catalyst.120	  In	  our	  case,	  we	  performed	  the	  reaction	  in	  the	  presence	  of	  the	  
inexpensive	   and	   readily	   available	   InCl3	   in	   ethanol	   during	   2	   hours	   at	   room	  
temperature	  to	  furnish	  compounds	  205-­‐208	  in	  high	  yields	  (Scheme	  6.15).	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Scheme	  6.15.	  Synthesis	  of	  compounds	  205-­‐208	  
	  
To	   obtain	   the	   4-­‐quinolone	   derivatives,	   we	   cyclized	   compounds	   205-­‐208	  
under	   thermal	   conditions	  with	   concomitant	   ethanol	   elimination.173	  We	   carried	  
out	   the	   reaction	   in	   refluxing	  diphenyl	   ether	   connected	   to	   a	  Dean-­‐Stark	   trap	   to	  
recollect	  ethanol,	  thereby	  shifting	  the	  equilibrium	  towards	  the	  formation	  of	  the	  
product.	  Once	  the	  reaction	  was	  completed,	  the	  flask	  was	  left	  to	  cool	  at	  r.t.	  and	  
the	  precipitated	  product	  was	  recovered	  by	  filtration	  and	  washed	  with	  petroleum	  
ether	   and	   acetone	   to	   give	   209-­‐212.	   Importantly,	   the	   preparation	   of	   these	  
compounds	   could	   be	   performed	   in	   multigram	   scale	   and	   did	   not	   require	  
chromatographic	  purification	  (Scheme	  6.16).	  
	  
 
Scheme	  6.16.	  Synthesis	  of	  compounds	  209-­‐212	  via	  the	  Conrad-­‐Limpach	  reaction	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
173	   Curran,	  T.	  T.	  Conrad-­‐Limpach	  reaction.	  In	  Name	  Reactions	  in	  Heterocyclic	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Afterwards,	   we	   prepared	   4-­‐chloroquinaldine	   (213)	   by	   chlorinating	  
compound	  209	  in	  the	  presence	  of	  a	  large	  excess	  of	  POCl3.	  With	  this	  compound	  in	  
hand,	  we	  attempted	  its	  condensation	  with	  benzaldehyde	  in	  the	  presence	  of	  Ac2O	  
under	  MW	  irradiation,	  but	  unexpectedly	  it	  did	  not	  work.	  Thus,	  we	  decided	  to	  use	  
the	   previously	   mentioned	   alternative	   method	   with	   potassium	   t-­‐butoxide,	   but	  
also	  in	  this	  case	  we	  recovered	  only	  the	  starting	  materials	  (Scheme	  6.17).	  
 
Scheme	  6.17.	  Synthesis	  of	  compound	  213	  and	  its	  failed	  reaction	  with	  benzhadeyde	  
In	  view	  of	  this	  result,	  we	  changed	  the	  order	  of	  the	  steps	  by	  carrying	  out	  first	  
the	   aldol	   condensation	   reaction	   between	   2-­‐methyl-­‐4-­‐quinolines	   and	  
benzaldehyde	  under	  our	  standard	  conditions	  by	  using	  MW	  irradiation	  to	  afford	  
compounds	  214-­‐217	   in	   excellent	   yields.171 In	   the	   cases	   of	   compounds	  214	   and	  
216,	   the	   quinolone	   oxygen	   was	   acetylated	   during	   the	   reaction	   due	   to	   the	  
presence	  of	  Ac2O,	  but	  this	  was	  of	  no	  consequence	  to	  the	  overall	  route,	  since	  the	  
desired	   4-­‐chloro-­‐2-­‐styrylquinolines	   were	   synthesized	   via	   treatment	   of	  
compounds	  214-­‐217	  with	  an	  excess	  of	  phosphorus	  oxychloride	   to	  give	  218-­‐221	  
(Scheme	  6.18).174	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Scheme	  6.18.	  Synthesis	  of	  the	  compounds	  214-­‐221	  
As	  the	  final	  step,	  the	  4-­‐chlorostrylquinolines	  were	  treated	  a	  slow	  stream	  of	  
ammonia	  in	  the	  presence	  of	  phenol,	  thereby	  replacing	  the	  chlorine	  atom	  with	  an	  
amino	  group	  and	  achieving	  the	  preparation	  of	  compounds	  222-­‐225	  in	  moderate	  
yields	  (Scheme	  6.19).28b	  
 
Scheme	  6.19.	  Synthesis	  of	  compound	  222-­‐225	  by	  using	  a	  slow	  stream	  of	  ammonia	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6.3.2.	  Preliminary	  biological	  evaluation	  in	  ScN2a	  cells	  
In	  order	  to	  investigate	  the	  effects	  of	  the	  shifting	  of	  the	  amino	  group	  compared	  to	  
compound	   139,	   compounds	   222,	   223	   and	   225	   were	   preliminary	   screened	   in	  
mouse	  prion-­‐infected	  ScN2a	  cells	  to	  test	  their	  antiprion	  activity.	  The	  experiments	  
were	   carried	   out	   by	   Suzana	   Aulić	   under	   the	   supervision	   of	   Prof.	   Giuseppe	  
Legname	  at	  SISSA,	  Trieste.	  Even	  though	  all	   the	  compounds	  were	  able	  to	   inhibit	  
the	  prion	  replication	  in	  a	  low	  micromolar	  range	  and	  to	  delay	  the	  fibril	  formation	  
(Figure	  6.12),	  the	  displacement	  of	  the	  amino	  group	  to	  the	  quinoline	  ring	  led	  to	  a	  
slight	  decrease	  in	  terms	  of	  activity	  and	  an	  increased	  toxicity	  in	  comparison	  with	  
139.	   Thus,	   at	   10	  µM	   compound	   139	   showed	   a	   60%	   cell	   viability,	   whereas	   for	  
these	  new	  molecules	  the	  cell	  viability	  was	  almost	  0	  (Figure	  6.12).	  
A	   B	  
	    
C	   D	  
  
Figure	  6.12.	  (A)	  Dose-­‐dependent	  capacity	  of	  222,	  223	  and	  225	  to	  decrease	  PrPSc	   levels.	  
(B)	  Western	  blotting	  of	  ScN2a	  cell	   lysates	  depicting	   the	  presence	  or	  absence	  of	  prions	  
(PrPSc)	   following	   treatment	   with	   222,	   223	   and	   225	   before	   (top)	   or	   after	   (bottom)	   PK	  
digestion.	  (C)	  Prion	  fibril	   formation	  inhibitory	  activity	   in	  vitro	  using	  ASA	  for	  compounds	  
222,	  223	  and	  225	  (5µM).	  (D)	  Chemical	  structure	  of	  222,	  223	  and	  225	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Figure	  6.13.	  Cell	  viability	  profiles	  of	  222,	  223	  and	  225	  
	  
6.3.3.	  Preliminary	  antiprion	  assessment	  in	  vitro	  by	  using	  PMCA	  
Furthermore,	  the	  anti-­‐prion	  potential	  of	  selected	  compounds	  (171-­‐180,	  200-­‐204,	  
Figure	   6.14)	  was	   preliminary	   assessed	   in	   vitro	   by	  Dr.	  Natalia	   Fernández-­‐Borges	  
under	   the	   supervision	   of	   Prof.	   Joaquín	   Castílla	   at	   the	   Center	   for	   Cooperative	  
Research	   in	   Biosciences,	   Bilbao.	   A	   model	   called	   protein-­‐misfolding	   cyclic	  
amplification	  (PMCA)	  was	  used	  instead	  of	  a	  cellular	  test.175	  PMCA	  reproduces	  the	  
infectious	   process	   of	   the	   prion	   propagation	   involving	   cyclic	   amplification	   of	  
protein	  misfolding	  that	  triggers	  a	  rapid	  conversion	  of	  a	  large	  amount	  of	  PrPC	  into	  
the	  PrPSc	  form	  in	  the	  presence	  of	  small	  quantities	  of	  PrPSc,	  acting	  as	  a	  template.	  
Furthermore,	  PMCA	  yields	  a	  very	  efficient	  and	  sensitive	  amplification	  of	  scrapie-­‐
prion	   concentration	  by	  a	   factor	  up	   to	  109,	   and	   this	  9	   log	  window	   is	   suitable	   to	  
analyze	  the	  behavior	  of	  new	  compounds	  as	  inhibitors.	  An	  inhibition	  at	  4-­‐5	  logs	  in	  
this	  model	  can	  be	  considered	  as	  proof	  of	  very	  potent	  activity.	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Figure	  6.14.	  Chemical	  structures	  of	  the	  compounds	  that	  were	  tested	  in	  vitro,	  namely	  
139,	  used	  as	  the	  reference	  compound,	  171-­‐180	  and	  200-­‐204	  
To	  perform	  the	  assay,	  PrPSc	  is	  incubated	  with	  Tg338	  mice	  brain	  homogenates	  rich	  
in	   PrPC	   and	   the	   resulting	   aggregates	   are	   disrupted	   by	   sonication	   to	   generate	  
multiple	   smaller	   units	   for	   the	   continued	   formation	   of	   new	   PrPSc.	   After	   cyclic	  
amplification	  more	  than	  97%	  of	  the	  protease-­‐resistant	  PrP	  present	  in	  the	  sample	  
corresponds	  to	  newly	  converted	  protein.	  When	  a	  compound	  is	  introduced	  in	  this	  
model,	   its	   capability	   to	   inhibit	   the	   PrPSc	   formation	   is	   measured	   through	  
densitometric	  analysis	  of	  immunoblots.	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The	   histogram	   in	   Figure	   6.15	   summarizes	   the	   results	   obtained	   for	   our	  
molecules,	  and	  shows	  that	  six	  of	  them	  (171,	  172,	  174,	  178,	  179	  and	  204)	  have	  a	  
higher	   inhibitor	   potency	   against	   prion	   replication	   than	   139,	   our	   reference	  
compound.	  Among	  them	  compound	  204	  is	  considered	  the	  best	  one,	  with	  a	  very	  
strong	  inhibition	  effect	  (5	  logs	  at	  2	  mM	  and	  6,5	  logs	  at	  8	  mM).	  Further	  studies	  on	  
these	  compounds	  are	  in	  progress.	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7.1.	  Introduction	  
Several	   lines	   of	   evidence	   suggest	   that	   polyamines	   play	   a	   fundamental	   role	   in	  
many	   biological	   processes.	   In	   the	   context	   of	   central	   nervous	   system	   (CNS)	  
diseases,	  it	  has	  been	  postulated	  that	  polyamines	  act	  as	  neuromodulators176	  and	  
influence	   the	   properties	   of	   several	   neurotransmitter	   pathways,	   including	  
catecholamines,	   γ-­‐aminobutyric	   acid,	   nitric	   oxide,	   and	   glutamate.177	  
Furthermore,	  polyamines	  that	  function	  as	  neuroprotectants,178	  and	  as	  antiprion	  
chemotherapeutics179	  have	  been	  described.	  
With	  these	  concepts	  in	  mind	  and	  building	  on	  our	  previous	  experience	  in	  the	  
polyamine	   drug	   discovery	   field,	   we	   planned	   to	   introduce	   diverse	   types	   of	  
polyamino	  chains	  at	  C-­‐4	  position	  of	  the	  styrylquinoline	  moiety	  in	  order	  to	  provide	  
novel	  molecules	  to	  treat	  PrDs	  and	  AD.	  The	  biological	  study	  of	  these	  compounds	  
in	  these	  neurodegenerative	  diseases	  is	  still	  in	  progress.	  
	  
	  
Based	   on	   the	   concept	   of	   privileged	   structure,	   the	   parallelism	   between	  
neurodegenerative	   and	   protozoan	   diseases	   and	   the	   literature	   search	  
summarized	  in	  Section	  7.2,	  we	  decided	  to	  also	  screen	  our	  4-­‐aminostrylquinoline	  
derivatives	  against	  trypanosomatid	  diseases	  (Leishmania,	  Trypanosoma).	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7.2.	  Styrylquinolines	  and	  polyamines	  against	  leishmaniasis	  
Leishmaniasis	   is	   a	   complex	   of	   protozoan	   diseases	   due	   to	   the	   infection	   of	  
mammals	  by	  different	  species	  of	  protozoans	  belonging	  to	  the	  genus	  Leishmania.	  
Several	   species	   are	   responsible	   of	   multiple	   clinical	   forms	   ranging	   from	   the	  
cutaneous	  form	  to	  the	  visceral,	   lethal	  if	  untreated.	  Such	  maladies	  belong	  to	  the	  
family	  of	  the	  neglected	  tropical	  diseases	  that	  affect	  the	  less	  developed	  countries,	  
for	   which	   no	   ideal	   therapeutic	   tools	   are	   available.	   A	   safe	   a	   reliable	   human	  
vaccine	   is	   not	   yet	   available,	   and	   therefore	   treatment	   is	   exclusively	   based	   on	  
chemotherapy.	   Indeed,	   classical	   therapies	   are	   expensive,	   toxic,	   and	   require	  
parenteral	  administration.180	  In	  this	  scenario,	  we	  have	  embarked	  on	  a	  new	  drug	  
discovery	  project	  devoted	  to	  the	   identification	  of	  novel	  small	  molecules	  for	  the	  
treatment	  of	  leishmanial	  diseases,	  using	  compounds	  initially	  targeted	  at	  fibrillar	  
proteins.	   With	   this	   in	   mind,	   we	   noticed	   that	   several	   2-­‐substituted	   quinoline	  
exhibited	  in	  vivo	  activities	  against	  Leishmania	  donovani	  (see	  chemical	  structures	  
in	  Figure	  7.1).	   In	  particular,	   it	   seems	  that	  a	  double	  bond	  on	   the	   lateral	   chain	   is	  
critical	   for	   antileishmanial	   activity.181	   Starting	   from	   this	   assumption,	   several	  
substituted	   styrylquinoline	   derivatives	   were	   synthesized	   and	   tested	   across	  
different	   cellular	   lines	   showing	   high	   in	   vitro	   antileishmanial	   activity	   and	   low	  
toxicity	  (Figure	  7.1).182	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   Mishra,	  B.	  B.;	  Singh,	  R.	  K.;	  Srivastava,	  A.;	  Tripathi,	  V.	  J.;	  Tiwari,	  V.	  K.	  Mini	  Med.	  Chem.	  2009,	  
9,	  107.	  
181	   (a)Fakhfakh,	   M.	   A.;	   Fournet,	   A.;	   Prina,	   E.;	   Mouscadet,	   J.	   F.;	   Franck,	   X.;	   Hocquemiller,	   R.;	  
Figadère,	   B.	   Bioorg.	   Med.	   Chem.	   2003,	   17,	   5013;	   (b)	   Franck,	   X.;	   Fournet,	   A.;	   Prina,	   E.;	  
Mahieux,	   R.;	   Hocquemiller,	   R.;	   Figadère,	   B.	   Bioorg.	   Med.	   Chem.	   Lett.	   2004,	   14,	   3635;	   (c)	  
Nakayama,	  H.;	  Desrivot,	  J.;	  Bories,	  C.;	  Franck,	  X.;	  Figadère,	  B.;	  Hocquemiller,	  R.;	  Fournet,	  A.;	  
Loiseau,	  P.	  M.	  Biomed.	  Pharmacother.	  2007,	  61,	  186.	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   Loiseau,	  P.	  M.;	  Gupta,	  S.;	  Verma,	  A.;	  Srivastava,	  S.;	  Puri,	  S.	  K.;	  Sliman,	  F.;	  Normand-­‐Bayle,	  M.;	  
Desmaele,	  D.	  Antimicrob.	  Agents	  Chemother.	  2011,	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Figure.	  7.1.	  Chemical	  structures	  of	  2-­‐substituted	  quinolines	  and	  styrylquinolines	  active	  
against	  Leishmania	  
	  
In	  this	  context,	   it	   is	   important	  to	  note	  that	  polyamines	  have	  been	  found	  to	  
exhibit	   selective	   uptake	   by	   Plasmodium	   infected	   erythrocytes.183	   Generally	  
speaking,	   polyamines	   play	   a	   vital	   role	   in	   all	   living	   systems,	   are	   found	   in	   large	  
amounts	   in	   mammalian	   cells	   and	   are	   mainly	   responsible	   for	   maintaining	   cell	  
viability.	   The	   presence	   of	   a	   polyamine	   tail	   is	   considered	   an	   attractive	   tool	   in	  
antileishmanial	  drug	  discovery	  for	  the	  following	  reasons:	  	  
(i)	  	   Many	  polyamines	  and	  their	  conjugates	  have	  been	  shown	  to	  be	  active	  against	  
trypanosomatid	  parasites.184	  
(ii)	  	   Enzymes	   involved	   in	   polyamine	   synthesis	   and	   metabolism	   are	   validated	  
targets	  for	  antiparasitic	  drug	  development.185	  
(iii)	  	  The	  polyamine	  chain	  could	  exploit	   the	  parasite's	  polyamine	  transporters	  to	  
improve	  the	  intracellular	  uptake	  of	  the	  conjugate.186	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   Stringer,T.;	  Taylor,	  D.;	  de	  Kock,	  C.;	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  et	  al.	  Europ.	  J.	  Med.	  Chem.	  2013,	  69,	  90.	  
184	   Pinheiro,	  A.	  C.;	  Rocha,	  M.	  N.;	  Nogueira,	  P.	  M.;	  Nogueira,	  T.	  C.;	  Jasmim,	  L.	  F.;	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  M.	  V.;	  
Soares,	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  Diagn.	  Microbiol.	  Infect.	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  273.	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   (a)	  Birkholtz,	  L.	  M.;	  Williams,	  M.;	  Niemand,	  J.;	  Louw,	  A.	  I.;	  Persson,	  L.;	  Heby,	  O.	  Biochem.	  J.	  
2011,	  438,	  229;	  (b)	  Willert,	  E.;	  Phillips,	  M.	  A.	  Trends	  Parasitol.	  2012,	  28,	  66.	  
186	   Reguera,	   R.	  M.;	   Tekwani,	   B.	   L.;	   Balana-­‐Fouce,	   R.	  Comp.	   Biochem.	   Physiol.,	   Part	   C:	   Toxicol.	  
Pharmacol.	  2005,	  140,	  151.	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(iv)	  	  Polyamine	  conjugation,	  by	  increasing	  the	  cationic	  character	  of	  the	  molecule,	  
may	  promote	  its	  accumulation	  directly	  into	  the	  mitochondrion.187	  	  
For	  instance,	  a	  fused	  benzoquinone	  compound	  conjugated	  with	  a	  polyamine	  
(cadaverine)	  (see	  chemical	  structure	  in	  Figure	  7.2)	  is	  an	  interesting	  hit	  compound	  
toward	   Trypanosoma	   brucei.	   The	   antiparasitic	   activity	   shown	   by	   this	   molecule	  
requires	  a	  fine-­‐tuning	  between	  hydrophobicity	  and	  charge,	  as	  the	  first	  is	  required	  
for	  passive	  translocation	  across	  membranes,	  whereas	  the	  second	   is	  responsible	  
for	   the	   mitochondrial	   localization	   and	   the	   interactions	   with	   intracellular	  
targets.188	  
	  
Figure	  7.2.	  A	  fused	  benzoquinone	  derivative	  endowed	  with	  a	  polyamino	  chain	  that	  
showed	  high	  antitrypanosomal	  activity.188	  
Also	  in	  the	  polyamine	  context,	  sitamaquine,	  a	  quinoline	  derivative	  featuring	  
a	  polyamino	  chain	  at	  C-­‐8	  position,	   showed	  very	  high	  antileishmanial	  efficacy	   in	  
preclinical	  models.189	  Its	  antileishmanial	  mechanism	  of	  action	  is	  still	  not	  clarified	  
but	  it	  seems	  due	  to	  its	  ability	  to	  interfere	  with	  an	  intracellular	  redox	  cycle	  within	  
the	   infected	   macrophages,	   thereby	   developing	   oxidative	   stress.190	   It	   has	   been	  
hypothesized	   that	   sitamaquine	  crosses	  parasite	  membrane	  by	  passive	  diffusion	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  Motterlini,	  R.;	  Cavalli,	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  10490.	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   Sanchez,	   J.;	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thanks	   to	   favourable	   hydrophobic	   interactions	   between	   its	   aromatic	   ring	   and	  
alkyl	   chains	   of	   membrane	   phospholipids,	   and	   between	   the	   positively	   charged	  
amino	   chain	   and	   the	   negative	   polar	   headgroups	   of	   the	   membrane	   driving	  
insertion	   of	   the	   drug	   (Figure	   7.3).191	   This	   mode	   of	   interaction	   would	   also	   be	  
possible	  for	  our	  compounds.	  
Drug
	  
Figure	  7.3.	  Sitamaquine	  is	  able	  to	  cross	  the	  parasite	  membrane.	  
In	   the	   light	   of	   these	   considerations,	   polyamine	   chains	   seem	   important	   for	  
antileishmanial	   activity.	   Thus,	   viewing	   styrylquinoline	   as	   a	   privileged	   structure,	  
we	   describe	   in	   this	   chapter	   novel	   compounds	   generated	   by	   introducing	  
polyamino	   chains	   at	   the	   styrylquinoline	   framework	   to	   target	   trypanosomatid	  
diseases,	  especially	  leishmaniasis.	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   Acta	  
2007,	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7.3.	  Synthesis	  of	  4-­‐(polyamino)styrylquinoline	  compounds	  
This	   work	   was	   aided	   by	   experimental	   contributions	   from	   the	   undergraduate	  
student	  Giulia	  Romanelli.	  
First,	   we	   generated	   the	   styrylquinoline	   nucleus	   followed	   by	   its	  
functionalization	   with	   different	   polyamino	   chains.	   We	   started	   with	   the	  
preparation	   of	   4-­‐chlorostyrylquinoline	   (218)	   following	   the	   experimental	  
procedure	  described	   in	   the	  previous	   chapter.	  With	  compound	  218	   in	  hand,	  we	  
carried	   out	   a	   nucleophilic	   aromatic	   substitution	   with	   ethylenediamine,	   which	  
allowed	   the	   incorporation	   of	   a	   short	   amino	   chain	   at	   the	   C-­‐4	   position	   of	   the	  
quinoline	   nucleus.	   As	   described	   in	   chapter	   3.2,	   in	   order	   to	   avoid	   a	   competing	  
double	   substitution	   involving	   two	   molecules	   of	   the	   haloquinoline	   and	   both	  
amino	  groups	  of	  ethylenediamine,	  we	  treated	  compound	  218	  with	  a	  large	  excess	  
(20	   equivalents	   of	   ethylenediamine),	   under	   focused	   microwave	   irradiation	   at	  
120°C	  during	  1	  hour	   to	  afford	   compound	  226	   (Scheme	  7.1).112 Importantly,	  we	  
avoided	   the	   use	   of	   chromatography	   for	   the	   isolation	   of	   the	   product,	   which	  
required	   tedious	   evaporation	   of	   the	   excess	   diamine	   and	   recrystallization	   from	  
methanol	  and	  hexane.	  
 
Scheme	  7.1.	  Coupling	  reaction	  to	  obtain	  compound	  226	  
Compound	   226	   was	   transformed	   into	   the	   halide	   227	   by	   acylation	   with	  
bromoacetyl	  bromide	  in	  the	  presence	  of	  pyridine	  (Scheme	  7.2).	   In	  this	  case	  the	  
work-­‐up	  consisted	  only	  on	  washing	  the	  crude	  with	  slightly	  acidic	  water	  to	  afford	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the	   final	   product	   in	   46%	   yield.	   Pyridine	   was	   used	   to	   activate	   the	   acyl	   halide	  
rather	   than	   the	  more	   commonly	   employed	  DMAP	   (see	   chapter	   5.1),	  which	  did	  
not	  give	  good	  results.	  
 
Scheme	  7.2.	  Transformation	  of	  226	  into	  the	  halide	  derivative	  227	  
With	   compound	   227	   in	   hand,	   we	   undertook	   its	   reaction	   with	   a	   variety	   of	  
amines,	   aiming	   at	   an	   initial	   exploration	   of	   structure-­‐activity	   relationships.	   The	  
required	   reaction	   is	   a	   simple	   nucleophilic	   substitution	   in	   which	   an	   incoming	  
nucleophile	   replaces	   an	   outgoing	   leaving	   group,	   in	   this	   case	   represented	   by	   a	  
bromide	   anion.	   We	   carried	   out	   the	   reaction	   between	   compound	   227	   and	   a	  
variety	  of	  amines	  under	  MW	  irradiation	   in	  the	  presence	  of	  Ce2CO3	  (Scheme	  7.3	  
and	  Table	  7.1).	  The	  final	  products	  were	  crystallized	  from	  MeOH-­‐hexane	  mixtures	  
or	  purified	  by	  chromatography	  using	  neutral	  alumina	  as	  stationary	  phase,	  since	  
the	   standard	   silica	   gel	   retained	   the	   polyamine	   derivatives.	   The	   design	   of	  
compound	   238	   (entry	   13)	   was	   based	   on	   the	   introduction	   of	   the	   side	   chain	   of	  
amodiaquine,	  which	  has	  µM	  activity	  against	  L.	  donovani	  amastigotes.192	  
 
Scheme	  7.3.	  Nucleophilic	  substitution	  reaction	  that	  affords	  compounds	  228-­‐238	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
192	  	   Guglielmo,	  S.;	  Bertinaria,	  M.;	  Rolando,	  B.;	  Crosetti,	  M.;	  Fruttero,	  R.;	  Yardley,	  V.;	  Croft,	  S.	  L.;	  
Gasco,	  A.	  Eur.	  J.	  Med.	  Chem.	  2009,	  44,	  5071.	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Table	  7.1.	  Scope	  and	  yields	  of	  the	  4-­‐aminostyrylquinoline	  derivatives	  
Entry	   Cmpd.	   NHR2	  
Reaction	  
time,	  h	  
Yield,	  %	  	  
1	   228	  
	  
0.5	   72	  
2	   229	  
	  
0.5	   71	  
4	   230	  
	  
0.5	   69	  
6	   231	  
	  
0.5	   70	  
7	   232	  
 
0.5	   59	  
8	   233	  
 
0.5	   59	  
9	   234	  
 
1	   45	  
10	   235	  
 
1	   43	  
11	   236	  
 
1	   88	  
12	   237	  
 
1	   42	  
13	   238	  
 
1	   54	  
	  
The	   3-­‐indolyl	   moiety	   is	   present	   in	   several	   compounds	   active	   against	  
Leishmania,	   including	   indolylquinolines.193	   Thus,	   we	   planned	   to	   combine	   such	  
motif	   with	   the	   styrylquinoline	   residue	   in	   order	   to	   obtain	   a	   potential	   new	   lead	  
compound.	  To	  this	  end,	  according	  to	  our	  procedure	  described	  in	  chapter	  3.3,119	  
we	   treated	   4-­‐chlorostyrylquinoline	   218	   with	   indole	   in	   the	   presence	   of	   InCl3,	  
under	  MW	  irradiation,	  to	  afford	  compound	  239	  (Scheme	  7.4).	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
193	   Chakrabarti,	   G.;	   Basu,	   A.;	   Manna,	   P.;	   Mahato,	   S.;	   Mandal,	   N.;	   Bandyopadhyay,	   S.	   J.	  
Antimicrob.	  Agents	  Chemother.	  1999,	  43,	  359.	  
7.	  Hybrid	  styrylquinoline-­‐polyamine	  scaffolds	   	   181	   	   	  
 
Scheme	  7.4.	  Coupling	  reaction	  between	  218	  and	  indole	  that	  led	  to	  the	  formation	  of	  
compound	  239	  
In	   an	   effort	   to	   enlarge	   the	   library,	   we	   planned	   to	   synthesize	   other	  
stryrylquinoline	   derivatives	   introducing	   hydroxyl	   groups	   on	   the	   phenyl	   residue,	  
since	   several	   potent	   antileishmanial	   compounds,	   including	   the	   styrylquinolines	  
mentioned	  in	  section	  7.2,	  feature	  such	  moieties194	  (Figure	  7.4).	  
 
Figure.	  7.4.	  The	  introduction	  of	  two	  hydroxyl	  groups	  could	  an	  improved	  anti-­‐leishmanial	  
activity.	  
To	   this	   end,	  we	   first	   reacted	   2-­‐methylquinolin-­‐4-­‐one,	   compound	  209,	  with	  
3,4-­‐dihydroxybenzaldehyde	   in	   the	   presence	   of	   acetic	   anhydride	   under	   MW	  
irradiation.	   As	   expected,	   we	   obtained	   compound	   240	   having	   both	   hydroxyl	  
groups	  acetylated	  because	  of	  their	  reaction	  with	  acetic	  anhydride	  (Scheme	  7.5).	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
194	   Loiseau,	  P.	  M.;	  Gupta,	  S.;	  Verma,	  A.;	  Srivastava,	  S.;	  Puri,	  S.	  K.;	  Sliman,	  F.;	  Normand-­‐Bayle,	  M.;	  
Desmaele,	  D.	  Antimicrob.	  Agents	  Chemother.	  2011,	  55,	  1777.	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Scheme	  7.5.	  Synthesis	  of	  compound	  240	  
The	  subsequent	  chlorination	  was	  carried	  out	  using	  the	  procedure	  previously	  
described,	   to	   give	   the	   4-­‐chlorostyrylquinoline	   derivative	   241	   in	   good	   yield	  
(Scheme	  7.6).	  
 
Scheme	  7.6.	  Chlorination	  of	  240	  to	  afford	  241	  
Unfortunately,	   all	   attempts	   to	   treat	   compound	  241	   with	   a	   large	   excess	   of	  
ethylenediamine	  gave	  only	  complex	  mixtures	  (Scheme	  7.7).	   In	  order	  to	  account	  
for	  this	   lack	  of	  success,	  we	  hypothesize	  that	  a	  reaction	  took	  place	  between	  the	  
acetyl	   groups	   and	   the	   amine,	   interfering	   with	   the	   nucleophilic	   aromatic	  
substitution.	  
 
Scheme	  7.7.	  The	  SnAr	  with	  ethylenediamine	  did	  not	  work	  because	  of	  the	  presence	  of	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In	  an	  effort	   to	  overcome	  this	  problem,	  we	  decided	  to	  protect	   the	  hydroxyl	  
groups	   with	   chloromethyl	   methyl	   ether,	   usually	   abbreviated	   as	   MOM-­‐Cl.	   The	  
protocol	   that	   we	   finally	   implemented	   is	   based	   on	   a	   published	   method	   using	  
NaH,195	   but	   unfortunately	   we	   isolated	   the	   product	   (242)	   only	   in	   low	   yield	  
(Scheme	  7.8).	  The	  optimization	  of	  these	  conditions	  will	  be	  tackled	   in	  the	  future	  
by	  other	  members	  of	  the	  group.	  
 
Scheme	  7.8.	  Preparation	  of	  compound	  242	  
	  
	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
195	   Flaherty,	   D.	   P.;	   Kiyota,	   T.;	   Dong,	   Y.;	   Ikezu,	   T.;	   Vennerstrom,	   J.	   L.	   J.	  Med.	   Chem.	  2010,	  53,	  
7992.	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7.4.	  Biological	  study	  
The	  biological	  studies	  were	  carried	  out	  by	  Drs.	  María	  Ángeles	  Abengózar	  and	  Luis	  
Rivas,	  at	   the	  Centro	  de	   Investigaciones	  Biológicas,	  CSIC,	  Madrid.	  As	  a	   first	   step,	  
the	   activity	   of	   compounds	   228-­‐239	   was	   evaluated	   against	   L.	   pifanoi	   axenic	  
amastigote	   (strain	   MHOM-­‐ET-­‐67/L82),	   and	   L.	   donovani	   promastigote	   (strain	  
MHOM/SD/00/1S-­‐2D)	  in	  a	  phenotypic	  screening.	  For	  Leishmania	  promastigotes,	  
all	  compounds	  inhibited	  the	  proliferation	  of	  the	  parasite	  (Figure	  7.5)	  showing	  IC50	  
values	   in	  the	  range	  between	  1.3	  µM	  and	  9.6	  µM	  (Table	  7.2).	   It	   is	   interesting	  to	  
note	   that	   the	   IC50	   of	   all	   these	   compounds	   was	   lower	   than	   that	   of	  miltefosine	  
(hexadecylphosphocholine,	  HePC),	  a	  reference	  antileishmanial	  drug.196	  
	  
Figure	  7.5.	  Inhibition	  of	  L.	  donovani	  promastigote	  proliferation	  by	  compounds	  228-­‐239	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
196	   Saugar,	   J.	  M.;	  Delgado,	   J.;	  Hornillos,	  V.;	   Luque-­‐Ortega,	   J.	  R.;	  Amat-­‐Guerri,	   F.;	  Acuna,	  A.	  U.;	  
Rivas,	  R.	  J.	  Med.	  Chem.	  2007,	  50,	  5994.	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Table	  7.2.	   In	  vitro	  activity	  of	  compounds	  146	  and	  
228-­‐239,	   expressed	   as	   IC50	   (µM),	   against	  
Leishmania	  donovani	  promastigotesa	  
Cmpd.	   IC50	  
146	   >50	  
228	   1.6	  ±	  0.0	  
229	   1.6	  ±	  0.0	  
230	   2.1	  ±	  0.2	  
231	   2.1±	  0.2	  
232	   1.3	  ±	  0.1	  
233	   3.5	  ±	  0.3	  
234	   2.1	  ±	  0.1	  
235	   1.5	  ±	  0.1	  
236	   3.9	  ±	  0.5	  
237	   5.1	  ±	  0.1	  
238	   9.6	  ±	  0.4	  
239	   1.5	  ±	  0.6	  
Mitefosine	   12.5	  ±	  2.9196	  
aIC50:	   drug	   concentration	   required	   to	   inhibit	   50%	   parasite	  
proliferation.	  
	  
In	   order	   to	   elucidate	   the	   role	   of	   the	   polyamine	   chains,	   2-­‐styrylquinoline	  
(146)	   was	   also	   tested	   and	   found	   to	   display	   a	   low	   activity	   (IC50	   >	   50	   µM),	  
confirming	  that	  the	  polyamine	  tail	   is	  critical	  for	  the	  activity.	  On	  the	  other	  hand,	  
an	  analysis	  of	  the	  data	  reported	  in	  Figure	  7.6	  discloses	  a	  high	  inhibitory	  potency	  
against	  L.	  amastigote	  cell	  proliferation	  for	  some	  of	  the	  compounds,	  namely	  234-­‐
235,	  237-­‐239.	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Figure	  7.6.	  Inhibition	  of	  L.	  pifanoi	  amastigote	  proliferation	  by	  compounds	  228-­‐239.	  
The	   anti-­‐leishmanial	   efficacy	   of	   compound	   237	   was	   confirmed	   with	   an	   in	  
vitro	  model	  of	  macrophage	  infection	  using	  peritoneal	  macrophages	  infected	  with	  
L.	  pifanoi	  amastigotes	  previously	   labelled	   intracellularly	  with	  carboxyfluorescein	  
succinimidyl	  ester	   (CFSE)	   to	   facilitate	   their	  visualization	   inside	   the	  macrophage.	  
As	  expected,	  237	  reduced	  the	  infection	  index	  (number	  of	  parasites/macrophage),	  
as	   assessed	   by	   counting	   intracellular	   parasites	   in	   a	   standard	   fluorescence	  
microscope	  (Figure	  7.7).	  
7.	  Hybrid	  styrylquinoline-­‐polyamine	  scaffolds	   	   187	   	   	  
	  
Figure	   7.7.	   Peritoneal	   infected	   macrophages	   with	   L.	   pifanoi	   amastigotes,	   after	   12h	  
incubation	   with	   237,	   were	   observed	   under	   a	   confocal	   microscope.	   Amastigotes	   were	  
preloaded	  with	  CFSE	   (carboxyfluorescein	  succinimidyl	  ester)	   (green)	  and	  the	  cell	  nuclei	  
were	   stained	  with	  DAPI	   (blue).	  237	   reduced	   the	   infection	   index	   (number	  of	   parasites/	  
macrophage).	  
	  
Furthermore,	  the	  toxicity	  of	  all	  the	  molecules	  was	  assessed	  on	  murine	  peritoneal	  
macrophages,	  revealing	  a	  good	  biological	  profile	  for	  232,	  233,	  236,	  238	  and	  239	  
(Figure	  7.8).	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Figure	  7.8.	  Toxicity	  of	  styrilquinolines	  (228-­‐239,	  25	  and	  50	  µM)	  on	  peritoneal	  
macrophages	  
	  
In	   an	   effort	   to	   shed	   light	   on	   the	   molecular	   mechanism	   of	   action	   of	   the	  
styrylquinoline	   compounds	   and	   locate	   their	   target,	   we	   decided	   to	   study	   their	  
activity	   towards	   mitochondrial	   function,	   which	   is	   one	   of	   the	   mechanisms	   of	  
action	   of	   polyamine	   compounds188	   and	   quinolines	   as	   Tafenoquine	   and	  
sitamaquine.197,198	   It	   is	  worth	   noting	   that	   drugs	   acting	   at	   a	  mitochondrial	   level	  
can	   be	   particularly	   effective	   against	   Leishmania,	   as	   for	   these	   parasites,	   with	   a	  
single	   mitochondrion,	   oxidative	   phosphorylation	   is	   essential	   to	   fulfill	   their	  
energetic	  requirements.199	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In	   order	   to	   study	   whether	   our	   compounds	   affected	   the	   bioenergetic	  
metabolism	   of	   Leishmania,	   for	   which	   the	   mitochondrial	   synthesis	   of	   ATP	  
accounts	  for	  nearly	  70%	  of	  the	  total	  production,	  we	  used	  an	  engineered	  parasite	  
strain	   (3-­‐Luc	  promastigotes)	   that	  allows	   real-­‐time	  monitoring	  of	   changes	   in	   the	  
cytoplasmic	  free	  ATP	  pool	   in	   living	  parasites,	  as	   it	  expresses	  a	  cytoplasmic	  form	  
of	  firefly	  luciferase.200	  Upon	  addition	  of	  a	  lipophilic	  luciferin	  ester	  that	  can	  cross	  
the	   parasite’s	   membrane,	   in	   vivo	   luminescence	   is	   generated,	   free	   cytoplasmic	  
ATP	  being	  the	  limiting	  substrate	  for	  this	  reaction	  
The	  in	  vivo	  luminescence	  measurements	  showed	  that	  most	  of	  the	  compounds	  
induced	   a	   fast	   and	   concentration-­‐dependent	   drop	   in	   the	   free	   cytoplasmic	   ATP	  
content	   after	   their	   addition.	   As	   an	   example,	   we	   show	   the	   behaviour	   of	  
compound	  237,	   which,	   at	   the	   concentration	   of	   25	  µM,	   reached	   the	   end	   point	  
15−20	  min	  after	  its	  addition	  (Figure	  7.9).	  	  
	  
Figure	  7.9.	  Decrease	  of	   luminescence	  caused	  by	  137.	  DMNEP-­‐luciferin	  was	  added	  to	  L.	  
donovani	  3-­‐Luc	  promastigote	  cell	   line,	  and	  when	   luminescence	  reached	  a	  steady	  state,	  
drug	  was	  added	  (t	  =	  0,	  100%	  luminescence).	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This	  dramatic	  drop	  in	  ATP	  levels	  can	  be	  attributed	  to	  alterations	  in	  mitochondrial	  
function,	  or	  to	  changes	   in	  cell	  membrane	  permeability.	  To	  discern	  which	  of	  the	  
two	  possibilities	  was	  real,	  we	  determined	  whether	  our	  compounds	  affected	  the	  
mitochondrial	   electrochemical	   potential	   (Δψm),	   which	   is	   essential	   to	   drive	   ATP	  
synthesis.	   We	   measured	   Δψm	   by	   using	   the	   fluorescent	   probe	   rhodamine	   123,	  
whose	   accumulation	   in	   mitochondria	   is	   driven	   by	   Δψm,	   as	   analyzed	   by	   flow	  
cytometry	   (Figure	   7.10).	   Compounds	   231,	   234,	   235	   and	   237	   had	   the	   highest	  
inhibitory	   potency	   at	   a	   concentration	   of	   50	  µM	  and	  were	   selected	   for	   further	  
study	  to	  establish	  the	  dependence	  of	  inhibition	  with	  concentration.	  We	  observed	  
that	   these	   molecules,	   at	   25	   µM,	   markedly	   decreased	   rhodamine	   fluorescence	  
reaching	  values	  similar	  to	  those	  induced	  by	  KCN	  used	  as	  a	  control	  for	  fully	  	  
	  
Figure	   7.10.	   Variation	   of	   the	   mitochondrial	   electrochemical	   potential	   (Ψm)	   by	  
styrylquinoline	  compounds	  on	  L.	  donovani	  promastigotes.	  Parasites	  were	  treated	  for	  4	  h	  
with	   the	   compounds	   at	   a	   concentration	   of	   50	   µM,	   and	   Rhodamine	   123	   uptake	   was	  
monitored	  by	  cytofluorometry	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depolarized	  mitochondria.	  This	  behavior	  can	  be	  a	  consequence	  of	  mitochondrial	  
damage,	   with	   dissipation	   of	   the	   electrochemical	   gradient	   across	   the	   inner	  
mitochondrial	  membrane	  and	  lower	  rhodamine	  123	  accumulation.	  
In	   addition,	   we	   discarded	   the	   possibility	   that	   changes	   in	   cytoplasmic	   ATP	  
concentration	   could	   be	   due	   to	   alterations	   in	   the	   permeability	   of	   the	   cell	  
membrane	   by	   the	   experiment	   summarized	   in	   Figure	   7.11.	   Promastigotes	  were	  
incubated	  with	  SYTOX	  Green,	  and	  its	  increase	  in	  fluorescence	  (λexc	  =	  504	  nm	  and	  
λem	   =	   524	   nm)	   due	   to	   its	   binding	   to	   intracellular	   nucleic	   acids	  was	  monitored.	  
Results	   were	   expressed	   as	   percentage	   relative	   to	   fully	   permeabilized	   cells,	  
achieved	   by	   addition	   of	   0.1%	   Triton	   X-­‐100,	   and	   show	   that	   none	   of	   our	  
compounds	  alter	  membrane	  permeability.	  
	  
	  
Figure	  7.11.	  Membrane	  permeability	  assays	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Owing	  to	  the	  key	  role	  of	  mitochondria	   in	  apoptosis,201	  we	  also	  investigated	  
the	  possibility	  that	  the	  killing	  of	  Leishmania	   involved	  some	  kind	  of	  programmed	  
death	  process,	  characterized	  by	  the	  appearance	  of	  the	  population	  sub-­‐G1,	  with	  
fragmented	  chromatin	  and	  lower	  binding	  of	  propidium	  iodide.	  The	  experiments	  
summarized	   in	  Figure	  7.12,	  using	  miltefosine	  (HePc)	  as	  a	  reference,	  discard	  this	  
possibility.	  
	  
Figure	  7.12.	  Absence	  of	  apoptosis	  induction	  from	  compounds	  229,	  230,	  233	  and	  237	  
In	  a	   further	   step,	   the	  morphological	  damage	   inflicted	   to	   the	  promastigote	  cells	  
was	  visualized	  by	  transmission	  electron	  microscopy	  (Figure	  7.13).	   In	  the	  case	  of	  
229,	  we	  noted	  the	  enlargement	  of	  acidocalsisomes	  (black	  spots);	  for	  230	  and	  237	  
multivesicular	   bodies	  were	   observed,	  whereas	   in	   the	   case	   of	  234	   an	   abnormal	  
division	  of	  the	  flagella	  and	  morphological	  alterations	  of	  the	  mitochondrion	  were	  
observed.	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Figure	  7.13.	  Electron	  microscopy	  images	  showing	  morphological	  changes	  in	  L.	  donovani	  
promastigotes	  treated	  with	  compounds	  229,	  230,	  234	  and	  237	  
Taken	  together,	  the	  results	  shown	  above	  suggested	  that	  our	  styrylquinolines	  
exert	  their	  leishmanicidial	  action	  by	  interfering	  with	  the	  mitochondrial	  activity	  on	  
the	  parasite	  leading	  to	  the	  exhaustion	  of	  ATP	  with	  the	  concomitant	  bioenergetic	  
collapse	   of	   the	   parasite.	   Some	   compounds,	   especially	  237,	   exhibit	   a	   promising	  
antileishmania	  profile.	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7.5.	  Synthesis	  of	  8-­‐aminostyrylquinolines	  
In	  the	   light	  of	  the	  good	  results	  obtained	  from	  the	  biological	  screening	  of	  the	  4-­‐
aminostyrylquinoline	   derivatives,	   and	   also	   taking	   into	   account	   the	   structure	   of	  
sitamaquine,	  we	  decided	   to	   investigate	   the	   shift	  of	   the	  amino	  chain	   to	   the	  C-­‐8	  
position	  on	  the	  quinoline	  nucleus.	  	  
As	  starting	  point,	  we	  prepared	  2-­‐methylquinoline	  (compound	  161)	  according	  
to	   the	   procedure	   described	   in	   chapter	   6.3.1	   involving	   a	   three-­‐component	  
reaction	  catalyzed	  by	  CAN.166	  Then,	  compound	  161	  was	  treated	  with	  a	  mixture	  of	  
HNO3	  and	  H2SO4	  (1:4)	  to	  afford	  a	  mixture	  of	  C-­‐5,	  and	  C-­‐8	  mononitrated	  products	  
243	  and	  244	  (35%	  and	  41%,	  respectively),	  which	  required	  a	  careful	  separation	  by	  
chromatography	  on	  silica	  gel	  (Scheme	  7.9).202	  
 
Scheme	  7.9.	  Nitration	  of	  2-­‐methylquinaldine	  led	  to	  the	  formation	  of	  two	  mononitrated	  
products	  
In	  order	  to	  obtain	  8-­‐nitro-­‐2-­‐styrylquinoline,	  we	  reacted	  compound	  244	  with	  
benzaldehyde	   following	   our	   standard	   protocol	   in	   the	   presence	   of	   Ac2O	   under	  
focused	   MW	   irradiation.171	   Unexpectedly,	   the	   condensation	   reaction	   did	   not	  
work.	  We	  supposed	  that	  it	  was	  due	  to	  the	  electron-­‐withdrawing	  effect	  and	  steric	  
hindrance	  of	  the	  nitro	  group	  at	  the	  C-­‐8	  position,	  which	  must	  hamper	  the	   initial	  
acetylation	  of	  the	  quinoline	  nitrogen	  (Scheme	  7.10).	  In	  an	  effort	  to	  overcome	  this	  
problem,	  we	  decided	  to	  deprotonate	  the	  quinaldine	  methyl	  group	  using	  as	  the	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Scheme	  7.10.	  Condensation	  reaction	  between	  244	  and	  benzaldehyde	  did	  not	  work	  
base	   potassium	   t-­‐butoxide,	   which	   had	   been	   previously	   employed	   for	   the	  
synthesis	   of	   some	   styrylquinoline	   derivatives	   (200-­‐204)	   as	   reported	   in	   chapter	  
6.3.1.	   Unfortunately,	   these	   conditions	   failed	   in	   this	   case.	   After	   several	  
unsuccessful	  additional	  attempts	  exploring	  bases	  such	  as	  LDA,	  NaH,	  n-­‐BuLi,	  TEA	  
and	   K2CO3,	   we	   changed	   our	   approach	   and	   decided	   to	   investigate	   the	   Wittig	  
olefination	   reaction.	   To	   this	   end,	  we	   first	   transformed	   compound	  244	   into	   the	  
corresponding	   aldehyde	   (245)	   carrying	   out	   the	   reaction	   with	   selenious	   acid	  
(H2SeO3)	   in	  a	  refluxing	  mixture	  of	  dioxane	  and	  water	  (10:1)	  during	  1	  h	  (Scheme	  
7.11).203	   Afterwards,	   we	   prepared	   the	   phosphonium	   salt	   (246)	   by	   reacting	  
benzylbromide	   with	   triphenylphosphine	   in	   toluene	   under	   focused	   MW	  
irradiation	  for	  10	  min	  (Scheme	  7.11).	  Finally,	  we	  carried	  out	  the	  Wittig	  reaction	  
according	  to	  a	  method	  reported	  by	  Kimber	  et	  al that	  involved	  stirring	  compounds	  
245	   and	   246	   in	   a	   biphasic	   system	   (dichloromethane	   and	   50%	   NaOH	   aqueous	  
solution)	  for	  2	  hours	  to	  afford	  the	  desired	  olefin	  as	  a	  mixture	  of	  the	  cis	  and	  trans	  
isomers.203	   In	  order	  to	   isolate	  the	  E	  adduct	  as	  the	  only	  product,	  we	  treated	  the	  
mixture	  with	   a	   catalytic	   amount	   of	  p-­‐toluenesulfonic	   acid	   in	   refluxing	   ethanol,	  
obtaining	  compound	  247	  in	  80%	  yield	  (Scheme	  7.11).	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   Kimber,	  M.	  C.;	  Mahadevan,	   I.	  B.;	   Lincoln,	   S.	   F.;	  Ward,	  A.	  D.;	  Tiekink,	  E.	  R.	  T.	   J.	  Org.	  Chem.	  
2000,	  65,	  8204.	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Scheme	  7.11.	  Synthetic	  route	  to	  compound	  247	  via	  the	  Wittig	  reaction	  
The	   reduction	   of	   compound	   247	   was	   achieved	   following	   the	   protocol	  
reported	   in	   the	   previous	   chapters	   (5.1	   and	   6.2.1),	   using	   iron	   powder	   in	   a	  
refluxing	  mixture	  of	  ethanol,	  acetic	  acid,	  water	  and	  hydrochloride	  acid	  (Scheme	  
7.12).154	  
 
Scheme	  7.12.	  Reduction	  of	  compound	  247	  to	  248	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8.1.	  Introduction	  
In	  the	  course	  of	  the	  three-­‐month	  stay	  abroad	  that	  is	  part	  of	  the	  requirements	  for	  
the	   European	   Ph.	   D.	   Mention,	   I	   carried	   out	   the	   following	   experimental	   work	  
under	  the	  supervision	  of	  Dr.	  Francesca	  Baldelli-­‐Bombelli	  at	  School	  of	  Pharmacy,	  
University	  of	  East	  Anglia,	  Norwich.	  	  
	  
Malignant	  melanoma	  is	  considered	  one	  of	  the	  most	  lethal	  cancers.	  It	  represents	  
a	   severe	   public	   health	   problem	   due	   its	   incidence	   that	   is	   rising	   quickly.204	  
Melanoma	  progression	   is	   related	   to	  altered	  expression	  of	   cell	   surface	  proteins,	  
including	   adhesion	   proteins	   and	   receptors.	   It	   is	   interesting	   to	   note	   that	   the	  
melanocortin	  type-­‐1	  receptor	  (MC1R)	  is	  overexpressed	  in	  many	  melanoma	  cells	  
at	  high	  levels.	  Thus,	  it	  seemed	  reasonable	  to	  consider	  MC1R	  as	  a	  validated	  target	  
for	   imaging	   and	   therapeutic	   intervention.205	   The	   endogenous	   agonist	   for	  
melanocortin	  receptors	   is	   the	  melanocyte	  stimulating	  hormone	  (MSH),206	  and	  a	  
wide	  number	  of	  analogous	   ligands	  have	  been	  developed	   in	  order	   to	   find	  out	  a	  
compound	  capable	  of	  targeting	  melanoma	  cells.	  Among	  them,	  a	  small-­‐molecular-­‐
weight	  peptide,	   [Nle4,	  D-­‐Phe7]-­‐α-­‐melanocyte-­‐stimulating	  hormone	   (NDP-­‐MSH),	  
showed	   very	   high	   affinity	   for	  MCR1	   (IC50	   =	   0.21	   nmol/L),	   turning	   out	   to	   be	   an	  
optimum	  targeting	  moiety.207	  
It	   must	   be	   borne	   that	   in	   cancer	   therapy	   most	   of	   the	   drawbacks	   are	  
represented	   by	   drug	   toxicity,	   non-­‐specificity	   and	   development	   of	   resistance	   to	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   Welch,	  H.	  G.;	  Woloshin,	  S.;	  Schwartz,	  L.	  M.	  Br.	  Med.	  J.	  2005,	  331,	  481.	  
205	   Siegrist,	  W.;	   Solca,	   F.;	   Stutz,	   S.;	   Giuffre,	   L.;	   Carrel,	   S.;	   Girard,	   J.;	   Eberle,	   A.	   N.	   Cancer	   Res.	  
1989,	  49,	  6352.	  
206	   Corander,	  M.	  P.;	  Fenech,	  M.;	  Coll,	  A.	  P.	  Circulation	  2010,	  120,	  2260.	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   a)	   Sawyer,	   T.	   K.;	   Sanfilippo,	   P.	   J.;	   Hruby,	   V.	   J.;	   Engel,	  M.	   H.;	   Heward,	   C.	   B.;	   Burnett,	   J.	   B.;	  
Hadley,	  M.	  E.	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  1980,	  77,	  5754;	  b)	  Chen,	  J.;	  Giblin,	  M.	  F.;	  Wang,	  N.;	  
Jurisson,	  S.	  S.;	  Quinn,	  T.	  P.	  Nucl.	  Med.	  Biol.	  1999,	  26,	  687.	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(MDR	   and	   other	   mechanisms).	   Moreover,	   in	   many	   cases	   the	   treatment	   is	  
effective	  only	  at	  an	  early	  stage	  of	  the	  disease,	   thus	  there	   is	  an	  urgent	  need	  for	  
new	  tools	  for	  an	  earlier	  diagnosis.	  In	  this	  regard,	  nanotechnology	  could	  improve	  
the	   pharmacokinetic	   and	   pharmacodynamic	   properties	   of	   existing	   molecules	  
combining	  them	  with	  nanomaterials.	  Indeed,	  theranostic	  targeted	  nanoparticles	  
can	  be	  developed	  with	  the	  aim	  of	  obtaining	  a	  platform	  that	  joins	  diagnostic	  and	  
therapeutic	   components	   in	   one	   unique	   particle.208	   Interestingly,	   nanosystems	  
can	  target	  a	  specific	  site	  through	  the	  functionalization	  with	  a	  ligand	  able	  to	  bind	  
specifically	  to	  a	  receptor	  particularly	  abundant	  in	  the	  site	  of	  interest	  with	  respect	  
to	  other	  tissues	  or	  organs.	  
With	   this	   in	   mind,	   Lu	   et	   al.	   associated	   NDP-­‐MSH	   to	   pegylated	   gold	  
nanoparticles	  (Au	  NPs)	  which	  were	  tested	  on	  melanoma	  cells.	  These	  NPs	  showed	  
a	   better	   biodistribution	   with	   respect	   to	   the	   pegylated	   ones	   and	   specific	  
photothermal	  ablation	  of	  melanoma	  cells	  was	  possible.209	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   Desai	  N.	  AAPS	  Journal	  2012,	  14,	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209	   Lu,	  W.;	  Xiong,	  C.;	  Zhang,	  G.;	  Huang,	  Q.;	  Zhang,	  R.;	  Zhang,	  J.	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  Clin.	  Cancer.	  Res.	  2009,	  
15,	  876.	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8.2.	  SPION	  coating	  and	  purification	  
Magnetic	   iron	   oxide	   nanoparticles	   were	   prepared	   according	   to	   the	   protocol	  
described	   by	   Sun	   et	   al.,	   treating	   iron(III)	   acetylacetonate,	   Fe(acac)3,	   with	   1,2-­‐
hexadecanediol	   in	   the	   presence	   of	   oleic	   acid	   and	   oleylamine	   to	   afford	  
monodispersed	   magnetite	   (Fe3O4)	   nanoparticles.
210	   Such	   NPs	   are	   soluble	   in	  
organic	  solvents	  and	  need	  to	  be	  transferred	  to	  aqueous	  solutions	  to	  be	  suitable	  
for	   biological	   applications.	  With	   this	   purpose,	   we	   planned	   to	   functionalize	   the	  
SPION	  surface	  with	  an	  amphiphilic	  polymer,	  and	  chose	  poly(maleic	  anhydride-­‐alt-­‐
1-­‐octadecene)	   (PMAO)	   for	   this	   purpose,	   following	   the	   approach	   reported	   by	  
Pellegrino	  et	  al.211	  PMAO,	  thanks	  to	  its	  octadecyl	  chains,	  can	  intercalate	  with	  the	  
oleate	   and	   dodecanethiol	   chains	   of	   SPIONs	   through	   hydrophobic	   interactions,	  
and	  simultaneously	  expose	  the	  anhydride	  ring.	  The	  latter,	  after	  hydrolysis	  to	  	  
	  
Figure	   8.1.	   Transfer	   of	   SPIONs	   to	   the	   aqueous	   phase	   through	   intercalation	   of	   the	  
hydrophobic	  tail	  of	  PMAO	  (a)	  with	  the	  first	  stabilizing	  ligand	  (oleic	  acid/	  dodecanethiol)	  
and	  exposure	  of	  hydrophilic	  head	  to	  water	  (b).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
210 Sun,	  S.;	  Zeng,	  H.;	  Robinson,	  D.	  B.;	  Raoux,	  S.;	  Rice,	  P.	  M.;	  Wang,	  S.	  X.;	  Li,	  G.	  J.	  Am.	  Chem.	  Soc.	  
2004,	  126,	  273.	  	  
211	   Pellegrino,	  T.;	  Manna,	  L.;	  Kudera,	  S.	  et	  al.	  Nano	  Lett.	  2004,	  4,	  703.	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carboxylic	  acid	  in	  the	  presence	  of	  a	  base	  such	  as	  TMAHP	  (tetramethylammonium	  
hydroxide	   pentahydrate),	   provides	   water	   solubility	   through	   charged	   groups	  
(COO-­‐)	  and	  also	  acts	  as	  an	  anchor	  for	  the	  attachment	  of	  biological	  molecules	  or	  
other	  kinds	  of	  linkers	  (Figure	  8.1).	  
Then,	   the	  SPION	  solution	  was	  dialyzed	  for	   three	  days	  against	  water	   (Figure	  
8.2),	   followed	   by	   ultracentrifugation	   through	   sucrose	   gradient	   to	   remove	   the	  
excess	  polymer	  used.	  Subsequently,	  another	  dialysis	  in	  water	  was	  carried	  out	  for	  
further	  three	  days	  in	  order	  to	  purify	  NPs	  from	  the	  residues	  of	  sucrose.	  	  
	  
Figure	  8.2.	  The	  purification	  of	  the	  SPIONs	  was	  carried	  out	  by	  a	  dialysis	  against	  water	  (a)	  
followed	   by	   ultracentrifugation	   through	   sucrose	   gradient	   to	   remove	   the	   excess	   of	   the	  
polymer	  (b)	  
	  
The	   coated	   SPIONs	   were	   characterized	   by	   dynamic	   light	   scattering	   (DLS),	  
which	   is	  one	  of	   the	  most	  used	   techniques	   to	   study	  particles	   in	   suspension	  and	  
measure	   their	   size	   and	   surface	   charge,	   expressed	   by	   the	   zeta	   potential.212	   The	  
prepared	  NPs	  turned	  out	  to	  be	  monodispersed,	  with	  a	  polydispersity	  index	  (PDI)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
212	   Berne,	  B.J.;	  Pecora,	  R.	  Dynamic	  light	  scattering:	  with	  applications	  to	  chemistry,	  biology,	  and	  
physics;	  Courier	  Dover	  Publications	  2000.	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of	  0.192,	  and	  small	  in	  size	  (average	  diameter	  =	  42.72	  nm).	  The	  zeta	  potential	  was	  
negative	  (-­‐21.1	  mV)	  due	  to	  the	  charge	  of	  carboxylic	  groups	  (Figure	  8.3).	  
	  
Figure	  8.3.	  DLS	  size	  distribution	  of	  coated	  SPIONs	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8.3.	  Functionalization	  of	  polystyrene	  NPs	  with	  PEG	  
As	   outlined	   above,	   we	   planned	   to	   functionalize	   SPION	   surfaces	   with	   a	   peg-­‐
peptide	  adduct	  through	  a	  coupling	  reaction	  between	  the	  carboxyl	  groups	  of	  the	  
polymer	  wrapping	  SPIONs	  and	  the	  terminal	  amino	  group	  of	  polyethylene	  glycol.	  
In	  an	  effort	  to	  tune	  this	  reaction,	  we	  decided	  to	  functionalize	  the	  surfaces	  of	  20	  
nm	   polystyrene	   NPs	   and	   Jeffamine	   M-­‐1000	   polyetheramine,	   a	   low	   molecular	  
weight	   amino-­‐PEG	   derivative,	   both	   of	   which	   were	   commercially	   available.	  We	  
carried	  out	  the	  coupling	  using	  an	  excess	  of	  PEG	  in	  the	  presence	  of	  1-­‐ethyl-­‐3-­‐(3-­‐	  
dimethylaminopropyl)carbodiimide	   (EDAC),	   as	   catalyst,	   in	   phosphate-­‐buffered	  
saline	  solution	  (PBS)	  at	  pH	  7.4	  (Scheme	  8.1).	  After	  several	  attempts,	  we	  found	  
	  
Scheme	  8.1.	  Coupling	  reaction	  between	  the	  carboxyl	  groups	  of	  the	  polystyrene	  surface	  
and	  PEG	  in	  the	  presence	  of	  EDAC	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that	  the	  ideal	  experimental	  conditions	  to	  saturate	  the	  surface	  involved	  the	  use	  of	  
50	  µl	  of	  polystyrene	  NPs	  solution	  (number	  of	  NPs	  =	  4.5302	  x	  1013)	  using	  700	  µl	  of	  
PEG	  in	  PBS	  (M	  =	  0.02)	  and	  700	  µl	  of	  EDAC	  in	  PBS	  (M	  =	  0.15).	  
Considering	  that	  the	  surface	  of	  polystyrene	  has	  a	  negative	  charge,	  due	  to	  the	  
presence	   of	   carboxylic	   groups,	   the	   fact	   that	   the	   zeta	   potential	   of	   the	   reaction	  
mixture	   is	   around	   0	   means	   that	   each	   carboxylic	   groups	   have	   reacted.	   The	  
functionalized	  NPs	  were	  dialyzed	  against	  PBS	  for	  three	  days	  to	  remove	  the	  excess	  
of	   PEG,	   and	   were	   characterized	   by	   DLS	   showing	   good	   monodispersity	   (PDI	   =	  
0.139	  ±	  0.014)	  and	  an	  average	  diameter	  of	  80.06	  ±	  0.075	  (Figure	  8.4).	  
	  
Figure	  8.4.	  DLS	  size	  distribution	  of	  polystyrene	  NPs	  functionalized	  with	  PEG.	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8.4.	  Synthesis	  of	  an	  analogue	  of	  the	  MSH	  peptide	  
The	   solid	   phase	   synthesis	   of	   the	   peptide	   (H-­‐Ser-­‐Tyr-­‐Ser-­‐Nle-­‐Glu-­‐His-­‐d-­‐Phe-­‐Arg-­‐
Trp-­‐Gly-­‐Lys(Dde)-­‐Pro-­‐Val-­‐NH2)	   was	   carried	   out	   according	   to	   the	   Lu	   et	   al
209	  
procedure.	  The	  peptide	  was	  synthesized	  manually	  by	  the	  successive	  coupling	  of	  
the	   required	   thirteen	   amino	   acids,	   with	   Fmoc	   protection,	   using	  
diisopropylethylamine	   (DIPEA)	   as	  base,	   20%	  piperazine	   in	  DMF	  as	  deprotecting	  
agent	   and	   Rink	   amide	   resin	   (4-­‐(2’,4’-­‐dimethoxyphenyl-­‐Fmocaminomethyl)	  
phenoxy	   resin	   (Scheme	   8.2).	   When	   coupling	   was	   complete,	   the	   peptide	   was	  
cleaved	  from	  the	  resin	  by	  a	  cocktail	  of	  trifluoroacetic	  acid	  (TFA),	  water	  and	  1,2-­‐
ethanedithiol	  and	  was	  precipitated	  out	  by	  the	  addition	  of	  diethyl	  ether	  to	  give	  a	  
white	   solid.	   The	   peptide	   structure	   was	   verified	   by	   mass	   spectroscopy,	  m/z	   =	  
1769,	  and	  analytical	  HPLC	  showing	  an	  intense	  peak	  with	  retention	  18.97	  min.	  
	  









1) 20% Piperidine in DMF
2) Fmoc-Val-OH (3 eq), HOBt (3 eq)









(1) and (2) is repeated for the whole sequence of A.A.
H-Ser-Tyr-Ser-Nle-Glu-His-d-Phe-Arg-Trp-Gly-Lys(Dde)-Pro-Val-
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8.5.	  Covalent	  coupling	  between	  the	  specific	  ligand	  (MSH)	  and	  PEG	  
The	   synthesis	   of	   the	   abduct	   between	   the	  MSH	   peptide	   and	   PEG	  was	   achieved	  
following	   a	   procedure	   found	   in	   lecterature.209	   First,	   we	   reacted	   NHS-­‐PEG	   750	  
with	  the	  scramble	  version	  of	  MSH	  peptide	  to	  have	  a	  negative	  control.	  We	  carried	  
out	   the	   coupling	   reaction	   using	   5	   mg	   of	   scramble	   peptide	   (0.003	   mmol),	   2.2	  
equivalents	   of	   NHS-­‐PEG	   750	   in	   the	   presence	   of	   DIPEA,	   in	   DMF	   for	   24	   h	   at	   r.t.	  
(Scheme	  8.3).	  When	  the	  reaction	  was	  completed	  we	  tried	  to	  remove	  the	  excess	  
of	  PEG	  by	  gel	  permeation	  chromatography	  unsuccessfully.	  We	  could	   isolate	  the	  
product	   by	   using	   a	   semi-­‐preparative	   HPLC	   and	   it	   was	   characterized	   by	   mass	  
spectroscopy	   MALDI-­‐TOF	   revealing	   a	   series	   of	   peaks	   around	   3000,	   typical	   of	  
polymers.	   Then,	   NSH-­‐PEG	   750	   was	   finally	   reacted	   with	   NDP-­‐MSH	   to	   give	   the	  
NDP-­‐MSH-­‐PEG	   adduct	   in	   94%	   yield.	   Both	   conjugated	   products	   are	   under	  
biological	   evaluation	   to	   check	   if	   they	   are	   able	   to	   induce	   proliferation	   of	  
melanoma	  cells.	  	  
 
Scheme	  8.3.	  Synthesis	  of	  the	  adduct	  PEG-­‐MSH	  
When	  we	  applied	   this	  method	   for	   the	   reaction	  between	  a	  bi-­‐dentate	  PEG,	  
BOC-­‐PEG-­‐NHS,	   and	   NDP-­‐MSH,	   unexpectedly,	   we	   could	   not	   separate	   the	  
conjugation	   product	   from	   the	   excess	   of	   PEG	   by	   the	   semi-­‐preparative	   HPLC	  
(Scheme	  8.4).	  Thus,	  we	  decided	  to	  purify	   the	  crude	  of	   the	  reaction	  through	  gel	  
permeation	   chromatography	   in	   order	   to	   separate	   compounds	   with	   different	  
molecular	   weight,	   followed	   by	   a	   dialysis	   against	   water.	   The	  whole	   purification	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procedure	  allowed	  us	   to	  achieve	  the	  adduct	  NDP-­‐MSH-­‐PEG-­‐BOC.	  The	  next	  step	  
would	  have	  been	  the	  cleavage	  of	  BOC	  to	  make	  free	  the	  amino	  group	  of	  PEG	  as	  
long	  as	  it	  could	  react	  with	  SPIONs.	  	  
	  










9.	  Experimental	  section	  
	  
	  
	   	  
9.	  Experimental	  section	   	   211	   	   	  
9.1.	  General	  information	  
All	   air-­‐and/or	   moisture	   sensitive	   reactions	   were	   carried	   out	   under	   an	   argon	  
atmosphere	  in	  oven-­‐dried	  glassware.	  Solvents	  and	  reagents	  were	  transferred	  by	  
syringe	  or	  via	  cannula	  through	  rubber	  septa.	  
Reagents:	   All	   reagents	   employed	   for	   the	   reactions	   which	   are	   commercially	  
available	   (Aldrich,	   Alfa-­‐Aesar,	   Fluka,	   Merck,	   Panreac,	   Probus,	   Scharlau)	   were	  
used	   directly	  without	   further	   purification.	  When	   required,	   solvents	  were	   dried	  
using	  standard	  procedures.	  
Chromatography:	   Analytical	   thin	   layer	   chromatography	   (TLC)	   was	   carried	   out	  
using	   commercially	   available	   aluminium-­‐backed	   plate	   coated	   with	   silica	   gel	  
(ScharlauCf530	   or	  Macherey-­‐Nagel	   AlugramSil	   G/UV254)	   or	   neutral	   aluminium	  
oxide	   60F254	   (UV254),	   with	   fluorescent	   indicator	   and	   visualized	   under	   ultra-­‐
violet	   (UV)	   light	   lamp	  Camag	  UV-­‐II	   (at	   254	   and	  366	  nm),	   staining	  with	   suitable	  
stained	  solvents	  which	  were	  prepared	  by	  standard	  reported	  procedure	  followed	  
by	   heating	   or	   with	   molecular	   iodine.	   Flash	   column	   chromatography	   was	  
performed	  using	  silica	  gel	  SDS	  60	  ACC	  or	  Scharlau	  Ge	  048	  or	  neutral	  aluminium	  
oxide	   Merck	   90	   standardized	   (0.063-­‐0.200	   mM,	   70-­‐230	   mesh	   ASTM)	   and	   the	  
eluent	  indicated	  in	  each	  case.	  Automated	  flash	  chromatography	  was	  performed	  
in	  a	  Combiflash	  RF	  200	  system.	  
Melting	   Point:	  Melting	   points	  were	   determined	   by	   Stuart	   Scientific	   apparatus,	  
SMP3	   Modelora	   Kofler-­‐type	   heating	   platinum	   microscope	   from	   Reicher,	   723	  
Model.	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IR	   Spectroscopy:	   Infrared	   spectra	   (IR)	   were	   taken	   using	   a	   Perkin-­‐Elmer	   FTIR	  
Paragon	  1000	  spectrometer.	  Samples	  were	  prepared	  on	  sodium	  chloride	  window	  
in	  a	  film	  form	  or	  as	  disks	  (potassium	  bromide).	  
NMR	   Spectroscopy:	   NMR	   spectra	   were	   obtained	   on	   a	   Bruker	   Avance	   250	  
spectrometer	   operating	   at	   250	   and	   62.9	   MHz	   for	   1H	   and	   13C	   NMR	   spectra,	  
respectively	   (CAI	   de	   Resonancia	  Magnética	   Nuclear,	   Universidad	   Complutense)	  
with	  the	  signal	  of	  the	  residual	  non-­‐deuterated	  solvent	  as	  an	  internal	  standard.	  All	  
the	   coupling	   constants	   are	   given	   in	   Hz	   and	   the	   multiplicities	   of	   1H	   signals	  
indicated	   as	   s	   (singlet),	   d	   (doublet),	   t	   (triplet),	   q	   (quartet),	   m	   (multiplet),	   m	  
complex	  (complex	  multiplet),	  br	  s	  (extend	  singlet).	  
Elemental	   Analysis:	   Quantitative	   combustion	   elemental	   analysis	   for	   carbon,	  
hydrogen	  and	  nitrogen	  were	  determined	  by	  the	  CAI	  de	  Microanálisis	  Elemental,	  
Universidad	  Complutense,	  using	  a	  Leco	  932	  CHNS	  microanalyzer.	  
	   	  
9.	  Experimental	  section	   	   213	   	   	  
9.2.	   Versatile	   and	   general	  methods	   for	   the	   functionalization	   of	  π-­‐
deficient	  heterocyclic	  substrates	  
9.2.1.	   General	   procedure	   for	   the	   free	   amination	   of	   π-­‐deficient	   nitrogen	  
heterocycles	  under	  MW	  using	  phenol	  as	  catalyst	  and	  reaction	  medium	  
The	   suitable	   starting	   heterocycle	   (1	   mmol),	   the	   corresponding	   amine,	   1	  
equivalent,	  except	  ethylene	  diamine	  (4	  eq),	  imidazole	  and	  benzimidazole	  (2	  eq),	  
and	   2	   equivalents	   of	   phenol	  were	   charged	   in	   a	   pressure-­‐tight	  microwave	   tube	  
containing	   a	   stirring	   bar.	   The	   reaction	   mixture	   was	   submitted	   to	   microwave	  
irradiation	  for	  30-­‐45	  min.	  at	  120	  °C,	  with	  an	  irradiation	  power	  of	  150	  W,	  using	  a	  
CEM	  Discover	  SP	  focused	  microwave	  reactor.	  The	  crude	  mixture	  was	  diluted	  with	  
5	  ml	  of	  a	  10%	  KOH	  aqueous	  solution	  and	  stirred	  until	  a	  precipitate	  was	  formed.	  
Filtration	  afforded	  a	  solid	  that	  was	  dried	  overnight	  to	  give	  the	  final	  products.	  
9.2.1.1.	  Synthesis	  of	  9-­‐aminoacridine	  derivatives	  
	  
Cmpd.	   R1	   R2	   	   Cmpd.	   R1	   R2	  
1	   C6H5	   H	   	   7	   C6H5-­‐CH2	   H	  
2	   4-­‐MeO-­‐C6H4	   H	  
	   8	  
	  
H	  
3	   4-­‐Me2N-­‐C6H4	   H	  




H	   	   10	   H2N-­‐CH2-­‐CH2	   H	  
5	  
	  
H	   	   11	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6-­‐Chloro-­‐2-­‐methoxy-­‐N-­‐phenylacridin-­‐9-­‐amine	  (1):	  
Prepared	  from	  6,9-­‐dichloro-­‐2-­‐methoxyacridine	  (280	  mg,	  
1	  mmol)	  and	  aniline	  (94	  mg,	  1	  mmol);	  reaction	  time:	  30	  
min;	  yield:	  95%;	  yellow	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C20H15ClN2O:	  C	  71.75,	  H	  
4.52,	  N	  8.37	  ;	  found:	  C	  71.43,	  H	  4.24,	  N	  7.91.	  
Mp:201	  –	  204	  °C	  
IR	  (neat)	  ν:	  2356,	  1629,	  1559,	  1493,	  1420,	  1226,	  828,	  753	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.21	  (d,	  J	  =	  2.0	  Hz,	  1H),	  8.11	  (d,	  J	  =	  9.4	  Hz,	  1H),	  7.99	  
(d,	  J	  =	  9.3	  Hz,	  1H),	  7.48	  (dd,	  J	  =	  9.4,	  2.7	  Hz,	  1H),	  7.36	  (dd,	  J	  =	  9.3,	  2.1	  Hz,	  1H),	  7.30	  
–	  7.24	  (m,	  2H),	  7.12	  (d,	  J	  =	  2.7	  Hz,	  1H),	  6.98	  (t,	  J	  =	  7.4	  Hz,	  1H),	  6.84	  (d,	  J	  =	  7.6	  Hz,	  
2H),	  6.48	  (br	  s,	  1H),	  3.79	  (s,	  3H)	  ppm.	  
13C	  NMR	   (63	  MHz,	   Acetone)	   δ	   158.0,	   149.6,	   149.0,	   146.8,	   135.3,	   133.0,	   130.8,	  




Prepared	   from	   6,9-­‐dichloro-­‐2-­‐methoxyacridine	   (280	  mg,	  
1	   mmol)	   and	   p-­‐anisidine	   (123	   mg,	   1	   mmol);	   reaction	  
time:	  30	  min;	  yield:	  90%;	  yellow	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C21H17ClN2O2:	  C	  69.14,	  H	  
4.70,	  N	  7.68;	  found:	  C	  68.99,	  H	  4.75,	  N	  7.55.	  
Mp:	  301	  –	  304	  °C	  	  
IR	  (neat)	  ν:	  3306,	  1630,	  1560,	  1507,	  1466,	  1420,	  1362,	  1237,	  1033	  cm-­‐1.	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1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.14	  (s,	  1H),	  8.04	  (d,	  J	  =	  9.4	  Hz,	  1H),	  7.93	  (d,	  J	  =	  9.3	  
Hz,	  1H),	  7.43	  (dd,	  J	  =	  9.4,	  2.7	  Hz,	  1H),	  7.29	  (dd,	  J	  =	  9.2,	  2.0	  Hz,	  1H),	  7.10	  (d,	  J	  =	  2.6	  
Hz,	  1H),	  6.92	  –	  6.83	  (m,	  4H),	  3.82	  (s,	  3H),	  3.76	  (s,	  3H)	  ppm.	  
13C	  NMR	   (63	  MHz,	   Acetone)	   δ	   157.6,	   156.4,	   149.8,	   148.9,	   145.3,	   140.0,	   135.1,	  
132.9,	   129.4,	   127.3,	   126.3,	   125.7,	   121.6	   (2C),	   121.4,	   119.2,	   115.7	   (2C),	   101.4,	  
56.2	  (2C)	  ppm.	  
	  
N1-­‐(6-­‐chloro-­‐2-­‐methoxyacridin-­‐9-­‐yl)-­‐N4,N4-­‐dimethylbenzene-­‐1,4-­‐diamine	  (3):	  
Prepared	  from	  6,9-­‐dichloro-­‐2-­‐methoxyacridine	  (280	  mg,	  
1	   mmol)	   and	   N,N-­‐dimethyl-­‐p-­‐phenylenediamine	   (136	  
mg,	   1	  mmol);	   reaction	   time:	   45	  min;	   yield:	   94%;	   deep	  
red	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C22H20ClN3O:	  C	  69.93,	  H	  5.33,	  N	  11.12;	  found:	  C	  
69.78,	  H	  5.65,	  N	  10.74.	  	  
Mp:	  197	  –	  200	  °C	  	  
IR	  (neat)	  ν:	  1629,	  1559,	  1515,	  1474,	  1420,	  1349,	  1260,	  1225	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.12	  (d,	  J	  =	  1.5	  Hz,	  1H),	  8.03	  (d,	  J	  =	  9.4	  Hz,	  1H),	  7.92	  
(d,	  J	  =	  9.3	  Hz,	  1H),	  7.40	  (dd,	  J	  =	  9.1,	  2.3	  Hz,	  1H),	  7.25	  (dd,	  J	  =	  11.5,	  1.9	  Hz,	  1H),	  
7.13	  (d,	  J	  =	  2.4	  Hz,	  1H),	  6.96	  (d,	  J	  =	  8.7	  Hz,	  2H),	  6.73	  (d,	  J	  =	  8.8	  Hz,	  2H),	  3.75	  (s,	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  9.	  Experimental	  section	  
6-­‐Chloro-­‐2-­‐methoxy-­‐N-­‐(4-­‐(piperidin-­‐1-­‐yl)phenyl)acridin-­‐9-­‐amine	  (4):	  
Prepared	  from	  6,9-­‐dichloro-­‐2-­‐methoxyacridine	  (280	  mg,	  
1	   mmol)	   and	   N-­‐(4-­‐aminophenyl)piperidine	   (177	   mg,	   1	  
mmol);	  reaction	  time:	  45	  min;	  yield:	  89%;	  deep	  red	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C25H24ClN3O:	  C	  71.85,	  H	  
5.79,	  N	  10.05;	  found:	  C	  71.70,	  H	  5.53,	  N	  9.72.	  
Mp:	  216	  –	  219	  °C	  	  
IR	  (neat)	  ν:	  1626,	  1570,	  1508,	  1269,	  1235,	  1157,	  1084,	  752	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.14	  (s,	  1H),	  8.04	  (d,	  J	  =	  9.4	  Hz,	  1H),	  7.93	  (d,	  J	  =	  9.3	  
Hz,	  1H),	  7.39	  –	  7.32	  (m,	  2H);	  7.25-­‐7.21	  (m,	  2H),	  7.15	  (s,	  1H),	  7.04	  –	  6.87	  (m,	  4H),	  
3.76	  (s,	  3H),	  3.13	  (t,	  J	  =	  5.4	  Hz,	  4H),	  1.75	  –	  1.60	  (m,	  6H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.2,	  156.2,	  154.7,	  151.0,	  139.8,	  130.0	  (2C),	  128.0,	  
127.2,	   125.0,	   124.5,	   122.4,	   120.9,	   119.8,	   117.4,	   116.5,	   115.8	   (2C),	   103.0,	   56.1,	  
50.8	  (2C),	  26.0	  (2C),	  24.6	  ppm.	  
	  
6-­‐Chloro-­‐2-­‐methoxy-­‐N-­‐(4-­‐morpholinophenyl)acridin-­‐9-­‐amine	  (5):	  
Prepared	   from	   6,9-­‐dichloro-­‐2-­‐methoxyacridine	   (280	  
mg,	   1	   mmol)	   and	   4-­‐morpholinoaniline	   (180	   mg,	   1	  
mmol);	   reaction	   time:	   45	   min;	   yield:	   85%;	   brown	  
solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C24H22ClN3O2:	   C	  
68.65,	  H	  5.28,	  N	  10.01;	  found:	  C	  68.34,	  H	  5.63,	  N	  9.67.	  
Mp:	  240	  –	  243	  °C	  
IR	  (neat)	  ν:	  1630,	  1560,	  1510,	  1420,	  1226,	  1119,	  928	  cm-­‐1.	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   217	   	   	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.14	  (s,	  1H),	  8.05	  (d,	  J	  =	  9.2	  Hz,	  1H),	  7.93	  (d,	  J	  =	  9.2	  
Hz,	  1H),	  7.42	   (dd,	   J	  =	  9.4,	  2.6	  Hz,	  1H),	  7.29	  –	  7.26	   (m,	  1H,	  overlapped	  with	   the	  
residual	  CHCl3	  signal),	  7.12	  (d,	  J	  =	  2.5	  Hz,	  1H),	  6.93	  –	  6.85	  (m,	  4H),	  3.91	  –	  3.90	  (t,	  J	  
=	  4.7	  Hz,	  4H),	  3.77	  (s,	  3H),	  3.12	  (t,	  J	  =	  4.7,	  4H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.7,	  148.2,	  147.3,	  143.7,	  138.4,	  135.5,	  131.2,	  128.0,	  
128.0,	  125.8,	  125.8,	  125.3,	  120.6,	  120.3	  (2C),	  118.5,	  117.6	  (2C),	  100.3,	  67.3	  (2C),	  
55.8,	  50.5	  (2C)	  ppm.	  
	  
6-­‐Chloro-­‐N-­‐hexyl-­‐2-­‐methoxyacridin-­‐9-­‐amine	  (6):	  
Prepared	   from	   6,9-­‐dichloro-­‐2-­‐methoxyacridine	   (280	  
mg,	   1	   mmol)	   and	   hexylamine	   (102	   mg,	   1	   mmol);	  
reaction	  time:	  30	  min;	  yield:	  88%;	  yellow	  solid.	  
Elemental	  analysis	   (%)	  calcd	   for	  C20H23ClN2O:	  C	  70.06,	  H	  6.76,	  N	  8.17;	   found:	  C	  
70.39,	  H	  6.80,	  N	  8.51.	  
Mp:	  102	  –	  105	  °C	  
IR	  (neat)	  ν:	  1665,	  1606,	  1561,	  1518,	  1465,	  1433,	  1356,	  1235,	  1112,	  1032	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.10	  (d,	  J	  =	  2.0	  Hz,	  1H),	  8.06	  (d,	  J	  =	  4.7	  Hz,	  1H),	  8.02	  
(d,	  J	  =	  4.9	  Hz,	  1H),	  7.46	  (dd,	  J	  =	  9.4,	  2.7	  Hz,	  1H),	  7.34	  (dd,	  J	  =	  9.3,	  2.1	  Hz,	  1H),	  7.23	  
(d,	  J	  =	  2.6	  Hz,	  1H),	  4.72	  (br	  s,	  1H),	  4.00	  (s,	  3H),	  3.77	  –	  3.69	  (m,	  2H),	  1.79	  (dt,	  J	  =	  
14.8,	  7.3	  Hz,	  2H),	  1.53	  –	  1.41	  (m,	  2H),	  1.36	  –	  1.30	  (m,	  4H),	  0.90	  (t,	  J	  =	  7.2	  Hz,	  3H)	  
ppm.	  
13C	   NMR	   (63	   MHz,	   DMSO)	   δ	   155.4,	   150.8,	   148.6,	   146.5,	   133.7,	   131.2,	   127.6,	  
126.9,	  124.6,	  123.0,	  117.4,	  114.9,	  100.9,	  56.0,	  49.8,	  31.3,	  30.8,	  26.3,	  22.4,	  14.2	  
ppm.	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  Experimental	  section	  
N-­‐Benzyl-­‐6-­‐chloro-­‐2-­‐methoxyacridin-­‐9-­‐amine	  (7):	  
Prepared	  from	  6,9-­‐dichloro-­‐2-­‐methoxyacridine	  (280	  mg,	  
1	  mmol)	   and	   benzylamine	   (107	  mg,	   1	  mmol);	   reaction	  
time:	  30	  min;	  yield:	  98%;	  yellow	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C21H17ClN2O:	  C	  72.31,	  H	  
4.91,	  N	  8.03;	  found:	  C	  72.29,	  H	  4.86,	  N	  7.73.	  
Mp:	  174	  –	  177	  °C	  
IR	  (neat)	  ν:	  1630,	  1557,	  1432,	  1345,	  1228,	  1069,	  1028,	  825	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.13	  (d,	  J	  =	  1.9	  Hz,	  1H),	  8.02	  (t,	  J	  =	  9.7	  Hz,	  2H),	  7.46	  –	  
7.39	  (m,	  6H),	  7.33	  (dd,	  J	  =	  9.3,	  2.0	  Hz,	  1H),	  7.17	  (d,	  J	  =	  2.5	  Hz,	  1H),	  4.90	  (s,	  2H),	  
3.81	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.6,	  149.9,	  148.6,	  147.3,	  139.7,	  135.3,	  131.9,	  129.5	  




Prepared	   from	   6,9-­‐dichloro-­‐2-­‐methoxyacridine	   (280	  
mg,	   1	   mmol)	   and	   4-­‐amino-­‐1-­‐benzylpiperidine	   (190	  
mg,	   1	   mmol);	   reaction	   time:	   45	   min;	   yield:	   93%;	  
yellow	  solid.	  
Elemental	  analysis	   calcd	   (%)	   for	  C26H26ClN3O:	  C	  72.29,	  H	  6.07,	  N	  9.73;	   found:	  C	  
72.19,	  H	  5.73,	  N	  9.75.	  
Mp:	  135	  –	  138	  °C	  
IR	  (neat)	  ν:	  1629,	  1518,	  1466,	  1344,	  1233,	  923	  cm-­‐1.	  
9.	  Experimental	  section	   	   219	   	   	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.12	  (d,	  J	  =	  1.8	  Hz,	  1H),	  8.06	  –	  7.99	  (m,	  2H),	  7.46	  (dd,	  
J=	  9.4,	  2.6	  Hz,	  1H),	  7.40	  –	  7.31	  (m,	  6H),	  7.21	  (d,	  J	  =	  2.5	  Hz,	  1H),	  3.99	  (s,	  3H),	  3.76	  –	  
3.67	  (m,	  1H),	  3.53	  (s,	  2H),	  2.93	  (d,	  J	  =	  11.3	  Hz,	  2H),	  2.07	  (t,	  J	  =	  10.5	  Hz,	  4H),	  1.83	  –	  
1.75	  (m,	  2H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.8,	  149.7,	  148.3,	  147.1,	  137.8,	  135.5,	  131.5,	  129.8	  
(2C),	  128.7	  (2C),	  128.2,	  127.8,	  125.7,	  125.5,	  124.5,	  120.2,	  118.0,	  99.4,	  63.5,	  57.8,	  
55.9,	  52.9	  (2C),	  34.2	  (2C)	  ppm.	  
	  
4-­‐(6-­‐Chloro-­‐2-­‐methoxyacridin-­‐9-­‐yl)morpholine	  (9):	  
Prepared	   from	   6,9-­‐dichloro-­‐2-­‐methoxyacridine	   (280	  mg,	  
1	  mmol)	  and	  morpholine	  (90	  mg,	  1	  mmol);	  reaction	  time:	  
45	  min;	  yield:	  96%;	  yellow	  solid.	  
Elemental	  analysis	  calcd	  (%)	  for	  C18H17ClN2O2:	  C	  65.75,	  H	  
5.21,	  N	  8.52;	  found:	  C	  65.69,	  H	  4.82,	  N	  8.39.	  
Mp:	  259	  –	  262	  °C	  
IR	  (neat)	  ν:	  1628,	  1553,	  1466,	  1417,	  1222,	  1113,	  1026,	  928	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.37	  (d,	  J	  =	  9.3	  Hz,	  1H),	  8.21	  (d,	  J	  =	  1.9	  Hz,	  1H),	  8.12	  
(d,	  J	  =	  9.4	  Hz,	  1H),	  7.58	  (d,	  J	  =	  2.7	  Hz,	  1H),	  7.52-­‐7.44	  (m,	  2H),	  4.08	  (t,	  J	  =	  4.4	  Hz,	  
4H),	  4.04	  (s,	  3H),	  3.61	  (t,	  J	  =	  4.4	  Hz,	  4H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  157.5,	  152.1,	  148.9,	  148.2,	  135.4,	  131.7,	  128.5,	  127.0,	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  9.	  Experimental	  section	  
N1-­‐(6-­‐Chloro-­‐2-­‐methoxyacridin-­‐9-­‐yl)ethane-­‐1,2-­‐diamine	  (10):	  
Prepared	   from	   6,9-­‐dichloro-­‐2-­‐methoxyacridine	   (280	  mg,	  
1	   mmol)	   and	   ethylenediamine	   (240	   mg,	   4	   mmol);	  
reaction	  time:	  30	  min;	  yield:	  82%;	  yellow	  solid.	  
Elemental	  analysis	  calcd	  (%)	  for	  C16H23ClN3O:	  C	  63.68,	  H	  5.34,	  N	  13.92;	  found:	  C	  
63.34,	  H	  5.23,	  N	  13.88.	  
Mp:	  127	  –	  130	  °C	  
IR	  (neat)	  ν:	  2922,	  1630,	  1560,	  1518,	  1466,	  1432,	  1234,	  1073,	  1031	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.18	  (d,	  J	  =	  9.3	  Hz,	  1H),	  8.10	  (d,	  J	  =	  2.0	  Hz,	  1H),	  8.03	  
(d,	  J	  =	  9.2	  Hz,	  1H),	  7.48	  –	  7.41	  (m,	  2H),	  7.34	  (dd,	  J	  =	  9.3,	  2.1	  Hz,	  1H),	  4.00	  (s,	  3H),	  
3.78	  –	  3.73	  (m,	  2H),	  3.04	  (t,	  J	  =	  5.6	  Hz,	  2H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.4,	  147.3,	  146.3,	  144.3,	  135.2,	  131.9,	  128.7,	  125.0,	  
124.9,	  118.9,	  116.8,	  110.0,	  104.3,	  55.9,	  52.1,	  42.4	  ppm.	  
	  
6-­‐Chloro-­‐9-­‐(1H-­‐imidazol-­‐1-­‐yl)-­‐2-­‐methoxy	  acridine	  (11):	  
Prepared	   from	   6,9-­‐dichloro-­‐2-­‐methoxyacridine	   (280	  mg,	  
1	  mmol)	  and	  imidazole	  (140	  mg,	  2	  mmol);	  reaction	  time:	  
30	  min;	  yield:	  64%;	  yellow	  solid.	  
Elemental	  analysis	  calcd	  (%)	  for	  C17H12ClN3O:	  C	  65.92,	  H	  3.90,	  N	  13.57;	  found:	  C	  
65.90,	  H	  4.03,	  N	  13.39.	  
Mp:	  221	  –	  224	  °C	  
IR	  (neat)	  ν:	  3095,	  1635,	  1560,	  1476,	  1423,	  1236,	  831	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.32	  (d,	  J	  =	  1.2	  Hz,	  1H),	  8.21	  (d,	  J	  =	  9.5	  Hz,	  1H),	  7.87	  
(s,	  1H),	  7.56	  (dd,	  J	  =	  9.5,	  2.8	  Hz,	  1H),	  7.53	  –	  7.45	  (m,	  3H),	  7.34	  (t,	  J	  =	  1.2	  Hz,	  1H),	  
6.63	  (d,	  J	  =	  2.7	  Hz,	  1H),	  3.85	  (s,	  3H)	  ppm.	  
9.	  Experimental	  section	   	   221	   	   	  
13C	   NMR	   (63	   MHz,	   CDCl3)	   δ	   159.5,	   147.8,	   147.7,	   139.2,	   136.7,	   136.1,	   131.90,	  
130.9,	  129.6,	  128.7,	  127.3,	  124.7,	  123.9,	  122.3,	  122.2,	  97.6,	  56.1	  ppm.	  
	  
9-­‐(1H-­‐benzo[d]imidazol-­‐1-­‐yl)-­‐6-­‐chloro-­‐2-­‐methoxyacridine	  (12):	  
Prepared	   from	   6,9-­‐dichloro-­‐2-­‐methoxyacridine	   (280	   mg,	   1	  
mmol)	  and	  benzimidazole	  (240	  mg,	  2	  mmol);	  reaction	  time:	  
30	  min;	  yield:	  87%;	  yellow	  solid.	  
Elemental	   analysis	   calcd	   (%)	   for	   C21H14ClN3O:	   C	   70.10,	   H	  
3.92,	  N	  11.68;	  found:	  C.69.77,	  H	  3.80,	  N	  11.62.	  
Mp:	  232	  –	  235	  °C	  
IR	  (neat)	  ν:	  1636,	  1475,	  1422,	  1236,	  828	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.40	  (d,	  J	  =	  1.6	  Hz,	  1H),	  8.30	  (d,	  J	  =	  9.5	  Hz,	  1H),	  8.25	  
(s,	  1H),	  8.08	  (d,	  J	  =	  8.1	  Hz,	  1H),	  7.59	  (dd,	  J	  =	  9.5,	  2.7	  Hz,	  1H),	  7.51	  –	  7.48	  (m,	  1H),	  
7.45	  (d,	  J	  =	  2.0	  Hz,	  1H),	  7.38	  (s,	  1H),	  7.33	  (d,	  J	  =	  5.5	  Hz,	  1H),	  6.95	  (d,	  J	  =	  8.1	  Hz,	  
1H),	  6.54	  (d,	  J	  =	  2.7	  Hz,	  1H),	  3.70	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  159.5,	  148.1,	  147.9,	  144.0,	  143.7,	  136.2,	  135.7,	  135.2,	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  9.	  Experimental	  section	  
9.2.1.2.	  1,4-­‐Bis(6-­‐chloro-­‐2-­‐methoxyacridin-­‐9-­‐yl)piperazine	  (13):	  
	  
Prepared	  from	  6,9-­‐dichloro-­‐2-­‐methoxyacridine	  (280	  mg,	  1	  mmol)	  and	  piperazine	  
(43	  mg,	  0.5	  mmol);	  reaction	  time:	  45	  min;	  yield:	  78%;	  brown	  solid.	  
Elemental	  analysis	  calcd	  (%)	  for	  C32H26Cl2N4O2:	  C	  67.49,	  H	  4.60,	  N	  9.84;	  found:	  C	  
67.19,	  H	  4.52,	  N	  9.62.	  
Mp:	  249	  –	  252	  °C	  
IR	  (neat)	  ν:	  1629,	  1556,	  1416,	  1374,	  1230,	  1010,	  927,	  808,	  752	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.55	  (d,	  J	  =	  9.3	  Hz,	  2H),	  8.27	  (d,	  J	  =	  2.0	  Hz,	  2H),	  8.18	  
(d,	  J	  =	  9.5	  Hz,	  2H),	  7.80	  (d,	  J	  =	  2.7	  Hz,	  2H),	  7.59	  –	  7.54	  (m,	  4H),	  4.11	  (s,	  6H),	  3.97	  
(s,	  8H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  157.5	  (2C),	  152.2	  (2C),	  149.3	  (2C),	  142.6	  (2C),	  137.8	  
(2C),	  135.2	  (2C),	  132.5	  (2C),	  132.4	  (2C),	  129.3	  (2C),	  127.0	  (2C),	  125.9	  (2C),	  125.5	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9.2.1.3.	  Synthesis	  of	  4-­‐aminoquinoline	  derivatives	  
	  
Cmpd.	   R1	   R2	  




16	   C6H5-­‐CH2-­‐	   H	  
17	   H2N-­‐CH2-­‐CH2	   H	  









Prepared	   from	   4,7-­‐dichloroquinoline	   (200	   mg,	   1	   mmol)	  
and	  p-­‐anisidine	  (123mg,	  1	  mmol);	  reaction	  time:	  30	  min;	  
yield:	  98%;	  pale	  brown	  solid.	  
Elemental	  analysis	  calcd	  (%)	  for	  C16H13ClN2O:	  C	  67.49,	  H	  
4.60,	  N	  9.84;	  found:	  C	  67.09,	  H	  4.63,	  N	  9.72.	  
Mp:	  207	  –	  210	  °C	  
IR	  (neat)	  ν:	  2938,	  1576,	  1509,	  1376,	  1251,	  772	  cm-­‐1.	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  9.	  Experimental	  section	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.51	  (d,	  J	  =	  5.4	  Hz,	  1H),	  8.03	  (d,	  J	  =	  2.1	  Hz,	  1H),	  7.89	  
(d,	  J	  =	  9.0	  Hz,	  1H),	  7.46	  (dd,	  J	  =	  8.9,	  2.1	  Hz,	  1H),	  7.26	  (d,	  J	  =	  8.9	  Hz,	  2H),	  7.00	  (d,	  J	  =	  
8.9	  Hz,	  2H),	  6.70	  (d,	  J	  =	  5.4	  Hz,	  1H),	  3.88	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  158.1,	  152.3,	  149.9,	  149.5,	  135.6,	  132.1,	  129.3,	  126.6	  
(2C),	  126.3,	  121.50,	  117.9,	  115.4	  (2C),	  101.8,	  56.0	  ppm.	  
	  
7-­‐Chloro-­‐N-­‐(4-­‐morpholinophenyl)quinolin-­‐4-­‐amine	  (15):	  
Prepared	   from	  4,7-­‐dichloroquinoline	   (200	  mg,	  1	  mmol)	  
and	   4-­‐morpholinoaniline	   (180	   mg,	   1	   mmol);	   reaction	  
time:	  45	  min;	  yield:	  94%;	  grey	  solid.	  
Elemental	  analysis	  calcd	  (%)	  for	  C19H18ClN3O:	  C	  67.15,	  H	  
5.34,	  N	  12.37;	  found:	  C	  67.30,	  H	  5.14,	  N	  12.64.	  
Mp:	  275	  –	  278	  °C	  
IR	  (neat)	  ν:	  2987,	  2358,	  1562,	  1515,	  1450,	  1327,	  1254	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.52	  (d,	  J	  =	  5.4	  Hz,	  1H),	  8.04	  (d,	  J	  =	  2.1	  Hz,	  1H),	  7.87	  
(d,	  J	  =	  9.0	  Hz,	  1H),	  7.47	  (dd,	  J	  =	  8.9,	  2.2	  Hz,	  1H),	  7.25	  (d,	  J	  =	  8.9	  Hz,	  2H),	  7.01	  (d,	  J	  =	  
8.9	  Hz,	  2H),	  6.73	  (d,	  J	  =	  5.4	  Hz,	  1H),	  6.57	  (br	  s,	  1H),	  3.93	  (t,	  J	  =	  4.8	  Hz,	  4H),	  3.22	  (t,	  
J	  =	  4.8	  Hz,	  4H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   DMSO)	   δ	   152.3,	   149.9,	   149.6,	   148.8,	   134.1,	   131.6,	   128.0,	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N-­‐Benzyl-­‐7-­‐chloroquinolin-­‐4-­‐amine	  (16):	  
Prepared	  from	  4,7-­‐dichloroquinoline	  (200	  mg,	  1	  mmol)	  and	  
benzylamine	  (107	  mg,	  1	  mmol);	  reaction	  time:	  30	  min;	  yield:	  
91%;	  white	  solid.	  
Elemental	  analysis	   calcd	   (%)	   for	  C16H13ClN2:	  C	  71.51,	  H	  4.88,	  N	  10.42;	   found:	  C	  
71.49,	  H	  4.64,	  N	  10.35.	  
Mp:	  167	  –	  170	  °C	  
IR	  (neat)	  ν:	  1576,	  1492,	  1430,	  1366,	  1281,	  1228,	  1132,	  894	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.57	  (d,	  J	  =	  5.3	  Hz,	  1H),	  8.01	  (d,	  J	  =	  2.1	  Hz,	  1H),	  7.72	  
(d,	  J	  =	  9.0	  Hz,	  1H),	  7.51	  –	  7.31	  (m,	  6H),	  6.49	  (d,	  J	  =	  5.3	  Hz,	  1H),	  5.34	  (br	  s,	  1H),	  
4.56	  (d,	  J	  =	  5.2	  Hz,	  2H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  152.7,	  149.9,	  149.5,	  137.6,	  135.4,	  129.4,	  129.3,	  128.4,	  
128.0,	  125.9,	  121.55,	  117.7,	  100.1,	  48.0	  ppm.	  
	  
N1-­‐(7-­‐Chloroquinolin-­‐4-­‐yl)ethane-­‐1,2-­‐diamine	  (17):	  
Prepared	  from	  4,7-­‐dichloroquinoline	  (200	  mg,	  1	  mmol)	  and	  
ethylenediamine	  (240	  mg,	  4	  mmol);	  reaction	  time:	  30	  min;	  
yield:	  90%;	  white	  solid.	  
Elemental	  analysis	  calcd	   (%)	   for	  C11H12ClN3:	  C	  59.60,	  H	  5.46,	  N	  18.95;	   found:	  C	  
59.46,	  H	  5.11,	  N	  18.82.	  
Mp:	  169	  –	  172	  °C	  
IR	  (neat)	  ν:	  1582,	  1532,	  1480,	  1451,	  1368,	  1165,	  1133	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.55	  (d,	  J	  =	  5.4	  Hz,	  1H),	  7.98	  (d,	  J	  =	  2.1	  Hz,	  1H),	  7.78	  
(d,	  J	  =	  8.9	  Hz,	  1H),	  7.39	  (dd,	  J	  =	  8.9,	  2.2	  Hz,	  1H),	  6.44	  (d,	  J	  =	  5.4	  Hz,	  1H),	  3.37	  (t,	  J	  =	  
5.7	  Hz,	  2H),	  3.14	  (t,	  J	  =	  5.7	  Hz,	  2H)	  ppm.	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  9.	  Experimental	  section	  
13C	   NMR	   (63	   MHz,	   DMSO)	   δ	   152.3,	   150.6,	   149.5,	   133.7,	   127.8,	   124.6,	   124.4,	  
117.9,	  99.1,	  45.8,	  40.1	  ppm.	  
	  
N1-­‐(7-­‐Chloroquinolin-­‐4-­‐yl)-­‐N1,N2-­‐dimethylethane-­‐1,2-­‐diamine	  (18):	  
Prepared	   from	   4,7-­‐dichloroquinoline	   (200	   mg,	   1	   mmol)	  
and	  N1,N2-­‐dimethylethane-­‐1,2-­‐diamine	  (350	  mg,	  4	  mmol);	  
reaction	  time:	  30	  min;	  yield:	  87%;	  yellow	  oil.	  
Elemental	  analysis	  calcd	   (%)	   for	  C13H10ClN3:	  C	  62.52,	  H	  6.46,	  N	  16.83;	   found:	  C	  
62.34,	  H	  6.16,	  N	  16.55.	  
IR	  (neat)	  ν:	  3029,	  2932,	  2842,	  1605,	  1569,	  1498,	  1432,	  1418,	  908,	  876	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.68	  (d,	  J	  =	  5.1	  Hz,	  1H),	  8.13	  (d,	  J	  =	  9.0	  Hz,	  1H),	  8.03	  
(d,	  J	  =	  2.1	  Hz,	  1H),	  7.43	  (dd,	  J	  =	  9.0,	  2.2	  Hz,	  1H),	  6.85	  (d,	  J	  =	  5.2	  Hz,	  1H),	  3.42	  (t,	  J	  =	  
6.4	  Hz,	  2H),	  3.01	  (s,	  3H),	  2.94	  (t,	  J	  =	  6.4	  Hz,	  2H),	  2.48	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  157.8,	  151.9,	  150.8,	  135.1,	  129.1,	  126.2,	  126.1,	  122.3,	  
109.2,	  56.0,	  49.5,	  41.3,	  37.1	  ppm.	  
	  
4-­‐(7-­‐Chloroquinolin-­‐4-­‐yl)morpholine	  (19):	  
Prepared	   from	   4,7-­‐dichloroquinoline	   (200	   mg,	   1	   mmol)	   and	  
morpholine	   (90	  mg,	  1	  mmol);	   reaction	   time:	  45	  min;	   yield:	   85%;	  
white	  solid.	  
Elemental	   analysis	   calcd	   (%)	   for	   C13H13ClN2:	   C	   62.78,	   H	   5.27,	   N	  
11.26;	  found:	  C	  62.56,	  H	  5.17,	  N	  10.94.	  
Mp:	  134	  –	  137	  °C	  
IR	  (neat)	  ν:	  2888,	  1606,	  1575,	  1498,	  1423,	  1259,	  922	  cm-­‐1.	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1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.77	  (d,	  J	  =	  5.0	  Hz,	  1H),	  8.08	  (d,	  J	  =	  2.1	  Hz,	  1H),	  7.98	  
(d,	  J	  =	  9.0	  Hz,	  1H),	  7.47	  (dd,	  J	  =	  9.0,	  2.1	  Hz,	  1H),	  6.89	  (d,	  J	  =	  5.0	  Hz,	  1H),	  4.02	  (t,	  J	  =	  
4.6	  Hz,	  4H),	  3.25	  (t,	  J	  =	  4.6	  Hz,	  4H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  157.2,	  152.4,	  150.6,	  135.4,	  129.4,	  126.8,	  125.4,	  122.2,	  
109.4,	  67.2	  (2C),	  53.0	  (2C)	  ppm.	  
	  
7-­‐Chloro-­‐4-­‐(4-­‐methylpiperazin-­‐1-­‐yl)quinoline	  (20):	  
Prepared	   from	   4,7-­‐dichloroquinoline	   (200	   mg,	   1	   mmol)	   and	   1-­‐
methylpiperazine	  (100	  mg,	  1	  mmol);	  reaction	  time:	  45	  min;	  yield:	  
89%;	  pale	  brown	  solid.	  
Elemental	   analysis	   calcd	   (%)	   for	   C14H16ClN3:	   C	   64.24,	   H	   6.16,	   N	  
16.05;	  found:	  C	  63.99,	  H	  6.23,	  N	  15.74.	  
Mp:	  79	  –	  82	  °C	  
IR	  (neat)	  ν:	  2936,	  2840,	  2793,	  1607,	  1573,	  1497,	  1455,	  1421,	  784	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.74	  (d,	  J	  =	  5.0	  Hz,	  1H),	  8.06	  (d,	  J	  =	  1.9	  Hz,	  1H),	  7.97	  
(d,	  J	  =	  9.0	  Hz,	  1H),	  7.45	  (dd,	  J	  =	  9.0,	  1.9	  Hz,	  1H),	  6.87	  (d,	  J	  =	  5.0	  Hz,	  1H),	  3.28	  (t,	  J	  =	  
4.3	  Hz,	  4H),	  2.74	  (t,	  J	  =	  4.3	  Hz,	  4H),	  2.45	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  157.4,	  152.3,	  150.5,	  135.3,	  129.2,	  126.6,	  125.6,	  122.3,	  
109.5,	  55.4	  (2C),	  52.5	  (2C),	  46.5	  ppm.	  
	  
4-­‐(1H-­‐Benzo[d]imidazol-­‐1-­‐yl)-­‐7-­‐chloroquinoline	  (21):	  
Prepared	   from	   4,7-­‐dichloroquinoline	   (200	   mg,	   1	   mmol)	   and	  
benzimidazole	  (240	  mg,	  2	  mmol);	  reaction	  time:	  30	  min;	  yield:	  
85%;	  white	  solid.	  
228	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  9.	  Experimental	  section	  
Elemental	  analysis	   calcd	   (%)	   for	  C16H10ClN3:	  C	  68.70,	  H	  3.60,	  N	  15.02;	   found:	  C	  
68.35,	  H	  3.39,	  N	  15.15.	  
Mp:	  149	  –	  152	  °C	  
IR	  (neat)	  ν:	  1592,	  1560,	  1490,	  1456,	  1426,	  1236,	  1209,	  948,	  745	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  9.14	  (d,	  J	  =	  4.6	  Hz,	  1H),	  8.32	  (d,	  J	  =	  1.9	  Hz,	  1H),	  8.21	  
(s,	  1H),	  8.00	  (d,	  J	  =	  8.1	  Hz,	  1H),	  7.66	  (d,	  J	  =	  9.0	  Hz,	  1H),	  7.59	  –	  7.53	  (m,	  2H),	  7.48	  –	  
7.42	  (m,	  1H),	  7.40	  –	  7.34	  (m,	  1H),	  7.23	  (d,	  J	  =	  7.7	  Hz,	  1H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  152.3,	  150.7,	  144.1,	  143.1,	  141.3,	  137.3,	  134.9,	  129.7,	  
129.5,	  124.8,	  124.7,	  124.0,	  122.9,	  121.4,	  118.6,	  111.0	  ppm.	  
	  
9.2.1.4.	  Synthesis	  of	  4-­‐amino-­‐2-­‐phenylquinazoline	  
	  
Cmpd.	   R1	   R2	  
22	   4-­‐Cl-­‐C6H4	   H	  
23	   C6H5-­‐CH2-­‐	   H	  







9.	  Experimental	  section	   	   229	   	   	  
N-­‐(4-­‐Chlorophenyl)-­‐2-­‐phenylquinazolin-­‐4-­‐amine	  (22):	  
Prepared	  from	  4-­‐chloro-­‐2-­‐phenylquinazoline	  (241	  mg,	  1	  mmol)	  
and	  4-­‐chloroaniline	  (130	  mg,	  1	  mmol);	  reaction	  time:	  30	  min;	  
yield:	  98%;	  grey	  solid.	  
Elemental	  analysis	  calcd	  (%)	  for	  C20H14ClN3:	  C	  72.40,	  H	  4.25,	  N	  
12.66;	  found:	  C	  72.43,	  H	  4.27,	  N	  12.31.	  
Mp:	  183	  –	  186	  °C	  
IR	  (neat)	  ν:	  1620,	  1598,	  1558,	  1520,	  1485,	  1441,	  1357,	  1327,	  757	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.57	  –	  8.54	  (m,	  2H),	  8.05	  (d,	  J	  =	  8.4	  Hz,	  1H),	  7.92	  –	  
7.85	  (m,	  4H),	  7.61	  –	  7.45	  (m,	  7H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  160.7,	  157.5,	  151.5,	  138.9,	  137.6,	  133.5,	  130.8,	  129.8,	  
129.4	  (2C),	  129.4,	  128.9	  (2C),	  128.9	  (2C),	  126.7,	  122.9	  (2C),	  120.5,	  114.1	  ppm.	  
	  
N-­‐Benzyl-­‐2-­‐phenylquinazolin-­‐4-­‐amine	  (23):	  
Prepared	  from	  4-­‐chloro-­‐2-­‐phenylquinazoline	  (241	  mg,	  1	  mmol)	  
and	   benzylamine	   (107	   mg,	   1	   mmol);	   reaction	   time:	   30	   min;	  
yield:	  94%;	  grey	  solid.	  
Elemental	   analysis	   calcd	   (%)	   for	   C21H17N3:	   C	   81.00,	   H	   5.50,	   N	  
13.49;	  found:	  C	  81.14,	  H	  5.57,	  N	  13.17.	  
Mp:	  121	  –	  124	  °C	  
IR	  (neat)	  ν:	  1586,	  1571,	  1529,	  1494,	  1455,	  1438,	  1407,	  678	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.61	  (dd,	  J	  =	  7.3,	  2.4	  Hz,	  2H),	  7.99	  (d,	  J	  =	  8.4	  Hz,	  1H),	  
7.75	  (dd,	  J	  =	  13.4,	  7.3	  Hz,	  2H),	  7.53	  –	  7.36	  (m,	  9H),	  6.03	  (br	  s,	  1H),	  5.06	  (d,	  J	  =	  5.2	  
Hz,	  2H)	  ppm.	  
230	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  9.	  Experimental	  section	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  161.0,	  159.8,	  151.1,	  139.3,	  139.1,	  133.0,	  130.6,	  129.3,	  




Prepared	   from	   4-­‐chloro-­‐2-­‐phenylquinazoline	   (241	   mg,	   1	  
mmol)	  and	  N1,N1-­‐dimethylpropane-­‐1,3-­‐diamine	   (105	  mg,	  1	  
mmol);	  reaction	  time:	  30	  min;	  yield:	  91%;	  grey	  solid.	  
Elemental	  analysis	  calcd	  (%)	   for	  C19H22N4:	  C	  74.48,	  H	  7.24,	  
N	  18.29;	  found:	  C	  74.19,	  H	  6.84,	  N	  18.09.	  
Mp:	  69	  –	  72	  °C	  
IR	  (neat)	  ν:	  3243,	  2942,	  2821,	  1616,	  1574,	  1534,	  1489,	  1457,	  692,	  675	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.62	  –	  8.58	  (m,	  2H),	  7.93	  (d,	  J	  =	  8.0	  Hz,	  1H),	  7.75	  –	  
7.69	   (m,	  1H),	  7.64	   (d,	   J	  =	  8.1	  Hz,	  1H),	  7.56	  –	  7.47	   (m,	  3H),	  7.44	  –	  7.38	   (m,	  1H),	  
3.91	  (q	  J	  =	  5.8	  Hz,	  2H),	  2.61	  (t,	  J	  =	  5.8	  Hz,	  2H),	  2.39	  (s,	  6H),	  1.97	  –	  1.88	  (m,	  2H)	  
ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  161.3,	  160.3,	  150.8,	  139.7,	  132.6,	  130.3,	  129.0,	  128.8	  
(2C),	  128.6	  (2C),	  125.6,	  121.4,	  114.69,	  60.2,	  46.0	  (2C),	  42.7,	  25.2	  ppm.	  
	  
4-­‐(4-­‐Methylpiperazin-­‐1-­‐yl)-­‐2-­‐phenylquinazoline	  (25):	  
Prepared	   from	   4-­‐chloro-­‐2-­‐phenylquinazoline	   (241	   mg,	   1	  
mmol)	   and	   1-­‐methylpiperazine	   (100	   mg,	   1	   mmol);	   reaction	  
time:	  45	  min;	  yield:	  90%;	  white	  solid.	  
Elemental	  analysis	   calcd	   (%)	   for	  C19H20N4:	  C	  74.97,	  H	  6.62,	  N	  
9.	  Experimental	  section	   	   231	   	   	  
18.41;	  found:	  C	  74.75,	  H	  6.61,	  N	  18.07.	  
Mp:	  92	  –	  95	  °C	  
IR	  (neat)	  ν:	  2935,	  2843,	  2793,	  1612,	  1563,	  1536,	  1502,	  1435,	  1351	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.58	  (dd,	  J	  =	  7.4,	  2.2	  Hz,	  2H),	  8.00	  (d,	  J	  =	  8.5	  Hz,	  1H),	  
7.93	  (d,	  J	  =	  8.2	  Hz,	  1H),	  7.76	  (t,	  J	  =	  7.1	  Hz,	  1H),	  7.53	  –	  7.42	  (m,	  4H),	  2.95	  (t,	  J	  =	  4.5	  
Hz,	  2H),	  2.72	  (t,	  J	  =	  4.5	  Hz,	  2H),	  2.45	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  165.2,	  159.8,	  153.3,	  139.1,	  132.8,	  130.6,	  129.4,	  128.8	  
(2C),	  128.8	  (2C),	  125.3,	  125.3,	  115.8,	  55.4	  (2C),	  50.1	  (2C),	  46.6	  ppm.	  
	  
4-­‐(1H-­‐Imidazol-­‐1-­‐yl)-­‐2-­‐phenylquinazoline	  (26):	  
Prepared	   from	  4-­‐chloro-­‐2-­‐phenylquinazoline	   (241	  mg,	  1	  mmol)	  
and	   imidazole	   (140	  mg,	   2	  mmol);	   reaction	   time:	   30	  min;	   yield:	  
87%;	  white	  solid.	  
Elemental	   analysis	   calcd	   (%)	   for	   C17H12N4:	   C	   74.98,	   H	   4.44,	   N	  
20.58;	  found:	  C	  74.70,	  H	  4.62,	  N	  20.86.	  
Mp:	  154	  –	  157	  °C	  
IR	  (neat)	  ν:	  1570,	  1551,	  1472,	  1420,	  1382,	  1354,	  1325,	  1255,	  654,	  706	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.68	  –	  8.64	  (m,	  2H),	  8.44	  (s,	  1H),	  8.22	  (t,	  J	  =	  8.9	  Hz,	  
2H),	  8.02	  (ddd,	  J	  =	  8.4,	  7.0,	  1.4	  Hz,	  1H),	  7.83	  (s,	  1H),	  7.72	  (ddd,	  J	  =	  8.2,	  7.0,	  1.2	  Hz,	  
1H),	  7.60	  –	  7.55	  (m,	  3H),	  7.41	  (s,	  1H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  160.6,	  155.6,	  154.3,	  138.2,	  137.2,	  135.1,	  131.7,	  131.1,	  
129.9,	  129.1	  (2C),	  129.0	  (2C),	  128.7,	  124.4,	  120.1,	  116.6	  ppm.	  
	  
	  
232	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  9.	  Experimental	  section	  
9.2.1.5.	  Amsacrine	  (27):	  
	  
Prepared	   from	   9-­‐chloroacridine	   (215	   mg,	   1	   mmol)	   and	   N-­‐(4-­‐amino-­‐3-­‐
methoxy)methanesulfonamide	  (220	  mg,	  1	  mmol)	  according	  to	  our	  method	  under	  
MW	  irradiation;	  reaction	  time:	  40	  min;	  yield:	  78%;	  orange	  solid.	  
Elemental	  analysis	   calcd	   (%)	   for	  C21H19N3O3S:	  C	  64.10,	  H	  4.87,	  N	  10.68,	   S	  8.15;	  
found:	  C	  64.39,	  H	  4.98,	  N	  10.85,	  S	  8.29.	  
Mp:	  233	  –	  236	  °C	  
IR	  (neat)	  ν:	  3347,	  1560,	  1512,	  1474,	  1321,	  1149,	  730,	  667	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  Acetone)	  δ	  8.36	  (br	  s,	  1H),	  8.04	  (s,	  2H),	  7.55	  –	  7.49	  (m,	  4H),	  
7.09	  –	  7.03	  (m,	  3H),	  6.92	  (dd,	  J	  =	  8.3,	  2.2	  Hz,	  1H),	  6.70	  (d,	  J	  =	  8.3	  Hz,	  1H),	  3.70	  (s,	  
3H),	  3.01	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  Acetone)	  δ	  150.3	  (2	  C),	  143.2	  (broad	  signal,	  2	  C),	  134.0,	  132.2	  
(4	  C)	  ,	  128.2	  (2	  C),	  121.8,	  121.8	  (broad	  signal,	  2	  C),	  119.9,	  115.8	  (2	  C),	  107.9	  (2	  C),	  
56.4,	  39.1	  ppm.	  
	  
9.2.1.6.	  Synthesis	  of	  bistacrine	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9-­‐chloro-­‐1,2,3,4-­‐tetrahydroacridine	  (28):	  
To	   a	   mixture	   of	   anthranilic	   acid	   (500	   mg,	   3.64	   mmol)	   and	  
cyclohexanone	  (357.8	  mg,	  3.64	  mmol)	  was	  carefully	  added	  5	  ml	  of	  
POCl3	  in	  an	  ice	  bath.	  The	  mixture	  was	  refluxed	  for	  2	  h,	  then	  cooled	  
at	   room	   temperature,	   and	   concentrated	   under	   reduced	   pressure.	   The	   residue	  
was	  diluted	  with	  ethyl	   acetate	   (10	  ml),	   neutralized	  with	   aqueous	  K2CO3	   (5	  ml),	  
and	  washed	  with	  brine.	  The	  organic	  layer	  was	  dried	  over	  anhydrous	  Na2SO4	  and	  
concentrated	  under	  reduced	  pressure	  to	  give	  a	  yellow	  solid	  in	  68%	  yield.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.19	  (dd,	  J	  =	  8.4,	  1.0	  Hz,	  1H),	  8.00	  (d,	  J	  =	  8.0	  Hz,	  1H),	  
7.69	  (ddd,	  J	  =	  8.4,	  6.9,	  1.4	  Hz,	  1H),	  7.56	  (ddd,	  J	  =	  8.2,	  6.9,	  1.2	  Hz,	  1H),	  3.15	  (t,	  J	  =	  
5.4	  Hz,	  2H),	  3.04	  (t,	  J	  =	  5.6	  Hz,	  2H),	  1.97	  (dt,	  J	  =	  6.7,	  3.3	  Hz,	  4H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  159.7,	  147.0,	  141.7,	  129.5,	  129.1,	  129.0,	  126.7,	  125.6,	  
123.9,	  34.5,	  27.8,	  23.0,	  22.9	  ppm.	  
	  
Bistacrine	  (29):	  
Prepared	   from	   9-­‐chloro-­‐1,2,3,4-­‐
tetrahydroacridine	   (220	   mg,	   1	   mmol)	   and	   1,7-­‐
heptanediamine	   (65	  mg,	  0.5	  mmol)	   according	   to	  
our	   method	   under	   MW	   irradiation;	   reaction	   time:	   40	   min;	   yield:	   98%;	   yellow	  
solid.	  
Elemental	   analysis	   calcd	   (%)	   for	   C33H40N4:	   C	   80.45,	   H	   8.18,	   N	   11.37;	   found:	   C	  
80.07,	  H	  8.03,	  N	  11.52.	  
Mp:	  65	  –	  68	  °C	  
IR	  (neat)	  ν:	  1614,	  1580,	  1561,	  1498,	  1420,	  1358,	  1296,	  1272,	  678	  cm-­‐1.	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1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  7.95	  (t,	  J	  =	  9.3	  Hz,	  4H),	  7.58	  (t,	  J	  =	  7.6	  Hz,	  2H),	  7.37	  (t,	  
J	  =	  7.6	  Hz,	  2H),	  3.96	  (br	  s,	  2H),	  3.51	  –	  3.46	  (m,	  4H),	  3.09	  (s,	  4H),	  2.73	  (s,	  4H),	  1.94	  
(s,	  8H),	  1.69	  –	  1.65	  (m,	  4H),	  1.40	  (s,	  6H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  158.9	  (2C),	  151.1	  (2C),	  148.0	  (2C),	  129.3	  (2C),	  128.6	  
(2C),	  124.0	  (2C),	  123.2	  (2C),	  120.7	  (2C),	  116.4	  (2C),	  49.8	  (2C),	  34.6	  (2C),	  32.1	  (2C),	  
29.5,	  27.3	  (2C),	  25.2	  (2C),	  23.5	  (2C),	  23.2	  (2C)	  ppm.	  
	  
9.2.2.	  General	  procedure	  for	  the	  preparation	  of	  β-­‐enamino	  esters	  
To	  a	  stirred	  solution	  of	  3	  mmol	  of	  amine	  and	  3	  mmol	  of	  ethyl	  acetoacetate	  in	  3	  
ml	  of	  EtOH	  was	  added	  5	  mol%	  of	  CAN	  (82	  mg).	  The	  mixture	  was	  stirred	  at	  r.t.	  for	  
1	   h.	   After	   completion	   of	   the	   reaction	   the	   mixture	   was	   dissolved	   in	   CH2Cl2,	  
washed	  with	  H2O,	  dried,	  and	  evaporated.	  No	  further	  purification	  was	  needed.	  
	  
Cmpd.	   R	  
35	   CH3	  
36	   n-­‐But	  
37	   sec-­‐But	  
38	  
	  
39	   C6H5-­‐CH2	  
	  (Z)-­‐ethyl	  3-­‐(methylamino)but-­‐2-­‐enoate	  (35):	  
Prepared	   from	   methylamine	   (93.2	   mg,	   3	   mmol)	   and	   ethyl	  
acetoacetate	  (390.4	  mg,	  3	  mmol);	  yield:	  71%;	  orange	  oil.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.50	  (br	  s,	  1H),	  4.48	  (s,	  1H),	  4.10	  (q,	  
J	  =	  7.1	  Hz,	  2H),	  2.93	  (d,	  J	  =	  5.2	  Hz,	  3H),	  1.94	  (s,	  3H),	  1.26	  (t,	  J	  =	  7.1	  Hz,	  3H)	  ppm.	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  (Z)-­‐ethyl	  3-­‐(butylamino)but-­‐2-­‐enoate	  (36):	  
Prepared	   from	  n-­‐butylamine	   (220	  mg,	   3	  mmol)	   and	   ethyl	  
acetoacetate	  (390.4	  mg,	  3	  mmol);	  yield:	  77%;	  yellow	  oil.	  
1H	  NMR	   (250	  MHz,	   CDCl3)	   δ	   8.56	   (br	   s,	   1H),	   4.43	   (s,	   1H),	  
4.08	  (q,	  J	  =	  7.1	  Hz,	  2H),	  3.20	  (q,	  J	  =	  7.0	  Hz,	  2H),	  1.92	  (s,	  3H),	  1.61	  –	  1.47	  (m,	  2H),	  
1.44	  –	  1.36	  (m,	  2H),	  1.25	  (t,	  J	  =	  7.1	  Hz,	  3H),	  0.94	  (t,	  J	  =	  7.2	  Hz,	  3H)	  ppm.	  
	  
(Z)-­‐ethyl	  3-­‐(sec-­‐butylamino)but-­‐2-­‐enoate	  (37):	  
Prepared	   from	   sec-­‐butylamine	   (220	  mg,	   3	  mmol)	   and	   ethyl	  
acetoacetate	  (390.4	  mg,	  3	  mmol);	  yield:82%;	  yellow	  oil.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.54	  (br	  s,	  1H),	  4.41	  (s,	  1H),	  4.10	  
(q,	  J	  =	  7.1	  Hz,	  2H),	  3.51	  –	  3.40	  (m,	  1H),	  1.94	  (s,	  3H),	  1.59	  –	  1.48	  (m,	  2H),	  1.27	  (t,	  J	  
=	  7.1	  Hz,	  3H),	  1.19	  (d,	  J	  =	  6.5	  Hz,	  3H),	  0.95	  (t,	  J	  =	  7.4	  Hz,	  3H)	  ppm.	  
	  
(Z)-­‐ethyl	  3-­‐(furan-­‐2-­‐ylmethylamino)but-­‐2-­‐enoate	  (38):	  
Prepared	   from	   furfurylamine	   (292	   mg,	   3	   mmol)	   and	   ethyl	  
acetoacetate	  (390.4	  mg,	  3	  mmol);	  yield:85%;	  orange	  oil.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.83	  (br	  s,	  1H),	  7.38	  –	  7.37	  (m,	  1H),	  
6.33	  (dd,	  J	  =	  3.2,	  1.9	  Hz,	  1H),	  6.22	  (dd,	  J	  =	  3.2,	  0.7	  Hz,	  1H),	  4.55	  (s,	  1H),	  4.40	  (d,	  J	  =	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(Z)-­‐ethyl	  3-­‐(benzylamino)but-­‐2-­‐enoate	  (39):	  
Prepared	   from	   benzylamine	   (322	   mg,	   3	   mmol)	   and	   ethyl	  
acetoacetate(390.4	  mg,	  3	  mmol);	  yield:	  81%;	  yellow	  oil.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.98	  (br	  s,	  1H),	  7.41	  –	  7.26	  (m,	  5H),	  
4.56	  (s,	  1H),	  4.46	  (d,	  J	  =	  6.4	  Hz,	  2H),	  4.13	  (q,	  J	  =	  7.1	  Hz,	  2H),	  1.94	  
(s,	  3H),	  1.28	  (t,	  J	  =	  7.2	  Hz,	  3H)	  ppm.	  
	  
9.2.2.1.	  (E)-­‐ethyl	  3-­‐(pyrrolidin-­‐1-­‐yl)but-­‐2-­‐enoate	  (40):	  
A	   mixture	   of	   pyrrolidine	   (320	   mg,	   4.5	   mmol)	   and	   ethyl	  
acetoacetate	   (390.4	  mg,	   3	  mmol)	   was	   stirred	   at	   r.t.	   for	   16	   h	  
until	  completion	  of	  the	  reaction.	  The	  crude	  mixture	  was	  dissolved	  in	  CH2Cl2	  and	  
was	  purified	  over	  alumina	  by	  chromatography	  to	  obtain	  a	  pale	  yellow	  oil	  in	  89%	  
yield.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  4.45	  (s,	  1H),	  4.08	  (q,	  J	  =	  7.1	  Hz,	  2H),	  3.30	  (br	  s,	  3H),	  
2.46	  (s,	  3H),	  1.95	  	  1.90	  (m,	  4H),	  1.25	  (t,	  J	  =	  7.1	  Hz,	  3H)	  ppm.	  
	  
9.2.3.	  General	  procedure	  for	  the	  InCl3	  catalyzed	  generation	  of	  C-­‐C	  and	  C-­‐N	  bond	  
on	  nitrogen	  heterocycles	  
The	   suitable	   starting	   heterocycle	   (0.5	  mmol),	   the	   corresponding	   nucleophile	   (1	  
equiv)	  and	  10	  mol%	  of	  InCl3	  (11	  mg)	  were	  charged	  in	  a	  pressure-­‐tight	  microwave	  
tube	  containing	  2	  ml	  of	  acetonitrile	  (except	  2-­‐methylfuran	  CH2Cl2)	  and	  a	  stirring	  
bar.	  The	  reaction	  mixture	  was	  submitted	  to	  microwave	  irradiation	  for	  30	  min	  –	  3	  
h	  at	  120	  °C	  (except	  4-­‐hydroxycumarine	  140	  °C),	  with	  an	  irradiation	  power	  of	  150	  
W,	   using	   a	   CEM	   Discover	   SP	   focused	   microwave	   reactor.	   If	   a	   precipitate	   was	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formed,	   simple	   filtration	   gave	   the	   final	   products	   otherwise	   the	   mixture	   was	  
dissolved	  in	  CH2Cl2,	  washed	  with	  H2O,	  dried,	  and	  evaporated.	  In	  the	  latter	  case,	  
analytically	   pure	   compounds	  were	   obtained	   by	   flash	   chromatography	   on	   silica	  
gel.	  
9.2.3.1.	  C-­‐C	  coupling	  reactions	  of	  4,7-­‐dichloroquinoline	  
	  



























7-­‐Chloro-­‐4-­‐(1H-­‐indol-­‐3-­‐yl)quinolinium	  chloride	  (30):	  
Prepared	   from	   4,7-­‐dichloroquinoline	   (100	  mg,	   0.5	  mmol)	   and	  
indole	   (60	   mg,	   0.05	   mmol);	   reaction	   time:2	   h;	   precipitate	  
formation	  to	  give	  the	  product	  as	  a	  yellow	  solid	  in	  89%.	  
Elemental	  analysis	  calcd	  (%)	  for	  C17H12Cl2N2:	  C	  64.78,	  H	  3.84,	  N	  
8.89;	  found:	  C	  64.61,	  H	  3.64,	  N	  8.85.	  
Mp:	  259	  	  262	  °C	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  9.	  Experimental	  section	  
IR	  (neat)	  ν:	  3291,	  3088,	  1626,	  1591,	  1517,	  1421,	  1234,	  830,	  739	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  DMSO)	  δ	  12.56	  (br	  s,	  1H),	  9.26	  (d,	  J	  =	  5.7	  Hz,	  1H),	  8.64	  (d,	  J	  =	  
9.2	  Hz,	  1H),	  8.55	  (d,	  J	  =	  1.8	  Hz,	  1H),	  8.31	  (d,	  J	  =	  2.7	  Hz,	  1H),	  8.18	  (d,	  J	  =	  5.7	  Hz,	  
1H),	  8.02	  (dd,	  J	  =	  9.1,	  1.9	  Hz,	  1H),	  7.88	  (d,	  J	  =	  7.7	  Hz,	  1H),	  7.75	  (d,	  J	  =	  7.9	  Hz,	  1H),	  
7.47	  –	  7.33	  (m,	  2H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  MeOD)	  δ	  152.7,	  147.4,	  144.1,	  140.6,	  139.3,	  131.3	  (2C),	  130.6,	  
127.5,	  126.9,	  124.9,	  123.8,	  123.1,	  122.0,	  120.5,	  114.0,	  113.2	  ppm.	  
	  
(Z)-­‐Ethyl	  3-­‐amino-­‐2-­‐(7-­‐chloroquinolin-­‐4-­‐yl)but-­‐2-­‐enoate	  (31):	  
Prepared	   from	   4,7-­‐dichloroquinoline	   (100	   mg,	   0.5	   mmol)	  
and	   ethyl	   3-­‐aminocrotonate	   (65	  mg,	   0.05	  mmol);	   reaction	  
time	   3	   h;	   purification	   by	   chromatography	   to	   give	   the	  
product	  as	  a	  white	  solid	  in	  75%	  yield.	  
Elemental	  analysis	  calcd	  (%)	  for	  C15H15ClN2O2:	  C	  61.97,	  H	  5.20,	  N	  9.64;	  found:	  C	  
61.32,	  H	  5.32,	  N	  9.15.	  
Mp:	  156	  	  159	  °C	  
IR	  (neat)	  ν:	  3416,	  3312,	  2979,	  2925,	  1664,	  1614,	  1251,	  1101	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3):	  δ	  8.89	  (d,	  J	  =	  4.5,	  1H),	  8.15	  (d,	  J	  =	  2.0,	  1H),	  7.83	  (d,	  J	  =	  
8.9,	  1H),	  7.47	  (dd,	  J	  =	  9.0,	  2.1	  Hz,	  1H),	  7.25	  (d,	  J	  =	  4.5,	  1H),	  4.08	  –	  3.95	  (m,	  2H),	  
1.66	  (s,	  3H),	  0.99	  (t,	  J	  =	  7.1	  Hz,	  3H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   CDCl3):	   δ	   169.2,	   159.3,	   151.5,	   149.3,	   146.2,	   135.3,	   128.8,	  
128.4,	  127.8,	  127.6,	  125.1,	  93.3,	  59.7,	  21.8,	  14.7	  ppm.	  	  
	  
	  
9.	  Experimental	  section	   	   239	   	   	  
7-­‐Chloro-­‐4-­‐(1H-­‐pyrrol-­‐2-­‐yl)quinolinium	  chloride	  (32):	  
Prepared	   from	   4,7-­‐dichloroquinoline	   (100	   mg,	   0.5	   mmol)	   and	  
pyrrole	   (35	   mg,	   0.05	   mmol);	   reaction	   time:	   2	   h;	   precipitate	  
formation	  to	  give	  the	  product	  as	  a	  yellow	  solid	  in	  90%	  yield.	  
Elemental	   analysis	  calcd	   (%)	   for	  C13H10Cl2N2:	  C	  58.89,	  H	  3.80,	  N	  
10.57;	  found:	  C	  58.49,	  H	  4.10,	  N	  10.48.	  
Mp:	  178	  	  181	  °C	  
IR	  (neat)	  ν:	  1583,	  1498,	  1431,	  1370,	  1257,	  1136,	  1041,	  916	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  9.01	  (br	  s,	  1H),	  8.83	  (d,	  J	  =	  4.6	  Hz,	  1H),	  8.35	  (d,	  J	  =	  9.1	  
Hz,	  1H),	  8.11	  (d,	  J	  =	  2.1	  Hz,	  1H),	  7.51	  (dd,	  J	  =	  9.1,	  2.2	  Hz,	  1H),	  7.35	  (d,	  J	  =	  4.6	  Hz,	  
1H),	  7.14	  –	  7.11	  (m,	  1H),	  6.75	  –	  6.72	  (m,	  1H),	  6.51	  –	  6.48	  (m,	  1H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  151.2,	  149.7,	  139.9,	  135.9,	  129.0,	  128.1,	  127.9,	  127.7,	  
124.5,	  121.5,	  119.2,	  112.8,	  111.1	  ppm.	  
	  
7-­‐Chloro-­‐4-­‐(4-­‐hydroxy-­‐2-­‐oxo-­‐2H-­‐chromen-­‐3-­‐yl)quinolinium	  chloride	  (33):	  
Prepared	  from	  4,7-­‐dichloroquinoline	  (100	  mg,	  0.5	  mmol)	  and	  4-­‐
hydroxycumarine	   (82	   mg,	   0.05	   mmol);	   reaction	   time:	   1	   h;	  
temperature:	  140	  °C;	  precipitate	   formation	  to	  give	  the	  product	  
as	  a	  yellow	  solid	  in	  84%	  yield.	  
Elemental	  analysis	  calcd	  (%)	  for	  C18H11Cl2NO3:	  C	  60.02,	  H	  3.08,	  N	  
3.89;	  found:	  C	  59.49,	  H	  3.11,	  N	  4.00.	  
Mp:	  257	  	  260	  °C	  
IR	  (neat)	  ν:	  2581,	  1732,	  1598,	  1494,	  1381,	  1199,	  1848,	  961	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  DMSO)	  δ	  9.20	  (d,	  J	  =	  5.1	  Hz,	  1H),	  8.34	  (s,	  1H),	  8.08	  (d,	  J	  =	  8.7	  
Hz,	  2H),	  7.92	  (d,	  J	  =	  5.1	  Hz,	  1H),	  7.78	  –	  7.71	  (m,	  2H),	  7.50	  –	  7.40	  (m,	  2H)	  ppm.	  
240	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  9.	  Experimental	  section	  
13C	   NMR	   (63	   MHz,	   DMSO)	   δ	   164.5,	   161.4,	   153.6,	   149.2,	   147.0,	   141.4,	   137.8,	  
133.6,	  129.8,	  129.5,	  127.3,	  125.8,	  124.9,	  124.5,	  122.4,	  117.2,	  116.9,	  100.4	  ppm.	  
	  
7-­‐Chloro-­‐4-­‐(5-­‐methylfuran-­‐2-­‐yl)quinoline	  (34):	  
Prepared	   from	   4,7-­‐dichloroquinoline	   (100	   mg,	   0.5	   mmol)	   and	   2-­‐
methyfurano	   (42	   mg,	   0.05	   mmol)	   in	   dichloromethane;	   reaction	  
time:	  3	  h;	  purification	  by	  chromatography	  to	  give	  the	  product	  as	  a	  
red	  solid	  in	  82%	  yield.	  
Elemental	   analysis	   calcd	   (%)	   for	  C14H10ClNO:	  C	   69.00,	  H	  4.14,	  N	  5.75;	   found:	  C	  
68.82,	  H	  4.05,	  N	  5.52.	  
Mp:	  69	  	  72	  °C	  
IR	  (neat)	  ν:	  3066,	  1619,	  1506,	  1207,	  1089	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  8.77	  (d,	  J	  =	  5.0	  Hz,	  1H),	  8.67	  (d,	  J	  =	  9.2	  Hz,	  1H),	  7.96	  
(s,	  1H),	  7.81	  (d,	  J	  =	  5.1	  Hz,	  1H),	  7.64	  (dd,	  J	  =	  9.0,	  1.0	  Hz,	  1H),	  7.30	  (d,	  J	  =	  3.3	  Hz,	  
1H),	  6.34	  (d,	  J	  =	  2.8	  Hz,	  1H),	  2.49	  (d,	  J	  =	  37.6	  Hz,	  3H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   MeOD)	   δ	   159.4,	   150.0,	   149.6,	   146.9,	   141.2,	   139.2,	   130.5,	  
130.0,	  126.0,	  123.9,	  119.7,	  118.8,	  111.4,	  14.3	  ppm.	  
	  
(Z)-­‐Ethyl	  2-­‐(7-­‐chloroquinolin-­‐4-­‐yl)-­‐3-­‐(methylamino)but-­‐2-­‐enoate	  (41):	  
Prepared	   from	  4,7-­‐dichloroquinoline	   (100	  mg,	   0.5	  mmol)	  
and	   (Z)-­‐ethyl	   3-­‐(methylamino)but-­‐2-­‐enoate	   (35)	   (72	   mg,	  
0.05	   mmol);	   reaction	   time:	   3	   h;	   purification	   by	  
chromatography	  to	  give	  the	  product	  as	  a	  pale	  brown	  solid	  
in	  66%	  yield.	  
9.	  Experimental	  section	   	   241	   	   	  
Elemental	  analysis	  calcd	  (%)	  for	  C16H17ClN2O2:	  C	  63.05,	  H	  5.62,	  N	  9.19;	  found:	  C	  
62.95,	  H	  5.44,	  N	  9.03.	  
Mp:	  98	  101	  °C	  
IR	  (neat)	  ν:	  3263,	  2974,	  2930,	  1647,	  1597,	  1265,	  1231,	  1061	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  9.60	  (br	  s,	  1H),	  8.78	  (d,	  J	  =	  4.4	  Hz,	  1H),	  8.03	  (d,	  J	  =	  2.1	  
Hz,	  1H),	  7.73	  (d,	  J	  =	  8.9	  Hz,	  1H),	  7.35	  (dd,	  J	  =	  9.0,	  2.1	  Hz,	  1H),	  7.11	  (d,	  J	  =	  4.4	  Hz,	  
1H),	  3.95	  –	  3.81	  (m,	  2H),	  2.94	  (d,	  J	  =	  5.2	  Hz,	  3H),	  1.56	  (s,	  3H),	  0.88	  (t,	  J	  =	  7.1	  Hz,	  
3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  169.7,	  162.5,	  151.7,	  149.4,	  146.7,	  135.1,	  128.9,	  128.8,	  
127.9,	  127.4,	  125.5,	  91.1,	  59.4,	  30.5,	  17.0,	  14.8	  ppm.	  
	  
(Z)-­‐Ethyl	  3-­‐(butylamino)-­‐2-­‐(7-­‐chloroquinolin-­‐4-­‐yl)but-­‐2-­‐enoate	  (42):	  
Prepared	   from	   4,7-­‐dichloroquinoline	   (100	   mg,	   0.5	   mmol)	  
and	  (Z)-­‐ethyl	  3-­‐(butylamino)but-­‐2-­‐enoate	  (36)	  (92	  mg,	  0.05	  
mmol);	   reaction	  time:	  3	  h;	  purification	  by	  chromatography	  
to	  give	  the	  product	  as	  a	  pale	  brown	  solid	  in	  95%	  yield.	  
Elemental	  analysis	  calcd	  (%)	  for	  C19H23ClN2O2:	  C	  65.79,	  H	  6.68,	  N	  8.08;	  found:	  C	  
65.29,	  H	  6.55,	  N	  8.12.	  
Mp:	  101	  –	  104	  °C	  
IR	  (neat)	  ν:	  3251,	  2970,	  2932,	  1645,	  1594,	  1264,	  1228,	  877	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  9.75	  (br	  t,	  J	  =	  5.0	  Hz,	  1H),	  8.88	  (d,	  J	  =	  4.4	  Hz,	  1H),	  8.12	  
(d,	  J	  =	  2.1	  Hz,	  1H),	  7.83	  (d,	  J	  =	  8.9	  Hz,	  1H),	  7.44	  (dd,	  J	  =	  8.9,	  2.1	  Hz,	  1H),	  7.21	  (d,	  J	  =	  
4.4	  Hz,	  1H),	  4.07	  –	  3.89	  (m,	  2H),	  3.37	  –	  3.29	  (m,	  2H),	  1.78	  –	  1.66	  (m,	  2H),	  1.65	  (s,	  
3H),	  1.58	  –	  1.43	  (m,	  2H),	  1.04	  –	  0.94	  (m,	  6H)	  ppm.	  
242	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  9.	  Experimental	  section	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  169.6,	  161.6,	  151.7,	  149.5,	  146.8,	  135.1,	  128.9,	  128.8,	  
128.0,	  127.4,	  125.5,	  90.8,	  59.3,	  43.7,	  32.6,	  20.6,	  17.2,	  14.8,	  14.3	  ppm.	  
	  
(Z)-­‐Ethyl	  3-­‐(sec-­‐butylamino)-­‐2-­‐(7-­‐chloroquinolin-­‐4-­‐yl)but-­‐2-­‐enoate	  (43):	  
Prepared	  from	  4,7-­‐dichloroquinoline	  (100	  mg,	  0.5	  mmol)	  and	  
(Z)-­‐ethyl	   3-­‐(sec-­‐butylamino)but-­‐2-­‐enoate	   (37)	   (92	   mg,	   0.05	  
mmol);	  reaction	  time:	  3	  h;	  purification	  by	  chromatography	  to	  
obtain	  the	  product	  as	  a	  white	  solid	  in	  96%	  yield.	  
Elemental	  analysis	  calcd	  (%)	  for	  C19H23ClN2O2:	  C	  65.79,	  H	  6.68,	  N	  8.08;	  found:	  C	  
65.73,	  H	  6.58,	  N	  8.13.	  
Mp:	  115	  	  118	  °C	  
IR	  (neat)	  ν:	  3250,	  2971,	  2927,	  1645,	  1594,	  1561,	  1536,	  1335,	  1241,	  710	  cm-­‐1.	  
1H	  NMR	   (250	  MHz,	  CDCl3)	  δ	  9.66	  (br	  d,	  J	  =	  8.9	  Hz,	  1H),	  8.78	  (d,	  J	  =	  4.4	  Hz,	  1H),	  
8.02	  (d,	  J	  =	  2.1	  Hz,	  1H),	  7.73	  (dd,	  J	  =	  8.9,	  4.9	  Hz,	  1H),	  7.35	  (dd,	  J	  =	  8.9,	  2.1	  Hz,	  1H),	  
7.13	  (dd,	  J	  =	  4.4,	  1.5	  Hz,	  1H),	  3.95	  –	  3.81	  (m,	  2H),	  3.55	  –	  3.39	  (m,	  1H),	  1.59	  –	  1.52	  
(m,	  2H),	  1.56	  (s,	  3H),	  1.20	  (dd,	  J	  =	  6.4,	  2.0	  Hz,	  3H),	  0.98	  –	  0.84	  (m,	  6H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  169.6,	  160.8,	  151.8,	  149.5,	  146.9,	  135.1,	  128.9,	  128.0,	  
127.9,	  127.4,	  125.6,	  90.5,	  59.3,	  50.9,	  31.4,	  22.2,	  17.2,	  14.8,	  11.0	  ppm.	  
	  
(Z)-­‐Ethyl	   2-­‐(7-­‐chloroquinolin-­‐4-­‐yl)-­‐3-­‐(furan-­‐2-­‐ylmethyl-­‐amino)but-­‐2-­‐enoate	  
(44):	  
Prepared	   from	   4,7-­‐dichloroquinoline	   (100	   mg,	   0.5	   mmol)	  
and(Z)-­‐ethyl	  3-­‐(furan-­‐2-­‐ylmethylamino)but-­‐2-­‐enoate	   (38)	   (104	  
mg,	   0.05	   mmol);	   reaction	   time	   3	   h;	   purification	   by	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chromatography	  to	  obtain	  the	  product	  as	  a	  yellow	  oil	  in	  75%	  yield.	  
Elemental	  analysis	  calcd	  (%)	  for	  C20H19ClN2O3:	  C	  64.78,	  H	  5.16,	  N	  7.55;	  found:	  C	  
64.55,	  H	  4.99,	  N	  7.23.	  
IR	   (neat)	  ν:	  3255,	  2980,	  2930,	  1651,	  1583,	  1444,	  1262,	  1231,	  1095,	  1071,	  1016	  
cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  10.03	  (br	  t,	  J	  =	  5.6	  Hz,	  1H),	  8.89	  (d,	  J	  =	  4.6	  Hz,	  1H),	  
8.23	  (d,	  J	  =	  2.0	  Hz,	  1H),	  7.85	  (d,	  J	  =	  9.0	  Hz,	  1H),	  7.49	  (dd,	  J	  =	  9.0,	  2.1	  Hz,	  1H),	  7.44	  
(dd,	  J	  =	  1.8,	  0.8	  Hz,	  1H),	  7.28	  (d,	  J	  =4.6	  Hz,	  1H),	  6.40	  (dd,	  J	  =	  3.2,	  1.9	  Hz,	  1H),	  6.31	  
(dd,	  J	  =	  3.2,	  0.8	  Hz,	  1H),	  4.52	  (d,	  J	  =	  5.9	  Hz,	  2H),	  4.04	  –	  3.94	  (m,	  2H),	  1.75	  (s,	  3H),	  
0.97	  (t,	  J	  =	  7.1	  Hz,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  167.9,	  159.6,	  150.1,	  149.2,	  146.8,	  146.4,	  141.6,	  134.5,	  
127.3,	  126.6,	  126.5	  (2C),	  123.9,	  109.5,	  106.4,	  91.0,	  58.2,	  39.5,	  15.8,	  13.3	  ppm.	  
	  
(Z)-­‐Ethyl	  3-­‐(benzylamino)-­‐2-­‐(7-­‐chloroquinolin-­‐4-­‐yl)but-­‐2-­‐enoate	  (45):	  
Prepared	   from	  4,7-­‐dichloroquinoline	   (100	  mg,	  0.5	  mmol)	   and	  
(Z)-­‐ethyl	   3-­‐(benzylamino)but-­‐2-­‐enoate	   (39)	   (110	   mg,	   0.05	  
mmol);	   reaction	   time	   3	   h;	   purification	   by	   chromatography	   to	  
obtain	  the	  product	  as	  a	  yellow	  oil	  in	  65%	  yield.	  
Elemental	  analysis	  calcd	  (%)	  for	  C22H21ClN2O2:	  C	  69.38,	  H	  5.56,	  
N	  7.36;	  found:	  C	  69.01,	  H	  5.34,	  N	  7.24.	  
IR	  (neat)	  ν:	  3237,	  2977,	  2923,	  1651,	  1607,	  1260,	  1230	  cm-­‐1.	  
1H	  NMR	   (250	  MHz,CDCl3)	  δ10.13	   (br	   t,	   J	  =	  5.9	  Hz,	  1H),	  8.88	   (d,	   J	  =	  4.4	  Hz,	  1H),	  
8.13	  (d,	  J	  =	  2.1	  Hz,	  1H),	  7.84	  (d,	  J	  =	  8.9	  Hz,	  1H),	  7.48	  –	  7.34	  (m,	  6H),	  7.23	  (d,	  J	  =	  4.4	  
Hz,	  1H),	  4.56	  (d,	  J	  =	  6.1	  Hz,	  2H),	  4.07	  –	  3.93	  (m,	  2H),	  1.66	  (s,	  3H),	  0.98	  (t,	  J	  =	  7.1	  
Hz,	  3H)	  ppm.	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  9.	  Experimental	  section	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  169.7,	  161.5,	  151.7,	  149.4,	  146.5,	  138.6,	  135.2,	  129.4	  
(2C),	  128.9,	  128.7,	  128.0,	  127.8,	  127.5,	  127.3	  (2C),	  125.4,	  92.2,	  59.5,	  47.7,	  17.3,	  
14.7	  ppm.	  
	  
9.2.3.2.	  C-­‐C	  coupling	  reaction	  of	  6,9-­‐dichloro-­‐2-­‐methoxyacridine	  
	  












6-­‐Chloro-­‐9-­‐(1H-­‐indol-­‐3-­‐yl)-­‐2-­‐methoxyacridinium	  chloride	  (46):	  
Prepared	   from	   6,9-­‐dichloro-­‐2-­‐methoxyacridine	   (139	  mg,	  
0.5	  mmol)	  and	  indole	  (60	  mg,	  0.05	  mmol);	  reaction	  time:	  
2	  h;	  precipitate	  formation	  to	  give	  the	  product	  as	  a	  yellow	  
solid	  in	  93%	  yield.	  
Elemental	  analysis	  calcd	  (%)	  for	  C22H16Cl2N2O:	  C,	  66.85;	  H,	  4.08;	  N,	  7.09;	  found:	  C	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66.72,	  H	  4.15,	  N	  7.24.	  
Mp:	  221	  	  224	  °C	  
IR	  (neat)	  ν:	  1628,	  1563,	  1535,	  1466,	  1419,	  1209,	  701	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.79	  (br	  s,	  1H),	  8.28	  (d,	  J	  =	  1.8	  Hz,	  1H),	  8.19	  (d,	  J	  =	  9.4	  
Hz,	  1H),	  7.89	  (d,	  J	  =	  9.3	  Hz,	  1H),	  7.63	  (d,	  J	  =	  8.2	  Hz,	  1H),	  7.51	  (dd,	  J	  =	  7.7,	  2.4	  Hz,	  
2H),	  7.39	  –	  7.31	  (m,	  2H),	  7.23	  –	  7.12	  (m,	  3H),	  3.69	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  157.5,	  147.6,	  146.9,	  139.5,	  136.5,	  135.3,	  131.3,	  128.9,	  
128.2,	  128.2,	  127.6,	  127.1,	  126.1,	  125.7,	  125.3,	  123.4,	  121.1,	  120.7,	  112.0,	  111.4,	  
103.2,	  55.8	  ppm.	  
	  
6-­‐Chloro-­‐2-­‐methoxy-­‐9-­‐(1H-­‐pyrrol-­‐2-­‐yl)acridinium	  chloride	  (47):	  
Prepared	   from	   6,9-­‐dichloro-­‐2-­‐methoxyacridine	   (139	  mg,	  
0.5	   mmol)	   and	   pyrrole	   (35	   mg,	   0.05	   mmol);	   reaction	  
time:	  2	  h;	  precipitate	  formation	  to	  give	  the	  product	  as	  a	  
yellow	  solid	  in	  90%.	  
Elemental	  analysis	  calcd	  (%)	  for	  C18H14Cl2N2O:	  C	  62.62,	  H	  4.09,	  N	  8.11;	  found:	  C	  
62.23,	  H	  4.25,	  N	  8.21.	  
Mp:	  236	  	  239	  °C	  
IR	  (neat)	  ν:	  1630,	  1473,	  1232,	  807	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  9.40	  (br	  s,	  1H),	  8.06	  (d,	  J	  =	  2.0	  Hz,	  1H),	  7.94	  (d,	  J	  =	  9.4	  
Hz,	  1H),	  7.82	  (d,	  J	  =	  9.4	  Hz,	  1H),	  7.35	  –	  7.27	  (m,	  3H),	  7.05	  (d,	  J	  =	  2.1	  Hz,	  1H),	  6.60	  –	  
6.57	  (m,	  2H),	  3.84	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  acetone-­‐d6)	  δ	  158.7,	  148.6,	  148.1,	  138.7,	  135.3,	  132.6,	  130.1,	  
129.1,	  127.9,	  127.8,	  126.7,	  125.6,	  121.6,	  121.4,	  113.5,	  110.3,	  103.8,	  56.2	  ppm.	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  9.	  Experimental	  section	  
6-­‐Chloro-­‐9-­‐(4-­‐hydroxy-­‐2-­‐oxo-­‐2H-­‐chromen-­‐3-­‐yl)-­‐2-­‐methoxyacridinium	   chloride	  
(48):	  
Prepared	   from	  6,9-­‐dichloro-­‐2-­‐methoxyacridine	   (139	  mg,	  
0.5	  mmol)	   and	  4-­‐hydroxycumarine	   (82	  mg,	   0.05	  mmol);	  
reaction	   time:	   1	   h;	   temperature:	   140°C;	   precipitate	  
formation	  to	  give	  the	  product	  as	  an	  orange	  solid	   in	  92%	  
yield.	  
Elemental	  analysis	  calcd	  (%)	  for	  C23H15Cl2NO4:	  C	  62.74,	  H	  3.43,	  N	  3.18;	  found:	  C	  
62.31,	  H	  3.39,	  N	  3.45.	  
Mp>	  300	  °C	  
IR	  (neat)	  ν:	  1696,	  1606,	  1228,	  1043,	  951,	  761	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  DMSO)	  δ	  8.43	  (d,	  J	  =	  2.0	  Hz,	  1H),	  8.34	  (d,	  J	  =	  9.4	  Hz,	  1H),	  8.14	  
(d,	  J	  =	  9.3	  Hz,	  1H),	  8.08	  (dd,	  J	  =	  7.9,	  1.4	  Hz,	  1H),	  7.85	  –	  7.76	  (m,	  2H),	  7.67	  (dd,	  J	  =	  
9.3,	  2.1	  Hz,	  1H),	  7.58	  (dd,	  J	  =	  8.3,	  0.7	  Hz,	  1H),	  7.51	  –	  7.44	  (m,	  1H),	  7.28	  (d,	  J	  =	  2.6	  
Hz,	  1H),	  3.85	  (s,	  3H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   DMSO)	   δ	   164.2,	   161.2,	   158.2,	   154.0,	   139.4,	   137.0,	   133.5,	  
129.3,	  129.1,	  129.0,	  128.3,	  128.1,	  127.3,	  127.3,	  125.2,	  124.6,	  124.5,	  123.9,	  117.0,	  
116.9,	  103.0,	  98.5,	  56.4	  ppm.	  
	  
6-­‐Chloro-­‐2-­‐methoxy-­‐9-­‐(5-­‐methylfuran-­‐2-­‐yl)acridinium	  chloride	  (49):	  
Prepared	   from	   6,9-­‐dichloro-­‐2-­‐methoxyacridine	   (139	  mg,	  
0.5	   mmol)	   and	   2-­‐methyfurano	   (42	   mg,	   0.05	   mmol)	   in	  
dichloromethane;	   reaction	   time:	   3	   h;	   precipitate	  
formation	   to	   give	   the	   product	   as	   a	   brown	   solid	   in	   84%	  
yield.	  
9.	  Experimental	  section	   	   247	   	   	  
Elemental	  analysis	  calcd	  (%)	  for	  C19H15Cl2NO2:	  C	  63.35,	  H	  4.20,	  N	  3.89;	  found:	  C	  
63,01,	  H	  3.97,	  N	  3,63.	  
Mp:	  170	  	  173	  °C	  
IR	  (neat)	  ν:	  3120,	  1626,	  1526,	  1453,	  1240	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  8.64	  (d,	  J	  =	  9.5	  Hz,	  1H),	  8.26	  –	  8.21	  (m,	  2H),	  7.99	  –	  
7.84	  (m,	  3H),	  7.47	  (s,	  1H),	  6.72	  (s,	  1H),	  4.05	  (s,	  3H),	  2.66	  (s,	  3H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   MeOD)	   δ	   159.6,	   145.0,	   143.4,	   142.0,	   139.8,	   131.8,	   130.3,	  





Prepared	   from	  6,9-­‐dichloro-­‐2-­‐methoxyacridine	   (139	  mg,	  
0.5	   mmol)	   and	   ethyl	   3-­‐aminocrotonate	   (65	   mg,	   0.05	  
mmol);	   reaction	   time:	   3	   h;	   purification	   by	  
chromatography	  to	  obtain	  the	  product	  as	  an	  orange	  solid	  
in	  88%	  yield.	  
Elemental	  analysis	  calcd	  (%)	  for	  C20H19ClN2O3:	  C	  58.98,	  H	  4.95,	  N	  6.88;	  found:	  C	  
58.78,	  H	  4.96,	  N	  7.06.	  
Mp:	  245	  	  246	  °C	  	  
IR	  (neat)	  ν:	  3348,	  3240,	  3164,	  1660,	  1628,	  1426,	  1239,	  1017	  cm-­‐1.	  
1H	  NMR	   (250	  MHz,	  MeOD)	  δ	  8.34	  –	  8.24	  (m,	  3H),	  7.96	  (dd,	  J	  =	  9.5,	  2.6	  Hz,	  1H),	  
7.83	  (d,	  J	  =	  9.5	  Hz,	  1H),	  7.47	  (d,	  J	  =	  2.5	  Hz,	  1H),	  4.02	  (s,	  3H),	  4.04	  –	  3.94	  (m,	  2H),	  
1.58	  (s,	  3H),	  0.88	  (t,	  J	  =	  7.1	  Hz,	  3H)	  ppm.	  
248	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  9.	  Experimental	  section	  
13C	   NMR	   (63	   MHz,	   DMSO)	   δ	   167.8,	   161.9,	   157.5,	   156.4,	   135.8,	   135.4,	   135.1,	  
132.8,	  128.9,	  128.4,	  127.5,	  127.5,	  127.4,	  125.9,	  102.3,	  86.5,	  58.4,	  55.9,	  20.4,	  14.7	  
ppm.	  
	  
9.2.3.3.	  C-­‐C	  coupling	  reaction	  of	  4-­‐chloro-­‐2-­‐phenylquinazoline	  
	  












4-­‐(1H-­‐Indol-­‐3-­‐yl)-­‐2-­‐phenylquinazolin-­‐1-­‐ium	  chloride	  (51):	  
Prepared	   from	   4-­‐dichloro-­‐2-­‐phenylquinazoline	   (120	   mg,	   0.5	  
mmol)	   and	   indole	   (60	   mg,	   0.05	   mmol);	   reaction	   time:	   2	   h;	  
precipitate	  formation	  to	  give	  the	  product	  as	  a	  pale	  yellow	  solid	  
in	  78%	  yield.	  
Elemental	  analysis	  calcd	   (%)	   for	  C22H16ClN3:	  C	  73.84,	  H	  4.51,	  N	  11.74;	   found:	  C	  
73.97,	  H	  4.76,	  N	  11.71.	  
9.	  Experimental	  section	   	   249	   	   	  
Mp:	  244	  	  247	  °C	  
IR	  (neat)	  ν:	  1524,	  1483,	  1456,	  1438,	  1341,	  1240,	  745,	  706	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.77	  (dd,	  J	  =	  8.0,	  1.7	  Hz,	  2H),	  8.42	  (d,	  J	  =	  6.9	  Hz,	  2H),	  
8.19	  (d,	  J	  =	  8.4	  Hz,	  1H),	  7.95	  –	  7.88	  (m,	  2H),	  7.63	  –	  7.54	  (m,	  5H),	  7.41	  –	  7.37	  (m,	  
2H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  164.0,	  160.8,	  152.3,	  139.0,	  137.1,	  136.9,	  133.7,	  130.8,	  
129.3,	   129.0	   (2C),	   129.0	   (2C),	   127.3,	   127.1,	   127.0,	   123.7,	   122.3,	   122.1,	   121.9,	  
114.8,	  111.9	  ppm.	  
	  
2-­‐Phenyl-­‐4-­‐(1H-­‐pyrrol-­‐2-­‐yl)quinazolin-­‐1-­‐ium	  chloride	  (52):	  
Prepared	   from	   4-­‐dichloro-­‐2-­‐phenylquinazoline	   (120	   mg,	   0.5	  
mmol)	   and	   pyrrole	   (35	   mg,	   0.05	   mmol);	   reaction	   time:	   2	   h;	  
precipitate	   formation	   to	   give	   the	   product	   as a	   brown	   solid	   in	  
96%	  yield.	  
Elemental	  analysis	  calcd	   (%)	   for	  C18H14ClN3:	  C	  70.24,	  H	  4.58,	  N	  13.65;	   found:	  C	  
70.63,	  H	  4.88;	  N	  13.62.	  
Mp:	  196	  	  199	  °C	  
IR	  (neat)	  ν:	  3440,	  2923,	  1561,1488,	  1431,	  1338,	  760	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  8.54	  –	  8.46	  (m,	  3H),	  7.90	  –	  7.79	  (m,	  2H),	  7.61	  –	  7.55	  
(m,	  1H),	  7.48	  –	  7.44	  (m,	  3H),	  7.28	  (d,	  J	  =	  3.9	  Hz,	  1H),	  7.20	  –	  7.19	  (m,	  1H),	  6.39	  (dd,	  
J	  =	  3.6,	  2.5	  Hz,	  1H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  MeOD)	  δ	  160.4,	  160.2,	  150.1,	  137.6,	  136.2,	  133.1,	  130.4	  (2C),	  
130.3	  (2C),	  130.2,	  129.6,	  128.3,	  127.1,	  124.4,	  120.8,	  120.4,	  113.9	  ppm.	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  section	  
4-­‐Hydroxy-­‐3-­‐(2-­‐phenylquinazolin-­‐4-­‐yl)-­‐1H-­‐isochromen-­‐1-­‐one	  (53):	  
Prepared	   from	   4-­‐dichloro-­‐2-­‐phenylquinazoline	   (120	   mg,	   0.5	  
mmol)	   and	   4-­‐hydroxycumarine	   (82	   mg,	   0.05	   mmol);	   reaction	  
time:	  1	  h;	  temperature:	  140	  °C;	  precipitate	  formation	  to	  give	  the	  
product	  as	  a	  yellow	  solid	  in	  80%	  yield.	  
Elemental	  analysis	  calcd	  (%)	  for	  C23H14N2O3:	  C	  75.40,	  H	  3.85,	  N	  
7.65;	  found:	  C	  75.28,	  H	  3.79,	  N	  7.78.	  
Mp:	  276	  	  279	  °C	  
IR	  (neat)	  ν:	  1704,	  1609,	  1558,	  1470,	  1381,	  1356,	  756	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  DMSO)	  δ	  8.57	  –	  8.53	  (m,	  2H),	  8.17	  –	  8.02	  (m,	  4H),	  7.82	  –	  7.76	  
(m,	  1H),	  7.70	  –	  7.45	  (m,	  6H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   MeOD)	   δ	   164.6,	   162.9,	   161.2,	   158.7,	   153.3,	   150.7,	   137.0,	  
134.9,	  133.5,	  131.0,	  128.9	  (2C),	  128.4,	  128.2	  (2C),	  127.7,	  127.2,	  124.4	  (2C),	  123.2,	  
116.6,	  116.6,	  101.5	  ppm.	  
	  
4-­‐(5-­‐Methylfuran-­‐2-­‐yl)-­‐2-­‐phenylquinazoline	  (54):	  
Prepared	   from	   4-­‐dichloro-­‐2-­‐phenylquinazoline	   (120	   mg,	   0.5	  
mmol)	   and	   2-­‐methyfurano	   (42	   mg,	   0.05	   mmol)	   in	  
dichloromethane;	   reaction	   time:	   3	   h;	   purification	   by	  
chromatography	  to	  obtain	  the	  product	  as	  a	  yellow	  solid	  in	  44%	  
yield.	  
Elemental	   analysis	   calcd	   (%)	   for	   C19H14N2O:	   C	   79.70,	   H	   4.93,	   N	   9.78;	   found:	   C	  
79.76,	  H	  4.54,	  N	  9.42.	  
Mp:	  99	  	  102	  °C	  
IR	  (neat)	  ν:	  3060,	  1563,	  1545,	  1515,	  1334,	  764,	  706	  cm-­‐1.	  
9.	  Experimental	  section	   	   251	   	   	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.95	  (d,	  J	  =	  8.5	  Hz,	  1H),	  8.69	  (dd,	  J	  =	  7.6,	  1.8	  Hz,	  2H),	  
8.10	  (d,	  J	  =	  8.6	  Hz,	  1H),	  7.92	  –	  7.86	  (m,	  1H),	  7.68	  –	  7.55	  (m,	  5H),	  6.35	  (d,	  J	  =	  2.6	  
Hz,	  1H),	  2.59	  (s,	  3H).	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  160.5,	  157.0,	  155.6,	  153.1,	  152.9,	  138.7,	  133.8,	  130.8,	  
129.5,	  128.9	  (2C),	  128.9	  (2C),	  127.5,	  127.2,	  119.9,	  118.0,	  109.5,	  14.8	  ppm.	  
	  
(Z)-­‐Ethyl	  3-­‐(sec-­‐butylamino)-­‐2-­‐(2-­‐phenylquinazolin-­‐4-­‐yl)but-­‐2-­‐enoate	  (55):	  
Prepared	  from	  4-­‐dichloro-­‐2-­‐phenylquinazoline	  (120	  mg,	  0.5	  
mmol)	   and	   (Z)-­‐ethyl	   3-­‐(sec-­‐butylamino)but-­‐2-­‐enoate	   (37)	  
(92	   mg,	   0.5	   mmol);	   reaction	   time:	   3	   h;	   purification	   by	  
chromatography	   to	   obtain	   the	   product	   as	   a	   pale	   yellow	  
solid	  in	  84%	  yield.	  
Elemental	  analysis	  calcd	  (%)	  for	  C24H27N3O2:	  C	  74.01,	  H	  6.99,	  N	  10.79;	   found:	  C	  
73.77,	  H	  6.86,	  N	  10.65.	  
Mp:	  123	  	  126	  °C	  
IR	  (neat)	  ν:	  3246,	  3147,	  3064,	  2974,	  2923,	  1646,	  1596,	  1254,	  710	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  9.93	  (br	  d,	  J	  =	  8.6	  Hz,	  1H),	  8.65	  –	  8.61	  (m,	  2H),	  8.09	  
(d,	  J	  =	  8.4	  Hz,	  1H),	  7.97	  (d,	  J	  =	  7.7	  Hz,	  1H),	  7.87	  –	  7.81	  (m,	  1H),	  7.59	  –	  7.47	  (m,	  
4H),	  4.05	  –	  3.94	  (m,	  2H),	  3.73	  –	  3.57	  (m,	  1H),	  1.94	  (s,	  3H),	  1.74	  –	  1.63	  (m,	  2H),	  
1.33	  (d,	  J	  =	  6.4	  Hz,	  3H),	  1.06	  (t,	  J	  =	  7.4	  Hz,	  3H),	  0.92	  (t,	  J	  =	  7.1	  Hz,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  169.8,	  169.2,	  162.6,	  160.9,	  151.6,	  139.1,	  133.6,	  130.6,	  
129.1,	   129.0	   (2C),	   128.9	   (2C),	   127.8,	   126.6,	   125.7,	   92.8,	   59.2,	   51.0,	   31.2,	   22.1,	  
17.1,	  14.7,	  10.9	  ppm.	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9.2.3.4.	  C-­‐C	  coupling	  reaction	  of2-­‐chloroquinaxoline	  
	  






2-­‐(1H-­‐Indol-­‐3-­‐yl)quinoxalin-­‐1-­‐ium	  chloride	  (56):	  
Prepared	   from	   2-­‐chloroquinaxoline	   (83	   mg,	   0.5	   mmol)	   and	  
pyrrole	   (35	   mg,	   0.05	   mmol)	   in	   dichloromethane;	   reaction	  
time:	   1	   h;	   precipitate	   formation	   to	   give	   the	   product	   as	   an	  
orange	  solid	  in	  89%	  yield.	  
Elemental	  analysis	   calcd	   (%)	   for	  C16H12ClN3:	  C	  68.21,	  H	  4.29,	  N	  14.91;	   found:	  C	  
67.96,	  H	  4.03,	  N	  14.42.	  
Mp:	  205	  	  208	  °C	  
IR	  (neat)	  ν:	  3255,	  1553,	  1446,	  1170,	  1133	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  9.33	  (s,	  1H),	  8.79	  –	  8.75	  (m,	  1H),	  8.31	  (s,	  1H),	  8.11	  
(d,	  J	  =	  7.7	  Hz,	  1H),	  8.01	  (d,	  J	  =	  8.4	  Hz,	  1H),	  7.83	  –	  7.77	  (m,	  1H),	  7.72	  –	  7.67	  (m,	  
1H),	  7.53	  –	  7.49	  (m,	  1H),	  7.29	  –	  7.26	  (m,	  2H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   DMSO)	   δ	   151.2,	   144.8,	   142.1,	   139.5,	   137.5,	   130.5,	   129.6,	  
128.9,	  128.7,	  128.2,	  125.8,	  123.1,	  122.7,	  121.3,	  113.1,	  112.5	  ppm.	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2-­‐(1H-­‐Pyrrol-­‐2-­‐yl)quinoxalin-­‐1-­‐ium	  chloride	  (57):	  
Prepared	   from	   2-­‐chloroquinaxoline	   (83	   mg,	   0.5	   mmol)	   and	  
indole	  (60	  mg,	  0.05	  mmol)	  in	  dichloromethane;	  reaction	  time:	  1	  
h;	  precipitate	  formation	  to	  give	  the	  product	  as	  a	  yellow	  solid	  in	  
97%	  yield.	  
Elemental	  analysis	  calcd	  (%)	  for:	  C12H10ClN3:	  C	  62.21,	  H	  4.35,	  N	  18.14;	   found:	  C	  
62.45,	  H	  4.52,	  N	  18.34.	  
Mp:	  149	  	  152	  °C	  
IR	  (neat)	  ν:	  3189,	  1568,	  1430,	  1128,	  1115,	  753,	  717	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  9.80	  (br	  s,	  1H),	  9.16	  (s,	  1H),	  8.07	  –	  7.96	  (m,	  2H),	  7.77	  
–	  7.63	  (m,	  2H),	  7.10	  –	  7.06	  (m,	  2H),	  6.44	  –	  6.425	  (m,	  1H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  145.4,	  143.1,	  142.4,	  141.2,	  130.7,	  129.9,	  129.6,	  128.8,	  
128.6,	  122.7,	  111.5,	  110.9	  ppm.	  
	  
9.2.3.5.	  4-­‐(Quinoxalin-­‐2-­‐yloxy)-­‐2H-­‐chromen-­‐2-­‐one	  (58):	  
Prepared	   from	  2-­‐chloroquinaxoline	   (83	  mg,	   0.5	  mmol)	   and	  
4-­‐hydroxycumarine	   (82	   mg,	   0.05	   mmol);	   purification	   by	  
chromatography	   to	  obtain	   the	  product	  as	  a	   yellow	  solid	   in	  
62%	  yield.	  
Elemental	  analysis	   calcd	   (%)	   for	  C17H10N2O3:	  C	  70.34,	  H	  3.47,	  N	  9.65;	   found:	  C,	  
70.11,	  H	  3.22,	  N	  9.45.	  
Mp:	  124	  	  127	  °C	  
IR	  (neat)	  ν:	  2923,	  1724,	  1384,	  1301,	  1216,	  1178,	  762	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.89	  (s,	  1H),	  8.23	  –	  8.19	  (m,	  1H),	  8.01	  –	  7.98	  (m,	  2H),	  
7.89	  –	  7.79	  (m,	  2H),	  7.70	  –	  7.65	  (m,	  1H),	  7.48	  –	  7.37	  (m,	  2H),	  6.72	  (s,	  1H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  162.5,	  161.6,	  154.4,	  154.1,	  141.2,	  139.9,	  139.2,	  133.4,	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  Experimental	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131.9,	  129.9,	  129.7,	  128.6,	  124.8,	  123.5,	  117.5,	  115.9,	  100.8	  ppm.	  
	  
9.2.3.6.	  (Z)-­‐Ethyl	  2-­‐(3-­‐chloroquinoxalin-­‐2-­‐yl)-­‐3-­‐(methylamino)but-­‐2-­‐enoate	  (59):	  
Prepared	  from	  2-­‐chloroquinaxoline	  (83	  mg,	  0.5	  mmol)	  and(Z)-­‐
ethyl	  3-­‐(methylamino)but-­‐2-­‐enoate	  (35)	  (72	  mg,	  0.05	  mmol);	  
purification	   by	   chromatography	   to	   obtain	   the	   product	   as	   a	  
yellow	  solid	  in	  47%	  yield. 
Elemental	  analysis	  calcd	  (%)	  for	  C15H16ClN3O2:	  C	  58.92,	  H	  5.27,	  N	  13.74;	  found:	  C	  
59.31,	  H	  5.74,	  N	  13.72.	  
Mp:	  114	  	  117	  °C	  
IR	  (neat)	  ν:	  3384,	  2920,	  1693,	  1431,	  1209,	  1105,	  760	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.38	  –	  8.34	  (m,	  1H),	  8.14	  –	  8.10	  (m,	  1H),	  7.74	  –	  7.70	  
(m,	  2H),	  4.55	  (q,	  J	  =	  7.1	  Hz,	  2H),	  3.96	  (s,	  3H),	  3.00	  (s,	  3H),	  1.53	  (t,	  J	  =	  7.1	  Hz,	  3H)	  
ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  164.6,	  156.9,	  142.1,	  142.0,	  141.1,	  139.1,	  130.3,	  128.4,	  
128.4,	  127.5,	  102.9,	  60.8,	  28.6,	  15.0,	  13.7	  ppm.	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9.2.3.5.	  C-­‐N	  coupling	  reaction	  of	  4,7-­‐dichloroquinoline	  
	  
Cmpd.	   R1	   R2	  





60	   C6H5	   H	  







Data	  for	  compounds	  16,	  19	  and	  21	  have	  been	  provided	  above	  (section	  9.2.1.3).	  
By	   using	   this	   method	   in	   the	   presence	   of	   InCl3,	   these	   compounds	   have	   been	  
obtained	  in	  88%,	  97%,	  85%	  yield,	  respectively.	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7-­‐Chloro-­‐4-­‐(phenylamino)quinolinium	  chloride	  (60):	  
Prepared	   from	   4,7-­‐dichloroquinoline	   (100	   mg,	   0.5	   mmol)	   and	  
aniline	   (47	   mg,	   0.5	   mmol);	   reaction	   time:	   30	   min;	   precipitate	  
formation	  to	  give	  the	  product	  as	  a	  yellow	  solid	  in	  92%	  yield.	  
Elemental	  analysis	  calcd	  (%)	  for	  C15H12N2:	  C	  61.87,	  H	  4.15,	  N	  9.62;	  
found:	  C	  61.17,	  H	  4.14,	  N	  9.57.	  
Mp:	  240	  	  243	  °C	  
IR	  (neat)	  ν:	  3416,	  2922,	  2644,	  1611,	  1540,	  1454,	  1365,	  1212,	  1093,	  898,	  743	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  DMSO)	  δ	  11.32	  (br	  s,	  1H),	  8.96	  (d,	  J	  =	  9.1	  Hz,	  1H),	  8.52	  (d,	  J	  =	  
7.0	  Hz,	  1H),	  8.22	  (d,	  J	  =	  2.1	  Hz,	  1H),	  7.87	  (dd,	  J	  =	  9.1,	  2.1	  Hz,	  1H),	  7.63	  –	  7.41	  (m,	  
5H),	  6.78	  (d,	  J	  =	  7.0	  Hz,	  1H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  DMSO)	  δ	  155.3,	  143.7,	  139.5,	  138.7,	  137.3,	  130.3	  (2C),	  128.0,	  
127.7,	  126.6,	  125.8	  (2C),	  119.5,	  116.3,	  100.6	  ppm.	  
	  
N-­‐Butylquinolin-­‐4-­‐amine	  (61):	  
Prepared	   from	  4,7-­‐dichloroquinoline	   (100	  mg,	   0.5	  mmol)	   and	  n-­‐
butylamine	  (37	  mg,	  0.5	  mmol);	  reaction	  time:	  30	  min;	  precipitate	  
formation	  to	  give	  the	  product	  as	  a	  pale	  yellow	  solid	  in	  92%	  yield.	  
Elemental	   analysis	   calcd	   (%)	   for	   C13H15N2:	   C	   66.52,	   H	   6.44,	   N	   11.93;	   found:	   C	  
66.21,	  H	  6.13,	  N	  11.64.	  
Mp:	  127	  	  130	  °C	  
IR	  (neat)	  ν:	  3266,	  2958,	  2932,	  2872,	  1612,	  1581,	  1542,	  1454,	  1367,	  1222,	  1142,	  
899,	  806	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.28	  (d,	  J	  =	  5.9	  Hz,	  1H),	  8.07	  (d,	  J	  =	  9.0	  Hz,	  1H),	  7.83	  
(d,	  J	  =	  2.1	  Hz,	  1H),	  7.21	  (dd,	  J	  =	  9.0,	  2.1	  Hz,	  1H),	  6.82	  (brs,	  1H),	  6.30	  (d,	  J	  =	  6.0	  Hz,	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1H),	  3.29–	  3.28	  (m2H),	  1.73	  –	  1.61	  (m,	  2H),	  1.45	  –	  1.28	  (m,	  2H),	  0.88	  (t,	  J	  =	  7.3	  Hz,	  
3H).ppm.	  
	  13C	   NMR	   (63	   MHz,	   CDCl3)	   δ	   152.2,	   148.9,	   146.1,	   136.6,	   126.1,	   125.8,	   123.5,	  
117.1,	  98.8,	  43.5,	  31.0,	  20.7,	  14.2	  ppm.	  
	  
Chloroquine	  (79):	  
Prepared	   from	   4,7-­‐dichloroquinoline	   (100	   mg,	   0.5	  
mmol)	  and	  2-­‐amino-­‐5-­‐diethylaminopentane	  (79	  mg,	  0.5	  
mmol);	   reaction	   time:	   1	   h;	   purification	   by	  
chromatography	  to	  obtain	  the	  product	  as	  a	  pale	  yellow	  solid	  in	  73%	  yield.	  
Elemental	  analysis	   calcd	   (%)	   for	  C18H26ClN3:	  C	  67.59,	  H	  8.19,	  N	  13.14;	   found:	  C	  
67.24,	  H	  8.01,	  N	  13.10.	  
Mp:	  89	  	  92	  °C	  
IR	  (neat)	  ν:	  3230,	  2917,	  2848,	  1571,	  1450,	  1077,	  800	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  8.36	  (d,	  J	  =	  5.7	  Hz,	  1H),	  8.22	  (d,	  J	  =	  9.1	  Hz,	  1H),	  7.79	  
(d,	  J	  =	  2.1	  Hz,	  1H),	  7.43	  (dd,	  J	  =	  9.0,	  2.2	  Hz,	  1H),	  6.60	  (d,	  J	  =	  6.1	  Hz,	  1H),	  3.91	  –	  
3.84	   (m,	  1H),	  2.71	  –	  2.60	   (m,	  6H),	  1.73	  –	  1.66	   (m,	  4H),	  1.36	   (d,	   J	  =	  6.4	  Hz,	  3H),	  
1.08	  (t,	  J	  =	  7.2	  Hz,	  6H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   MeOD)	   δ	   152.8,	   152.6,	   150.2,	   136.8,	   127.9,	   126.3,	   124.9,	  
119.2,	  100.3,	  53.8,	  48.2,	  35.3,	  31.2,	  24.1,	  20.8,	  11.2	  ppm.	  
	  
Amodiaquine	  hydrochloride	  (80):	  
Prepared	  from	  4,7-­‐dichloroquinoline	  (100	  mg,	  0.5	  mmol)	  
and	   4-­‐amino-­‐alpha-­‐diethylamino-­‐o-­‐cresol	   (97	   mg,	   0.5	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mmol);	  reaction	  time:	  2	  h;	  precipitate	  formation	  to	  give	  the	  product	  as	  a	  yellow	  
solid	  in	  71%	  yield.	  
Elemental	  analysis	  calcd	  (%)	  for	  C20H23Cl2N3O:	  C	  61.23,	  H	  5.91,	  N	  10.71;	  found:	  C	  
61.31,	  H	  6.11,	  N	  10.89.	  
Mp:	  207	  	  210	  °C	  
IR	  (neat)	  ν:	  1565,	  1535,	  1255,	  869,	  847,	  815	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  8.58	  (d,	  J	  =	  9.0	  Hz,	  1H),	  8.41	  (dd,	  J	  =	  6.9,	  1.0	  Hz,	  1H),	  
7.97	  (s,	  1H),	  7.79	  (dd,	  J	  =	  9.1,	  1.9	  Hz,	  1H),	  7.56	  (d,	  J	  =	  1.5	  Hz,	  1H),	  7.46	  (dd,	  J	  =	  8.7,	  
1.6	  Hz,	  1H),	  7.15	  (dd,	  J	  =	  8.7,	  0.8	  Hz,	  1H),	  6.84	  (dd,	  J	  =	  6.9,	  1.0	  Hz,	  1H),	  4.41	  (s,	  
2H),	  3.37	  –	  3.25	  (m,	  4H),	  1.42	  (t,	  J	  =	  7.2	  Hz,	  6H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   MeOD)	   δ	   158.1,	   157.4,	   145.6,	   142.1,	   141.3,	   131.6,	   130.8,	  
130.6,	   129.3,	   126.6,	   121.7,	   119.8,	   118.4,	   117.8,	   102.1,	   52.8,	   49.2	   (2C),	   9.6	   (2C)	  
ppm.	  
	  
9.2.3.6.	  C-­‐N	  coupling	  reaction	  of	  6,9-­‐dichloro-­‐2-­‐methoxyacridine	  
	  
Cmpd.	   R1	   R2	   Reaction	  time,	  h	   Yield,	  %.	  
5	  
	  
H	   1	   88	  
6	   n-­‐Hex	   H	   0.5	   98	  
7	   C6H5-­‐CH2	   H	   1	   100	  
9	  
	  
0.5	   100	  
11	  
	  
1	   100	  
81	  
	  
H	   2	   75	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Data	  of	  compound	  5-­‐7,	  9	  and	  11	  have	  been	  provided	  above	  (section	  9.2.1.1).	  
Quinacrine	  (81):	  
Prepared	   from	   6,9-­‐dichloro-­‐2-­‐methoxyacridine	   (140	  
mg,	   1	   mmol)	   and	   2-­‐amino-­‐5-­‐diethylaminopentane	   (79	  
mg,	   0.5	   mmol);	   purification	   by	   chromatography	   to	  
obtain	  the	  product	  as	  a	  yellow	  solid.	  
Elemental	  analysis	  calcd	  (%)	  for	  C23H30ClN3O:	  C	  69.07,	  H	  7.56,	  N	  10.51;	  found:	  C	  
69.34,	  H	  7.21,	  N	  10.38.	  
Mp:	  247	  	  250	  °C	  
IR	  (neat)	  ν:	  3260,	  2921,	  1628,	  1558,	  1462,	  1434,	  1226,	  1067,	  1028	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.12	  (d,	  J	  =	  2.1	  Hz,	  1H),	  8.04	  (d,	  J	  =	  9.4	  Hz,	  2H),	  7.46	  
(dd,	  J	  =	  9.4,	  2.7	  Hz,	  1H),	  7.37	  (dd,	  J	  =	  9.3,	  2.1	  Hz,	  1H),	  7.26	  (d,	  J	  =	  2.6	  Hz,	  1H),	  4.49	  
(br	  d,	  J	  =	  10.7	  Hz,	  1H),	  4.11	  –	  4.00	  (m,	  1H),	  4.01	  (s,	  3H),	  2.55	  –	  2.40	  (m,	  6H),	  1.74	  –	  
1.62	  (m,	  4H),	  1.30	  (d,	  J	  =	  6.4	  Hz,	  3H),	  1.00	  (t,	  J	  =	  7.2	  Hz,	  6H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.6,	  149.7,	  148.6,	  147.4,	  135.2,	  132.0,	  128.8,	  125.4,	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9.2.3.7.	  C-­‐N	  coupling	  reaction	  of	  4-­‐chloro-­‐2-­‐phenylquinazoline	  
	  
Cmpd.	   R1	   R2	  
23	   C6H5-­‐CH2	   H	  
25	  
	  
62	   C6H5	   H	  
63	   n-­‐But	   H	  
	  
Data	  of	  compound	  23	  and	  25	  have	  been	  provided	  above	  (section	  9.2.1.4).	  
	  
2-­‐Phenyl-­‐4-­‐(phenylamino)quinazolin-­‐1-­‐ium	  chloride	  (62):	  
Prepared	   from	   4-­‐dichloro-­‐2-­‐phenylquinazoline	   (120	   mg,	   0.5	  
mmol)	   and	   aniline	   (47	   mg,	   0.5	   mmol);	   reaction	   time:	   30	   min;	  
precipitate	   formation	   to	   give	   the	   product	   as	   a	   yellow	   solid	   in	  
98%	  yield.	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Elemental	   analysis	   calcd	   (%)	   for	   C20H16N3:	   C	   71.96,	   H	   4.83,	   N	   12.59;	   found:	   C	  
71.25,	  H	  4.78,	  N	  12.66.	  
Mp:	  162	  	  165	  °C	  
IR	  (neat)	  ν:	  3211,	  1628,	  1608,	  1549,	  1457,	  1421,	  754,	  698	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  8.67	  (d,	  J	  =	  8.3	  Hz,	  1H),	  8.30	  –	  8.26	  (m,	  2H),	  8.19	  –	  
8.07	  (m,	  2H),	  7.93	  –	  7.73	  (m,	  4H),	  7.70	  –	  7.55	  (m,	  4H),	  7.47	  –	  7.40	  (m,	  1H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   MeOD)	   δ	   161.7,	   159.9,	   141.4,	   138.3,	   138.1,	   135.4,	   132.8,	  




Prepared	  from	  4-­‐dichloro-­‐2-­‐phenylquinazoline	  (120	  mg,	  0.5	  
mmol)	  and	  n-­‐butylamine	  (37	  mg,	  0.5	  mmol);	  reaction	  time:	  
30	  min;	  precipitate	  formation	  to	  give	  the	  product	  as	  a	  white	  
solid	  in	  100%	  yield.	  
Elemental	   analysis	   calcd	   (%)	   for	   C18H19N3:	   C	   77.95,	   H	   6.90,	   N	   15.15;	   found:	   C	  
77.52,	  H	  6.47,	  N	  14.79.	  
Mp:	  103	  	  106	  °C	  	  
IR	  (neat)	  ν:	  3237,	  3138,	  2953,	  2956,	  1631,	  1563,	  1458,	  1375,	  716	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  8.41	  –	  8.35	  (m,	  3H),	  8.10	  –	  7.98	  (m,	  2H),	  7.82	  –	  7.67	  
(m,	  4H),	  3.97	  (t,	  J	  =	  7.2	  Hz,	  2H),	  1.93	  –	  1.81	  (m,	  2H),	  1.63	  –	  1.47	  (m,	  2H),	  1.06	  (t,	  J	  
=	  7.3	  Hz,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  MeOD)	  δ	  162.5,	  159.9,	  140.9,	  137.5,	  135.2,	  133.3,	  130.8	  (2C),	  
130.4	  (2C),	  130.0,	  125.2,	  121.2,	  114.0,	  43.7,	  32.4,	  21.7,	  14.6	  ppm.	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  9.	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9.2.3.8.	  C-­‐N	  coupling	  reaction	  of	  2-­‐chloroquinaxoline	  
	  
Cmpd.	   R1	   R2	  
64	   C6H5	   H	  




2-­‐(phenylamino)quinoxalin-­‐1-­‐ium	  chloride	  (64):	  
Prepared	   from	   2-­‐chloroquinaxoline	   (83	   mg,	   0.5	   mmol)	   and	  
aniline	   (47	   mg,	   0.5	   mmol);	   reaction	   time:	   1	   h;	   precipitate	  
formation	  to	  give	  the	  product	  as	  an	  orange	  solid	  in	  95%	  yield.	  
Elemental	   analysis	   calcd	   (%)	   for	   C14H12N3:	   C	   65.25,	   H	   4.69,	   N	   16.30;	   found:	   C	  
65.41,	  H	  4.57,	  N	  16.27.	  
Mp:	  211	  	  214°C	  
IR	  (neat)	  ν:	  3278,	  3189,	  1644,	  1553,	  1501,	  760	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  8.75	  (s,	  1H),	  8.06	  (d,	  J	  =	  8.1	  Hz,	  1H),	  7.80	  –	  7.79	  (m,	  
2H),	  7.69	  –	  7.59	  (m,	  5H),	  7.52	  –	  7.46	  (m,	  1H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  MeOD)	  δ	  148.0,	  145.1,	  143.8,	  137.5,	  136.6,	  134.1,	  131.9	  (2C),	  
130.9,	  129.7,	  128.7,	  125.4	  (2C),	  121.1	  ppm.	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N-­‐butylquinoxalin-­‐2-­‐amine	  (65):	  
Prepared	   from	   2-­‐chloroquinaxoline	   (83	   mg,	   0.5	   mmol)	  
and	  n-­‐butylamine	  (37	  mg,	  0.5	  mmol);	  reaction	  time:	  1	  h;	  
precipitate	  formation	  to	  give	  the	  product	  as	  a	  yellow	  solid	  
in	  98%	  yield.	  
Elemental	   analysis	   calcd	   (%)	   for	   C12H15N3:	   C	   71.61,	   H	   7.51,	   N	   20.88;	   found:	   C	  
71.14,	  H	  7.45,	  N	  20.75.	  
Mp:	  59	  	  62	  °C	  
IR	  (neat)	  ν:	  3421,	  3278,	  2958,	  2930,	  2801,	  1588,	  1547,	  759	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.21	  (s,	  1H),	  7.88	  (dd,	  J	  =	  8.1,	  1.2	  Hz,	  1H),	  7.71	  (dd,	  J	  
=	  8.3,	  1.4	  Hz,	  1H),	  7.62	  –	  7.55	  (m,	  1H),	  7.42	  –	  7.35	  (m,	  1H),	  4.92	  (brs,	  1H),	  3.61	  –	  
3.53	  (m,	  2H),1.77	  –	  1.65	  (m,	  2H),	  7.57	  –	  7.42	  (m,	  2H),	  1.01	  (t,	  J	  =	  7.2	  Hz,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  152.4,	  142.3,	  138.8,	  137.5,	  130.4,	  129.2,	  126.6,	  124.6,	  
41.4,	  32.0,	  20.6,	  14.3	  ppm.	  
	  
2-­‐(4-­‐methylpiperazin-­‐1-­‐yl)quinoxaline	  (66):	  
Prepared	  from	  2-­‐chloroquinaxoline	   (83	  mg,	  0.5	  mmol)	  and	  
1-­‐methylpiperazine	   (50	  mg,	  0.5	  mmol);	   reaction	   time:	  1	  h;	  
precipitate	   formation	  to	  give	  the	  product	  as	  a	  yellow	  solid	  
in	  75%	  yield.	  
Elemental	   analysis	   calcd	   (%)	   for	   C13H16N4:	   C	   68.39,	   H	   7.06,	   N	   24.54;	   found:	   C	  
68.11,	  H	  6.83,	  N	  24.17.	  
Mp:	  108	  	  112	  °C	  
IR	  (neat)	  ν:	  2942,	  2844,	  2803,	  1553,	  1439,	  1298,	  1268,	  760	  cm-­‐1.	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  Experimental	  section	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.62	  (s,	  1H),	  7.95	  –	  7.91	  (m,	  1H),	  7.73	  (dd,	  J	  =	  8.3,	  1.0	  
Hz,	  1H),	  7.66	  –	  7.60	  (m,	  1H),	  7.50	  –	  7.43	  (m,	  1H),	  4.04–	  4.03	  (m,	  4H),	  2.86	  (s,	  4H),	  
2.57	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  152.4,	  141.7,	  137.0,	  135.8,	  130.3,	  128.8,	  126.6,	  125.0,	  
54.8	  (2C),	  46.2,	  44.7	  (2C)	  ppm.	  
	  
9.2.3.9.	  C-­‐N	  coupling	  reaction	  of	  6-­‐chloropurine	  
	  
Cmpd.	   R1	   R2	  
67	   C6H5	   H	  




70	   n-­‐Hex	   H	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6-­‐(Phenylamino)-­‐9H-­‐purin-­‐3-­‐ium	  chloride	  (67):	  
Prepared	   from	  6-­‐chloropurine	   (77	  mg,	  0.5	  mmol)	  and	  aniline	   (47	  
mg,	   0.5	   mmol);	   reaction	   time:	   30	   min;	   precipitate	   formation	   to	  
give	  the	  product	  as	  a	  pale	  yellow	  solid	  in	  97%	  yield.	  
Elemental	   analysis	   calcd	   (%)	   for	   C11H10N5:	   C	   53.34,	   H	   4.07,	   N	  
28.28;	  found:	  C	  53.79,	  H	  3.89,	  N	  28.23.	  
Mp:	  281	  	  284	  °C	  
IR	  (neat)	  ν:	  3321,	  3100,	  1655,	  1595,	  1501,	  1449,	  1388,	  754	  cm-­‐1.	  
1H	  NMR	   (250	  MHz,	  MeOD)	  δ	  8.55	   (s,	  1H),	  8.49	   (s,	  1H),	  7.75	   (d,	   J	  =	  7.8	  Hz,	  2H),	  
7.56	  –	  7.49	  (m,	  2H),	  7.36	  (t,	  J	  =	  7.4	  Hz,	  1H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  MeOD)	  δ	  151.7,	  150.7,	  148.3,	  145.2,	  138.1,	  131.2,	  131.1	  (2C),	  
128.2,	  124.7	  (2C)	  ppm.	  
	  
6-­‐(4-­‐Methoxyphenylamino)-­‐9H-­‐purin-­‐3-­‐ium	  chloride	  (68):	  
Prepared	   from	   6-­‐chloropurine	   (77	   mg,	   0.5	   mmol)	   and	   p-­‐
anisidine	   (62	   mg,	   0.5	   mmol);	   reaction	   time:	   30	   min;	  
precipitate	   formation	   to	  give	   the	  product	  as	  a	  yellow	  solid	  
in	  85%	  yield.	  
Elemental	   analysis	   calcd	   (%)	   for	   C12H12N5:	   C	   51.90,	   H	   4.36,	   N	   25.22;	   found:	   C	  
51.63,	  H	  4.12,	  N	  24.81.	  
Mp:	  279	  	  282	  °C	  
IR	  (neat)	  ν:	  3321,	  1652,	  1617,	  1512,	  1444,	  1205,	  1026,	  835	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  DMSO)	  δ	  11.51	  (br	  s,	  1H),	  8.72	  (s,	  1H),	  8.68	  (s,	  1H),	  7.76	  (d,	  J	  =	  
8.9	  Hz,	  2H),	  7.03	  (d,	  J	  =	  8.9	  Hz,	  2H),	  3.79	  (s,	  3H)	  ppm.	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  9.	  Experimental	  section	  
13C	  NMR	  (63	  MHz,	  DMSO)	  δ	  157.1,	  149.9,	  148.5,	  148.3,	  143.6,	  130.6,	  123.8	  (2C),	  
123.7,	  114.6	  (2C),	  55.7	  ppm.	  
6-­‐(4-­‐Morpholinophenylamino)-­‐9H-­‐purin-­‐3-­‐ium	  chloride	  (69):	  
Prepared	   from	   6-­‐chloropurine	   (77	   mg,	   0.5	   mmol)	   and	   4-­‐
morpholinoaniline	   (90	  mg,	   0.5	  mmol);	   reaction	   time:	   1	   h;	  
precipitate	  formation	  to	  give	  the	  product	  as	  a	  pale	  brown	  
solid	  in	  100%	  yield.	  
Elemental	  analysis	  calcd	  (%)	  for	  C15H17N6:	  C	  54.14,	  H	  5.15,	  
N	  25.25;	  found:	  C	  54.60,	  H	  5.27,	  N	  25.72.	  	  
Mp:	  238	  	  241	  °C	  
IR	  (neat)	  ν:	  3315,	  3237,	  1656,	  1585,	  1512,	  1238,	  1120,	  636	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  DMSO)	  δ	  11.27	  (br	  s,	  1H),	  8.65	  (s,	  1H),	  8.63	  (s,	  1H),	  7.73	  (d,	  J	  =	  
8.5	  Hz,	  2H),	  7.12	  (d,	  J	  =	  8.7	  Hz,	  2H),	  3.80	  (br	  s,	  4H),	  3.18	  (br	  s,	  4H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  DMSO)	  δ	  153.3,	  149.9,	  148.8,	  148.5,	  143.4,	  130.6,	  123.1	  (2C),	  
116.4	  (2C),	  114.0,	  66.2	  (2C),	  49.5	  (2C)	  ppm.	  
	  
N-­‐hexyl-­‐9H-­‐purin-­‐6-­‐amine	  (70):	  
Prepared	   from	   6-­‐chloropurine	   (77	   mg,	   0.5	   mmol)	   and	  
hexylamine	   (51	   mg,	   0.5	   mmol);	   reaction	   time:	   1.5	   h;	  
precipitate	  formation	  to	  give	  the	  product	  as	  a	  white	  solid	  
in	  99%	  yield.	  
Elemental	   analysis	   calcd	   (%)	   for	   C11H17N5:	   C	   60.25,	   H	   7.81,	   N	   31.94;	   found:	   C,	  
60.49,	  H	  7.87,	  N	  31.60.	  
Mp:	  158	  	  161	  °C	  
IR	  (neat)	  ν:	  3474,	  3025,	  2930,	  1633,	  1565,	  1330,	  1142,	  928	  cm-­‐1.	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1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  8.24	  (s,	  1H),	  8.09	  (s,	  1H),	  3.61	  (t,	  J	  =	  6.1	  Hz,	  2H),	  1.78	  
–	  1.67	  (m,	  2H),	  1.47	  –	  1.38	  (m,	  6H),	  0.94	  (t,	  J	  =	  6.7	  Hz,	  3H)	  ppm.	  
13C	  NMR	   (63	  MHz,	  MeOD)	  δ	  156.1,	  156.1,	  154.2,	  141.0,	  119.4,	  42.2,	  33.2,	  31.0,	  
28.1,	  24.1,	  14.8	  ppm.	  
	  
N-­‐benzyl-­‐9H-­‐purin-­‐6-­‐amine	  (71):	  
Prepared	   from	   6-­‐chloropurine	   (77	   mg,	   0.5	   mmol)	   and	  
benzylamine	  (54	  mg,	  0.5	  mmol);	  reaction	  time:	  1	  h;	  precipitate	  
formation	  to	  give	  the	  product	  as	  a	  white	  solid	  in	  93%	  yield.	  
Elemental	  analysis	  calcd	  (%)	  C12H11N5:	  C	  63.99,	  H	  4.92,	  N	  31.09;	  found:	  C	  63.70,	  H	  
4.81,	  N	  31.12.	  
Mp:	  235	  	  238	  °C	  
IR	  (neat)	  ν:	  3474,	  3281,	  1652,	  1453,	  1120,	  891,	  698	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  8.37	  (s,	  1H),	  8.22	  (s,	  1H),	  7.42	  –	  7.30	  (m,	  5H),	  4.89	  
(s,	  2H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  MeOD)	  δ	  154.8,	  152.0,	  150.8,	  142.9,	  139.7,	  130.1	  (2C),	  129.3,	  
129.2	  (2C),	  129.0,	  46.2	  ppm.	  
	  
4-­‐(9H-­‐purin-­‐6-­‐yl)morpholine	  (72):	  
Prepared	  from	  6-­‐chloropurine	  (77	  mg,	  0.5	  mmol)	  and	  morpholine	  (44	  
mg,	   0.5	  mmol);	   reaction	   time:	   30	  min;	   precipitate	   formation	   to	   give	  
the	  product	  as	  a	  pale	  yellow	  solid	  in	  100%	  yield.	  
Elemental	   analysis	   calcd	   (%)	   for:	   C9H11N5:	   C	   52.67,	   H	   5.40,	  N	   34.13;	  
found:	  C	  53.00,	  H	  5.31,	  N	  34.01.	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  9.	  Experimental	  section	  
Mp:	  299	  	  302	  °C	  
IR	  (neat)	  ν:	  3423,	  3091,	  2965,	  2932,	  2857,	  1600,	  1299,	  1258,	  1114,	  647	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  8.06	  (s,	  1H),	  7.82	  (s,	  1H),	  4.09	  (t,	  J	  =	  4.7	  Hz,	  4H),	  3.71	  
(t,	  J	  =	  5.0	  Hz,	  4H)	  ppm.	  
13C	  NMR	   (63	  MHz,	  MeOD)	   δ	   160.1,	   155.5,	   154.5,	   151.7,	   119.6,	   68.5	   (2C),	   47.6	  
(2C)	  ppm.	  
	  
9.2.3.10.	  C-­‐N	  coupling	  reaction	  of	  2-­‐chlorobenzimidazole	  
	  
Cmpd.	   R1	   R2	  
73	   3-­‐Cl-­‐C6H4	   H	  







2-­‐(3-­‐chlorophenylamino)-­‐1H-­‐benzo[d]imidazol-­‐3-­‐ium	  chloride	  (73):	  
Prepared	   from	  2-­‐chlorobenzimidazole	   (76	  mg,	  0.5	  mmol)	   and	  
3-­‐chloroaniline	   (64	   mg,	   0.5	   mmol);	   reaction	   time:	   2	   h;	  
precipitate	   formation	   to	   give	   the	   product	   as	   a	  white	   solid	   in	  
97%	  yield.	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Elemental	   analysis	   calcd	   (%)	   for	   C13H11N3:	   C	   55.73,	   H	   3.96,	   N	   15.00;	   found:	   C	  
55.85,	  H	  3.83,	  N	  14.67.	  
Mp:	  182	  	  185	  °C	  
IR	   (neat)	  ν:	   3396,	  3054,	  2922,	  1591,	  1557,	  1462,	  1350,	  1264,	  1242,	  1053,	  922,	  
747	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  7.60	  –	  7.53	  (m,	  2H),	  7.50	  –	  7.41	  (m,	  4H),	  7.40	  –	  7.36	  
(m,	  2H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  MeOD)	  δ	  150.0,	  139.0,	  137.1,	  133.1,	  131.4	  (2C),	  128.7,	  125.9	  
(2C),	  125.0,	  123.3,	  113.3	  (2C)	  ppm.	  
	  
N-­‐benzyl-­‐1H-­‐benzo[d]imidazol-­‐2-­‐amine	  (74):	  
Prepared	  from	  2-­‐chlorobenzimidazole	  (76	  mg,	  0.5	  mmol)	  and	  
benzylamine	   (54	   mg,	   0.5	   mmol);	   reaction	   time:	   2	   h;	  
precipitate	  formation	  to	  give	  the	  product	  as	  a	  white	  solid	  in	  
90%	  yield.	  
Elemental	   analysis	   calcd	   (%)	   for	   C14H13N3:	   C	   75.31,	   H	   5.87,	   N	   18.82;	   found:	   C	  
75.04,	  H	  5.93,	  N	  18.76.	  
Mp:	  164	  	  167	  °C	  
IR	  (neat)	  ν:	  3395,	  1632,	  1580,	  1464,	  1268,	  738	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  7.43	  –	  7.26	  (m,	  5H),	  7.23	  –	  7.19	  (m,	  2H),	  7.00	  –	  6.97	  
(m,	  2H),	  4.60	  (s,	  2H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   MeOD)	   δ	   157.3,	   141.1	   (2C),	   139.6,	   129.9	   (2C),	   128.7	   (2C),	  
128.6,	  121.7	  (2C),	  113.2	  (2C),	  47.8	  ppm.	  
	  




Prepared	   from	  2-­‐chlorobenzimidazole	   (76	  mg,	  0.5	  mmol)	  
and	  1-­‐methylpiperazine	  (50	  mg,	  0.5	  mmol);	  reaction	  time:	  
2	  h;	  precipitate	  formation	  to	  give	  the	  product	  as	  a	  white	  solid	  in	  86%	  yield.	  
Elemental	   analysis	   calcd	   (%)	   for	   C12H16N4:	   C	   66.64,	   H	   7.46,	   N	   25.90;	   found:	   C	  
66.68,	  H	  7.38,	  N	  25.68.	  
Mp:	  91	  	  93	  °C	  
IR	  (neat)	  ν:	  3395,	  2936,	  2844,	  2797,	  1626,	  1558,	  1463,	  1000	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ7.34	  –	  7.29	  (m,	  2H),	  7.14	  –	  7.09	  (m,	  2H),3.67	  –	  3.65	  
(m,	  4H),	  2.82	  –	  2.80	  (m,	  4H),	  2.52	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  MeOD)	  δ	  156.1,	  137.5	  (2C),	  123.2	  (2C),	  113.6	  (2C),	  55.0	  (2C),	  
47.0	  (2C),	  45.9	  ppm.	  
	  
2-­‐(4-­‐Morpholinophenylamino)-­‐1H-­‐benzo[d]imidazol-­‐3-­‐ium	  chloride	  (76):	  
Prepared	   from	   2-­‐chlorobenzimidazole	   (76	  mg,	   0.5	  mmol)	  
and	  4-­‐morpholinoaniline	  (90	  mg,	  0.5	  mmol);	  reaction	  time:	  
2	   h;	   precipitate	   formation	   to	   give	   the	   product	   as	   a	   grey	  
solid	  in	  74%	  yield.	  
Elemental	   analysis	   calcd	   (%)	   for	   C17H19N4:	   C	   61.72,	   H	   5.79,	   N	   16.94;	   found:	   C	  
61.62,	  H	  5.63,	  N	  16.88.	  
Mp:	  257	  	  260	  °C	  
IR	  (neat)	  ν:	  3213,	  1666,	  1515,	  1238,	  1115,	  922,	  765	  cm-­‐1.	  
9.	  Experimental	  section	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1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  7.43	  –	  7.30	  (m,	  6H),	  7.15	  (d,	  J	  =	  9.0	  Hz,	  2H),	  3.88	  (t,	  J	  
=	  4.8	  Hz,	  4H),	  3.23	  (t,	  J	  =	  4.9	  Hz,	  4H)	  ppm.	  
13C	  NMR	   (63	  MHz,	  MeOD)	   δ	   152.9,	   151.4,	   131.6	   (2C),	   128.7,	   127.4	   (2C),	   125.5	  
(2C),	  118.4	  (2C),	  113.0	  (2C),	  68.3	  (2C),	  50.7	  (2C)	  ppm.	  
	  
9.2.3.11.	  C-­‐N	  coupling	  reaction	  of	  2-­‐chloropyridine	  
	  
Cmpd.	   R1	   R2	  





Prepared	  from	  2-­‐chloropyridine	  (76	  mg,	  0.5	  mmol)	  and	  aniline	  (47	  
mg,	   0.5	   mmol);	   reaction	   time:	   30	   min;	   precipitate	   formation	   to	  
give	  the	  product	  as	  a	  pale	  brown	  solid	  in	  97%	  yield.	  
Elemental	   analysis	   calcd	   (%)	   for	   C11H10N2:	   C	   77.62,	   H	   5.92,	   N	   16.46;	   found:	   C	  
77.27,	  H	  5.88,	  N	  16.47.	  
Mp:	  106	  	  109	  °C	  
IR	  (neat)	  ν:	  3225,	  3178,	  3009,	  1592,	  1444,	  1328,	  769	  cm-­‐1.	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  9.	  Experimental	  section	  
1H	  NMR	   (250	  MHz,	  CDCl3)	  δ	  8.24	   (dd,	   J	  =	  5.0,	  1.0	  Hz,	  1H),	  7.56	  –	  7.49	   (m,	  1H),	  
7.36	  (d,	  J	  =	  4.4	  Hz,	  4H),	  7.14	  –	  7.02	  (m,	  1H),	  6.91	  (d,	  J	  =	  8.4	  Hz,	  1H),	  6.79	  –	  6.74	  
(m,	  1H),	  6.64	  (br	  s,	  1H)	  ppm.	  
13C	  NMR	   (63	  MHz,	  CDCl3)	  δ	  156.6,	  148.8,	  141.0,	  138.2,	  129.7	  (2C),	  123.2,	  120.8	  
(2C),	  115.4,	  108.6	  ppm.	  
	  
4-­‐(pyridin-­‐2-­‐yl)morpholine(78):	  
Prepared	  from	  2-­‐chloropyridine	  (76	  mg,	  0.5	  mmol)	  and	  morpholine	  
(44	   mg,	   0.5	   mmol);	   reaction	   time:	   30	   min;	   purification	   by	  
chromatography	  to	  obtain	  the	  product	  as	  a	  yellow	  oil	  in	  72%	  yield.	  
Elemental	   analysis	   calcd	   (%)	   for	   C9H12N2:	   C	   65.83,	   H	   7.37,	   N	   17.06;	   found:	   C	  
65.52,	  H	  7.28,	  N	  16.95.	  
IR	  (neat)	  ν:	  2961,	  2852,	  1591,	  1481,	  1437	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.25	  –	  8.22	  (m,	  1H),	  7.56	  –	  7.49	  (m,	  1H),	  6.71	  –	  6.65	  
(m,	  2H),	  3.85	  (t,	  J	  =	  4,7	  Hz,	  4H),	  3.52	  (t,	  J	  =	  5,0	  Hz,	  4H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  160.0,	  148.4,	  138.0,	  114.3,	  107.4,	  67.2	  (2C),	  46.0	  (2C)	  
ppm.	  9.2.3.13.	  	  
	  
9.2.3.12.	  Bistacrine	  (29):	  
Prepared	  from	  compound	  28	  (220	  mg,	  1	  mmol)	  and	  
1,7-­‐heptanediamine	   (65	  mg,	  0.5	  mmol);	   reaction	  
time	  2	  h;	  purification	  by	  chromatography	  to	  give	  
the	  product	  as	  a	  yellow	  solid	  in	  88%	  yield.	  
Data	   of	   29	   have	   been	   provided	   above	   (section	  
9.1.2.6).	  
9.	  Experimental	  section	   	   273	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  9.	  Experimental	  section	  
9.3.	  Synthesis	  of	  DKPs	  
9.3.1.	  Synthesis	  of	  starting	  materials	  
9.3.1.1	  N,N-­‐Diacetylation	  of	  2,5	  piperazine	  dione	  (82):	  
	  
4.0	  g	   (35.06	  mmol)	  of	  2,5-­‐piperazinedione	  were	  placed	   in	  a	   flask	  with	  30	  ml	  of	  
acetic	  anhydride.	  The	  flask	  was	  connected	  to	  a	  condenser	  with	  a	  calcium	  chloride	  
guard	   tube	   and	   heated	   at	   150°C.	   The	   solution	   was	   stirred	   for	   3	   hours	   at	   this	  
temperature	  and	  then	  evaporated	  under	  vacuum.	  To	  the	  dark	  residue	  was	  added	  
hexane	   (5	   ml),	   which	   was	   evaporated	   obtaining	   a	   pale	   brown	   solid.	   After	  
recrystallization	  in	  ethanol,	  compound	  82	  was	  obatained	  in	  97%	  yield	  (6.692	  g).	  	  
IR	  (KBr	  disk):	  2945.6,	  1708.2,	  1706.0,	  1432.4,	  1363.6	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  CDCl3)	  δ	  4.60	  (s,	  4H),	  2.58	  (s,	  6H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  172.3	  (2C),	  170.5	  (2C),	  47.8	  (2C),	  27.2	  (2C)	  ppm.	  
	  
9.3.1.2.	  Preparation	  of	  β-­‐carboline-­‐1	  and	  3-­‐carboxaldehyde	  
9.3.1.2.1.	  1,2,3,4-­‐Tetrahydro-­‐β-­‐carboline-­‐3-­‐carboxylic	  acid	  (96):	  
	  
9.	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Ten	  grams	  (0.049	  mol)	  of	  dl-­‐tryptophan	  was	  dissolved	  in	  500	  ml	  of	  0.1	  N	  sodium	  
hydroxide	  containing	  5,6	  ml	  (0.07	  mol)	  of	  aqueous	  formalin	  (40%).	  The	  solution	  
was	  incubated	  at	  37	  °C	  for	  46	  hours.	  It	  was	  neutralized	  with	  4	  ml	  of	  glacial	  acetic	  
acid,	  and	  the	  resulting	  precipitate	  was	  filtered	  and	  washed	  with	  water	  to	  obtain	  
96	  in	  80%	  yield	  as	  yellow	  powder.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ 11.02	  (br	  s,	  1H),	  7.44	  (d,	  J	  =	  7.5	  Hz,	  1H),	  7.34	  (d,	  J	  =	  
7.9	  Hz,	  1H),	  7.11	  –	  6.97	  (m,	  2H),	  4.30	  –4.24	  (m,	  1H),	  3.2	  (d,	  1H,	  J	  =	  4.5	  Hz),	  3.13	  
(d,	  1H,	  J	  =	  4.7	  Hz),	  2.93	  –2.77	  (m,	  2H)	  ppm.	  
	  
9.3.1.2.2.	  1,2,3,4-­‐Tetrahydro-­‐ β 	  -­‐carboline-­‐1-­‐carboxylic	  acid	  (97):	  
	  
9	  grams	  (0.049	  mol)	  of	  tryptamine	  were	  dissolved	  in	  100	  ml	  of	  THF	  and	  10	  ml	  of	  
37%	  HCl	  aqueous	  solution	  were	  added.	  The	  resulting	  precipitate	  was	  filtered	  to	  
obtain	   tryptamine	   hydrochloride.	   This	   compound	   was	   dissolved	   in	   200	   ml	   of	  
water	   by	   stirring	   and	  warming	   on	   a	   steam	   bath	   to	   approximately	   45	   °C.	   After	  
cooling	  to	  r.t.,	  a	  solution	  of	  4.6	  g	  (0.05	  mol)	  of	  glyoxylic	  acid	  monohydrate	  in	  12	  
ml	   of	   water	   was	   added	   followed	   by	   the	   slow	   addition	   (about	   3	  minutes)	   of	   a	  
cooled	  solution	  of	  2.3	  g	   (0.04	  mol)	  of	  NaOH	   in	  12	  ml	  of	  water.	  Precipitation	  of	  
tetrahydro-­‐β-­‐carboline-­‐1-­‐carboxylic	   acid	   took	   place	   during	   the	   addition	   of	   the	  
potassium	   hydroxide	   solution.	   After	   stirring	   at	   r.t.	   for	   1	   hour,	   the	   solid	   was	  
filtered	  and	  washed	  with	  20	  ml	  of	  water	  to	  give	  97	  in	  82%	  yield	  as	  grey	  powder.	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  9.	  Experimental	  section	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  10.72	  (br	  s,	  1H),	  7.47	  (d,	  J	  =	  8.3	  Hz,	  1H),	  7.40	  (d,	  J	  =	  
7.7	  Hz,	  1H),	  7.08	  –	  6.94	  (m,	  2H),	  4.70	  (1H),	  3.48	  –	  3.25	  (m,	  2H,	  overlapped	  with	  
the	  residual	  DMSO	  signal),	  2.99	  –2.80	  (m,	  2H)	  ppm.	  
	  
9.3.1.2.3.	   General	   procedure	   to	   convert	   the	   acid	   derivatives	   to	   the	   methy	  
esters	  
The	  acid	  derivatives	  96	  and	  97	  (0.028	  mol)	  was	  dissolved	  in	  saturated	  methanolic	  
HCl	  solution	  (150	  ml),	  and	  the	  mixture	  was	  held	  at	  refluxed	  under	  argon	  for	  6	  h.	  
The	   solvent	   was	   removed	   under	   reduced	   pressure,	   and	   a	   saturated	   Na2CO3	  
solution	   was	   added	   to	   the	   residue.	   The	   aqueous	   alkaline	   suspension	   was	  
extracted	   with	   CHCl3	   (2	   x	   50	   ml)	   and	   EtOAc	   (3	   x	   50	   ml),	   and	   the	   combined	  
extracts	   were	   dried	   (anhydrous	   Na2SO4)	   and	   evaporated	   in	   vacuo	   to	   give	  




Prepared	   from	   compound	   96	   (6	   g,	   0.028	   mol);	   yield	   60%;	  
yellow-­‐off	  oil.	  
1H-­‐RMN	   (250	  MHz,	  CDCl3)	  δ	  8.10	  (br	  s,	  1H),	  7.50	  (d,	  J	  =	  7.2,	  
1H),	  7.32	  (d,	  J	  =	  7.6,1H),	  7.21	  –	  7.10	  (m,	  2H),	  4.19	  –	  4.08	  (m,	  2H),	  3.85–3.78	  (m,	  
4H),	  3.21	  –	  3.13	  (m,	  1H),	  2.98	  –	  2.88	  (m,	  1H),	  2.50	  (br	  s,	  1H)	  ppm.	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1-­‐Carbomethoxy-­‐1,2,3,4-­‐tetrahydro-­‐ β-­‐carboline	  (99):	  
Prepared	  from	  compound	  97	  (6	  g,	  0.028	  mol);	  yield	  55%;	  red	  
powder.	  	  
1H-­‐RMN	  (250	  MHz,	  DMSO)	  δ:	  10.73	  (br	  s,	  1H),	  7.42	  –	  7.34	  (m,	  
2H),	  7.10	  –	  6.94	  (m,	  2H),	  4.74	  (s,	  1H),	  3.73	  (s,	  3H),	  3.18	  –	  3.01	  (m,	  2H),	  2.64	  –	  2.60	  
(m,	  2H)	  ppm.	  
	  
9.3.1.2.4.	  3-­‐Carbomethoxy-­‐β-­‐carboline	  (100):	  
	  
A	  solution	  of	  98	  (2.66	  g,	  0.012	  mol)	  in	  dioxane	  (125	  ml)	  and	  xilene	  (125	  ml)	  was	  
treated	  with	   sulfur	   (3,3	   g),	   and	   the	  mixture	  was	   held	   at	   reflux	   for	   4	   days.	   The	  
mixture	  was	   then	   refluxed	   for	  an	  additional	  2	  days	  with	   sulfur	   (1.4	  g)	  added	  at	  
the	  beginning	  of	  each	  day.	  The	  solvent	  was	  removed	  under	  reduced	  pressure	  to	  
provide	  a	  brown	  residue.	  A	  fine	  suspension	  of	  this	  residue	  was	  made	  in	  HCl	  (1N,	  
75	  ml).	  The	  suspension	  was	  filtered	  and	  the	  precipitate	  was	  washed	  with	  H2O	  (50	  
ml).	   The	   combined	  aqueous	   fractions	  were	  extracted	  with	  benzene	   (3	   x	   13	  ml)	  
and	  then	  basified	  with	  concentrated	  aqueous	  solution	  of	  NH3	   (40	  ml)	   to	  yield	  a	  
thick,	   cream-­‐colored	   precipitate,	   which	   was	   filtered	   and	   dried	   for	   12	   h	   under	  
vacuum	   at	   40	   °C.	   The	   crude	   mixture	   was	   purified	   through	   silica	   column	  
chromatography	  using	  petroleum	  ether-­‐ethyl	   acetate	  mixture	  as	  eluent	   (7:1)	   to	  
afford	  the	  pure	  product	  100	  as	  a	  yellow	  solid	  in	  91%.	  
1H-­‐RMN	  (250	  MHz,	  CDCl3)	  δ	  10.00	  (br	  s,	  1H),	  9.25	  (s,	  1H),	  8.87	  (s,	  1H),	  8.20	  (d,	  J	  =	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7.9	  Hz,	  1H),	  7.69	  –	  7.60	  (m,	  2H),	  7.42	  –	  7.36	  (m,	  1H),	  3.82	  (s,	  3H)	  ppm.	  
	  
9.3.1.2.5.	  1-­‐Carbomethoxy-­‐β-­‐carboline	  (101):	  
	  
A	  solution	  of	  99	  (3.3	  g,	  0.014	  mol)	   in	  methanol	  (250	  ml)	  was	  refluxed	  with	  30%	  
Pd/C	  (1.1	  g)	  for	  4	  days.	  After	  completation	  of	  the	  reaction,	  as	   indicated	  by	  TLC,	  
the	  mixture	  was	   filtered	   through	   celite	   and	   the	   filtrate	  was	   evaporated	   under	  
reduced	   pressure.	   The	   crude	   mixture	   was	   purified	   through	   silica	   column	  
chromatography	  using	  petroleum	  ether/ethyl	  acetate	  mixture	  as	  eluent	  (7/1)	  to	  
afford	  the	  pure	  product	  101	  as	  a	  white	  solid	  in	  78%	  yield.	  	  
1H-­‐RMN	  (250	  MHz,	  CDCl3)	  δ:	  9.96	  (br	  s,	  1H),	  8.61	  (d,	  J	  =	  5	  Hz,	  1H),	  8.20	  –	  8.17	  (m,	  
2H),	  7.68	  –	  7.60	  (m,	  2H),	  7.39	  –	  7.33	  (m,	  1H),	  4.15	  (s,	  3H)	  ppm.	  
 
9.3.1.2.6.	   General	   procedure	   for	   the	   ester	   group	   reduction	   to	   aldehyde	  with	  
DIBALH	  
To	   a	   stirred	   solution	   of	   carbomethoxy-­‐β-­‐carboline	   (100-­‐101)	   (100	   mg,	   0.39	  
mmol)	  in	  CH2Cl2	  (5	  ml),	  was	  added	  2.3	  ml	  of	  DIBAL	  solution	  (1.0	  M,	  in	  CH2Cl2)	  at	  -­‐
40°C	  under	  an	  argon	  atmosphere.	  The	  mixture	  was	  stirred	  at	  –40°C	  for	  8	  min	  and	  
then	  quenched	  by	  the	  sequential	  addition	  of	  MeOH	  (0.5	  ml)	  and	  10	  %	  NaOH	  (0.5	  
ml).	  The	  mixture	  was	  stirred	  at	  r.t.	  for	  an	  additional	  0.5	  h.	  The	  reaction	  mixture	  
was	   diluted	   with	   10	   ml	   of	   CHCl3,	   dried	   over	   anhydrous	   Na2SO4,	   and	   then	  
evaporated	   in	   vacuo.	   The	   residue	   was	   subjected	   to	   column	   chromatography	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using	   petroleum	   ether-­‐ethyl	   acetate	   mixture	   as	   eluent	   (1:1)	   to	   give	   the	   pure	  




Prepared	  from	  compound	  100	  (100	  mg,	  0.39	  mmol);	  yield:	  77%;	  
white	  crystal.	  
1H-­‐RMN	   (250	  MHz,	  CDCl3)	  δ	  10.23	  (s,	  1H),	  9.89	  (br	  s,	  1H),	  9.34	  




Prepared	  from	  compound	  101	  (100	  mg,	  0.39	  mmol);	  yield:	  85%;	  
white-­‐off	  crystal.	  
1H-­‐RMN	  (250	  MHz,	  CDCl3)	  δ	  10.39	  (s,	  1H),	  10.10	  (br	  s,	  1H),8.68	  (d,	  J	  =	  
5	  Hz,	  1H),	  8.23–8.20(m,	  2H),	  7.71	  –7.62	  (m,	  2H),7.44	  –7.37	  (m,	  1H)	  ppm.	  
	  
9.3.2.	  General	  procedure	  for	  the	  double	  aldol	  condensation	  at	  r.t.	  
A	  solution	  of	  1,4-­‐diacetylpiperazine-­‐2,5-­‐dione	  82	  (1.0	  g,	  5.05	  mmol)	  ,	  the	  suitable	  
aromatic	   aldehyde	   (10	   mmol)	   and	   triethylamine	   (2	   ml,	   1.45	   g,	   14.3	   mmol)	   in	  
dimethylformamide	  (10	  ml)	  was	  stirred	  at	  25	  °C	  for	  14	  h,	   in	  a	  system	  protected	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with	   a	   CaCl2	   tube.	   The	   resulting	   precipitate	   was	   filtered,	   washed	   with	   ethyl	  
acetate	  and	  then	  with	  refluxing	  ethanol	  or	  methanol	  for	  1	  h	  to	  give	  compounds	  
83-­‐86	  as	  powders.	  
	  
3,6-­‐Bis(2-­‐pyridylmethylidene)piperazine-­‐2,5-­‐dione	  (83):	  
Prepared	   from	   82	   (1.0	   g,	   5.05	   mmol)	   and	   2-­‐
pyridinecarbaldehyde	  (1.07	  g,	  10	  mmol);	  yield:	  64%;	  light	  
yellow	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C16H12N4O2:	  C,	  71.40;	  H,	  7.67;	  N,	  13.32;	  O,	  7.61;	  
found:	  C	  64.87,	  H	  4.34,	  N	  18.89.	  
Mp	  >	  300	  °C	  
IR	   (KBr	   disk) ν:	   3421.8,	   3120.5,	   1694.8,	   1647.7,	   1581.8,	   1450.0,	   1412.3,	   1346.4	  
cm-­‐1.	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1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  12.73	  (br	  s,	  2H),	  8.77	  (dd,	  J	  =	  7.4,	  0.9	  Hz,	  2H),	  7.95	  
(td,	  J	  =	  7.7,	  1.7	  Hz,	  2H),	  7.74	  (d,	  J	  =	  7.9	  Hz,	  2H),	  7.42	  (ddd,	  J	  =	  7.5,	  7.4,	  0.9	  Hz,	  2H),	  
6.81	  (s,	  2H)ppm.	  
13C-­‐NMR	   (63	   MHz,	   CF3CO2D)	   δ	   157.9	   (2C),	   148.3	   (2C),	   144.9	   (2C),	   142.7	   (2C),	  
131.7	  (2C),	  128.7	  (2C),	  127.0	  (2C),	  107.9	  (2C)	  ppm.	  
	  
3,6-­‐Bis(3-­‐pyridylmethylidene)piperazine-­‐2,5-­‐dione	  (84):	  
Prepared	   from	   82	   (1.0	   g,	   5.05	   mmol)	   and	   3-­‐
pyridinecarbaldehyde	   (1.07	   g,	   10	   mmol);	   yield:	   41%;	  
yellow	  powder.	  
Elemental	  analysis	   (%)	   calcd	   for	  C16H12N4O2:	  C	  65.75,	  H	  4.14,	  N	  19.17;	   found	  C	  
64.79;	  H	  4.43;	  N	  18.83.	  
Mp	  >	  300	  °C	  
IR	  (KBr	  disk)	  ν:	  3440,	  3194,	  3031,	  1666,	  1639,	  1411,	  699	  cm-­‐1.	  
1H-­‐NMR	   (250	  MHz,	  DMSO)	  δ	  10.79	   (br	  s,	  2H),	  8.72	   (s,	  2	  H),	  8.50	   (d,	   J	  =	  3.7	  Hz,	  
2H),	  7.95	  (d,	  J	  =	  8	  Hz,	  2H),	  7.45	  (dd,	  J	  =	  7.88,	  3.7	  Hz,	  2H),	  6.79	  (s,	  2H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  CF3CO2D)	  δ	  158.9	  (2C),	  146.1	  (2C),	  141.7(2C),	  141.0	  (2C),	  133.4	  
(2C),	  129.4	  (2C),	  126.6	  (2C),	  112.3	  (2C)	  ppm.	  
	  
3,6-­‐Bis(4-­‐pyridylmethylidene)piperazine-­‐2,5-­‐dione	  (85):	  
Prepared	   from	   82	   (1.0	   g,	   5.05	   mmol)	   and	   4-­‐
pyridinecarbaldehyde	   (1.07	   g,	   10	   mmol);	   yield:	   68%;	  
yellow	  powder.	  
Elemental	  analysis	   (%)	  calcd	  for	  C16H12N4O2:	  C	  65.75,	  H	  4.14,	  N	  19.17;	   found:	  C	  
59.75,	  H	  4.19,	  N	  19.19.	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  9.	  Experimental	  section	  
Mp	  >	  300	  °C	  
IR	  (KBr	  disk)	  ν:	  3428,	  3213,	  1684,	  1632,	  1396,	  808	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  10.87	  (br	  s,	  2H),	  8.64	  (d,	  J	  =	  5.9	  Hz,	  4H),	  7.60	  (d,	  J	  =	  
5.9	  Hz,	  4H),	  6.77	  (s,	  2H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  157.9	  (2C),	  150.1	  (4C),	  141.0	  (2C),	  129.7	  (2C),	  124.0	  
(4C),	  112.5	  (2C)	  ppm.	  
	  
3,6-­‐Bis(4-­‐quinolylmethylidene)piperazine-­‐2,5-­‐dione	  (86):	  
Prepared	  from	  82	  (1.0	  g,	  5.05	  mmol)	  and	  quinoline-­‐4-­‐
carbaldehyde	   (1.6	   g,	   10	   mmol);	   yield:	   84%;	   yellow	  
solid.	  	  
Elemental	  analysis	   (%)	  calcd	  for	  C24H16N4O2:	  C	  73.46,	  H	  4.11,	  N	  14.28;	   found:	  C	  
71.96,	  H	  4.41,	  N	  13.82.	  
Mp	  >	  300	  °C	  
IR	  (KBr	  disk)	  ν:	  3433,	  3046,	  1686,	  1633,	  1506,	  756	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  10.71	  (br	  s,	  2H),	  8.95	  (d,	  J	  =	  4.5	  Hz,	  2H),	  8.10	  (d,	  J	  =	  
7.5	  Hz,	  2H),	  8.01	  (d,	  J	  =	  7.5	  Hz,	  2H),	  7.86	  –7.80	  (m,	  2H),	  7.70	  – 7.64	  (m,	  2H),	  7.60	  
(d,	  J	  =	  4.5	  Hz,	  2H)	  ),	  7.18	  (s,	  2H	  )	  ppm.	  
13C-­‐NMR	   (63	   MHz,	   CF3CO2D)	   δ	   160.8	   (2C),	   153.7	   (2C),	   146.0	   (2C),	   140.4	   (2C),	  
139.3	  (2C),	  134.4	  (2C),	  132.9	  (2C),	  130.6	  (2C),	  128.3	  (2C),	  124.5	  (2C),	  123.5	  (2C),	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Prepared	   from	   82	   (1.0	   g,	   5.05	   mmol)	   and	   quinoline-­‐2-­‐
carbaldehyde	  (1.6	  g,	  10	  mmol);	  yield:	  95%;	  orange	  solid.	  	  
Mp	  >	  300	  °C	  
1H-­‐NMR	   (250	  MHz,	  DMSO)	  δ	  13.09	   (br	   s,	   1H),	   8.50	   (d,	   J	   =	  
8.8	  Hz,	  1H),	  8.06	  –	  8.01	  (m,	  2H),	  7.97	  –	  7.96	  (m,	  1H),	  7.90	  –	  7.83	  (m,	  1H),	  7.71	  –	  
7.65	  (m,	  1H),	  7.05	  (s,	  1H),	  4.42	  (s,	  2H),	  2.57	  (s,	  3H)	  ppm.	  
	  
1-­‐Acetyl-­‐3-­‐(3-­‐quinolylmethylidene)piperazine-­‐2,5-­‐dione	  (88):	  
Prepared	   from	   82	   (1.0	   g,	   5.05	   mmol)	   and	   quinoline-­‐3-­‐
carbaldehyde	  (1.6	  g,	  10	  mmol);	  yield:	  100%;	  yellow	  solid.	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  9.	  Experimental	  section	  
Mp	  >	  300	  °C	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  10.83	  (br	  s,	  1H),	  9.04	  (d,	  J	  =	  2.1	  Hz,	  1H),	  8.56	  (d,	  J	  =	  
1.9	  Hz,	  1H),	  8.06	  –	  8.01	  (m,	  2H),	  7.84	  –	  7.77	  (m,	  1H),	  7.66	  (t,	  J	  =	  7.5	  Hz,	  1H),	  7.14	  
(s,	  1H),	  4.42	  (s,	  2H),	  2.55	  (s,	  3H)	  ppm.	  
 
1-­‐Acetyl-­‐3-­‐benzylidenepiperazine-­‐2,5-­‐dione	  (89):	  
Prepared	  from	  82	  (1.0	  g,	  5.05	  mmol)	  and	  benzaldehyde	  (1.02	  
g,	  10.8	  mmol);	  yield:	  83%;	  white	  solid.	  
Mp	  >	  300	  °C	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  10.40	  (br	  s,	  1H),	  7.63	  –	  7.60	  (m,	  2H),	  7.48	  –7.37	  (m,	  
3H),	   6.98	   (s,	   1H),	   4.39	   (s,	   2H),	   2.51	   (s,	   3H	   overlapped	  with	   the	   residual	   DMSO	  
signal)	  ppm.	  
	  
9.3.3.	  General	  procedure	  for	  the	  double	  aldol	  condensation	  at	  reflux	  
A	  solution	  of	  1,4-­‐diacetylpiperazine-­‐2,5-­‐dione	  82	  (0.5	  g,	  2.52	  mmol),	  the	  suitable	  
aromatic	   aldehyde	   (5.05	   mmol),	   triethylamine	   (3	   ml,	   21.51	   mmol)	   in	  
dimethylformamide	   (2	  ml)	  was	   refluxed	  at	  150	  °C	   in	  a	  system	  protected	  with	  a	  
CaCl2	  tube	  for	  16	  h.	  Partial	  evaporation	  of	  the	  solvent	  was	  compensated	  by	  the	  
addition	   of	   a	   5:1	  mixture	   of	   triethylamine	   and	   dimethylformamide	   (2	  ml).	   The	  
reaction	   mixture	   was	   cooled	   and	   the	   resulting	   precipitate	   was	   filtered	   and	  
washed	  with	   5	  ml	   of	   ethyl	   acetate	   and	   1	  ml	   of	  water.	   The	   resulting	   solid	  was	  
washed	  with	  refluxing	  methanol	   for	  1	  hour	  to	  complete	   its	  purification,	   leading	  
to	  compounds	  90-­‐95,	  104	  and	  105.	  




Prepared	  from	  82	  (0.5	  g,	  2.52	  mmol)	  and	  quinoline-­‐2-­‐
carbaldehyde	   (0.93	   g,	   5.05	  mmol);	   yield:	   80%;	   green	  
solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C24H16N4O2:	  C	  73.46,	  
H	  4.11,	  N	  14.28;	  found:	  C	  72.85,	  H	  4.27,	  N	  14.06.	  
Mp	  >	  300	  °C	  	  
IR	  (KBr	  disk)	  ν:	  3426,	  3134,	  1680,	  1637,	  1418,	  835	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  CF3CO2D)	  δ	  8.94	  (d,	  J	  =	  7.2	  Hz,	  2H),	  8.13	  –	  8.02	  (m,	  8H),	  7.89	  –	  
7.85	  (m,	  2H),	  7.36	  (s,	  2H)	  ppm.	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  section	  
13C-­‐NMR	   (63	   MHz,	   CF3CO2D)	   δ	   160.3	   (2C),	   150.9	   (2C),	   149.2	   (2C),	   141.2	   (2C),	  
139.5	  (2C),	  134.8	  (2C),	  133.8	  (2C),	  131.5	  (2C),	  131.4	  (2C),	  124.5	  (2C),	  122.4	  (2C),	  
111.1	  (2C)	  ppm.	  
	  
3,6-­‐Bis(3-­‐quinolylmethylidene)piperazine-­‐2,5-­‐dione	  (91):	  
Prepared	   from	   82	   (0.5	   g,	   2.52	   mmol)	   and	  
quinoline-­‐3-­‐carbaldehyde	   (0.93	   g,	   5.05	   mmol);	  
yield:	  65%;	  yellow	  solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C24H16N4O2:	  C	  73.46,	  H	  4.11,	  N	  14.28;	   found:	  C	  
72.21,	  H	  4.16,	  N	  13.95.	  
Mp	  >	  300	  °C	  
IR	  (KBr	  disk)	  ν:	  3446,	  3186,	  1680,	  1627,	  1399,	  758	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  11.00	  (br	  s,	  2H),	  9.00	  (d,	  J	  =	  2.2	  Hz,	  2H),	  8.57	  (d,	  J	  =	  
1.6	  Hz,	  2H),	  8.04	  –	  7.94	  (m,	  4H),	  7.78–	  7.72	  (m,	  2H),	  7.66	  –	  7.61	  (m,	  2H),	  6.95	  (s,	  
2H)	  ppm.	  
13C-­‐NMR	   (63	   MHz,	   CF3CO2D)	   δ	   159.0	   (2C),	   147.6	   (2C),	   144.0	   (2C),	   137.3	   (2C),	  
137.0	  (2C),	  131.7	  (2C),	  129.8	  (2C),	  129.6	  (2C),	  128.9	  (2C),	  126.3	  (2C),	  119.8	  (2C),	  
113.0	  (2C)	  ppm.	  
	  
3,6-­‐Dibenzylidenepiperazine-­‐2,5-­‐dione	  (92):	  
Prepared	  from	  82	   (0.5	  g,	  2.52	  mmol)	  and	  benzaldheyde	  
(0.55	  g,	  5.05	  mmol);	  yield:	  60%;	  white	  solid.	  	  
Elemental	  analysis	   (%)	   calcd	   for	  C18H14N2O2:	  C	  74.47,	  H	  
4.86,	  N	  9.65,	  found:	  C	  73.81,	  H	  4.84,	  N	  9.67.	  
Mp	  >	  300	  °C	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   287	   	   	  
IR	  (KBr	  disk)	  ν:	  3191.5,	  3079.4,	  1679.2,	  1629.4,	  1390.0,	  1000.2,	  926.4	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  CF3CO2D)	  δ	  7.38	  – 7.33	  (m,	  10H),	  7.27	  (s,	  2H)	  ppm.	  
13C-­‐NMR	   (63	   MHz,	   CF3CO2D)	   δ	   162.8	   (2C),	   133.4	   (2C),	   132.7	   (2C),	   131.9	   (4C),	  
130.9	  (4C),	  126.3	  (2C),	  125.6	  (2C)	  ppm.	  
	  
3,6-­‐Bis(4-­‐formylphenylmethylidene)piperazine-­‐2,5-­‐dione	  (93):	  
Prepared	   from	   82	   (0.5	   g,	   2.52	   mmol)	   and	  
terephthaldicarbaldehyde	  (0.68	  g,	  5.05	  mmol);	  
yield:	  64%;	  yellow	  solid.	  	  
Elemental	   analysis	   (%)	   calcd	   forC20H14N2O4:	   C	  
69.36,	  H	  4.07,	  N	  8.09;	  found:	  C	  68.36,	  H	  4.28,	  N	  8.47.	  
Mp	  >	  300	  °C	  
IR	  (KBr	  disk):	  3448,	  3239,	  2852,	  1683,	  1564,	  820	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  CF3CO2D)	  δ	  9.90	  (s,	  2H),	  8.08	  (d,	  J	  =	  6.2	  Hz,	  4H),	  7.65	  (d,	  J	  =	  
6.3	  Hz,	  4H),	  7.36	  (s,	  2H)	  ppm.	  
13C-­‐NMR	   (63	   MHz,	   CF3CO2D)	   δ	   199.1	   (2C),	   161.8	   (2C),	   141.5	   (2C),	   137.7	   (2C),	  
133.9	  (4C),	  131.7	  (4C),	  127.8	  (2C),	  123.0	  (2C)	  ppm.	  
	  
3,6-­‐Bis(2-­‐furylmethylene)piperazine-­‐2,5-­‐dione	  (94):	  
Prepared	   from	   82	   (0.5	   g,	   2.52	   mmol)	   and	   furane-­‐2-­‐
carbaldehyde	   (0.5	   g,	   5.05	   mmol);	   yield:	   68%;	   yellowish	  
green	  solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C14H10N2O4:	  C	  62.22,	  H	  3.73,	  N	  10.37;	   found:	  C	  
62.47,	  H	  3.34,	  N	  10.89.	  
Mp	  >	  300	  °C	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  9.	  Experimental	  section	  
IR	  (NaCl)	  ν:	  3277,	  1688,	  1631,	  1482,	  1340,	  944	  cm-­‐1.	  	  
1H-­‐NMR	  (250	  MHz,	  CDCl3)	  δ	  9.31	  (br	  s,	  2H),	  7.62	  (d,	  J	  =	  1.3,	  2H),	  6.79	  (s,	  2H),	  6.62	  
(d,	  J	  =	  3.5,	  2H),	  6.57	  – 6.55	  (m,	  2H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  CDCl3)	  δ	  157.1,	  151.1,	  144.6,	  123.8,	  115.2,	  112.9,	  103.3	  ppm.	  
	  
3,6-­‐Bis(2-­‐thienylmethylene)piperazine-­‐2,5-­‐dione	  (95):	  
Prepared	   from	   82	   (0.5	   g,	   2.52	   mmol)	   and	   thiophene-­‐2-­‐
carbaldehyde	   (0.57	   g,	   5.05	   mmol);	   yield:	   61%;	   yellow	  
solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C14H10N2O2S2:	  C	  55.61,	  H	  3.33,	  N	  9.26,	  S	  21.21;	  
found:	  C	  55.87,	  H	  3.34,	  N	  8.89,	  S	  21.41.	  
Mp	  >	  300	  °C	  
IR	  (KBr	  disk)	  ν:	  3218,	  3102,	  1678,	  1613,	  1416,	  816	  cm-­‐1.	  
1H-­‐NMR	   (250	  MHz,	   CF3CO2D)	  δ	  7.53	   (d,	   J	  =	  5.05,	   2H),	   7.40	   (s,	   2H),	   7.36	   (d,	   J	  =	  
3.08,	  2H),	  7.12	  – 7.09	  (m,	  2H)	  ppm.	  
13C-­‐NMR	   (63	   MHz,	   CF3CO2D)	   δ	   162.1	   (2C),	   135.8	   (2C),	   134.8	   (2C),	   132.3	   (2C),	  
130.6	  (2C),	  122.4	  (2C),	  118.1	  (2C)	  ppm.	  
	  
3,6-­‐Bis(1-­‐β-­‐carbolinylmethylene)piperazine-­‐2,5-­‐dione	  (104):	  
Prepared	   from	   82	   (0.5	   g,	   2.52	   mmol)	   and	   β-­‐
carboline-­‐1-­‐carbaldehyde	   103	   (1	   g,	   5.05	  
mmol);	  yield:	  58%;	  yellowish	  green	  solid.	  	  
Elemental	  analysis	   (%)	  calcd	  for	  C28H18N6O2:	  C	  
71.48,	  H	  3.86,	  N	  17.86;	  found:	  C	  71.61,	  H	  3.74,	  N	  17.87.	  
9.	  Experimental	  section	   	   289	   	   	  
Mp	  >	  300	  °C	  	  
IR	  (KBr	  disk)	  ν:	  3385,	  3058,	  1676,	  1561,	  1457,	  1322,	  1275,	  824	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  CF3CO2D)	  δ	  8.62	  (d,	  J	  =	  6.3,	  2H),	  8.53	  (d,	  J	  =	  6.3,	  2H),	  8.42	  (d,	  J	  
=	  8.2,	  2H),	  7.96	  –	  7.90	  (m,	  2H),	  7,80	  (d,	  J	  =	  8.4,	  2H),	  7.69	  (s,	  2H),	  7.64	  –	  7.59	  (m,	  
2H)	  ppm.	  
13C-­‐NMR	   (63	   MHz,	   CF3CO2D)	   δ	   163.2	   (2C),	   136.6	   (2C),	   134.0	   (2C),	   132.5	   (2C),	  
129.7	  (2C),	  125.9	  (2C),	  125.3	  (2C),	  122.5	  (2C),	  119.9	  (2C),	  118.2	  (2C),	  115.4	  (2C),	  
115.1	  (2C),	  113.7	  (2C),	  108.8	  (2C)	  ppm.	  
	  
3,6-­‐Bis(3-­‐ β-­‐carbolinylmethylene)piperazine-­‐2,5-­‐dione	  (105):	  
Prepared	  from	  82	  (0.5	  g,	  2.52	  mmol)	  and	  β-­‐
carboline-­‐3-­‐carbaldehyde	   102	   (1	   g,	   5.05	  
mmol);	  yield:	  52%;	  green-­‐off	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	  
C28H18N6O2:	  C	  71.48,	  H	  3.86,	  N	  17.86;	  found:	  C	  71.81,	  H	  3.86,	  N	  17.67.	  
Mp	  >	  300	  °C	  	  
IR	  (KBr	  disk)	  ν:	  3424,	  3161,	  1673,	  1644,	  1472,	  742	  cm-­‐1.	  	  
1H-­‐NMR	  (250	  MHz,	  CF3CO2D)	  δ	  9.01	  (s,	  2H),	  8.72	  (s,	  2H),	  8.36	  (d,	  J=8.0,	  2H),	  7.87	  
–	  7.81(m,	  2H),	  7,71	  (d,	  J=8.0,	  2H),	  7.54	  –	  7.48	  (m,	  2H),	  7.50	  (s,	  2H)	  ppm.	  
13C-­‐NMR	   (63	   MHz,	   CF3CO2D)	   δ	   156.7	   (2C),	   141.1	   (2C),	   140.3	   (2C),	   134.8	   (2C),	  
134.5	  (2C),	  128.7	  (2C),	  127.4	  (2C),	  126.9	  (2C),	  122.7	  (2C),	  120.1	  (2C),	  119.6	  (2C),	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  9.	  Experimental	  section	  
9.3.4.	   General	   Procedure	   for	   the	   monoreduction	   of	   double	   condensation	  
compounds	  
A	   mixture	   of	   83	   or	   93	   and	   an	   excess	   of	   zinc	   in	   10	   ml	   glacial	   acetic	   acid	   was	  
refluxed	  at	  125	  °C	  for	  1-­‐16	  h,	  as	  specified	   in	  each	  case.	  Thereafter	  the	  reaction	  
mixture	   was	   filtered	   to	   remove	   zinc	   and	   zinc	   diacetate,	   as	   a	   white	   salt.	   The	  
filtrate	  was	  concentrated	  and	  the	  residue	  was	  solubilized	   in	  CH2Cl2	  and	  washed	  
with	  a	  1	  M	  NaHCO3	  aqueous	  solution.	  This	  solution	  was	  extracted	  with	  four	  3	  ml	  
portions	   of	   CH2Cl2,	   and	   the	   combined	   extracts	  were	   dried	   (anhydrous	   Na2SO4)	  




Prepared	  from	  83	   (0.200	  g,	  0.68	  mmol)	  and	  zinc	  (0.500	  g	  
7.54	  mmol);	  reaction	  time:	  1	  h;	  yield:	  55%;	  white	  powder.	  
Elemental	   analysis	   (%)	   calcd	   forC16H14N4O2:	   C	   65.30,	   H	  
4.79,	  N	  19.04;	  found:	  C	  64.60,	  H	  5.20,	  N	  18.66.	  
Mp:	  215	  °C	  
9.	  Experimental	  section	   	   291	   	   	  
IR	  (NaCl)	  ν:	  3266.6,	  1685.3,	  1643.5,	  1588.4,	  1379.7	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  CDCl3)	  δ	  12.75	  (br	  s,	  1H),	  8.65	  (d,	  J	  =	  4.7	  Hz,	  1H),	  8.57	  (d,	  J	  =	  
4.6	  Hz,	  1H),	  7.93	  (br	  s,	  1H),	  7.79	  – 7.67	  (m,	  2H),	  7.38	  – 7.21	  (m,	  4H),	  6.78	  (s,	  1H),	  
4.85	  – 4.79	  (m,	  1H),	  3.76	  (dd,	  J	  =	  15.8,	  2.5	  Hz,	  1H),	  3.34	  – 3.24	  (dd,	  J	  =	  16.0,	  10.6	  
Hz,	  1H)	  ppm.	  
13C-­‐NMR	   (63	   MHz,	   CDCl3)	   δ	   166.0,	   158.9,	   157.5,	   155.4,	   149.4,	   148.8,	   137.5,	  




Prepared	  from	  93	  (0.200	  g,	  0.57	  mmol)	  and	  zinc	  
(0.47	  g,	  6.31	  mmol);	  reaction	  time:	  16	  h;	  yield:	  
20%;	  yellow	  powder.	  
Elemental	  analysis	   (%)	   calcd	   for	  C20H20N2O4:	  C	  
68.17,	  H	  5.72,	  N	  7.95;	  found:	  C	  68.26,	  H	  5.99,	  N	  7.57.	  
Mp:	  170	  °C	  	  
IR	  (NaCl)	  ν:	  3198,	  3058,	  1737,	  1671,	  1629,	  1024	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  CDCl3)	  δ	  7.82	  (br	  s,	  1H),	  7.45	  – 7.13	  (m,	  8H),	  6.84	  (s,	  1H),	  6.33	  
(br	  s,	  1H),	  5.13	  (s,	  2H),	  5.08	  (s,	  2H),	  4.47	  – 4.43	  (m,	  1H),	  3.43	  (dd,	  J	  =	  13.6,	  3.8	  Hz,	  
1H),	  3.12	  (dd,	  J	  =	  13.8,	  8.1	  Hz,	  1H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  CDCl3)	  δ:	  165.2,	  159.9,	  137.1,	  136.0,	  135.0,	  133.0,	  130.4	  (2C),	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  9.	  Experimental	  section	  
9.3.5.	  3,6-­‐Bis(pyridin-­‐2-­‐ylmethyl)piperazine-­‐2,5-­‐dione	  (107):	  
	  
Method	  A.	  To	  a	  solution	  of	  0.11	  g	  (0.37	  mmol)	  of	  106	  in	  15	  ml	  of	  methanol	  was	  
added	  0.03	  g	  of	  30%	  palladium	  on	  charcoal,	  and	  the	  mixture	  was	  shaken	  in	  a	  Parr	  
hydrogenator	   at	  30	  psi	   for	  24	  h.	   Thereafter,	   the	  Pd/C	  was	   removed	  by	   suction	  
filtration	  through	  a	  funnel	  with	  celite	  and	  the	  filtrate	  was	  evaporated	  in	  vacuo	  to	  
give	  compound	  107	  as	  a	  white	  powder	  in	  34%	  yield.	  
Method	  B.A	  mixture	  of	  0.20	  g	  (0.68	  mmol)	  of	  83	  and	  0.50	  g	  (7.54	  mmol)	  of	  zinc	  
in	  10	  ml	  of	  glacial	  
acetic	  acid	  was	  refluxed	  at	  125	  °C	  for	  22	  h.	  Thereafter,	  the	  reaction	  mixture	  was	  
filtered	   to	   remove	   zinc	   and	   zinc	   diacetate	   as	   a	   white	   salt.	   The	   filtrate	   was	  
concentrated	  and	  the	  residue	  was	  solubilized	  in	  10	  ml	  of	  CH2Cl2	  and	  washed	  with	  
a	  1	  M	  aqueous	  NaHCO3	  solution.	  The	  aqueous	  solution	  was	  extracted	  with	  four	  3	  
ml	  portions	  of	  CH2Cl2,	  and	  the	  combined	  extracts	  were	  dried	  (anhydrous	  Na2SO4)	  
and	  evaporated	  in	  vacuo	  to	  give	  107	  as	  a	  white	  powder	  in	  58%	  yield.	  
9.	  Experimental	  section	   	   293	   	   	  
Elemental	  analysis	   (%)	  calcd	  for	  C16H16N4O2:	  C	  64.85,	  H	  5.44,	  N	  18.91;	   found:	  C	  
64.55,	  H	  5.69,	  N	  19.17.	  
Mp:	  180	  °C	  	  
IR	  (NaCl)	  ν:	  3228,	  1676,	  1592,	  1438,	  1329	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  CDCl3)	  δ:	  8.56	  –	  8.54	  (m,	  2H),	  7.	  90	  (br	  s,	  2H),	  7.72	  –	  7.64	  (m,	  
2H),	  7.26	  –	  7.20	  (m,	  4H),	  4.54	  (dd,	  J	  =	  10.6,	  1.2	  Hz,	  2H),	  3.76	  –	  3.60	  (m,	  2H),	  3.26	  – 
3.05	  (m,	  2H)	  ppm.	  
13C-­‐NMR	   (63	  MHz,	   CDCl3)	   δ:	   39.3,	   40.0,	   53.9,	   54.0,	   122.0,	   122.1,	   124.1,	   136.9,	  
136.9,	  149.0,	  157.2,	  157.4,	  167.2,	  167.2	  ppm.	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  9.	  Experimental	  section	  
9.4.	  Synthesis	  of	  GN8	  analogues	  
9.4.1.	  Synthesis	  of	  GN8	  
9.4.1.1.	  N,N'-­‐[4,4'-­‐methylenebis(4,1-­‐phenylene)]bis(2-­‐bromoacetamide)	  (109):	  
	  
A	  solution	  of	  4,4'-­‐methylenedibenzenamine	  (0.202	  g,	  1.02	  mmol),	  2-­‐bromoacetic	  
acid	   (0.284	   g,	   2.06	   mmol),	   EDC	   (0.382	   g,	   2.00	   mmol)	   and	   triethylamine	   (2.00	  
mmol),	  in	  dry	  DMF	  (5	  ml)	  was	  stirred	  under	  argon	  for	  2	  hours.	  After	  dilution	  with	  
EtOAc	  (15	  ml),	  the	  organic	  layer	  was	  separated,	  washed	  with	  1	  N	  aqueous	  HCl	  (2	  
x	   5	   ml),	   5%	   aqueous	   NaHCO3	   (2	   x	   5	   ml)	   and	   dried	   over	   anhydrous	   Na2SO4.	  
Evaporation	  afforded	  compound	  109	  as	  a	  pale	  brown	  solid	  in	  46%	  yield.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  10.34	  (br	  s,	  2H),	  7.50	  (d,	  J	  =	  8.5	  Hz,	  4H),	  7,17	  (d,	  J	  =	  
8.5	  Hz,	  4H),	  4.02	  (s,	  4H),	  3.86	  (s,	  2H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO,)	  δ	  165.5	  (2C),	  137.7	  (2C),	  137.5	  (2C),	  129.9	  (4C),	  120.2	  
(4C),	  41.0,	  31.3	  (2C)	  ppm.	  
	  
9.4.1.2.	  GN8	  (110):	  
	  
Compound	  109	   (0.100	  g,	  0.227	  mmol)	  and	  2	  equivalents	  of	  pyrrolidine	   (32	  mg,	  
0.454	  mmol),	  were	  stirred	  for	  24	  h	  at	  75	  °C.	  The	  mixture	  was	  cooled,	  and	  then	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diluted	  with	   EtOAc	   (5	  ml),	   washed	  with	   H2O	   (3	   x	   1	  ml),	   dried	   over	   anhydrous	  
Na2SO4	   and	   concentrated	   to	   give	   compound	  110	   as	   a	   pale	   brown	   solid	   in	   64%	  
yield.	  
Elemental	  analysis	   (%)	  calcd	  for	  C25H32N4O2:	  C	  71.40,	  H	  7.67,	  N	  13.32;	   found:	  C	  
71.16,	  H	  7.72,	  N	  13.35.	  
Mp:	  144	  –	  147	  °C	  
IR	  (NaCl)	  ν:	  3257,	  2954,	  2799,	  1681,	  1664,	  1513814	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  9.70	  (br	  s,	  2H),	  7.54	  (d,	  J	  =	  8.4	  Hz,	  4H),	  7.13	  (d,	  J	  =	  
8.4	  Hz,	  4H),	  3.84	  (s,	  2H),	  3.30	  (s,	  4H),	  2.64	  (br	  s,	  8H),	  1.76	  (br	  s,	  8H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO,)	  δ	  169.0	  (2C),	  137.5	  (2C),	  137.3	  (2C),	  129.6	  (4C),	  120.4	  
(4C),	  60.1	  (2C),	  54.6	  (4C),	  41.0,	  24.2	  (4C)	  ppm.	  
	  
9.4.2.	  Preparation	  of	  the	  fluorene	  derivatives	  
9.4.2.1.	  N,N’-­‐(9H-­‐fluorene-­‐2,7-­‐diyl)bis(2-­‐bromoacetamide)	  (111):	  
	  
To	   a	   stirred	  mixture	   of	   9H-­‐fluorene-­‐2,7-­‐diamine	   (0.3	   g,	   1.53	  mmol)	   and	  DMAP	  
(0.46	   g,	   3.8	   mmol)	   in	   15	   mL	   of	   THF	   under	   inert	   atmosphere,	   bromoacetyl	  
bromide	   (0.33	  ml,	   3.8	   mmol)	   was	   added	   dropwise.	   The	   resulting	   mixture	   was	  
stirred	  at	  r.t.	  for	  24	  h,	  then	  15	  mL	  of	  0.1N	  HCl	  were	  added	  to	  remove	  the	  DMAP	  
excess	   and	   the	   solution	  was	   left	   stirring	   for	   30	  minutes.	   Then	   the	  mixture	  was	  
filtered	  under	  vacuum,	  the	  solid	  washed	  with	  water	  until	  acid-­‐free	  and	  dried	  to	  
give	  compound	  111	  as	  a	  pale	  brown	  solid	  in	  97%	  yield.	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IR	  (KBr	  disk)	  ν:	  3257,	  1683	  cm-­‐¹.	  
¹H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  10.49	  (br	  s,	  2H),	  7.91	  (s,	  2H),	  7.80	  (d,	  J	  =	  8.2	  Hz,	  2H),	  
7.55	  (dd,	  J	  =	  8.2,	  2.5	  Hz,	  2H),	  4,08	  (s,	  4H,	  H2),	  3,94	  (s,	  2H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  165.5	  (2C),	  144.6	  (2C),	  138.1	  (2C),	  137.6	  (2C),	  120.7	  
(2C),	  118.9	  (2C),	  116.9	  (2C),	  37.5,	  31.4	  (2C)	  ppm.	  
	  
9.4.2.2.	  Amino-­‐fuorene	  derivatives:	  
To	  a	  stirred	  mixture	  of	  compound	  111	  (0.2	  g,	  0.45	  mmol)	  in	  2	  ml	  of	  dry	  DMF	  at	  75	  
°C	  was	  added	  two	  equivalents	  of	  the	  suitable	  amine.	  The	  reaction	  was	  stirred	  for	  
24	   hours,	   cooled	   to	   r.t.	   and	   then	   5	   mL	   of	   EtOAc	   were	   added.	   The	   resulting	  
precipitate	  was	  filtered	  under	  vacuum,	  washed	  with	  ice-­‐cooled	  water	  (3	  x	  1	  ml)	  
and	  dried	  to	  give	  compounds	  112-­‐120.	  
	  
Cmpd.	   R2NH	   	   Cmpd.	   R2NH	  
112	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2-­‐(Dimethylamino)-­‐N-­‐(7-­‐[2-­‐(dimethylamino)acetylamino]-­‐9H-­‐fluoren-­‐2-­‐
yl)acetamide	  (112):	  
Prepared	   from	   111	   (0.2	   g,	   0.45	  mmol)	   and	  
dimethylamine	   (0.045	  ml,	   0.9	  mmol);	   yield:	  
90%;	  pale	  brown	  solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C21H26N4O2:	  C	  68.83,	  H	  7.15,	  N	  15.29;	   found:	  C	  
68.69,	  H	  6.98,	  N	  15.18.	  
Mp:	  204	  –	  207°C	  
IR	  (KBr	  disk)	  ν:	  3258,	  1682,	  1518	  cm-­‐¹.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  9.78	  (br	  s,	  2H),	  7.96	  (s,	  2H),	  7.74	  (d,	  J	  =	  8.2	  Hz,	  2H),	  
7.61	  (d,	  J	  =	  8.2,	  2H),	  3.88	  (s,	  2H),	  3.10	  (s,	  4H),	  2.50	  (s,	  6H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  168.8	  (2C),	  143.8	  (2C),	  137.5	  (2C),	  136.7	  (2C),	  119.8	  
(2C),	  118.6	  (2C),	  116.6	  (2C),	  63.7	  (2C),	  45.7	  (4C),	  37.0	  ppm.	  
	  
N,N'-­‐(9H-­‐fluorene-­‐2,7-­‐diyl)bis(2-­‐(diethylamino)acetamide)	  (113):	  
Prepared	   from	   111	   (0.2	   g,	   0.45	   mmol)	   and	  
diethylamine	   (0.09	   ml,	   0.9	   mmol);	   yield:	  
34%;	  pale	  brown	  solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C25H34N4O2:	  C	  71.06,	  H	  8.11,	  N	  13.26;	   found:	  C	  
70.89,	  H	  7.98,	  N	  13.18.	  
Mp:	  210	  	  213	  °C	  
IR	  (KBr	  disk)	  ν:	  3260,	  1672,	  1434	  cm-­‐¹.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  10.41	  (br	  s,	  2H),	  7.92	  (s,	  2H),	  7.80	  (d,	  J	  =	  8.2	  Hz,	  2H),	  
7.60	  (d,	  J	  =	  8.2,	  2H),	  3.94	  (s,	  2H),	  3.82	  (s,	  4H),	  3.03	  (br	  s,	  8H),	  1.18	  (t,	  J	  =	  7.5,	  12H)	  
ppm.	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13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  171.3	  (2C),	  149.3	  (2C),	  142.4	  (2C),	  142.3	  (2C),	  125.4	  
(2C),	  123.8	  (2C),	  121.8	  (2C),	  60.5	  (2C),	  53.9	  (4C),	  42.3,	  15.7	  (4C)	  ppm.	  
	  
N,N'-­‐(9H-­‐fluorene-­‐2,7-­‐diyl)bis(2-­‐(diisopropylamino)acetamide)	  (114):	  
Prepared	   from	   111	   (0.2	   g,	   0.45	   mmol)	  
and	   diisopropylamine	   (0.13	   ml,	   0.9	  
mmol);	  yield:	  64%;	  pale	  brown	  solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C29H42N4O2:	  C	  72.77,	  H	  8.84,	  N	  11.70;	   found:	  C	  
72.89,	  H	  8.98,	  N	  11.48.	  
Mp:	  215	  	  218	  °C	  
IR	  (KBr	  disk)	  ν:	  3206,	  1655,	  1493	  cm-­‐¹.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  9.40	  (br	  s,	  2H),	  7.66	  (br	  s,	  2H),	  7.51	  (br	  s,	  2H),	  7.19	  
(br	  s,	  2H),	  3.66	  (s,	  2H),	  2.88	  (s,	  4H),	  2.27	  (br	  s,	  4H),	  0.80	  (br	  s,	  24H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  171.5	  (2C),	  144.1	  (2C),	  136.9	  (2C),	  120.1	  (2C),	  118.7	  
(2C),	  118.2	  (2C),	  116.2	  (2C),	  50.2	  (4C),	  50.1	  (2C),	  36.9,	  20.6	  (8C)ppm.	  
	  
N,N'-­‐(9H-­‐fluorene-­‐2,7-­‐diyl)bis(2-­‐(pyrrolidin-­‐1-­‐yl)acetamide	  (115):	  
Prepared	   from	   111	   (0.2	   g,	   0.45	   mmol)	   and	  
pyrrolidine	  (0.076	  ml,	  0.9	  mmol);	  yield:	  80%;	  
yellow	  solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C25H30N4O2:	  C	  71.74,	  H	  7.22,	  N	  13.39;	   found:	  C	  
71.51,	  H	  7.15,	  N	  13.23.	  
Mp:	  174	  –	  177	  °C	  
IR	  (KBr	  disk)	  ν:	  3324,	  1689,	  1475	  cm-­‐1.	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1H-­‐NMR	   (250	  MHz,	  DMSO)	  δ	  9.77	   (s,	  2H),	  7.94	   (s,	  2H),	  7.74	   (d,	   J	  =	  8.2	  Hz,	  2H),	  
7.59	  (d,	  J	  =	  8.2,	  2H),	  3.86	  (s,	  2H),	  3.26	  (s,	  4H),	  2.63	  –	  2.59	  (m,	  8H),	  1.80	  –	  1.78	  (m,	  
8H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  168.9	  (2C),	  143.8	  (2C),	  137.5	  (2C),	  136.7	  (2C),	  119.8	  




Prepared	   from	   111	   (0.2	   g,	   0.45	   mmol)	   and	  
imadazole	   (61	   mg,	   0.9	   mmol);	   yield	   57%;	  
pale	  brown	  solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C23H20N6O2:	  C	  66.98,	  H	  4.89,	  N	  20.38;	   found:	  C	  
66.85,	  H	  4.82,	  N	  20.28.	  
Mp:	  236	  	  239	  °C	  
IR	  (KBr	  disk)	  ν:	  3268,	  2932,	  1685,	  1666,	  1470,	  1299,	  1083,	  820	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  10.43	  (s,	  2H),	  7.87	  (s,	  2H),	  7.75	  (d,	  J	  =	  8.5	  Hz,	  2H),	  
7.65	  (s,	  2H),	  7.53	  (d,	  J	  =	  8.5	  Hz,	  2H),	  7.18	  (s,	  2H),	  6.90	  (s,	  2H),	  4.93	  (s,	  4H),	  3.89	  (s,	  
2H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  166.0	  (2C),	  144.0	  (2C),	  138.7	  (2C),	  137.6	  (2C),	  136.8	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N,N'-­‐(9H-­‐fluorene-­‐2,7-­‐diyl)bis(2-­‐(piperidin-­‐1-­‐yl)acetamide)	  (117):	  
Prepared	   from	  111	   (0.2	  g,	  0.45	  mmol)	   and	  
piperidine	   (0.09	  ml,	  0.9	  mmol);	   yield:	  73%;	  
orange	  solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C27H34N4O2:	  C	  72.62,	  H	  7.67,	  N	  12.55;	   found:	  C	  
72.16,	  H	  7.67,	  N	  12.28.	  
Mp:	  179	  –	  182	  °C	  
IR	  (KBr	  disk)	  ν:	  3298,	  1613	  cm-­‐1.	  
1H-­‐NMR	   (250	  MHz,	  DMSO)	  δ	  9.73	   (s,	  2H),	  7.92	   (s,	  2H),	  7.75	   (d,	   J	  =	  8.9	  Hz,	  2H),	  
7.59	  (d,	  J	  =	  8.9,	  2H),	  3.89	  (s,	  2H),	  3.09	  (s,	  4H),	  2.49	  –	  2.47	  (m,	  8H),	  1.59	  –	  1.55	  (m,	  
8H),	  1.43	  –	  1.41	  (m,	  4H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  168.8	  (2C),	  143.9	  (2C),	  137.4	  (2C),	  136.8	  (2C),	  119.9	  
(2C),	  118.5	  (2C),	  116.5	  (2C),	  63.1	  (2C),	  54.5	  (4C),	  36.9,	  25.9	  (4C),	  23.9	  (2C)	  ppm.	  
	  
N,N'-­‐(9H-­‐fluorene-­‐2,7-­‐diyl)bis(2-­‐morpholinoacetamide)	  (118):	  
Prepared	  from	  111	  (0.2	  g,	  0.45	  mmol)	  and	  
morpholine	   (0.08	   ml,	   0.9	   mmol);	   yield:	  
64%;	  yellow	  solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C25H30N4O4:	  C	  66.65,	  H	  6.71,	  N	  12.44;	   found:	  C	  
66.77,	  H	  6.32,	  N	  12.17.	  
Mp:	  204	  –	  207	  °C	  
IR	  (KBr	  disk)	  ν:	  3124,	  1689,	  1175	  cm-­‐1.	  
1H-­‐NMR	   (250	  MHz,	  DMSO)	  δ	  9.81	   (s,	  2H),	  7.93	   (s,	  2H),	  7.74	   (d,	   J	  =	  8.9	  Hz,	  2H),	  
7.58	   (d,	   J	   =	  8.9,	  2H),	  3.89	   (s,	  2H),	  3.66	   (t,	   8H)	  3.15	   (s,	  4H),	  2.54	  –	  2.51	   (m,	  8H)	  
ppm.	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13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  168.4	  (2C),	  143.9	  (2C),	  137.4	  (2C),	  136.9	  (2C),	  119.9	  
(2C),	  118.6	  (2C),	  116.7	  (2C),	  66.3	  (4C),	  62.3	  (2C),	  53.6	  (4C),	  37.0	  ppm.	  
	  
N,N'-­‐(9H-­‐fluorene-­‐2,7-­‐diyl)bis(2-­‐(4-­‐methylpiperazin-­‐1-­‐yl)acetamide)	  (119):	  
Prepared	   from	   111	   (0.2	   g,	   0.45	  
mmol)	  and	  4-­‐methylpiperazine	  (0.09	  
ml,	   0.9	   mmol);	   yield:	   72%;	   yellow	  
solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C27H36N6O2:	  C	  68.04,	  H	  7.61,	  N	  17.63;	  found:	  C	  
67.92,	  H	  7.26,	  N	  17.45.	  
Mp:	  139	  –	  142	  °C	  
IR	  (KBr	  disk)	  ν:	  3278,	  1683,	  1472	  cm-­‐1.	  
1H-­‐NMR	   (250	  MHz,	  DMSO)	  δ	  9.77	   (s,	  2H),	  7.93	   (s,	  2H),	  7.75	   (d,	   J	  =	  8.1	  Hz,	  2H),	  
7.59	  (d,	  J	  =	  8.1,	  2H),	  3.90	  (s,	  2H),	  3.14	  (s,	  4H),	  2.41	  –	  2.32	  (m,	  16H),	  2.20	  (s,	  6H)	  
ppm.	  
13C-­‐NMR	  (63	  MHz,	  CDCl3)	  δ	  168.7	  (2C),	  144.7	  (2C),	  138.0	  (2C),	  136.5	  (2C),	  120.2	  
(2C),	  118.6	  (2C),	  116.7	  (2C)	  62.3	  (2C),	  55.7	  (4C),	  53.9	  (4C),	  46.4	  (2C),	  37.5	  ppm.	  
	  
N,N'-­‐(9H-­‐fluorene-­‐2,7-­‐diyl)bis(2-­‐(4-­‐phenylpiperazin-­‐1-­‐yl)acetamide)	  (120):	  
Prepared	   from	   111	   (0.2	   g,	   0.45	  
mmol)	   and	   1-­‐phenylpiperazine	  
(0.14	  ml,	  0.9	  mmol);	   yield:	  67%;	  
yellow	  solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C37H40N6O2:	  C	  73.97,	  H	  6.71,	  N	  13.99;	   found:	  C	  
73.59,	  H	  6.66,	  N	  13.82.	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Mp:	  224	  –	  227°C	  
IR	  (KBr	  disk)	  ν:	  3291,	  2825,	  1681	  cm-­‐1.	  
1H-­‐NMR	   (250	  MHz,	  CDCl3)	  δ	  9.27	   (s,	   2H),	  7.93	   (s,	   2H),	  7.70	   (d,	   J	   =	  8.2	  Hz,	  2H),	  
7.48	  (d,	  J	  =	  8.25,	  2H),	  7.36	  –	  7.29	  (m,	  4H),	  7.01	  –	  6.90	  (m,	  6H),	  3.93	  (s,	  2H),	  3.34	  –	  
3.31	  (m,	  8H),	  3.27	  (s,	  4H),	  2.87	  –	  2.85	  (m,	  8H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  CDCl3)	  δ	  168.4	  (2C),	  151.4	  (2C),	  144.7	  (2C),	  138.1	  (2C),	  136.5	  
(2C),	  129.7	   (4C),	  120.6	   (2C),	  120.2	   (2C),	  118.6	   (2C),	  116.8	   (2C),	  116.7	   (4C),	  62.4	  
(2C),	  54.0	  (4C),	  49.9	  (4C),	  37.6	  ppm.	  
	  
9.4.3.	  Preparation	  of	  the	  carbazole	  derivatives	  
9.4.3.1.	  Nitration	  of	  carbazole	  
	  
Carbazole	   (10.03	   g,	   60.0	   mmol)	   was	   dissolved	   in	   glacial	   AcOH	   (80	   ml).	   The	  
mixture	  was	  stirred	  for	  1.5	  h	  at	  40	  °C.	  Then,	  a	  mixture	  of	  30%	  HNO3-­‐AcOH	  (1:1,	  
16.4	  ml)	  was	  added	  dropwise	  and	  the	  solution	  was	  stirred	  for	  16	  h	  at	  90-­‐100	  °C.	  
The	  brown	  precipitate	  was	  filtered	  and	  washed	  with	  cold	  AcOH	  (50	  ml)	  and	  then	  
with	  water.	  The	  solid	  was	  warmed	   in	  KOH/EtOH	  (200	  ml,	  60	  g/l)	  at	  50°C	  for	  30	  
min	  and	  filtered.	  Water	  was	  added	  and	  the	  yellow	  precipitate	  was	  filtered.	  The	  
insoluble	   solid	  was	  digested	   in	  10%	  HCl	  at	  100	   °C	   for	  2	  h.	  The	   insoluble	  yellow	  
solid	   was	   filtered,	   washed	  with	  water,	   and	   dried	   overnight	   in	   the	   presence	   of	  
P2O5.	  Chromatography	  on	  neutral	  alumina,	  eluting	  with	  EtOAc:petroleum	  ether	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(50:50),	   followed	  by	  EtOAc	  and	  then	  EtOAc:MeOH	  (145:5),	  provided	  compound	  
121	  and	  122.	  
	  
3,6-­‐dinitro-­‐9H-­‐carbazole	  and	  3-­‐nitro-­‐9H-­‐	  carbazole	  (121):	  
Yield:	  20%;	  orange	  solid.	  
Mp	  >	  300	  °C	  
IR	  (KBr	  disk):	  3379,	  1611,	  1584,	  1510,	  1335,	  1306	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  12.72	  (br	  s,	  1H),	  9.50	  (d,	  J	  =	  2.2,	  2H),	  8.40	  (dd,	  J	  =	  
9.0,	  2.2	  Hz,	  2H),	  7.77	  (d,	  J	  =	  9.0	  Hz,	  2H)	  ppm.	  
	  
3-­‐nitro-­‐9H-­‐carbazole	  (122):	  
Yield:	  20%;	  red	  solid.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  12.10	  (	  brs,	  1H),	  9.19	  (s,	  1H),	  8.39	  
(d,	  J	  =	  7.5	  Hz,	  1H),	  8.31	  (d,	  J	  =	  10	  Hz,	  1H),	  7.66	  –	  7.60	  (m,	  2H),	  
7.53	  (t,	  J	  =7.6	  Hz,	  1H),	  7.30	  (t,	  J	  =	  7.3	  Hz,	  1H)	  ppm.	  
	  
9.4.3.2.	  9H-­‐carbazole-­‐3,6-­‐diamine	  (123):	  
	  
A	   mixture	   of	   121	   (0.500	   g,	   1.944	   mmol),	   iron	   powder	   (2.50	   g)	   and	   37%	   HCl	  
aqueous	  solution	  (3.8	  ml)	   in	  40	  ml	  of	  a	  mixture	  of	  EtOH,	  AcOH	  and	  H2O	  (2:2:1)	  
was	   refluxed	   for	   4h	  with	  magnetic	   stirring.	   The	   solution	  was	   filtered	   on	   celite,	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diluted	  with	  water	  (50	  ml)	  and	  extracted	  with	  EtOAc	  (3	  x	  100	  ml).	  The	  combined	  
organic	   layers	  were	  washed	  with	   saturated	  NaHCO3	   aqueous	   solution	   (200	  ml)	  
and	   H2O	   (2	   x	   200	   ml)	   and	   dried	   over	   anhydrous	   Na2SO4.	   Evaporation	   of	   the	  
solvent	  afforded	  compound	  123	  as	  a	  greyish	  yellow	  solid	  in	  96%	  yield.	  
IR	  (KBr	  disk):	  3428,	  2364,	  2344,	  1735,	  1636,	  1097	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  10.13	  (s,	  1H),	  7.09	  –	  7.05	  (m,	  4H),	  6.67	  (d,	  J	  =	  8.8	  Hz,	  
2H),	  4.60	  (br	  s,	  4H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  140.7	  (2C),	  133.9	  (2C),	  123.3	  (2C),	  115.1	  (2C),	  111.3	  
(2C),	  104.1	  (2C)	  ppm.	  
	  
9.4.3.3.	  N,N'-­‐(9H-­‐carbazole-­‐3,6-­‐diyl)bis(2-­‐bromoacetamide)	  (124):	  
	  
A	  solution	  of	  9H-­‐carbazole-­‐3,6-­‐diamine	  123	  (0.200	  g,	  1.014	  mmol),	  bromoacetyl	  
bromide	  (0.511	  g,	  2.535	  mmol)	  and	  DMAP	  (0.309	  g,	  2.535	  mmol)	  in	  dry	  THF	  (10	  
mL)	  was	  stirred	  under	  argon	  for	  24	  h.	  When	  the	  reaction	  was	  finished,	  THF	  was	  
removed	  and	  an	  aqueous	  solution	  of	  2N	  HCl	  (7	  mL)	  was	  added	  and	  stirred	  for	  1	  
h.	   The	   solid	   was	   filtered	   and	   washed	   with	   water.	   The	   product,	   after	   dried	  
overnight	   under	   reduced	   pressure	   in	   the	   presence	   of	   P2O5,	   was	   identified	   as	  
compound	  124	  and	  appeared	  as	  a	  grey	  brown	  solid	  in	  80%	  yield.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  11.22	  (s,	  1H),	  10.41	  (s,	  2H),	  8.39	  (s,	  2H),	  7.48	  –	  7.56	  
(m,	  4H),	  4.09	  (s,	  4H)	  ppm.	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13C	  NMR	  (63	  MHz,	  DMSO)	  δ	  165.5	  (2C),	  134.6	  (2C),	  131.1	  (2C),	  122.6	  (2C),	  118.9	  
(2C),	  116.9	  (2C),	  113.7	  (2C),	  31.4	  (2C)	  ppm.	  
	  
9.4.3.4.	  Amino-­‐carbazole	  derivatives	  
To	  a	  stirred	  mixture	  of	  compound	  124	  (0.200	  g,	  0.445	  mmol)	  in	  2	  ml	  of	  dry	  DMF	  
was	   added	   two	   equivalents	   of	   the	   suitable	   amine.	   The	   reaction	   mixture	   was	  
stirred	  while	  heated	  at	  75	  °C	  for	  24	  h.	  The	  mixture	  was	  cooled,	  and	  then	  diluted	  
with	  EtOAc	  (5	  ml),	  washed	  with	  H2O	  (3	  x	  2	  ml),	  dried	  over	  anhydrous	  Na2SO4	  and	  
concentrated	  under	  reduced	  pressure	  to	  give	  compounds	  125-­‐133.	  
	  
Cmpd.	   R2NH	   	   Cmpd.	   R2NH	  
125	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  9.	  Experimental	  section	  
N,N'-­‐(9H-­‐carbazole-­‐3,6-­‐diyl)bis(2-­‐(dimethylamino)acetamide)	  (125):	  
Prepared	   from	   123	   (0.200	   g,	   0.445	   mmol)	  
and	   dimethylamine	   (0.046	  ml,	   0.91	  mmol);	  
yield:	  58%;	  reddish	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C20H25N5O2:	  
C	  65.37,	  H	  6.66,	  N	  19.06;	  found:	  C	  65.09,	  H	  6.31,N	  19.35.	  
Mp:	  131	  –	  134	  °C	  
IR	  (KBr	  disk):	  3279,	  1667,	  1586,	  868	  cm-­‐1.	  
1H-­‐NMR	   (250	  MHz,	  DMSO)	  δ	  9.71	   (br	   s,	   2H),	   8.41	   (s,	   2H),	   7.57	  –	  7.54	   (m,	  2H),	  
7.41	  –	  7.38	  (m,	  2H),	  3.11	  (s,	  4H),	  2.33	  (s,	  12H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  168.5	  (2C),	  137.3	  (2C),	  130,7	  (2C),	  122.4	  (2C),	  119.5	  
(2C),	  111.4	  (2C),	  111.2	  (2C),	  63.7	  (2C),	  45.8	  (4C)	  ppm.	  
	  
N,N'-­‐(9H-­‐carbazole-­‐3,6-­‐diyl)bis(2-­‐(diethylamino)acetamide)	  (126):	  
Prepared	  from	  123	   (0.200	  g,	  0.445	  mmol)	  and	  
diethylamine	   (0.094	   ml,	   0.91	   mmol);	   yield:	  
60%;	  brown	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C24H29N5O2:	  C	  
68.06,	  H	  7.85,	  N	  16.53;	  found:	  C	  67.8,	  H	  7.55,	  N	  16.44.	  
Mp:	  134	  –	  137	  °C	  
IR	  (KBr	  disk):	  3269,	  2968,	  1870,	  1584,	  1297,	  808	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  9.65	  (br	  s,	  2H),	  8.39	  (d,	  J	  =	  1.6	  Hz),	  7.58	  (dd,	  J	  =	  8.7,	  
1.9	  Hz,	  2H),	  7.40	  (d,	  J	  =	  8.6	  Hz,	  2H),	  3.18	  (s,	  4H),	  2.65	  (q,	  J	  =	  7.1	  Hz,	  8H),	  1.07	  (t,	  J	  =	  
7.1	  Hz,	  12H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  169.6	  (2C),	  137.3	  (2C),	  130.5	  (2C),	  122.5	  (2C),	  119.3	  
(2C),	  111.3	  (2C),	  111.2	  (2C),	  57.9	  (2C),	  48.3	  (4C),	  12.4	  (4C')	  ppm.	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N,N'-­‐(9H-­‐carbazole-­‐3,6-­‐diyl)bis(2-­‐(diisopropylamino)acetamide)	  (127):	  
Prepared	   from	   123	   (0.200	   g,	   0.445	   mmol)	  
and	  diisopropilamine	   (0.13	  ml,	   0.91	  mmol);	  
yield:	  47%;	  brown	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C28H41N5O2:	  
C	  70.11,	  H	  8.62,	  N	  14.60;	  found:	  C	  69.90,	  H	  8.37,	  N	  14.34.	  
mp:	  138	  –	  141	  °C	  
IR	  (KBr	  disk):	  3279,	  2945,	  1667,	  1586,	  1538,	  868	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  11.14	  (br	  s,	  1H),	  9.60	  (br	  s,	  2H),	  8.36	  (s,	  2H),	  7.62	  (d,	  
J	  =	  8.1	  Hz),	  7.42	  (d,	  J	  =	  8.1	  Hz,	  2H),	  3.13	  (s,	  8H),	  1.08	  (d,	  J	  =	  5.5	  Hz,	  24H)	  ppm.	  
13C-­‐NMR	   (63	  MHz,	  DMSO)	  δ	  171.09	  (2C),	  137.40	  (2C),	  130.30	  (2C),	  122.52	  (2C),	  
119.14	  (2C),	  111.28	  (2C),	  111.23	  (2C),	  50.22	  (2C),	  50.09	  (4C),	  20.64	  (8C)	  ppm.	  
	  
N,N'-­‐(9H-­‐carbazole-­‐3,6-­‐diyl)bis(2-­‐(pyrrolidin-­‐1-­‐yl)acetamide)(128):	  
Prepared	  from	  123	   (0.200	  g,	  0.445	  mmol)	  and	  
pyrrolidine	   (0.076	  ml,	  0.91	  mmol);	   yield:	  40%;	  
reddish	  solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C24H29N5O2:	  C	  
68.71,	  H	  6.97,	  N	  16.69;	  found:	  C	  68.32,	  H	  6.59,	  N	  16.33.	  
Mp:	  169	  –	  172	  °C	  
IR	  (KBr	  disk):	  3399,	  1654,	  1560,	  1492,	  1228,	  814	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  11.12	  (br	  s,	  1H),	  9.78	  (br	  s,	  2H),	  8.39	  (s,	  2H),	  7.54	  (d,	  
J	   =	   7.5	   Hz,	   2H),	   7.42	   (s,	   2H),	   3.38	   (s,	   4H,	   overlapped	   with	   the	   residual	   DMSO	  
signal),	  2.72	  (s,	  8H),	  1.81	  (s,	  8H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  168.0	  (2C),	  137.3	  (2C),	  130.7	  (2C),	  122.4	  (2C),	  119.5	  
(2C),	  111.3	  (2C),	  108.9	  (2C),	  59.5	  (2C),	  54.2	  (4C),	  23.8	  (4C)	  ppm.	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  9.	  Experimental	  section	  
N,N'-­‐(9H-­‐carbazole-­‐3,6-­‐diyl)bis(2-­‐(1H-­‐imidazol-­‐1-­‐yl)acetamide)(129):	  
Prepared	  from	  123	  (0.200	  g,	  0.445	  mmol)	  and	  
imidazole	   (0.077	   g,	   0.91	   mmol);	   yield:	   38%;	  
black	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C22H19N7O2:	  C	  
63.91,	  H	  4.63,	  N	  23.72;	  found:	  C	  63.53,	  H	  4.48,	  N	  23.34.	  
Mp:	  193	  –	  196	  °C	  
IR	  (KBr	  disk):	  3854,	  1654,	  1493,	  1400,	  1297,	  814	  cm	  -­‐1.	  
1H-­‐NMR	   (250	  MHz,	  DMSO)	  δ	  10.38	   (br	   s,	   1H),	  8.32	   (s,	   2H),	  7.69	   (s,	   2H),	  7.50	  –	  
7.45	  (m,	  4H),	  7.22	  (s,	  2H),	  6.93	  (s,	  2H),	  3.20	  (s,	  4H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  166.0	  (2C),	  139.1	  (2C),	  137.8	  (2C),	  128.8	  (2C),	  122.9	  
(2C),	  121.5	  (2C),	  119.7	  (2C),	  112.1	  (2C),	  112.0	  (2C),	  111.5	  (2C),	  50.1	  (2C)	  ppm.	  
	  
N,N'-­‐(9H-­‐carbazole-­‐3,6-­‐diyl)bis(2-­‐(piperidin-­‐1-­‐yl)acetamide)(130):	  
Prepared	   from	   123	   (0.200	   g,	   0.445	   mmol)	  
and	  piperidine	  (0.089	  ml,	  0.91	  mmol);	  yield:	  
55%;	  brown	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C26H33N5O2:	  
C	  69.77,	  H	  7.43,	  N	  15.65;	  found:	  C	  69.39,	  H	  7.05,	  N	  15.97.	  
Mp:	  161	  –	  164°C	  
IR	  (KBr	  disk):	  3278.0,	  2933.1,	  2811.4,	  1664.6,	  1584.6,	  1533.4,	  1492,	  745.7,	  642.7	  
cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  10.74	  (br	  s,	  1H),	  9.27	  (br	  s,	  2H),	  8.01	  (s,	  2H),	  7.16	  (s,	  
2H),	  7.04	  (s,	  2H),	  3.00	  (s,	  4H),	  2.13	  (s,	  8H),	  1.22	  –	  0.84	  (m,	  12H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  168.4	  (2C),	  137.3	  (2C),	  130.6	  (2C),	  122.5	  (2C),	  119.5	  
(2C),	  111.4	  (2C),	  111.2	  (2C),	  63.1	  (2C),	  54.6	  (4C),	  25.9	  (4C),	  24.0	  (2C)	  ppm.	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N,N'-­‐(9H-­‐carbazole-­‐3,6-­‐diyl)bis(2-­‐morpholinoacetamide)	  (131):	  
Prepared	   from	   123	   (0.200	   g,	   0.445	  mmol)	  
and	   morpholine	   (0.082	   ml,	   0.91	   mmol);	  
yield:	  48%;	  brown	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	  
C24H29N5O4:	  C	  63.84,	  H	  6.47,	  N	  15.51;	  found:	  C	  63.67,	  H	  6.17,	  N	  15.55.	  
Mp:	  171	  –	  174	  °C	  
IR	  (KBr	  disk):	  3288,	  1668,	  1494,	  1297,	  911	  cm	  -­‐1.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  11.08	  (br	  s,	  1H),	  9.69	  (br	  s,	  2H),	  8.34	  (s,	  2H),	  7.50	  (d,	  
J	  =	  8.1	  Hz,	  2H),	  7.36	  (d,	  J	  =	  8.5	  Hz,	  2H),	  3.33	  (s,	  8H),	  3.12	  (s,	  4H),	  2.47	  (s,	  8H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  167.92	  (2C),	  137.3	  (2C),	  130.6	  (2C),	  122.4	  (2C),	  119.6	  
(2C),	  111.6	  (2C),	  111.2	  (2C),	  66.5	  (4C),	  62.5	  (2C),	  53.7	  (4C)	  ppm.	  
	  
N,N'-­‐(9H-­‐carbazole-­‐3,6-­‐diyl)bis(2-­‐(4-­‐methylpiperazin-­‐1-­‐yl)acetamide)(132):	  
Prepared	   from	   123	   (0.200	   g,	   0.445	  
mmol)	   and	   1-­‐methyl-­‐piperazine	  
(0.10	   ml,	   0.91	   mmol);	   yield:	   30%;	  
reddish	  solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C26H35N7O2:	  C	  65.38,	  H	  7.39,	  N	  20.53;	   found:	  C	  
65.03,	  H	  7.05,	  N	  20.78.	  
Mp:	  185	  –	  188	  °C	  
IR	  (KBr	  disk):	  3409,	  2948,	  1654,	  1542,	  1492,	  1459	  cm	  -­‐1.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  11.20	  (br	  s,	  1H),	  9.89	  (	  br	  s,	  2H),	  8.43	  (s,	  2H),	  7.55	  
(d,	  J	  =	  8.2	  Hz,	  2H),	  7.43	  (d,	  J	  =	  8.7Hz,	  2H),	  3.55	  –	  3.11	  (m,	  10H),	  2.79	  (s,	  6H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  164.7	  (2C),	  137.4	  (2C),	  130.6	  (2C),	  122.4	  (2C),	  120.8	  
(2C),	  111.4	  (2C),	  111.3	  (2C),	  65.3	  (2C),	  53.1	  (4C),	  49.9	  (2C),	  42.8	  (4C)	  ppm.	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N,N'-­‐(9H-­‐carbazole-­‐3,6-­‐diyl)bis(2-­‐(4-­‐phenylpiperazin-­‐1-­‐yl)acetamide)(133):	  
Prepared	   from	   123	   (0.200	   g,	  
0.445	   mmol)	   and	   1-­‐
phenylpiperazine	   (0.14	   ml,	  
0.91	  mmol);	  yield:	  40%;	  brown	  
solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C36H39N7O2:	  C	  71.86,	  H	  6.53,	  N	  16.29;	   found:	  C	  
71.48,	  H	  6.29,	  N	  15.97.	  
Mp:	  176	  –	  179	  °C	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  11.16	  (br	  s,	  1H),	  9.87	  (br	  s,	  2H),	  8.42	  (s,	  2H),	  7.57	  (d,	  
J	  =	  8.3	  Hz,	  2H),	  7.42	  (d,	  J	  =	  8.4	  Hz,	  2H),	  7.27	  –	  7.21	  (m,	  4H),	  6.83	  –	  6.77	  (m,	  4H),	  
6.81	  (d,	  J	  =	  7.0	  Hz,	  2H),	  3.28	  (s,	  12H),	  2.81	  (s,	  8H)	  ppm.	  
13C-­‐NMR	  (63	  MHz,	  DMSO)	  δ	  151.2	  (2C),	  137.4	  (2C),	  130.6	  (2C),	  129.3	  (4C),	  122.4	  
(2C),	  119.9	   (2C),	  119.6	   (2C),	  119.3	   (2C),	  115.8	   (4C),	  111.6	   (2C),	  111.3	   (2C),	  53.0	  
(6C),	  48.2	  (4C)	  ppm.	  
	  
9.4.4.	  Non-­‐symmetric	  carbazole	  derivative	  
9.4.4.1.	  9H-­‐carbazol-­‐3-­‐amine	  (134):	  
	  
A	   mixture	   of	   122	   (0.100	   g,	   0.472	   mmol),	   iron	   powder	   (2.50	   g)	   and	   37%	   HCl	  
aqueous	  solution	  (3.8	  ml)	   in	  40	  ml	  of	  a	  mixture	  of	  EtOH,	  AcOH	  and	  H2O	  (2:2:1)	  
was	   refluxed	   for	  4	  h	  with	  magnetic	   stirring.	  The	  solution	  was	   filtered	  on	  celite,	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diluted	  with	  water	  (50	  ml)	  and	  extracted	  with	  EtOAc	  (3	  x	  100	  mL).	  The	  combined	  
organic	  layers	  were	  washed	  with	  saturated	  aqueous	  NaHCO3	  (200	  ml)	  and	  H2O	  (2	  
x	  200	  ml)	  and	  dried	  over	  anhydrous	  Na2SO4.	  Evaporation	  of	  the	  solvent	  afforded	  
compound	  134	  as	  a	  yellow	  solid	  in	  95%	  yield.	  
1H-­‐NMR	   (250	  MHz,	  d6-­‐acetone,)	  δ	  10.29	  (s,	  1H),	  8.08	  (d,	  J	  =	  7.5	  Hz,	  1H),	  7.52	  –	  
7.35	   (m,	  4H),	  7.19	  –	  7.13	   (m,	  1H),	  6.81	   (dd,	   J	  =	  8.5,	  2.0	  Hz,	  1H),	  3.06	   (br	  s,	  2H)	  
ppm.	  
	  
9.4.4.2.	  2-­‐bromo-­‐N-­‐(9H-­‐carbazol-­‐3-­‐yl)acetamide	  (135):	  
	  
A	   solution	  of	  134	   (0.100	  g,	   0.507	  mmol),	   bromoacetyl	   bromide	   (0.102	  g,	   0.507	  
mmol),	  DMAP	  (0.062	  g,	  0.507	  mmol)	  in	  dry	  THF	  (10	  ml)	  was	  stirred	  under	  argon	  
for	  24	  hours.	  When	  the	  reaction	  was	  finished,	  an	  aqueous	  solution	  of	  2N	  HCl	  (7	  
mL)	  was	  added	  and	  the	  solution	  was	  stirred	  for	  1h.	  An	  extraction	  with	  EtOAc	  (3	  x	  
15	  ml)	  afforded	  the	  organic	   layer,	  that	  was	  washed	  with	  water	  (3	  x	  15	  mL)	  and	  
then	  was	  dried	  over	  anhydrous	  Na2SO4.	  Evaporation	  afforded	  compound	  135	  as	  a	  
yellow-­‐grey	  solid	  in	  80%	  yield.	  
1H-­‐NMR	  (250	  MHz,	  DMSO)	  δ	  11.28	  (s,	  1H),	  10.45	  (s,	  1H),	  8.44	  (s,	  1H),	  8.08	  (d,	  J	  =	  
7.7	  Hz,	  1H),	  7.58	  –	  7.44	  (m,	  3H),	  7.41	  (t,	  J	  =	  7.6	  Hz,	  1H),	  7.17	  (t,	  J	  =	  7.4	  Hz,	  1H),	  
4.13	  (s,	  2H)	  ppm.	  
13C-­‐NMR	   (63	   MHz,	   DMSO)	   δ	   165.2,	   141.2,	   137.5,	   131.2,	   126.6,	   123.2,	   123.0,	  
121.0,	  119.7,	  119.4,	  112.1,	  112.0,	  111.9,	  31.6	  ppm.	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9.4.4.3.	  N-­‐(9H-­‐carbazol-­‐3-­‐yl)-­‐2-­‐(pyrrolidin-­‐1-­‐yl)acetamide	  (136):	  
	  
Compound	  135	  (0.050	  g,	  0.114	  mmol)	  and	  pyrrolidine	  (0.21	  ml,	  0.25	  mmol)	  were	  
refluxed	  in	  THF	  (8	  ml)	  for	  24	  h.	  THF	  was	  removed	  to	  give	  an	  yellow	  oil	  that	  was	  
purified	   by	   chromatography	   on	   neutral	   alumina,	   eluting	  with	   EtOAc:Petroleum	  
ether	  (50:50),	  to	  isolate	  compound	  136	  as	  a	  yellow-­‐grey	  solid	  in	  89%	  yield.	  
Elemental	   analysis	   (%)	   calcd	   for	  C18H19N3O:	  C	  73.69,	  H	  6.53,	  N	  14.32;	   found:	  C	  
73.32,	  H	  6.57,	  N	  13.95.	  
Mp:	  146	  –	  149	  °C	  
IR	  (KBr	  disk):	  3406,	  3328,	  2962,	  1676,	  1560,	  817	  cm-­‐1.	  
1H-­‐NMR	  (250	  MHz,	  d6-­‐acetone)	  δ	  9.23	  (br	  s,	  1H),	  8.62	  (	  br	  s,	  1H),	  8.35	  (d,	  J	  =	  1.8	  
Hz,	  1H),	  8.07	  (d,	  J	  =	  7.8	  Hz,	  1H),	  7.54	  (dd,	  J	  =	  8.6,	  2.0	  Hz,	  1H),	  7.41	  (d,	  J	  =	  3.8	  Hz,	  
2H),	  7.36	  –	  7.29	  (m,	  1H),	  7.26	  –	  7.19	  (m,	  1H),	  3.38	  (s,	  2H),	  2.76	  –	  2.74	  (m,	  4H),	  
1.94	  –	  1.88	  (m,	  4H)	  ppm.	  
13C-­‐NMR	   (63	   MHz,	   d6-­‐acetone,)	   δ	   169.64,	   140.7,	   137.2,	   130.4,	   126.4,	   123.9,	  
123.6,	  121.0,	  119.6	  (2C),	  112.5,	  111.2,	  111.2,	  60.2,	  55.1	  (2C),	  24.5	  (2C)	  ppm.	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9.5.	  Synthesis	  of	  styrylquinolines	  
9.5.1.	  Preparation	  of	  styrylquinoline	  compounds	  by	  using	  the	  Povarov	  reaction	  
9.5.1.1.	  Synthesis	  of	  cinnamaldheyde	  compounds	  
To	  a	  stirred	  solution	  of	  the	  suitable	  aryl	  iodides	  (0.5	  mmol)	  in	  2	  ml	  of	  DMF	  were	  
added	   acrolein	   diethyl	   acetal	   (1.5	   mmol)	   Bu4NOAc	   (1.0	   mmol),	   K2CO3	   (0.75	  
mmol),	  KCl	  (0.5	  mmol)	  and	  Pd(OAc)2	  (0.015	  mmol).	  The	  mixture	  was	  stirred	  for	  2	  
h	  at	  90	  °C.	  After	  cooling,	  2N	  HCl	  was	  slowly	  added	  and	  the	  solution	  was	  stirred	  
for	  10	  min.	  Then,	  it	  was	  diluted	  with	  ether	  and	  washed	  with	  water.	  The	  organic	  
layer	   was	   dried	   with	   anhydrous	   Na2SO4	   and	   concentrated	   under	   reduced	  
pressure.	  The	  residue	  was	  purified	  by	  chromatography	  to	  give	  141-­‐145.	  
	  
(E)-­‐2-­‐chlorocinnamaldehyde	  (141):	  
Prepared	  from	  1-­‐chloro-­‐2-­‐iodobenzene	  (0.119	  g,	  0.5	  mmol)	  and	  
acrolein	   diethyl	   acetal	   (0.195	   g,	   1.5	   mmol);	   yield	   70%;	   yellow	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solid.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  9.79	  (d,	  J	  =	  7.7	  Hz,	  1H),	  7.97	  (d,	  J	  =	  16.0	  Hz,	  1H),	  7.70	  
(dd,	  J	  =	  7.2,	  2.0	  Hz,	  1H),	  7.51	  –	  7.33	  (m,	  3H),	  6.74	  (dd,	  J	  =	  16.0,	  7.7	  Hz,	  1H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   DMSO)	   δ	   195.0,	   167.5,	   147.7,	   139.1,	   133.9,	   130.3,	   128.6,	  
128.1,	  122.6	  ppm.	  
	  
(E)-­‐3-­‐chlorocinnamaldehyde(142):	  
Prepared	   from	  1-­‐chloro-­‐3-­‐iodobenzene	   (0.119	   g,	   0.5	  mmol)	  
and	   acrolein	   diethylacetal	   (0.195	   g,	   1.5	   mmol);	   yield	   80%;	  
yellow	  solid.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  9.71	  (d,	  J	  =	  7.6	  Hz,	  1H),	  7.54	  –	  7.53	  (m,	  1H),	  7.47	  –	  
7.37	  (m,	  4H),	  6.70	  (dd,	  J	  =	  16.0,	  7.6	  Hz,	  1H)	  ppm.	  




Prepared	   from	  1-­‐chloro-­‐4-­‐iodobenzene	   (0.119	   g,	   0.5	  mmol)	  
and	   acrolein	   diethyl	   acetal	   (0.195	   g,	   1.5	  mmol);	   yield	   83%;	  
yellow	  solid.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  9.73	  (d,	  J	  =	  7.6	  Hz,	  1H),	  7.55	  –	  7.42	  (m,	  5H),	  6.72	  (dd,	  
J	  =	  16.0,	  7.6	  Hz,	  1H)	  ppm.	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(E)-­‐2-­‐methoxycinnamaldehyde	  (144):	  
Prepared	   from1-­‐iodo-­‐2-­‐methoxybenzene(0.117	   g,	   0.5	   mmol)	  
and	   acrolein	   diethyl	   acetal	   (0.195	   g,	   1.5	   mmol);	   yield:57%;	  
yellow	  solid.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  9.72	  (d,	  J	  =	  7.9	  Hz,	  1H),	  7.88	  (d,	  J	  =	  16.1	  Hz,	  1H),	  7.58	  
(dd,	  J	  =	  7.7,	  1.7	  Hz,	  1H),	  7.45	  (ddd,	  J	  =	  8.4,	  7.5,	  1.7	  Hz,	  1H),	  7.13	  –	  6.91	  (m,	  2H),	  
6.82	  (dd,	  J	  =	  16.1,	  7.9	  Hz,	  1H),	  3.95	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  195.0,	  158.7,	  148.7,	  133.2,	  129.4,	  129.3,	  123.3,	  121.3,	  
111.7,	  56.0	  ppm.	  
	  
(E)-­‐4-­‐methylcinnamaldehyde	  (145):	  
Prepared	  from1-­‐iodo-­‐4-­‐methylbenzene	  (0.109	  g,	  0.5	  mmol)	  
and	  acrolein	  diethyl	  acetal	  (0.195	  g,	  1.5	  mmol);	  yield:	  81%;	  
white	  solid.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  9.70	  (d,	  J	  =	  7.7	  Hz,	  1H),	  7.50	  –	  7.44	  (m,	  3H),	  7.26	  (d,	  J	  
=	  8.0	  Hz,	  2H),	  6.70	  (dd,	  J	  =	  15.9,	  7.7	  Hz,	  1H),	  2.42	  (s,	  3H)	  ppm.	  
	  
9.5.1.2.	  Synthesis	  of	  2-­‐styrlquinolines	  
An	  equimolar	   (3	  mmol)	  mixture	  of	   the	   suitable	   arylamine	   and	   cinnamaldehyde	  
was	  dissolved	   in	  acetonitrile	   (20	  ml)	  at	   r.t.	  Ethyl	  vinyl	  ether	   (0.320	  g,	  4.5	  mmol)	  
and	   15	  mol%	  of	   cerium	   ammonium	  nitrate	   (CAN),	   0.247	   g,	  were	   added	   to	   the	  
stirred	   solution,	   and	   stirring	   was	   continued	   for	   5	   h.	   Upon	   completion	   of	   the	  
reaction,	  as	  indicated	  by	  TLC,	  the	  mixture	  was	  extracted	  with	  dichloromethane	  (2	  
x	  20	  ml),	  dried	  (anhydrous	  Na2SO4)	  and	  evaporated.	  The	  resulting	  crude	  product	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was	   dissolved	   in	   20	   ml	   of	   benzene	   and	   2,3-­‐dichloro-­‐5,6-­‐dicyano-­‐1,4-­‐
benzoquinone	  (DDQ)	  (0.454	  g,	  2	  mmol)	  was	  added	  slowly.	  The	  black	  suspension	  
was	   stirred	   for	   3	  h	   at	   r.t.	  Upon	   completion	   of	   the	   reaction,	   CH2Cl2	   (30	  ml)	   and	  
water	   (10	   ml)	   were	   added,	   and	   the	   mixture	   was	   thoroughly	   shaken	   with	  
saturated	   aqueous	   NaHCO3	   solution	   (5	   ml)	   to	   get	   clear	   layer	   separation.	   The	  
organic	   layer	   was	   separated	   and	   the	   aqueous	   layer	   was	   again	   extracted	   with	  
CH2Cl2	  (30	  ml).	  The	  combined	  organic	  layers	  were	  dried	  (anhydrous	  Na2SO4)	  and	  
evaporated.	   The	   crude	   product	   was	   purified	   through	   silica	   gel	   column	   using	   a	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  (E)-­‐6-­‐methyl-­‐2-­‐styrylquinoline	  (137):	  
Prepared	   from	   p-­‐toluidine	   (0.321	   g,	   3	   mmol)	   and	  
cinnamaldehyde	   (0.396	  g,	  3	  mmol);	  overall	   yield:	  69%;	  
white	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C18H15N:	  C	  88.13,	  H	  6.16,	  N	  5.71;	  found:	  C	  87.96,	  
H	  6.08,	  N	  5.60.	  
Mp:	  129	  –	  132	  °C	  
IR	  (neat)	  ν:	  3028,	  2909,	  1634,	  1590,	  1496,	  1445,	  1371,	  1122	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.06	  (d,	  J	  =	  8.7	  Hz,	  1H),	  8.01	  (d,	  J	  =	  9.2	  Hz,	  1H),	  7.71	  –	  
7.65	  (m,	  4H),	  7.58	  –	  7.55	  (m,	  2H),	  7.46	  –	  7.35	  (m,	  4H),	  2.56	  (s,	  3H).	  ppm.	  	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  155.5,	  147.2,	  137.0,	  136.5,	  136.2,	  134.3,	  132.5,	  129.5,	  
129.2,	  129.2	  (2C),	  128.9,	  127.8,	  127.6	  (2C),	  126.9,	  119.7,	  22.0	  ppm.	  
	  
(E)-­‐6-­‐methoxy-­‐2-­‐styrylquinoline	  (138):	  
Prepared	   from	   p-­‐anisidine	   (0.370	   g,	   3	   mmol)	   and	  
cinnamaldehyde	  (0.396	  g,	  3	  mmol);	  overall	  yield:	  72%;	  
yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C18H15NO:	   C	   82.73,	   H	   5.79,	   N	   5.36.	   found:	   C	  
82.52,	  H	  5.65,	  N	  5.17.	  
Mp:	  133	  –	  136	  
IR	  (neat)	  ν:	  3028,	  2935,	  1618,	  1597,	  1557,	  1500,	  1478,	  1336,	  1162,	  1113	  cm-­‐1. 
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.05	  (d,	  J	  =	  6.7	  Hz,	  1H),	  8.01	  (d,	  J	  =	  7.2	  Hz,	  1H),	  7.68	  –	  
7.62	  (m,	  4H),	  7.46	  –	  7.34	  (m,	  5H),	  7.08	  (d,	  J	  =	  2.7	  Hz,	  1H),	  3.96	  (s,	  3H).	  ppm.	  	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  158.1,	  154.1,	  144.6,	  137.1,	  135.6,	  133.7,	  131.0,	  129.4,	  
129.2	  (2C),	  128.8,	  128.7,	  127.6	  (2C),	  122.8,	  120.0,	  105.6,	  56.0.ppm.	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(E)-­‐2-­‐styrylquinoline	  (146):	  
Prepared	   from	   aniline	   (0.279	   g,	   3	   mmol)	   and	  
cinnamaldehyde	   (0.396	   g,	   3	   mmol);	   overall	   yield:	   62%;	  
white	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C17H13N:	  C	  88.28,	  H	  5.67,	  N	  6.06;	  found:	  C	  87.97,	  
H	  5.53,	  N	  6.01.	  
Mp:	  97	  	  100	  °C	  
IR	  (neat)	  ν:	  3056,	  3031,	  1612,	  1596,	  1504,	  1446,	  1316,	  1204,	  1118	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.13	  (d,	  J	  =	  8.5	  Hz,	  2H),	  7.81	  –	  7.66	  (m,	  6H),	  7.55	  –	  
7.36	  (m,	  5H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.4,	  148.7,	  136.9,	  136.8,	  134.9,	  130.2,	  129.6,	  129.4,	  
129.2	  (2C),	  129.1,	  127.9,	  127.8,	  127.7	  (2C),	  126.6,	  119.7	  ppm.	  
	  
(E)-­‐6-­‐chloro-­‐2-­‐styrylquinoline	  (147):	  
Prepared	   from	   4-­‐chloroaniline	   (0.383	   g,	   3	   mmol)	   and	  
cinnamaldehyde	   (0.396	   g,	   3	   mmol);	   overall	   yield:	   75%;	  
white	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C17H12ClN:	  C	  76.84,	  H	  4.55,	  N	  5.27;	  found:	  C	  
76.55,	  H	  4.40,	  N	  5.21.	  
Mp:	  138	  –	  141	  °C	  
IR	  (neat)	  ν:	  3042,	  2999,	  1631,	  1593,	  1492,	  1447,	  1390,	  1328,	  1186,	  1074	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.06	  (d,	  J	  =	  8.6	  Hz,	  1H),	  8.04	  (d,	  J	  =	  8.9	  Hz,	  1H),	  7.79	  –	  
7.64	  (m,	  6H),	  7.48	  –	  7.37	  (m,	  4H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.6,	  147.1,	  136.7,	  135.8,	  135.3,	  131.2,	  131.1,	  129.3	  
(2C),	  129.2,	  128.9,	  128.6,	  128.3	  (2C),	  127.7,	  126.6,	  120.6	  ppm. 
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(E)-­‐2-­‐(4-­‐chlorostyryl)quinoline	  (148):	  
Prepared	  from	  aniline	  (0.279	  g,	  3	  mmol)	  and	  143	  (0.500	  
g,	  3	  mmol);	  overall	  yield:	  42%;	  white	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C17H12ClN:	  C	  76.84,	  H	  
4.55,	  N	  5.27;	  found:	  C	  76.54,	  H	  4.61,	  N	  5.26.	  
Mp:	  124	  	  126	  °C	  
IR	  (neat)	  ν:	  1593,	  1504,	  1405,	  968,	  824	  cm-­‐1.	  
1H	  NMR	  (CDCl3,	  250	  MHz)	  δ 7.44	  –	  7.37	  (m,	  3H),	  7.84	  	  7.51	  (m,	  7H),	  8.10	  (d,	  J	  =	  
8.3	  Hz,	  1H),	  8.20	  (d,	  J	  =	  8.6	  Hz,	  1H)	  ppm.	  
13C	  NMR	  (CDCl3,	  63	  MHz)	  δ 156.0,	  148.6,	  136.9,	  135.4,	  134.7,	  133.5,	  130.3,	  129.9,	  
129.6,	  129.4	  (2C),	  128.8	  (2C),	  127.9,	  127.8,	  126.7,	  119.7	  ppm.	  
	  
(E)-­‐2-­‐(4-­‐chlorostyryl)-­‐6-­‐methylquinoline	  (149):	  
Prepared	   from	   p-­‐toluidine	   (0.321	   g,	   3	   mmol)	   and	  
143	   (0.500	   g,	   3	   mmol);	   overall	   yield:	   38%;	   white	  
solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C18H14ClN:	   C	   77.28,	   H	   5.04,	   N	   5.01;	   found:	   C	  
77.56,	  H	  4.79,	  N	  5.38.	  
Mp:	  122	  –	  125	  °C	  
IR	  (neat)	  ν:	  1587,	  1555,	  1490,	  1085,	  1006,	  964,	  826	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.08	  (d,	  J	  =	  8.5	  Hz,	  1H),	  8.00	  (d,	  J	  =	  9.2	  Hz,	  1H),	  7.68	  –	  
7.57	  (m,	  6H),	  7.41	  –	  7.29	  (m,	  3H),	  2.57	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  155.2,	  147.2,	  136.7,	  136.2,	  135.6,	  134.6,	  132.9,	  132.6,	  
130.0,	  129.4	  (2C),	  129.3,	  128.7	  (2C),	  127.8,	  126.9,	  119.8,	  22.0	  ppm.	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(E)-­‐6-­‐chloro-­‐2-­‐(4-­‐chlorostyryl)quinoline	  (150):	  
Prepared	  from	  4-­‐chloroaniline	  (0.383	  g,	  3	  mmol)	  and	  
143	   (0.500	   g,	   3	   mmol);	   overall	   yield:	   30%;	   pale	  
yellow	  solid. 
Elemental	   analysis	   (%)	   calcd	   for	   C17H11Cl2N:	   C	   68.02,	   H	   3.69,	   N	   4.67;	   found:	   C	  
67.97,	  H	  3.84,	  N	  5.07. 
Mp:	  158	  –	  161	  °C	  
IR	  (neat)	  ν:	  1584,	  1488,	  1388,	  1186,	  1087,	  1070,	  966,	  818	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.08	  (d,	  J	  =	  8.7	  Hz,	  1H),	  8.03	  (d,	  J	  =	  9.1	  Hz,	  1H),	  7.80	  
(d,	  J	  =	  2.3	  Hz,	  1H),	  7.72	  –	  7.65	  (m,	  3H),	  7.61	  –	  7.58	  (m,	  2H),	  7.43	  –	  7.25	  (m,	  3H)	  
ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.3,	  147.0,	  135.9,	  135.3,	  134.9,	  134.5,	  133.9,	  132.4,	  
131.2,	  129.5	  (2C),	  129.4,	  128.9	  (2C),	  128.3,	  126.7,	  120.8	  ppm.	  
	  
(E)-­‐2-­‐(4-­‐chlorostyryl)-­‐6-­‐methoxyquinoline	  (151):	  
Prepared	   from	  p-­‐anisidine	   (0.370	  g,	  3	  mmol)	  and	  
143	   (0.500	  g,	  3	  mmol);	  overall	   yield:	  44%;	  yellow	  
solid.	  
Elemental	   analysis	   (%)	   calcd	   for	  C18H14ClNO:	  C	   73.10,	  H	  4.77,	  N	  4.74;	   found:	  C	  
72.74,	  H	  4.68,	  N	  4.98.	  
Mp:	  137	  –	  140	  °C	  
IR	  (neat)	  ν:	  1621,	  1597,	  1491,	  1377,	  1226,	  1159,	  1028,	  831	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.05	  (d,	  J	  =	  8.6	  Hz,	  1H),	  8.00	  (d,	  J	  =	  9.3	  Hz,	  1H),	  7.64	  –	  
7.56	  (m,	  4H),	  7.42	  –	  7.32	  (m,	  4H),	  7.09	  (d,	  J	  =	  2.8	  Hz,	  1H),	  3.96	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  158.2,	  153.7,	  144.7,	  135.7,	  135.6,	  134.4,	  132.2,	  131.1,	  
130.0,	  129.4	  (2C),	  128.8,	  128.7	  (2C),	  122.9,	  120.1,	  105.6,	  56.0	  ppm.	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  (E)-­‐2-­‐(3-­‐chlorostyryl)-­‐6-­‐methylquinoline	  (152):	  
Prepared	   from	   p-­‐toluidine	   (0.321	   g,	   3	   mmol)	   and	  
142	   (0.500	   g,	   3	   mmol);	   overall	   yield:	   39%;	   pale	  
yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C18H14ClN:	   C	   77.28,	   H	   5.04,	   N	   5.01;	   found:	   C	  
77.01,	  H	  4.81,	  N	  4.78.	  
Mp:	  115	  –	  118	  °C	  
IR	  (neat)	  ν:	  1737,	  1591,	  1560,	  1494,	  1200,	  1095,	  961,	  824	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.12	  (d,	  J	  =	  8.2	  Hz,	  1H),	  8.05	  (d,	  J	  =	  9.0	  Hz,	  1H),	  7.69	  –	  
7.53	  (m,	  6H),	  7.42	  –	  7.29	  (m,	  3H),	  2.58	  (s,	  3H)	  ppm	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  154.6,	  146.3,	  138.7,	  137.2,	  137.0,	  135.2,	  133.0,	  130.5,	  
130.0,	  129.2,	  129.0,	  128.7,	  127.9,	  127.6,	  126.9,	  125.9,	  119.7,	  22.3	  ppm.	  
	  
(E)-­‐2-­‐(3-­‐chlorostyryl)-­‐6-­‐methoxyquinoline	  (153):	  
Prepared	   from	  p-­‐anisidine	   (0.370	  g,	  3	  mmol)	  and	  
142	   (0.500	  g,	  3	  mmol);	  overall	   yield:	  34%;	  yellow	  
solid.	  
Elemental	   analysis	   (%)	   calcd	   for	  C18H14ClNO:	  C	   73.10,	  H	  4.77,	  N	  4.74;	   found:	  C	  
72.66,	  H	  4.80,	  N	  4.98.	  
Mp:	  98	  –	  101	  °C	  
IR	  (neat)	  ν:	  1617,	  1592,	  1560,	  1497,	  1475,	  1223,	  1028,	  831	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.07	  (d,	  J	  =	  8.6	  Hz,	  1H),	  8.01	  (d,	  J	  =	  9.2	  Hz,	  1H),	  7.65	  –	  
7.51	  (m,	  4H),	  7.42	  –	  7.32	  (m,	  4H),	  7.10	  (d,	  J	  =	  2.7	  Hz,	  1H),	  3.97	  (s,	  3H)	  ppm.	  	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  158.2,	  153.5,	  144.7,	  139.1,	  135.6,	  135.1,	  132.0,	  131.2,	  
130.8,	  130.4,	  128.9,	  128.6,	  127.4,	  125.7,	  122.9,	  120.2,	  105.6,	  56.0	  ppm.	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  (E)-­‐2-­‐(2-­‐chlorostyryl)-­‐6-­‐methylquinoline	  (154):	  
Prepared	  from	  p-­‐toluidine	  (0.321	  g,	  3	  mmol)	  and	  141	  
(0.500	  g,	  3	  mmol);	  overall	  yield:	  42%;	  white	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C18H14ClN:	  C	  77.28,	  H	  
5.04,	  N	  5.01;	  found:	  C	  76.95,	  H	  4.63,	  N	  4.69.	  
Mp:	  73	  –	  76	  °C	  
IR	  (neat)	  ν:	  1738,	  1591,	  1436,	  1371,	  1216,	  957,	  823,	  745	  cm-­‐1.	  
1H	  NMR	   (250	  MHz,	  CDCl3)	  δ	  8.01	  –	  7.89	   (m,	  3H),	  7.75	   (dd,	   J	  =	  7.5,	  1.9	  Hz,	  1H),	  
7.67	  (d,	  J	  =	  8.6	  Hz,	  1H),	  7.50	  –	  7.46	  (m,	  2H),	  7.38	  –	  7.14	  (m,	  4H),	  2.47	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  155.4,	  147.2,	  136.8,	  136.2,	  135.1,	  134.4,	  132.5,	  132.3,	  
130.4,	  130.1,	  129.8,	  129.4,	  127.9,	  127.5,	  127.3,	  126.9,	  119.4,	  22.4	  ppm.	  
 
(E)-­‐2-­‐(2-­‐chlorostyryl)-­‐6-­‐methoxyquinoline	  (155):	  
Prepared	  from	  p-­‐anisidine	  (0.370	  g,	  3	  mmol)	  and	  141	  
(0.500	  g,	  3	  mmol);	  overall	  yield:	  46%;	  white	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C18H14ClNO:	  C	  73.10,	  
H	  4.77,	  N	  4.74;	  found:	  C	  72.68,	  H	  4.63,	  N	  4.69.	  
Mp:	  88	  –	  91	  °C	  	  
IR	  (neat)	  ν:	  1613,	  1594,	  1498,	  1465,	  1374,	  1244,	  1223,	  746	  cm-­‐1.	  
1H	  NMR	   (250	  MHz,	  CDCl3)	  δ	  8.04	  –	  7.95	   (m,	  3H),	  7.81	   (dd,	   J	  =	  7.5,	  1.7	  Hz,	  1H),	  
7.72	  (d,	  J	  =	  8.6	  Hz,	  1H),	  7.45	  –	  7.21	  (m,	  5H),	  7.06	  (d,	  J	  =	  2.7	  Hz,	  1H),	  3.93	  (s,	  3H)	  
ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  158.2,	  153.9,	  144.6,	  135.6,	  135.2,	  134.3,	  132.2,	  131.2,	  
130.3,	  129.7,	  129.4,	  128.9,	  127.5,	  127.2,	  122.8,	  119.7,	  105.6,	  55.9.	  ppm.	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(E)-­‐6-­‐methyl-­‐2-­‐(4-­‐methylstyryl)quinoline	  (156):	  
Prepared	  from	  p-­‐toluidine	  (0.321	  g,	  3	  mmol)	  and	  
145	  (0.439	  g,	  3	  mmol);	  overall	  yield:	  47%;	  yellow	  
solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C19H17N:	  C	  87.99,	  H	  6.61,	  N	  5.40;	  found:	  C	  87.72,	  
H	  6.62,	  N	  5.49.	  
Mp:	  160	  –	  163	  °C	  
IR	  (neat)	  ν:	  1588,	  1548,	  1510,	  1490,	  1177,	  1118,	  980,	  830	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.06	  (d,	  J	  =	  8.6	  Hz,	  1H),	  7.99	  (d,	  J	  =	  9.2	  Hz,	  1H),	  7.68	  –	  
7.55	  (m,	  6H),	  7.38	  (d,	  J	  =	  16.3	  Hz,	  1H),	  7.24	  (d,	  J	  =	  7.9	  Hz,	  2H),	  2.56	  (s,	  3H),	  2.41	  (s,	  
3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  155.8,	  147.2,	  139.0,	  136.4,	  136.0,	  134.3,	  132.4,	  129.9	  
(2C),	  129.2,	  128.6,	  127.7,	  127.6	  (2C),	  126.9,	  119.6,	  31.3,	  22.0,	  21.8	  ppm.	  
	  
(E)-­‐6-­‐chloro-­‐2-­‐(4-­‐methylstyryl)quinoline	  (157):	  
Prepared	   from	   4-­‐chloroaniline	   (0.383	   g,	   3	   mmol)	  
and	   145	   (0.439	   g,	   3	   mmol);	   overall	   yield:	   45%;	  
yellow	  solid. 
Elemental	   analysis	   (%)	   calcd	   for	   C18H14ClN:	   C	   77.28,	   H	   5.04,	   N	   5.01;	   found:	   C	  
76.82,	  H	  5.02,	  N	  5.29. 
Mp:	  179	  –	  181	  °C	  
IR	  (neat)	  ν:	  1590,	  1487,	  1186,	  1114,	  1072,	  973,	  828,	  816	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.04	  (t,	  J	  =	  8.5	  Hz,	  2H),	  7.79	  (d,	  J	  =	  2.2	  Hz,	  1H),	  7.74	  –	  
7.64	  (m,	  3H),	  7.57	  (d,	  J	  =	  8.1	  Hz,	  2H),	  7.36	  (d,	  J	  =	  16.3	  Hz,	  1H),	  7.25	  (d,	  J	  =	  8.0	  Hz,	  
2H),	  2.42	  (s,	  3H)	  ppm.	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13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.9,	  147.1,	  139.4,	  135.7,	  135.3,	  134.0,	  132.1,	  131.1,	  
131.0,	  130.0	  (2C),	  128.2,	  128.0,	  127.7	  (2C),	  126.6,	  120.6,	  21.8	  ppm.	  
	  
(E)-­‐6-­‐methoxy-­‐2-­‐(4-­‐methylstyryl)quinoline	  (158):	  
Prepared	   from	  p-­‐anisidine	   (0.370	  g,	  3	  mmol)	  and	  
145	   (0.439	  g,	  3	  mmol);	  overall	  yield:	  41%;	  yellow	  
solid. 
Elemental	   analysis	   (%)	   calcd	   for	   C19H17NO:	   C	   82.88,	   H	   6.22,	   N	   5.09;	   found:	   C	  
82.53,	  H	  6.34,	  N	  5.28.	  
Mp:	  158	  –	  161	  °C	  
IR	  (neat)	  ν:	  1619,	  1586,	  1481,	  1375,	  1331,	  1226,	  989,	  834	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.06	  –	  7.98	  (m,	  2H),	  7.68	  –	  7.54	  (m,	  4H),	  7.40	  –	  7.22	  
(m,	  5H),	  3.97	  (s,	  3H),	  2.41	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  158.0,	  154.4,	  144.7,	  138.9,	  135.5,	  134.3,	  133.7,	  131.0,	  
129.9,	  128.6,	  128.5,	  127.5,	  122.7,	  119.9,	  105.7,	  56.0,	  21.8	  ppm.	  
	  
(E)-­‐2-­‐(2-­‐methoxystyryl)-­‐6-­‐methylquinoline	  (159):	  
Prepared	  from	  p-­‐toluidine	  (0.321	  g,	  3	  mmol)	  and	  144	  
(0.486	  g,	  3	  mmol);	  overall	  yield:	  29%;	  yellow	  solid.	  
Elemental	  analysis	   (%)	  calcd	   for	  C19H17NO:	  C	  82.88,	  
H	  6.22,	  N	  5.09;	  found:	  C	  83.04,	  H	  6.46,	  N	  4.98.	  
Mp:	  100	  –	  103	  °C	  
IR	  (neat)	  ν:	  1587,	  1490,	  1460,	  1239,	  1024,	  965,	  828,	  755	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.08	  –	  7.98	  (m,	  3H),	  7.78	  –	  7.73	  (m,	  2H),	  7.57	  –	  7.44	  
(m,	  3H),	  7.37	  –	  7.30	  (m,	  1H),	  7.06	  –	  6.95	  (m,	  2H),	  3.96	  (s,	  3H),	  2.56	  (s,	  3H)	  ppm.	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13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  157.8,	  156.3,	  147.1,	  136.4,	  136.0,	  132.3,	  130.1,	  129.2,	  
127.7,	  127.6,	  126.8,	  126.0,	  121.2,	  119.4,	  111.4,	  55.9,	  22.0	  ppm.	  
	  
(E)-­‐6-­‐chloro-­‐2-­‐(2-­‐methoxystyryl)quinoline	  (160):	  
Prepared	  from	  4-­‐chloroaniline	  (0.383	  g,	  3	  mmol)	  and	  
144	   (0.486	   g,	   3	   mmol);	   overall	   yield:	   25%;	   yellow	  
solid.	  
Elemental	   analysis	   (%)	   calcd	   for	  C18H14ClNO:	  C	   73.10,	  H	  4.77,	  N	  4.74;	   found:	  C	  
72.91,	  H	  4.46,	  N	  5.02.	  
Mp:	  99	  –	  102	  °C	  
IR	  (neat)	  ν:	  1590,	  1488,	  1455,	  1240,	  1020,	  827,	  754	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.10	  –	  8.03	  (m,	  3H),	  7.81	  –	  7.64	  (m,	  4H),	  7.49	  –	  7.32	  
(m,	  2H),	  7.07	  –	  6.96	  (m,	  2H),	  3.97	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  157.9,	  156.3,	  146.9,	  135.7,	  132.0,	  131.1,	  130.9,	  130.4,	  
130.3,	  129.4,	  128.2,	  127.7,	  126.6,	  125.7,	  121.3,	  120.4,	  111.4,	  56.0	  ppm.	  
	  
9.5.1.3.	  Introduction	  of	  an	  amino	  group	  on	  137	  
6-­‐Methyl-­‐2-­‐styrylquinoline	   (137)	   (0.25	   g,	   1.019	   mmol)	   was	   added	   over	   10	  
minutes	  to	  a	  stirred	  mixture	  of	  acid	  nitric	  65%	  (8	  ml)	  and	  fuming	  nitric	  acid	  (2	  ml)	  
at	   0-­‐5°C.	   The	  mixture	  was	   stirred	   at	   room	   temperature	  overnight.	   The	   solution	  
was	  poured	   into	   ice	  water,	   and	   the	   solid	  was	   filtered,	  washed	  with	  water	   until	  
acid-­‐free,	  and	  dried	  to	  give	  an	  orange	  solid	  corresponding	  to	  the	  mixture	  of	  two	  
nitro	  derivatives.	   This	   solid	   (0.670	   g,	   2.3	  mmol),	   iron	  powder	   (1.05	   g)	   and	  37%	  
aqueous	  HCl	  (0.1	  ml)	  were	  refluxed	  for	  4	  h	  in	  21.6	  ml	  of	  a	  mixture	  of	  EtOH,	  AcOH	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and	  H2O	  (8.7:8.7:4.2)	  with	  magnetic	  stirring.	  The	  solution	  was	  filtered	  on	  celite,	  
diluted	  with	  water	  (20	  ml)	  and	  extracted	  with	  EtOAc	  (3	  x	  50	  ml).	  The	  combined	  
organic	   layers	  were	  washed	  with	   saturated	   aqueous	  NaHCO3	  and	  H2O	   (2	   x	   100	  
ml),	   dried	   over	   anhydrous	  Na2SO4	   and	   evaporated	   of	   the	   solvent	   to	   achieve	   a	  
mixture	   of	   the	   two	   amino	   derivatives,	   139	   and	   140,	   which	   were	   separated	  





Overall	  yield:	  68%;	  orange	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C18H16N2:	   C	   83.04,	   H	   6.19,	   N	   10.76;	   found:	   C	  
78.53,	  H	  5.95,	  N	  10.26.	  
Mp:	  164	  	  167	  °C	  
IR	   (neat)	  ν:	  3416,	  3319,	  3212,	  3030,	  2918,	  1593,	  1517,	  1497,	  1394,	  1318,	  1123	  
cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.06	  –	  7.98	  (m,	  2H),	  7.66	  –	  7.47	  (m,	  7H),	  6.73	  (d,	  J	  =	  
8.5	  Hz,	  2H),	  3.87	  (br	  s,	  2H),	  2.55	  (s,	  3H)	  ppm.	  	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.3,	  147.5,	  147.1,	  136.1,	  136.0,	  134.6,	  132.3,	  131.0,	  
129.1	  (2C),	  129.0,	  127.5,	  126.9,	  125.7,	  119.4,	  115.5	  (2C),	  22.0.ppm.	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MS	  (electrospray):	  261	  (M+	  +	  1).	  
	  
(E)-­‐6-­‐Methyl-­‐2’-­‐amino-­‐2-­‐styrylquinoline	  (140):	  
Yield:	  28%;	  yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C18H16N2:	   C	   83.04,	   H	   6.19,	   N	   10.76;	   found:	   C	  
82.24,	  H	  6.20,	  N	  10.82.	  
Mp:	  167	  –	  170	  °C	  
IR	  (neat)	  ν:	  3363,	  3212,	  1637,	  1596,	  1456,	  1319,	  963	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.07	  (d,	  J	  =	  8.6	  Hz,	  1H),	  8.01	  (d,	  J	  =	  9.2	  Hz,	  1H),	  7.85	  
(d,	  J	  =	  16.2	  Hz,	  1H),	  7.62	  (d,	  J	  =	  8.6	  Hz,	  1H),	  7.58	  	  7.55	  (m,	  3H),	  7.30	  (d,	  J	  =	  16.0	  Hz,	  
1H),	  7.18	  (td,	  J	  =	  7.9,	  1.5	  Hz,	  1H),	  6.85	  (t,	  J	  =	  7.5	  Hz,	  1H),	  6.77	  (dd,	  J	  =	  8.0,	  0.9	  Hz,	  
1H),	  4.02	  (br	  s,	  2H),	  2.57	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  155.6,	  147.0,	  145.1,	  136.5,	  136.3,	  132.5,	  130.0,	  129.9,	  
129.9,	  129.1,	  127.9,	  127.7,	  126.9,	  123.1,	  120.1,	  119.5,	  116.9,	  22.0	  ppm.	  
MS	  (electrospray):	  261	  (M+	  +	  1).	  
	  
9.5.1.4.	  6-­‐Methyl-­‐4’-­‐amino-­‐2-­‐styrylquinolinium	  hydrochloride	  (139·∙HCl):	  
	  
The	  hydrochloride	  salt	  was	  prepared	  by	  adding	  compound	  139	  (0.5	  g,	  1.9	  mmol)	  
to	  a	  solution	  of	  methanol	  saturated	  with	  HCl	  (3	  ml).	  The	  resulting	  suspension	  was	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stirred	  overnight,	  the	  precipitate	  was	  filtered	  and	  dried	  to	  obtain	  139·∙HCl	  in	  98%	  
yield	  as	  a	  red	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C18H17ClN2:	   C	   72.84,	   H	   5.77,	   N	   9.44;	   found:	   C	  
72.98,	  H	  5.81,	  N	  9.40.	  
1H	  NMR	  (250	  MHz,	  D2O)	  δ	  8.31	  (d,	  J	  =	  8.9	  Hz,	  1H),	  7.70	  (d,	  J	  =	  9.0	  Hz,	  1H),	  7.45	  –	  
7.41	  (m,	  3H),	  7.33	  (d,	  J	  =	  16.3	  Hz,	  1H),	  7.21	  (d,	  J	  =	  8.3	  Hz,	  2H),	  6.85	  (d,	  J	  =	  8.5	  Hz,	  
2H),	  6.56	  (d,	  J	  =	  16.2	  Hz,	  1H),	  2.14	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  D2O)	  δ	  150.5,	  144.5,	  142.8,	  140.7,	  138.0,	  137.0,	  135.1,	  131.1,	  
130.3	  (2C),	  127.7,	  127.0,	  121.2	  (2C),	  118.9,	  117.7,	  116.2,	  20.8	  ppm.	  
	  
9.5.2.	  Preparation	  of	  styrylquinoline	  compounds	  under	  focused	  MW	  irradiation	  
9.5.2.1.	  Synthesis	  of	  quinaldines	  
An	  equimolar	   (3	  mmol)	  mixture	  of	   the	   suitable	  arylamine	  and	  ethyl	   vinyl	  ether	  
(0.541	  g,	  7.5	  mmol)	  was	  dissolved	  in	  acetonitrile	  (20	  ml).	  15	  mol%	  of	  CAN	  (0.247	  
g)	  was	   added	   to	   the	   stirred	   solution,	   and	   stirring	  was	   continued	   for	   1	  h.	  Upon	  
completion	  of	  the	  reaction,	  as	  indicated	  by	  TLC,	  the	  mixture	  was	  extracted	  with	  
dichloromethane	   (2	   x	   20	   ml),	   dried	   (anhydrous	   Na2SO4)	   and	   evaporated.	   The	  
resulting	  crude	  product	  was	  dissolved	   in	  20	  ml	  of	   toluene	  and	  refluxed	  for	   two	  
hours	   in	   presence	   of	   200	   mg	   of	   10%	   Pd	   on	   activated	   carbon	   (Pd–C).	   Upon	  
completion	   of	   the	   reaction,	   the	   mixture	   was	   filtered	   through	   Celite	   and	   the	  
solvent	  was	  evaporated	  under	  reduced	  pressure.	  The	  crude	  product	  was	  purified	  
through	  silica	  gel	  column	  using	  a	  petroleum	  ether/ethyl	  acetate	  mixture	  (95:05,	  
v/v)	  as	  mobile	  phase.	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Cmpd.	   R1	   R2	  
161	   H	   H	  
162	   CH3	   H	  
163	   Cl	   H	  
164	   OMe	   H	  
165	   H	   CH3	  
166	   H	   Cl	  
	  
2-­‐methylquinoline	  (161):	  
Prepared	  from	  aniline	  (0.279	  g,	  3	  mmol);	  overall	  yield:	  78	  %;	  
pale	  yellow	  oil.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.08	  (d,	  J	  =	  8.2	  Hz,	  1H),	  8.06	  (d,	  J	  =	  8.2	  Hz,	  1H),	  7.81	  
(dd,	  J	  =	  8.1,	  1.2	  Hz,	  1H),	  7.75	  –	  7.68	  (m,	  1H),	  7.52	  (ddd,	  J	  =	  8.1,	  7.0,	  1.2	  Hz,	  1H),	  
7.32	  (d,	  J	  =	  8.4	  Hz,	  1H),	  2.79	  (s,	  3H)	  ppm.	  
 
2,6-­‐dimethylquinoline	  (162):	  
Prepared	  from	  p-­‐toluidine	  (0.321	  g,	  3	  mmol);	  overall	  yield:	  82	  
%;	  yellow	  oil.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  7.83	  (d,	  J	  =	  8.7	  Hz,	  2H),	  7.43	  –	  
7.37	  (m,	  2H),	  7.12	  (d,	  J	  =	  8.3	  Hz,	  1H),	  2.62	  (s,	  3H),	  2.40	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  158.4,	  146.7,	  136.1,	  135.8,	  132.1,	  128.6,	  126.9,	  126.8,	  
122.4,	  25.6,	  21.9	  ppm.	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  9.	  Experimental	  section	  
6-­‐chloro-­‐2-­‐methylquinoline	  (163):	  
Prepared	  from	  4-­‐chloroaniline	  (0.383	  g,	  3	  mmol);	  overall	  yield:	  
67	  %;	  yellow	  oil.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  7.95	  (d,	  J	  =	  5.2	  Hz,	  1H),	  7.91	  (d,	  J	  =	  4.6	  Hz,	  1H),	  7.72	  
(d,	  J	  =	  2.3	  Hz,	  1H),	  7.60	  (dd,	  J	  =	  9.0,	  2.3	  Hz,	  1H),	  7.28	  (d,	  J	  =	  8.5	  Hz,	  1H),	  2.73	  (s,	  
4H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  159.7,	  146.6,	  135.6,	  131.7,	  130.6	  (2C),	  127.4,	  126.6,	  
123.3,	  25.7	  ppm.	  
	  
6-­‐methoxy-­‐2-­‐methylquinoline	  (164):	  
Prepared	  from	  p-­‐anisidine	  (0.370	  g,	  3	  mmol);	  overall	  yield:	  
70	  %;	  orange	  oil.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  7.92	  (d,	  J	  =	  9.7	  Hz,	  2H),	  7.36	  –	  7.31	  (m,	  1H),	  7.22	  (dd,	  
J	  =	  8.4,	  1.3	  Hz,	  1H),	  7.02	  (d,	  J	  =	  2.6	  Hz,	  1H),	  3.89	  (s,	  3H),	  2.70	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  157.5,	  156.7,	  144.3,	  135.5,	  130.4,	  127.7,	  122.6,	  122.3,	  
105.6,	  55.9,	  25.4	  ppm. 
	  
2,7-­‐dimethylquinoline	  (165):	  
Prepared	  from	  m-­‐toluidine	  (0.321	  g,	  3	  mmol);	  overall	  yield:	  
40	  %;	  white	  solid.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.17	  (d,	  J	  =	  8.6	  Hz,	  1H),	  7.97	  –	  7.81	  (m,	  1H),	  7.65	  –	  
7.53	  (m,	  1H),	  7.30	  –	  7.17	  (m,	  2H),	  2.72	  (s,	  3H),	  2.64	  (s,	  3H)	  ppm.	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7-­‐chloro-­‐2-­‐methylquinoline(166):	  
Prepared	  from	  3-­‐chloroaniline	  (0.383	  g,	  3	  mmol);	  overall	  yield:	  
45	  %;	  grey	  solid.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.09	  –	  8.02	  (m,	  2H),	  7.74	  (d,	  J	  =	  8.7	  Hz,	  1H),	  7.47	  (dd,	  




m-­‐Aminophenol	   (775	   mg,	   7.1	   mmol)	   was	   dissolved	   in	   2	   ml	   of	   concentrated	  
hydrochloric	   acid	   (12N),	   and	   then	  p-­‐chloranil	   (1.75	   g,	   7.1	  mmol)	   and	  1-­‐butanol	  
(2.5	  ml)	   were	   added.	   The	  mixture	  was	   stirred	   and	   heated	   to	   reflux	   (105°C)	   at	  
which	  point	  a	  solution	  of	  crotonaldehyde	   (0.8	  ml,	  9.23	  mmol)	   in	  1-­‐butanol	   (0.2	  
ml)	  was	  added	  to	  the	  refluxing	  solution	  dropwise	  over	  20	  min.	  After	  the	  addition	  
was	  complete,	  the	  mixture	  was	  allowed	  to	  reflux	  for	  another	  30	  minutes.	  The	  1-­‐
butanol	   was	   removed	   by	   reduced	   pressure,	   and	   the	   residue	   was	   dissolved	   in	  
water	   and	   washed	   with	   ether.	   The	   aqueous	   layer	   was	   neutralized	   with	   10%	  
NaOH	   and	   extracted	   with	   EtOAc.	   The	   EtOAc	   layer	   was	   dried	   over	   Na2SO4	   and	  
evaporated.	   The	   crude	   material	   was	   purified	   through	   column	   on	   silica	   using	  
EtOAc/hexane	  (6:4)	  as	  mobile	  phase	  to	  yield	  168	  in	  40%	  yield	  as	  a	  white	  solid.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  7.87	  (d,	  J	  =	  8.9	  Hz,	  1H),	  7.35	  –	  7.30	  (m,	  1H),	  7.21	  (s,	  
1H),	  7.04	  (d,	  J	  =	  8.3	  Hz,	  1H),	  6.77	  (dd,	  J	  =	  8.8,	  2.1	  Hz,	  1H),	  2.66	  (s,	  3H)	  ppm.	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  9.	  Experimental	  section	  
7-­‐methoxy-­‐2-­‐methylquinoline	  (167):	  
	  
7-­‐Hydroxyquinaldine	  168	   (3.18	  g,	   20	  mmol)	   and	  K2CO3	   (5.52	  g,	   40	  mmol)	  were	  
dissolved	  in	  18	  ml	  of	  DMF.	  The	  CH3I	  was	  added	  to	  the	  mixture,	  and	  the	  reaction	  
was	   stirred	   overnight	   at	   r.t.	   When	   the	   reaction	   was	   finished,	   the	   CH3I	   was	  
removed	   by	   evaporation.	   The	   residue	   was	   diluted	   with	   150	   ml	   of	   water	   and	  
extracted	  with	  EtOAc.	   The	  organic	   layer	  was	  dried	  over	   anhydrous	  Na2SO4	   and	  
evaporated	   under	   reduced	   pressure.	   The	   crude	   material	   was	   purified	   through	  
column	   on	   silica	   using	   EtOAc/petroleum	   ether	   (1:1)	   as	  mobile	   phase	   to	   afford	  
167	  in	  78%	  yield	  as	  brown	  solid.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  7.99	  (d,	  J	  =	  8.3	  Hz,	  1H),	  7.68	  (d,	  J	  =	  8.9	  Hz,	  1H),	  7.40	  
(d,	  J	  =	  2.4	  Hz,	  1H),	  7.21	  –	  7.15	  (m,	  2H),	  3.98	  (s,	  3H),	  2.77	  (s,	  3H)	  ppm.	  
	  
9.5.2.2.	  Preparation	  of	  2-­‐styrylquinolines	  by	  aldol	  condensation	  
The	   suitable	   quinaldine	   derivative	   (1	   mmol)	   and	   the	   corresponding	   aromatic	  
aldehyde	   (1	   equiv)	  were	   suspended	   in	   acetic	   anhydride	   (0.5	  ml)	   in	   a	   pressure-­‐
tight	  microwave	  tube	  containing	  a	  stirring	  bar.	  The	  reaction	  mixture	  was	  heated	  
under	  microwave	  irradiation	  for	  1	  h	  at	  130-­‐180	  °C,	  with	  an	  irradiation	  power	  of	  
200	  W.	  The	  solvent	  was	  removed	  under	  reduced	  pressure	  to	  give	  a	  black	  residue	  
which	  was	  purified	  by	  chromatography	  through	  a	  silica	  column	  using	  petroleum	  
ether/ethyl	  acetate	  (90:10,	  v/v)	  as	  the	  mobile	  phase	  to	  give	  compounds	  169-­‐199.	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  9.	  Experimental	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(E)-­‐6-­‐methyl-­‐2-­‐(2-­‐(pyridin-­‐2-­‐yl)vinyl)quinoline	  (169):	  
Prepared	   from	   162	   (0.157	   g,	   1	  mmol)	   and	   pirydine-­‐2-­‐
carbaldehyde	   (0.107	   g,	   1	   mmol);	   temperature	   of	  
reaction:	  130	  °C;	  yield:	  87	  %;	  brown	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C17H14N2:	   C	   82.90,	   H	   5.73,	   N	   11.37;	   found:	   C	  
83.19,	  H	  5.59,	  N	  11.33.	  
Mp:	  120	  –	  123	  °C	  
IR	  (neat)	  ν:	  2918,	  1585,	  1558,	  1495,	  1468,	  1429,	  975,	  825	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.57	  (ddd,	  J	  =	  4.8,	  1.6,	  0.8	  Hz,	  1H),	  7.98	  (d,	  J	  =	  8.6	  Hz,	  
1H),	  7.92	  (d,	  J	  =	  9.3	  Hz,	  1H),	  7.73	  (d,	  J	  =	  4.2	  Hz,	  2H),	  7.63	  (ddd,	  J	  =	  7.6,	  3.3,	  1.8	  Hz,	  
1H),	  7.57	  (d,	  J	  =	  8.5	  Hz,	  1H),	  7.51	  –	  7.44	  (m,	  3H),	  7.12	  (ddd,	  J	  =	  7.4,	  4.8,	  1.2	  Hz,	  
1H),	  2.46	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  155.6,	  154.9,	  150.2,	  147.3,	  137.1,	  136.8,	  136.3,	  133.6,	  
133.1,	  132.5,	  129.5,	  128.1,	  126.9,	  123.1,	  123.1,	  120.8,	  22.0	  ppm.	  
	  
(E)-­‐6-­‐methyl-­‐2-­‐(2-­‐(pyridin-­‐2-­‐yl)vinyl)quinoline	  (170):	  
Prepared	   from	   163	   (0.178	   g,	   1	  mmol)	   and	   pirydine-­‐2-­‐
carbaldehyde	   (0.107	   g,	   1	   mmol);	   temperature	   of	  
reaction:	  130	  °C;	  yield:	  91	  %;	  pale	  brown	  solid.	  
Elemental	  analysis	   (%)	   calcd	   for	  C16H11ClN2:	  C	  72.05,	  H	  4.16,	  N	  10.50;	   found:	  C	  
72.27,	  H	  4.16,	  N	  10.59.	  
Mp:	  138	  –	  141	  °C	  
IR	  (neat)	  ν:	  1590,	  1581,	  1562,	  1488,	  1426,	  1069,	  983,	  822	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.69	  –	  8.67	  (m,	  1H),	  8.09	  –	  8.03	  (m,	  2H),	  7.84	  (s,	  2H),	  
7.79	  (d,	  J	  =	  2.3	  Hz,	  1H),	  7.77	  –	  7.64	  (m,	  3H),	  7.59	  –	  7.55	  (m,	  1H),	  7.24	  (ddd,	  J	  =	  7.5,	  
4.8,	  1.1	  Hz,	  1H)	  ppm.	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13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.0,	  155.3,	  150.3,	  147.1,	  137.1,	  136.0,	  134.5,	  132.5,	  
132.5,	  131.4,	  131.1,	  128.5,	  126.7,	  123.4	  (2C),	  121.7	  ppm.	  
	  
(E)-­‐6-­‐methoxy-­‐2-­‐(2-­‐(pyridin-­‐2-­‐yl)vinyl)quinoline	  (171):	  
Prepared	  from	  164	  (0.173	  g,	  1	  mmol)	  and	  pirydine-­‐2-­‐
carbaldehyde	   (0.107	   g,	   1	   mmol);	   temperature	   of	  
reaction:	  130	  °C;	  yield:	  75%;	  pale	  brown	  solid.	  
Elemental	  analysis	   (%)	  calcd	   for	  C17H14N2O:	  C	  77.84,	  
H	  5.38,	  N	  10.68;	  found:	  C	  77.15,	  H	  5.32,	  N	  10.50.	  
Mp:	  107	  –	  110	  °C	  
IR	  (neat)	  ν:	  1613,	  1590,	  1558,	  1499,	  1463,	  1427,	  1218,	  1023,	  975,	  848	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.67	  (ddd,	  J	  =	  4.8,	  1.7,	  0.8	  Hz,	  1H),	  8.04	  (t,	  J	  =	  9.4	  Hz,	  
2H),	  7.88	  –	  7.56	  (m,	  5H),	  7.39	  (dd,	  J	  =	  9.2,	  2.8	  Hz,	  1H),	  7.22	  (ddd,	  J	  =	  7.4,	  4.8,	  1.2	  
Hz,	  1H),	  7.08	  (d,	  J	  =	  2.8	  Hz,	  1H),	  3.96	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  158.2,	  155.7,	  153.4,	  150.2,	  144.8,	  137.0,	  135.6,	  133.1,	  
132.9,	  131.3,	  129.0,	  123.1,	  123.0,	  122.9,	  121.1,	  105.5,	  56.0	  ppm.	  
	  
(E)-­‐6-­‐methyl-­‐2-­‐(2-­‐(pyridin-­‐3-­‐yl)vinyl)quinoline	  (172):	  
Prepared	   from	  162	   (0.157	   g,	   1	  mmol)	   and	   pirydine-­‐3-­‐
carbaldehyde	   (0.107	   g,	   1	   mmol);	   temperature	   of	  
reaction:	  130	  °C;	  yield:	  62%;	  pale	  yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C17H14N2:	   C	   82.90,	   H	   5.73,	   N	   11.37;	   found:	   C	  
82.03,	  H	  5.64,	  N	  11.38.	  
Mp:	  105	  –	  108	  °C	  
IR	  (neat)	  ν:	  3025,	  1589,	  1555,	  1493,	  1412,	  1215,	  963,	  827	  cm-­‐1.	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  9.	  Experimental	  section	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.86	  (d,	  J	  =	  2.0	  Hz,	  1H),	  8.57	  (dd,	  J	  =	  4.8,	  1.4	  Hz,	  1H),	  
8.10	  (d,	  J	  =	  8.6	  Hz,	  1H),	  8.03	  –	  7.96	  (m,	  2H),	  7.69	  (d,	  J	  =	  9.8	  Hz,	  1H),	  7.64	  (d,	  J	  =	  1.9	  
Hz,	  1H),	  7.60	  –	  7.56	  (m,	  2H),	  7.46	  (d,	  J	  =	  16.4	  Hz,	  1H),	  7.36	  (dd,	  J	  =	  7.9,	  4.8	  Hz,	  
1H),	  2.57	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  154.7,	  149.8,	  149.6,	  147.2,	  136.9,	  136.3,	  133.6,	  132.8,	  
132.7,	  131.5,	  130.4,	  129.4,	  128.0,	  126.9,	  124.1,	  119.8,	  22.0	  ppm.	  
	  
(E)-­‐6-­‐chloro-­‐2-­‐(2-­‐(pyridin-­‐3-­‐yl)vinyl)quinoline	  (173):	  
Prepared	   from	  163	   (0.178	   g,	   1	  mmol)	   and	   pirydine-­‐3-­‐
carbaldehyde	   (0.107	   g,	   1	   mmol);	   temperature	   of	  
reaction:	  130	  °C;	  yield:	  86%;	  yellow	  solid.	  
Elemental	  analysis	   (%)	   calcd	   for	  C16H11ClN2:	  C	  72.05,	  H	  4.16,	  N	  10.50;	   found:	  C	  
72.22,	  H	  4.16,	  N	  10.67.	  
Mp:	  130	  –	  133	  °C	  
IR	  (neat)	  ν:	  3030,	  1595,	  1547,	  1491,	  1189,	  1072,	  962,	  880,	  817	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.87	  (d,	  J	  =	  2.1	  Hz,	  1H),	  8.59	  (dd,	  J	  =	  4.8,	  1.6	  Hz,	  1H),	  
8.10	  (d,	  J	  =	  8.6	  Hz,	  1H),	  8.05	  (d,	  J	  =	  9.0	  Hz,	  1H),	  7.99	  (dt,	  J	  =	  8.0,	  1.8	  Hz,	  1H),	  7.81	  
(d,	  J	  =	  2.3	  Hz,	  1H),	  7.74	  (d,	  J	  =	  13.1	  Hz,	  1H),	  7.71	  –	  7.66	  (m,	  2H),	  7.45	  (d,	  J	  =	  16.4	  
Hz,	  1H),	  7.37	  (dd,	  J	  =	  8.0,	  4.8	  Hz,	  1H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  155.8,	  150.0,	  149.7,	  147.0,	  136.1,	  133.8,	  132.6,	  132.5,	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(E)-­‐6-­‐methoxy-­‐2-­‐(2-­‐(pyridin-­‐3-­‐yl)vinyl)quinoline	  (174):	  
Prepared	   from	  164	   (0.173	  g,	  1	  mmol)	  and	  pirydine-­‐3-­‐
carbaldehyde	   (0.107	   g,	   1	   mmol);	   temperature	   of	  
reaction:	  130	  °C;	  yield:	  83%;	  yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	  C17H14N2O:	  C	  77.84,	  H	  5.38,	  N	  10.68;	   found:	  C	  
76.89,	  H	  5.41,	  N	  10.53.	  
Mp:	  118	  –	  121	  °C	  	  
IR	  (neat)	  ν:	  1613,	  1594,	  1496,	  1375,	  1222,	  1021,	  964,	  821	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.84	  (d,	  J	  =	  2.0	  Hz,	  1H),	  8.56	  (dd,	  J	  =	  4.8,	  1.5	  Hz,	  1H),	  
8.08	  –	  7.94	  (m,	  3H),	  7.67	  –	  7.60	  (m,	  2H),	  7.47	  –	  7.31	  (m,	  3H),	  7.09	  (d,	  J	  =	  2.8	  Hz,	  
1H),	  3.96	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  158.3,	  153.3,	  149.6,	  149.5,	  144.7,	  135.7,	  133.6,	  132.8,	  
131.4,	  131.1,	  129.7,	  128.9,	  124.1,	  123.0,	  120.1,	  105.6,	  56.0	  ppm.	  
	  
(E)-­‐2-­‐(2-­‐(pyridin-­‐4-­‐yl)vinyl)quinoline	  (175):	  
Prepared	   from	   161	   (0.143	   g,	   1	   mmol)	   and	   pirydine-­‐4-­‐
carbaldehyde	  (0.107	  g,	  1	  mmol);	  temperature	  of	  reaction:	  
130	  °C;	  yield:	  65%;	  yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C16H12N2:	   C	   82.73,	   H	   5.21,	   N	   12.06;	   found:	   C	  
82.56,	  H	  5.25,	  N	  12.07.	  
Mp:	  120	  	  123	  °C	  
IR	  (neat)	  ν:	  1673,	  1596,	  1522,	  1474,	  1413,	  1139,	  827	  cm-­‐1.	  
1H	  NMR	  (CDCl3,	  250	  MHz)	  δ	  7.87	  −	  7.51	  (m,	  8H),	  8.13	  (d,	  J	  =	  8.5,	  1H),	  8.22	  (d,	  J	  =	  
8.6,	  1H),	  8.69	  	  8.67	  (m,	  2H)	  ppm.	  
13C	  NMR	  (CDCl3,	  63	  MHz)	  δ	  155.1,	  150.8	  (2C),	  148.6,	  144.2,	  137.1,	  133.6,	  131.9,	  
130.4,	  129.8,	  128.1,	  127.9,	  127.2,	  121.8	  (2C),	  120.0	  ppm.	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(E)-­‐6-­‐methyl-­‐2-­‐(2-­‐(pyridin-­‐4-­‐yl)vinyl)quinoline	  (176):	  
Prepared	  from	  162	   (0.157	  g,	  1	  mmol)	  and	  pirydine-­‐4-­‐
carbaldehyde	   (0.107	   g,	   1	   mmol);	   temperature	   of	  
reaction:	  130	  °C;	  yield:	  76%;	  yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C17H14N2:	   C	   82.90,	   H	   5.73,	   N	   11.37;	   found:	   C	  
82.36,	  H	  5.64,	  N	  11.16.	  
Mp:	  131	  –	  134	  °C	  
IR	  (neat)	  ν:	  3028,	  1670,	  1593,	  1579,	  1408,	  1373,	  955,	  832	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.66	  –	  8.64	  (m,	  2H),	  8.10	  (d,	  J	  =	  8.5	  Hz,	  1H),	  8.01	  (d,	  J	  
=	  9.2	  Hz,	  1H),	  7.65	  (d,	  J	  =	  8.6	  Hz,	  1H),	  7.59	  –	  7.57	  (m,	  4H),	  7.49	  (dd,	  J	  =	  4.6,	  1.5	  Hz,	  
2H),	  2.57	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  154.3,	  150.8	  (2C),	  147.2,	  144.3,	  137.2,	  136.4,	  133.8,	  
132.8,	  131.3,	  129.5,	  128.1,	  126.9,	  121.7	  (2C),	  120.0,	  22.1	  ppm.	  
	  
(E)-­‐6-­‐chloro-­‐2-­‐(2-­‐(pyridin-­‐4-­‐yl)vinyl)quinoline	  (177):	  
Prepared	   from	  163	   (0.178	   g,	   1	  mmol)	   and	   pirydine-­‐4-­‐
carbaldehyde	   (0.107	   g,	   1	   mmol);	   temperature	   of	  
reaction:	  130	  °C;	  yield:	  80%;	  yellow	  solid.	  
Elemental	  analysis	   (%)	   calcd	   for	  C16H11ClN2:	  C	  72.05,	  H	  4.16,	  N	  10.50;	   found:	  C	  
71.67,	  H	  4.23,	  N	  9.95.	  
Mp:	  138	  –	  141	  °C	  
IR	  (neat)	  ν:	  3019,	  1667,	  1592,	  1581,	  1407,	  1372,	  1072,	  955,	  826	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.69	  (d,	  J	  =	  5.7	  Hz,	  2H),	  8.12	  (d,	  J	  =	  8.6	  Hz,	  1H),	  8.06	  
(d,	  J	  =	  9.0	  Hz,	  1H),	  7.83	  (d,	  J	  =	  2.1	  Hz,	  1H),	  7.72	  –	  7.68	  (m,	  2H),	  7.62	  (d,	  J	  =	  14.2	  Hz,	  
2H),	  7.53	  –	  7.51	  (m,	  2H)	  ppm.	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13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  155.3,	  150.7	  (2C),	  147.0,	  144.2,	  136.2,	  133.3,	  132.9,	  
132.3,	  131.4	  (2C),	  128.6,	  126.7,	  121.8	  (2C),	  121.0	  ppm.	  
	  
(E)-­‐6-­‐methoxy-­‐2-­‐(2-­‐(pyridin-­‐4-­‐yl)vinyl)quinoline	  (178):	  
Prepared	   from	  164	   (0.173	  g,	  1	  mmol)	  and	  pirydine-­‐4-­‐
carbaldehyde	   (0.107	   g,	   1	   mmol);	   temperature	   of	  
reaction:	  130	  °C;	  yield:	  85%;	  yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	  C17H14N2O:	  C	  77.84,	  H	  5.38,	  N	  10.68;	   found:	  C	  
78.12,	  H	  5.23,	  N	  10.40.	  
Mp:	  127	  –	  130	  °C	  
IR	  (neat)	  ν:	  1617,	  1593,	  1500,	  1479,	  1409,	  1378,	  1225,	  1026,	  834	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.67	  –	  8.65	  (m,	  2H),	  8.09	  (d,	  J	  =	  8.5	  Hz,	  1H),	  8.02	  (d,	  J	  
=	  9.3	  Hz,	  1H),	  7.66	  (d,	  J	  =	  8.6	  Hz,	  1H),	  7.58	  (s,	  2H),	  7.50	  (dd,	  J	  =	  4.6,	  1.6	  Hz,	  2H),	  
7.42	  (dd,	  J	  =	  9.2,	  2.8	  Hz,	  1H),	  7.10	  (d,	  J	  =	  2.8	  Hz,	  1H),	  3.97	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  158.5,	  152.7,	  150.5	  (2C),	  144.7,	  144.6,	  135.8,	  133.8,	  
131.3,	  130.6,	  129.2,	  123.2,	  121.7	  (2C),	  120.4,	  105.5,	  56.0	  ppm.	  
	  
(E)-­‐7-­‐methyl-­‐2-­‐(2-­‐(pyridin-­‐4-­‐yl)vinyl)quinoline	  (179):	  
Prepared	   from	  165	   (0.157	  g,	  1	  mmol)	  and	  pirydine-­‐4-­‐
carbaldehyde	   (0.107	   g,	   1	   mmol);	   temperature	   of	  
reaction:	  130	  °C;	  yield:	  45%;	  yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C17H14N2:	   C	   82.90,	   H	   5.73,	   N	   11.37;	   found:	   C	  
82.75,	  H	  5.44,	  N	  11.01.	  
Mp:	  136	  –	  139	  °C	  
IR	  (neat)	  ν:	  1671,	  1620,	  1592,	  1414,	  1301,	  984,	  835,	  812	  cm-­‐1.	  
340	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  9.	  Experimental	  section	  
1H	  NMR	   (250	  MHz,	  CDCl3)	  δ	  8.66	  –	  8.64	   (m,	  2H),	  8.35	   (dd,	   J	  =	  8.7,	  0.6	  Hz,	  1H),	  
7.97	  (d,	  J	  =	  8.5	  Hz,	  1H),	  7.69	  (d,	  J	  =	  8.8	  Hz,	  1H),	  7.64	  –	  7.58	  (m,	  3H),	  7.49	  (dd,	  J	  =	  
4.6,	  1.6	  Hz,	  2H),	  7.37	  –	  7.36	  (m,	  1H),	  2.71	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  154.6,	  150.8	  (2C),	  148.9,	  144.3,	  134.9,	  133.6,	  133.6,	  
131.7,	  130.2,	  128.1,	  127.7,	  127.4,	  121.8	  (2C),	  119.6,	  19.1	  ppm.	  
	  
(E)-­‐7-­‐chloro-­‐2-­‐(2-­‐(pyridin-­‐4-­‐yl)vinyl)quinoline	  (180):	  
Prepared	   from	  166	   (0.178	   g,	   1	  mmol)	   and	   pirydine-­‐4-­‐
carbaldehyde	   (0.107	   g,	   1	   mmol);	   temperature	   of	  
reaction:	  130	  °C;	  yield:	  87%;	  orange	  solid.	  
Elemental	  analysis	   (%)	   calcd	   for	  C16H11ClN2:	  C	  72.05,	  H	  4.16,	  N	  10.50;	   found:	  C	  
72.45,	  H	  4.34,	  N	  10.81.	  
Mp:	  149	  –	  152	  °C	  
IR	  (neat)	  ν:	  3339,	  1591,	  1495,	  1409,	  1216,	  1143,	  1065,	  980,	  836	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.70	  –	  8.67	  (m,	  2H),	  8.19	  (d,	  J	  =	  8.6	  Hz,	  1H),	  8.13	  (d,	  J	  
=	  2.0	  Hz,	  1H),	  7.77	  (d,	  J	  =	  16.5	  Hz,	  1H),	  7.73	  (d,	  J	  =	  17.8	  Hz,	  1H),	  7.67	  (d,	  J	  =	  2.3	  Hz,	  
1H),	  7.57	  (d,	  J	  =	  11.0	  Hz,	  1H),	  7.54	  –	  7.50	  (m,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.0,	  150.8	  (2C),	  149.1,	  144.0,	  136.9,	  136.3,	  133.1,	  
132.7,	  129.2,	  128.8,	  128.1,	  126.4,	  121.8	  (2C),	  120.4	  ppm.	  
	  
(E)-­‐2-­‐(4-­‐methoxystyryl)quinoline	  (181):	  
Prepared	   from	   161	   (0.143	   g,	   1	   mmol)	   and	   4-­‐
methoxybenzaldehyde	   (0.136	   g,	   1	   mmol);	  
temperature	   of	   reaction:	   180	   °C;	   yield:	   70%;	   white	  
solid.	  
9.	  Experimental	  section	   	   341	   	   	  
Elemental	   analysis	   (%)	   calcd	   for	   C18H15NO:	   C	   82.73,	   H	   5.79,	   N	   5.36;	   found:	   C	  
82.35,	  H	  6.91,	  N	  5.01.	  
Mp:	  128	  –	  131	  °C	  
IR	  (neat)	  ν:	  1615,	  1534,	  1425,	  982,	  836	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.15	  (d,	  J	  =	  8.6	  Hz,	  1H),	  8.10	  (d,	  J	  =	  8.4	  Hz,	  1H),	  7.82	  
(d,	  J	  =	  8.4	  Hz,	  1H),	  7.77	  –	  7.61	  (m,	  5H),	  7.55	  –	  7.49	  (m,	  1H),	  7.32	  (d,	  J	  =	  16.2	  Hz,	  
1H),	  6.98	  (d,	  J	  =	  8.7	  Hz,	  2H),	  3.89	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  163.9,	  160.4,	  155.9,	  136.2,	  136.0,	  134.1,	  131.0,	  129.8,	  
129.1,	  128.9	  (2C),	  127.6,	  126.8,	  119.5	  (2C),	  114.6,	  114.0,	  55.7	  ppm.	  
	  
(E)-­‐2-­‐(4-­‐methoxystyryl)-­‐6-­‐methylquinoline	  (182):	  
Prepared	   from	   162	   (0.157	   g,	   1	   mmol)	   and	   4-­‐
methoxybenzaldehyde	   (0.136	   g,	   1	   mmol);	  
temperature	   of	   reaction:	   180	   °C;	   yield:	   93%;	  
yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C19H17NO:	   C	   82.88,	   H	   6.22,	   N	   5.09;	   found:	   C	  
82.49,	  H	  5.98,	  N	  5.23.	  
Mp:	  155	  –	  158	  °C	  
IR	  (neat)	  ν:	  1651,	  1482,	  1333,	  1215,	  981,	  816	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.06	  (d,	  J	  =	  8.6	  Hz,	  1H),	  7.99	  (d,	  J	  =	  9.3	  Hz,	  1H),	  7.67	  –	  
7.55	  (m,	  6H),	  7.30	  (d,	  J	  =	  16.3	  Hz,	  1H),	  6.97	  (d,	  J	  =	  8.8	  Hz,	  2H),	  3.89	  (s,	  3H),	  2.57	  (s,	  
3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  163.9,	  160.4,	  155.9,	  136.3,	  136.1,	  134.2,	  132.4,	  132.1,	  
131.0,	  129.8,	  129.2,	  129.0	  (2C),	  126.9,	  119.5,	  114.7	  (2C),	  55.8,	  22.0	  ppm.	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(E)-­‐6-­‐chloro-­‐2-­‐(4-­‐methoxystyryl)quinoline	  (183):	  
Prepared	   from	   163	   (0.178	   g,	   1	   mmol)	   and	   4-­‐
methoxybenzaldehyde	   (0.136	   g,	   1	   mmol);	  
temperature	   of	   reaction:	   180	   °C;	   yield:	   80%;	   pale	  
yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	  C18H14ClNO:	  C	   73.10,	  H	  4.77,	  N	  4.74;	   found:	  C	  
73.30,	  H	  5.09,	  N	  4.76.	  
Mp:	  154	  	  157	  °C	  
IR	  (neat)	  ν:	  1592,	  1510,	  1487,	  1290,	  1255,	  1179,	  1026,	  968,	  824	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.05	  (d,	  J	  =	  8.5	  Hz,	  1H),	  8.02	  (d,	  J	  =	  8.6	  Hz,	  1H),	  7.78	  
(d,	  J	  =	  2.2	  Hz,	  1H),	  7.71	  (d,	  J	  =	  3.8	  Hz,	  1H),	  7.68	  –	  7.60	  (m,	  4H),	  7.28	  (d,	  J	  =	  16.3	  Hz,	  
1H),	  6.97	  (d,	  J	  =	  8.7	  Hz,	  2H),	  3.89	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  160.7,	  157.0,	  147.1,	  135.7,	  135.0,	  131.9,	  131.0,	  131.0,	  
129.5,	  129.1	  (2C),	  128.1,	  126.8,	  126.6,	  120.5,	  114.7	  (2C),	  55.8	  ppm.	  
	  
(E)-­‐6-­‐methoxy-­‐2-­‐(4-­‐methoxystyryl)quinoline	  (184):	  
Prepared	   from	   164	   (0.173	   g,	   1	   mmol)	   and	   4-­‐
methoxybenzaldehyde	   (0.136	   g,	   1	   mmol);	  
temperature	   of	   reaction:	   180	   °C;	   yield:	   80%;	  
yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C19H17NO2:	   C	   78.33,	   H	   5.88,	   N	   4.81;	   found:	   C	  
77.46,	  H	  5.87,	  N	  4.93.	  
Mp:	  155	  –	  158	  °C	  
IR	  (neat)	  ν:	  1591,	  1508,	  1479,	  1248,	  1222,	  1173,	  1025,	  829	  cm-­‐1.	  
9.	  Experimental	  section	   	   343	   	   	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.03	  (d,	  J	  =	  9.0	  Hz,	  1H),	  7.99	  (d,	  J	  =	  9.5	  Hz,	  1H),	  7.66	  –	  
7.57	  (m,	  4H),	  7.38	  (dd,	  J	  =	  9.2,	  2.8	  Hz,	  1H),	  7.27	  (d,	  J	  =	  16.4	  Hz,	  1H),	  7.08	  (d,	  J	  =	  2.7	  
Hz,	  1H),	  6.96	  (d,	  J	  =	  8.8	  Hz,	  2H),	  3.96	  (s,	  3H),	  3.88	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  160.3,	  157.9,	  154.5,	  144.7,	  135.5,	  133.3,	  130.9,	  129.9,	  
128.9	  (2C),	  128.5,	  127.3,	  122.6,	  119.9,	  114.6	  (2C),	  105.7,	  56.0,	  55.8	  ppm.	  
	  
(E)-­‐2-­‐(4-­‐methoxystyryl)-­‐7-­‐methylquinoline	  (185):	  
Prepared	   from	   165	   (0.157	   g,	   1	   mmol)	   and	   4-­‐
methoxybenzaldehyde	   (0.136	   g,	   1	   mmol);	  
temperature	   of	   reaction:	   180	   °C;	   yield:	   77%;	  
white	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C19H17NO:	   C	   82.88,	   H	   6.22,	   N	   5.09;	   found:	   C	  
82.57,	  H	  6.18,	  N	  5.32.	  
Mp:	  133	  	  135	  °C	  
IR	  (neat)	  ν:	  1594,	  1513,	  1252,	  1178,	  1030,	  814	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.31	  (d,	  J	  =	  8.8	  Hz,	  1H),	  7.95	  (d,	  J	  =	  8.5	  Hz,	  1H),	  7.72	  –	  
7.58	  (m,	  5H),	  7.35	  –	  7.29	  (m,	  2H),	  6.97	  (d,	  J	  =	  8.7	  Hz,	  2H),	  3.88	  (s,	  3H),	  2.71 (s,	  3H)	  
ppm.	  
 13C	   NMR	   (63	   MHz,	   CDCl3)	   δ	   160.5,	   156.2,	   148.9,	   134.8,	   134.3,	   133.1,	   129.9,	  
129.8,	  129.0	  (2C),	  127.8,	  127.3,	  126.9,	  126.9,	  119.1,	  114.7	  (2C),	  55.8,	  19.1,	  ppm.	  
	  
(E)-­‐7-­‐chloro-­‐2-­‐(4-­‐methoxystyryl)quinoline	  (186):	  
Prepared	   from	   166	   (0.178	   g,	   1	   mmol)	   and	   4-­‐
methoxybenzaldehyde	   (0.136	   g,	   1	   mmol);	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temperature	  of	  reaction:	  180	  °C;	  yield:	  84%;	  white	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C18H14ClNO:	  C	  73.10,	  H	  4.77,	  N	  4.74;	  found:	  C	  
73.19,	  H	  4.81,	  N	  4.86.	  
Mp:	  149	  	  151	  °C	  
IR	  (neat)	  ν:1604,	  1511,	  1408,	  1251,	  1178,	  1033,	  970,	  832	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.13	  –	  8.09	  (m,	  2H),	  7.75	  –	  7.61	  (m,	  5H),	  7.46	  (dd,	  J	  =	  
8.6,	  2.1	  Hz,	  1H),	  7.23	  (d,	  J	  =	  16.1	  Hz,	  1H),	  6.98	  (d,	  J	  =	  8.7	  Hz,	  2H),	  3.89	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  160.7,	  157.7,	  149.1,	  136.4,	  135.9,	  135.2,	  129.5,	  129.2	  
(2C),	  129.1,	  128.5,	  127.3,	  126.7,	  125.9,	  120.0,	  114.7	  (2C),	  55.8	  ppm.	  
	  
(E)-­‐7-­‐methoxy-­‐2-­‐(4-­‐methoxystyryl)quinoline	  (187):	  
Prepared	   from	   167	   (0.173	   g,	   1	   mmol)	   and	   4-­‐
methoxybenzaldehyde	   (0.136	   g,	   1	   mmol);	  
temperature	   of	   reaction:	   180	   °C;	   yield:	   81%;	  
yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C19H17NO2:	   C	   78.33,	   H	   5.88,	   N	   4.81;	   found:	   C	  
77.99,	  H	  5.79,	  N	  4.93.	  
Mp:	  167	  –	  170	  °C	  
IR	  (neat)	  ν:	  1613,	  1593,	  1509,	  1453,	  1253,	  1208,	  1171,	  1026,	  837	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.06	  (d,	  J	  =	  8.5	  Hz,	  1H),	  7.71	  –	  7.53	  (m,	  5H),	  7.43	  (d,	  J	  
=	  2.4	  Hz,	  1H),	  7.28	  (d,	  J	  =	  16.1	  Hz,	  1H),	  7.17	  (dd,	  J	  =	  7.3,	  2.5	  Hz,	  1H),	  6.97	  (d,	  J	  =	  
8.8,	  2H),	  4.00	  (s,	  3H),	  3.89	  (s,	  3H)	  ppm.	  
1C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  161.3,	  160.5,	  156.9,	  150.4,	  136.3,	  134.1,	  129.8,	  129.0	  
(2C),	  128.9,	  127.3,	  122.8,	  119.5,	  117.6,	  114.7	  (2C),	  107.05,	  55.9,	  55.8	  ppm.	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(E)-­‐2-­‐(3-­‐methoxystyryl)-­‐6-­‐methylquinoline	  (188):	  
Prepared	   from	   162	   (0.157	   g,	   1	   mmol)	   and	   3-­‐
methoxybenzaldehyde	   (0.136	   g,	   1	   mmol);	  
temperature	  of	  reaction:	  180	  °C;	  yield:	  65%;	  white	  
solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C19H17NO:	   C	   82.88,	   H	   6.22,	   N	   5.09;	   found:	   C	  
83.00,	  H	  6.12,	  N	  4.71.	  
Mp:	  71	  –	  74	  C°	  
IR	  (neat)	  ν:	  2829,	  1576,	  1486,	  1431,	  1255,	  1151,	  1046,	  823	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.08	  (d,	  J	  =	  8.6	  Hz,	  1H),	  8.01	  (d,	  J	  =	  9.2	  Hz,	  1H),	  7.69	  
(d,	  J	  =	  3.9	  Hz,	  1H),	  7.64	  (d,	  J	  =	  11.7	  Hz,	  1H),	  7.59	  –	  7.56	  (m,	  2H),	  7.42	  (d,	  J	  =	  16.4	  
Hz,	  1H),	  7.38	  –	  7.22	  (m,	  3H),	  6.94	  –	  6.90	  (m,	  1H),	  3.90	  (s,	  3H),	  2.57	  (s,	  3H)	  ppm.	  	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  160.3,	  155.5,	  147.2,	  138.4,	  136.6,	  136.1,	  134.2,	  132.5,	  
130.2,	  129.8,	  129.3,	  127.8,	  126.9,	  120.5,	  119.6,	  115.1,	  112.2,	  55.7,	  22.0	  ppm.	  
	  
(E)-­‐6-­‐chloro-­‐2-­‐(3-­‐methoxystyryl)quinoline	  (189):	  
Prepared	   from	   163	   (0.178	   g,	   1	   mmol)	   and	   3-­‐
methoxybenzaldehyde	   (0.136	   g,	   1	   mmol);	  
temperature	  of	  reaction:	  180	  °C;	  yield:	  90%;	  white	  
solid.	  
Elemental	   analysis	   (%)	   calcd	   for	  C18H14ClNO:	  C	   73.10,	  H	  4.77,	  N	  4.74;	   found:	  C	  
73.04,	  H	  4.80,	  N	  4.82.	  	  
Mp:	  108	  	  111	  °C	  
IR	  (neat)	  ν:	  1580,	  1428,	  1393,	  1272,	  969,	  884	  cm-­‐1.	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1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.06	  (J	  =	  7.9	  Hz,	  1H),	  8.03	  (d,	  J	  =	  8.1	  Hz,	  1H),	  7.79	  (d,	  J	  
=	  2.3	  Hz,	  1H),	  7.72	  –	  7.65	  (m,	  3H),	  7.39	  (d,	  J	  =	  16.6,	  1H),	  7.38	  –	  7.21	  (m,	  3H),	  6.92	  
(ddd,	  J	  =	  8.0,	  2.5,	  2.4	  Hz,	  1H),	  3.89	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  55.7,	  112.4,	  115.3,	  120.5,	  120.6,	  126.7,	  128.2,	  129.2,	  
130.2,	  131.0,	  131.1,	  132.2,	  135.2,	  135.8,	  138.1,	  147.0,	  156.6,	  160.3	  ppm.	  
	  
(E)-­‐2-­‐(4-­‐fluorostyryl)quinoline	  (190):	  
Prepared	   from	   161	   (0.143	   g,	   1	   mmol)	   and	   4-­‐
fluorobenzaldehyde	   (0.124	   g,	   1	   mmol);	   temperature	   of	  
reaction:	  150	  °C;	  yield:	  65%;	  white	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C17H12FN:	   C	   81.91,	   H	   4.85,	   N	   5.62;	   found:	   C	  
82.06,	  H	  4.71,	  N	  5.29.	  
Mp:	  114	  –	  117	  °C	  
IR	  (neat)	  ν:	  1593,	  1552,	  1505,	  1216,	  826,	  751	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.16	  (d,	  J	  =	  8.8	  Hz,	  1H),	  8.11	  (d,	  J	  =	  8.5	  Hz,	  1H),	  7.83	  –	  
7.80	  (m,	  1H),	  7.78	  –	  7.62	  (m,	  5H),	  7.53	  (ddd,	  J	  =	  8.1,	  7.0,	  1.1	  Hz,	  1H),	  7.35	  (d,	  J	  =	  
16.3	  Hz,	  1H),	  7.12	  (dd,	  J	  =	  9.6,	  7.7	  Hz,	  2H)	  ppm.	  
13C	  NMR	   (63	  MHz,	  CDCl3)	  δ	  163.4	   (d,	   J	   =	  248.7	  Hz),	  156.2,	  148.7,	  136.8,	  133.6,	  
133.1	  (d,	  J	  =	  3.4	  Hz),	  130.2,	  129.6,	  129.3	  (d,	  J	  =	  8.2	  Hz,	  2C),	  129.1,	  127.9,	  127.8,	  
126.6,	  119.7,	  116.3	  (d,	  J	  =	  21.8	  Hz,	  2C).	  ppm.	  
	  
(E)-­‐2-­‐(4-­‐fluorostyryl)-­‐6-­‐methylquinoline	  (191):	  
Prepared	   from	   162	   (0.157	   g,	   1	   mmol)	   and	   4-­‐
fluorobenzaldehyde	  (0.124	  g,	  1	  mmol);	  temperature	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of	  reaction:	  150	  °C;	  yield:	  84%;	  white	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C18H14FN:	   C	   82.11,	   H	   5.36,	   N	   5.32;	   found:	   C	  
81.73,	  H	  5.27,	  N	  4.95.	  
Mp:	  145	  –	  148	  °C	  
IR	  (neat)	  ν:	  3031,	  1740,	  1591,	  1507,	  1373,	  1215,	  966,	  830	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.07	  (d,	  J	  =	  8.6	  Hz,	  1H),	  8.00	  (d,	  J	  =	  9.2	  Hz,	  1H),	  7.69	  –	  
7.56	  (m,	  6H),	  7.33	  (d,	  J	  =	  16.6	  Hz,	  1H),	  7.16	  	  7.09	  (m,	  2H),	  2.57	  (s,	  3H)	  ppm.	  
13C	  NMR	   (63	  MHz,	  CDCl3)	  δ	  167.21	  (d,	  J	  =	  245.8	  Hz),	  161.3,	  155.4,	  147.2,	  136.6,	  
136.2,	  133.3	  (d,	  J	  =	  3.4	  Hz),	  133.0,	  132.5,	  129.3	  (2C),	  129.1,	  127.8,	  126.9,	  119.7,	  
116.2	  (d,	  J	  =	  21.7	  Hz,	  2C),	  22.0	  ppm.	  
	  
(E)-­‐6-­‐chloro-­‐2-­‐(4-­‐fluorostyryl)quinoline	  (192):	  
Prepared	   from	   163	   (0.178	   g,	   1	   mmol)	   and	   4-­‐
fluorobenzaldehyde	   (0.124	   g,	   1	  mmol);	   temperature	  
of	  reaction:	  150	  °C;	  yield:	  95%;	  pale	  yellow	  solid.	  	  
Elemental	   analysis	   (%)	   calcd	   for	   C17H11ClFN:	   C	   71.96,	   H	   3.91,	   N	   4.94;	   found:	   C	  
72.18,	  H	  4.05,	  N	  5.16.	  
Mp:	  140	  	  143	  °C	  
IR	  (neat)	  ν:	  1593,	  1512,	  1222,	  968,	  887,	  830	  cm-­‐1.	  
1H	  NMR	   (250	  MHz,	  CDCl3)	  δ	  8.06	   	  8.04	  (m,	  2H),	  7.80	   (d,	   J	  =	  2.2	  Hz,	  1H),	   ,	  7.73	   	  
7.61	  (m,	  5H),	  7.30	  (d,	  J	  =	  16.3	  Hz,	  1H),	  7.16	  	  7.10	  (m,	  2H)	  ppm.	  
13C	  NMR	   (63	  MHz,	  CDCl3)	  δ	  163.4	   (d,	   J	   =	  249.2	  Hz),	  156.4,	  147.0,	  134.0,	  135.9,	  
133.0,	  132.3,	  131.2,	  131.1,	  129.4	   (d,	  J	  =	  8.2	  Hz,	  2C),	  128.6,	  128,3,	  126.6,	  120.7,	  
116.3	  (d,	  J	  =	  21.8	  Hz,	  2C),	  ppm.	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  (E)-­‐2-­‐(4-­‐fluorostyryl)-­‐6-­‐methoxyquinoline	  (193):	  
Prepared	   from	   164	   (0.173	   g,	   1	   mmol)	   and	   4-­‐
fluorobenzaldehyde	  (0.124	  g,	  1	  mmol);	  temperature	  
of	  reaction:	  150	  °C;	  yield:	  86%;	  pale	  yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C18H14FNO:	   C	   77.40,	   H	   5.05,	   N	   5.01;	   found:	   C	  
77.15,	  H	  5.01,	  N	  4.77.	  
Mp:	  138	  	  141°C	  
IR	  (neat)	  ν:	  1592,	  1510,	  1232,	  1164,	  1031,	  965,	  856,	  837	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.05	  (d,	  J	  =	  8.4	  Hz,	  1H),	  8.02	  (d,	  J	  =	  8.9	  Hz,	  1H),	  7.65	  	  
7.58	  (m,	  4H),	  7.39	  (dd,	  J	  =	  9.3,	  2.8	  Hz,	  1H),	  7.33	  (d,	  J	  =	  16.6	  Hz,	  1H),	  7.14	  	  7.08	  (m,	  
3H),	  3.96	  (s,	  3H),	  ppm.	  
13C	  NMR	   (63	  MHz,	   CDCl3)	   δ163.2	   (d,	   J	  =	   248.4	  Hz),	   158.1,	   153.9,	   144.6,	   135.7,	  
133.3,	  133.2,	  132.5,	  130.9,	  129	  (d,	  J	  =	  8.1	  Hz,	  2C),	  128.7,	  122.9,	  119.2,	  116.2	  (d,	  J	  
=	  21.7	  Hz,	  2C),	  105.6,	  56.0	  ppm.	  	  
	  
(E)-­‐2-­‐(4-­‐fluorostyryl)-­‐7-­‐methylquinoline	  (194):	  
Prepared	   from	   165	   (0.157	   g,	   1	   mmol)	   and	   4-­‐
fluorobenzaldehyde	  (0.124	  g,	  1	  mmol);	  temperature	  
of	  reaction:	  150	  °C;	  yield:	  64%;	  white	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C18H14FN:	   C	   82.11,	   H	   5.36,	   N	   5.32;	   found:	   C	  
81.83,	  H	  5.30,	  N	  5.44.	  
Mp:	  105	  –	  108	  °C	  
IR	  (neat)	  ν:	  1590,	  1505,	  1226,	  1160,	  984,	  833	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.31	  (d,	  J	  =	  8.8	  Hz,	  1H),	  7.96	  (d,	  J	  =	  8.5	  Hz,	  1H),	  7.69	  –	  
7.60	  (m,	  5H),	  7.37	  	  7.31	  (m,	  2H),	  7.15	  	  7.08	  (m,	  2H),	  2.71	  (s,3H)	  ppm.	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13C	  NMR	   (63	  MHz,	  CDCl3)	  δ	  163.3	   (d,	   J	   =	  248.6	  Hz),	  155.7,	  148.9,	  134.9,	  133.4,	  
133.3,	  133.2	  (d,	  J	  =	  3.4	  Hz),	  129.9,	  129.3	  (d,	  J	  =	  8.1	  Hz,	  2C),	  129.1,	  127.9,	  127.2,	  
127.1,	  119.3,	  116.2	  (d,	  J	  =	  21.8	  Hz,	  2C),	  19.1	  ppm.	  
	  
	  (E)-­‐2-­‐(4-­‐fluorostyryl)-­‐7-­‐methoxyquinoline	  (195):	  
Prepared	   from	   167	   (0.173	   g,	   1	   mmol)	   and	   4-­‐
fluorobenzaldehyde	   (0.124	   g,	   1	   mmol);	  
temperature	  of	  reaction:	  150	  °C;	  yield:	  61%;	  white	  
solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C18H14FNO:	   C	   77.40,	   H	   5.05,	   N	   5.01;	   found:	   C	  
77.04,	  H	  5.01,	  N	  5.11.	  
Mp:	  123	  –	  126	  °C	  
IR	  (neat)	  ν:	  1618,	  1593,	  1458,	  1381,	  1217,	  1024,	  831	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.08	  (d,	  J	  =	  8.4	  Hz,	  1H),	  7.71	  –	  7.60	  (m,	  4H),	  7.53	  (d,	  J	  
=	  8.5	  Hz,	  1H),	  7.44	  (d,	  J	  =	  2.4	  Hz,	  1H),	  7.31	  (d,	  J	  =	  16.3	  Hz,	  1H),	  7.19	  (dd,	  J	  =	  8.9,	  
2.5	  Hz,	  1H),	  7.16	  	  7.09	  (m,	  J	  =	  2H),	  4.00	  (s,	  3H)	  ppm.	  
13C	  NMR	   (63	  MHz,	  CDCl3)	  δ	  163.1	   (d,	   J	   =	  273.3	  Hz),	  161.4,	  156.3,	  150.3,	  136.5,	  
133.3,	  133.2,	  129.2	  (d,	  J	  =	  8.2	  Hz,	  2C),	  129.1,	  128.9,	  123.0,	  119.8,	  117.7,	  116.2	  (d,	  
J	  =	  21.8	  Hz,	  2C),	  107.5,	  56.0	  ppm	  
	  
(E)-­‐7-­‐methoxy-­‐2-­‐styrylquinoline	  (196):	  
Prepared	   from	   167	   (0.173	   g,	   1	   mmol)	  
andbenzaldehyde	   (0.106	  g,	  1	  mmol);	   temperature	  of	  
reaction:	  150	  °C;	  yield:	  78%;	  white	  solid.	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  section	  
Elemental	   analysis	   (%)	   calcd	   for	   C18H15NO:	   C	   82.73,	   H	   5.79,	   N	   5.36;	   found:	   C	  
82.55,	  H	  5.82,	  N	  5.57.	  
Mp:	  86	  	  89	  °C	  	  
IR	  (neat)	  ν:	  1619,	  1596,	  1510,	  1458,	  1383,	  1262,	  1218,	  1028,	  922,	  835	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ 8.09	  (d,	  J	  =	  8.4Hz,1H),	  7.75	  	  7.66	  (m,	  4H),	  7.56	  (d,	  J	  =	  
8.4	  Hz,	  1H),	  7.47	  	  7.35	  (m,	  5H),	  7.18	  (dd,	  J	  =	  8.9,	  2.5	  Hz,	  1H),	  4.00	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ 161.4,	  156.5,	  150.4,	  137.0,	  136.4,	  134.5,	  129.4,	  129.2	  
(2C),	  128.9,	  128.9,	  127.6	  (2C),	  123.0,	  119.7,	  117.7,	  107.5,	  55.9	  ppm.	  
	  
6-­‐chloro-­‐2-­‐((1E,3E)-­‐4-­‐phenylbuta-­‐1,3-­‐dienyl)quinoline	  (197):	  
Prepared	   from	   163	   (0.178	   g,	   1	   mmol)	   and	  
cinnamaldehyde	  (0.132	  g,	  1	  mmol);	  temperature	  of	  
reaction:	  150	  °C;	  yield:	  93%;	  yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C19H14ClN:	   C	   78.21,	   H	   4.84,	   N	   4.80;	   found:	   C	  
78.45,	  H	  5.01,	  N	  5.03. 
Mp:	  105	  	  108	  °C	  
IR	  (neat)	  ν:1590,	  1486,	  1070,	  1002,	  892,	  826,	  752	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.04	  (d,	  J	  =	  8.5	  Hz,	  1H),	  8.01	  (d,	  J	  =	  8.9	  Hz,	  1H),	  7.78	  
(d,	  J	  =	  2.3	  Hz,	  1H),	  7.65	  (dd,	  J	  =	  9.0,	  2.3	  Hz,	  1H),	  7.62	  	  7.52	  (m,	  4H),	  7.43	  	  7.31	  (m,	  
3H),	  7.15	  	  6.87	  (m,	  3H),	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.6,	  147.1,	  137.3,	  136.8,	  135.8,	  135.7,	  132.7,	  132.1,	  
131.1,	  131.0,	  129.2	  (2C),	  128.8,	  128.7,	  128.2,	  127.2	  (2C),	  126.6,	  120.8	  ppm.	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2-­‐((1E,3E)-­‐4-­‐(4-­‐chlorophenyl)buta-­‐1,3-­‐dienyl)-­‐6-­‐methylquinoline	  (198):	  
Prepared	   from	  165	   (0.157	   g,	   1	  mmol)	   and	  143	  
(0.167	  g,	  1	  mmol);	  temperature	  of	  reaction:	  150	  
°C;	  yield:	  74%;	  yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C20H16ClN:	   C	  
78.55,	  H	  5.27,	  N	  4.58;	  found:	  C	  78.26,	  H	  5.05,	  N	  4.26.	  
Mp:	  210	  	  213°C	  
IR	  (neat)	  ν:	  1589,	  1489,	  1087,	  986,	  820	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.07	  	  7.98	  (m,	  2H)	  7.60	  	  7.33	  (m,	  8H),	  7.11	  	  6.97	  (m,	  
2H),	  6.82	  (d,	  J	  =	  15.6	  Hz,	  1H),	  2.56	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  155.3,	  147.2,	  136.6,	  136.1,	  135.9,	  134.6,	  134.4,	  134.0,	  
133.8,	  132.5,	  129.6,	  129.3	  (2C),	  129.2,	  128.3	  (2C),	  127.7,	  126.8,	  119.8,	  22.0	  ppm.	  
	  
6-­‐methoxy-­‐2-­‐((1E,3E)-­‐4-­‐(2-­‐nitrophenyl)buta-­‐1,3-­‐dienyl)quinoline	  (199):	  
Prepared	  from	  164	  (0.173	  g,	  1	  mmol)	  and	  trans-­‐2-­‐
nitrocinnamaldehyde	   (0.177	   g,	   1	   mmol);	  
temperature	  of	  reaction:	  130	  °C;	  yield:	  72%;	  yellow	  
solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C20H16N2O3:	   C	   72.28,	  H	   4.85,	  N	   8.43;	   found:	   C	  
72.01,	  H	  5.01,	  N	  8.21.	  
Mp:	  181	  –	  183	  °C	  
IR	  (neat)	  ν:	  1647,	  1629,	  1517,	  1345,	  1282,	  986	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.07	  –	  7.95	  (m,	  3H),	  7.78	  (d,	  J	  =	  7.5	  Hz,	  1H),	  7.65	  –	  
7.32	  (m,	  6H),	  7.12	  	  7.02	  (m,	  3H),	  3.96	  (s,	  3H)	  ppm.	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  9.	  Experimental	  section	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  158.4,	  153.3,	  148.3,	  144.3,	  135.8,	  135.5,	  134.0,	  133.7,	  
133.4,	  132.8,	  130.9,	  129.8,	  128.9,	  128.6,	  128.3,	  125.3,	  123.1,	  119.9,	  105.6,	  56.0	  
ppm.	  
	  
9.5.3.	  Synthesis	  of	  2-­‐styryquinolines	  by	  base-­‐catalyzed	  aldol	  condensation	  
Equivalent	  moles	   of	   the	   suitable	   quinaldine	   (1.5	  mmol)	   and	   the	   corresponding	  
aldehyde	  (1.5	  mmol)	  were	  dissolved	  in	  3	  ml	  of	  dry	  DMF.	  The	  solution	  was	  stirred	  
in	  a	  round	  bottom	  flask	  attached	  to	  a	  drying	  tube.	  Lithium	  hydride	  (30	  mg,	  3.75	  
mmol)	  and	  potassium	  t-­‐butoxide	  (0.213	  g,	  1.9	  mmol)	  were	  added	  to	  solution	  one	  
after	  another	  and	  the	  reaction	  mixture	  was	  stirred	  for	  24	  h.	  Then,	  it	  was	  poured	  
into	  the	  beaker	  containing	  ice	  and	  saturated	  ammonium	  chloride	  (NH4Cl)	  and	  the	  
mixture	  was	  stirred	  for	  about	  15	  minutes	  until	  the	  formation	  of	  a	  precipitate.	  The	  
resulting	   solid	   was	   filtered	   and	   washed	   with	   cold	   water,	   collected	   and	   dried	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(E)-­‐N,N-­‐dimethyl-­‐4-­‐(2-­‐(quinolin-­‐2-­‐yl)vinyl)aniline	  (200):	  
Prepared	   from	   161	   (0.215	   g,	   1.5	   mmol)	   and	   4-­‐
(dimethylamino)benzaldehyde	   (0.223	   g,	   1.5	   mmol);	  
yield:	  66%;	  red	  solid.	  
Elemental	  analysis	   (%)	  calcd	  for	  C19H18N2:	  C	  83.18,	  H	  
6.61,	  N	  10.21;	  found:	  C	  83.46,	  H	  6.66,	  N	  10.43.	  
Mp:	  129	  	  132	  °C	  
IR	  (neat)	  ν:	  3023,	  2804,	  1594,	  1524,	  1363,	  1187,	  965,	  823	  cm-­‐1.	  
1H	  NMR	   (250	  MHz,	  CDCl3)	  δ	  8.11	   (d,	   J	  =	  8.6	  Hz,	  2H),	  7.80	   	  7.74	   (m,	  1H),	  7.71	  –	  
7.68	  (m,	  2H),	  7.62	  –	  7.51	  (m,	  3H),	  7.52	  7.46	  (m,	  1H),	  7.28	  (d,	  J	  =	  16.3	  Hz,	  1H),	  6.76	  
(d,	  J	  =	  8.8	  Hz,	  2H),	  3.05	  (s,	  6H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  157.2,	  151.2,	  136.7,	  130.3,	  130.1,	  129.2,	  129.1	  (2C),	  
127.9,	  127.4,	  126.1,	  124.9,	  124.4,	  123.7,	  119.4,	  112.6	  (2C),	  40.7	  (2C)	  ppm.	  
	  
(E)-­‐N,N-­‐dimethyl-­‐4-­‐(2-­‐(6-­‐methylquinolin-­‐2-­‐yl)vinyl)aniline	  (201):	  
Prepared	   from	   162	   (0.236	   g,	   1.5	   mmol)	   and	   4-­‐
(dimethylamino)benzaldehyde	   (0.223	   g,	   1.5	  
mmol);	  yield:	  81%;	  orange	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C20H20N2:	   C	  
83.30,	  H	  6.99,	  N	  9.71;	  found:	  C	  83.64,	  H	  7.00,	  N	  10.03.	  
Mp:	  146	  –	  149	  °C	  
IR	  (neat)	  ν:	  3147,	  3029,	  2910,	  1606,	  1587,	  1523,	  1364,	  1181,	  1164,	  827	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.02	  (d,	  J	  =	  8.5	  Hz,	  1H),	  7.99	  (d,	  J	  =	  8.7	  Hz,	  1H),	  7.67	  	  
7.52	  (m,	  6H),	  7.26	  (d,	  J	  =	  16.9	  Hz,	  1H),	  6.76	  (d,	  J	  =	  8.8	  Hz,	  2H),	  3.04	  (s,	  6H),	  2.55	  (s,	  
3H)	  ppm.	  
354	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  9.	  Experimental	  section	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.4,	  151.1,	  138.8,	  136.0,	  135.9,	  135.0,	  132.3,	  129.0	  
(2C),	  128.8,	  127.4,	  126.9,	  125.1,	  124.6,	  119.3,	  112.6	  (2C),	  40.8	  (2C),	  22.0	  ppm.	  
	  
(E)-­‐4-­‐(2-­‐(6-­‐chloroquinolin-­‐2-­‐yl)vinyl)-­‐N,N-­‐dimethylaniline	  (202):	  
Prepared	   from	   163	   (0.266	   g,	   1.5	  mmol)	   and	   4-­‐
(dimethylamino)benzaldehyde	   (0.223	   g,	   1.5	  
mmol);	  yield:	  90%;	  red	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C19H17ClN2:	   C	  
73.90,	  H	  5.55,	  N	  9.07;	  found:	  C	  73.67,	  H	  5.39,	  N	  9.19.	  
Mp:155	  –	  158	  °C	  
IR	  (neat)	  ν:	  3025,	  2801,	  1591,	  1521,	  1357,	  1065,	  971,	  822	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  7.99	  (d,	  J	  =	  8.8	  Hz,	  2H),	  7.75	  –	  7.54	  (m,	  6H),	  7.20	  (d,	  J	  
=	  16.3	  Hz,	  1H),	  6.75	  (d,	  J	  =	  8.3	  Hz,	  2H),	  3.04	  (s,	  6H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  157.6,	  151.3,	  147.1,	  135.8,	  135.5,	  131.5,	  130.8,	  129.3,	  
129.1	  (2C),	  127.9,	  126.6,	  124.8,	  124.2,	  120.4,	  112.6	  (2C),	  40.7	  (2C)	  ppm.	  
	  
(E)-­‐4-­‐(2-­‐(6-­‐methoxyquinolin-­‐2-­‐yl)vinyl)-­‐N,N-­‐dimethylaniline	  (203):	  
Prepared	   from	   164	   (0.260	   g,	   1.5	  mmol)	   and	   4-­‐
(dimethylamino)benzaldehyde	   (0.223	   g,	   1.5	  
mmol);	  yield:	  63%;	  red	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C20H20N2O:	   C	  
78.92,	  H	  6.62,	  N	  9.20;	  found:	  C	  77.82,	  H	  6.51,	  N	  9.97.	  
Mp:	  160	  –	  163	  °C	  
IR	  (neat)	  ν:	  3130,	  3033,	  2890,	  1607,	  1591,	  1226,	  1163,	  831	  cm-­‐1.	  
9.	  Experimental	  section	   	   355	   	   	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  7.99	  (d,	  J	  =	  8.9	  Hz,	  2H),	  7.65	  –	  7.53	  (m,	  4H),	  7.36	  (dd,	  
J	  =	  9.2,	  2.7	  Hz,	  1H),	  7.22	  (d,	  J	  =	  16.3	  Hz,	  1H),	  7.06	  (d,	  J	  =	  2.7	  Hz,	  1H),	  6.75	  (d,	  J	  =	  
8.8	  Hz,	  2H),	  3.94	  (s,	  3H),	  3.03	  (s,	  6H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  157.7,	  155.0,	  151.1,	  144.4,	  135.4,	  134.3,	  130.6,	  128.9	  
(2C),	  128.3,	  125.2,	  124.7,	  122.5,	  119.7,	  112.6	  (2C),	  105.8,	  55.9,	  40.8	  (2C)	  ppm.	  
	  
(E)-­‐1,2-­‐di(quinolin-­‐2-­‐yl)ethene	  (204):	  
Prepared	  from	  161	  (0.215	  g,	  1.5	  mmol)	  and	  quinoline-­‐
2-­‐carbaldehyde	   (0.236	   g,	   1.5	   mmol);	   yield:	   58%;	  
yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	   C20H14N2:	   C	   85.08,	   H	   5.00,	   N	   9.92;	   found:	   C	  
84.81,	  H	  5.23,	  N	  10.01.	  
Mp:	  115	  –	  118	  °C	  
IR	  (neat)	  ν:	  1622,	  1407,	  1328,	  1213,	  1140,	  828,	  745	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.34	  (s,	  2H),	  8.24	  (d,	  J	  =	  8.5	  Hz,	  1H),	  7.90	  (dd,	  J	  =	  8.1,	  
0.9	  Hz,	  1H),	  7.82	  –	  7.76	  (m,	  2H),	  7.65	  –	  7.56	  (m,	  4H),	  7.37	  –	  7.29	  (m,	  2H),	  7.11	  –	  
7.01	  (m,	  2H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  182.7,	  156.6,	  155.0,	  147.8,	  138.1,	  137.3,	  137.0,	  131.6,	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  9.	  Experimental	  section	  
9.5.4.	  Synthesis	  of	  4-­‐amino-­‐2-­‐styrylquinolines	  
9.5.4.1.	  Preparation	  of	  β-­‐enaminones	  
To	   a	   stirred	   solution	   of	   3	   mmol	   of	   the	   suitable	   amine	   and	   3	   mmol	   of	   ethyl	  
acetoacetate	   in	  3	  ml	  of	  EtOH	  was	  added	  5%	  mol	  of	  CAN	  (0.247	  g).	  The	  mixture	  
was	  stirred	  at	  r.t.	  for	  2	  hours.	  After	  completion	  of	  the	  reaction	  the	  mixture	  was	  
dissolved	   in	   CH2Cl2,	   washed	   with	   H2O,	   dried,	   and	   evaporated.	   No	   further	  
purification	  was	  needed.	  
	  
Cmpd.	   R1	  
205	   H	  
206	   CH3	  
207	   Cl	  
208	   OCH3	  
	  
(Z)-­‐ethyl	  3-­‐(phenylamino)but-­‐2-­‐enoate	  (205):	  
Prepared	   from	   aniline	   (0.280	   g,	   3	   mmol)	   and	   ethyl	  
acetoacetate	  (0.390	  g,	  3	  mmol);	  yield:	  89%;	  black	  oil.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  10.42	  (br	  s,	  1H),	  7.35	  (dd,	  J	  =	  10.6,	  
5.1	  Hz,	  2H),	  7.22	  –	  7.09	  (m,	  3H),	  4.72	  (s,	  1H),	  4.18	  (q,	  J	  =	  7.1	  Hz,	  2H),	  2.02	  (s,	  3H),	  
1.31	  (t,	  J	  =	  7.1	  Hz,	  3H)	  ppm.	  	  
13C	   NMR	   (63	  MHz,	   CDCl3)	   δ	   170.8,	   159.3,	   139.8,	   129.5	   (2C),	   125.3,	   124.7(2C),	  
86.5,	  59.1,	  20.7,	  15.0	  ppm.	  
9.	  Experimental	  section	   	   357	   	   	  
(Z)-­‐ethyl	  3-­‐(p-­‐tolylamino)but-­‐2-­‐enoate	  (206):	  
Prepared	   from	   p-­‐toluidine	   (0.321	   g,	   3	   mmol)	   and	   ethyl	  
acetoacetate	  (0.390	  g,	  3	  mmol);	  yield:	  86%;	  black	  oil.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  10.31	  (br	  s,	  1H),	  7.15	  (d,	  J	  =	  8.1	  
Hz,	  2H),	  7.00	  (d,	  J=	  8.3	  Hz,	  2H),	  4.69	  (s,	  1H),	  4.17	  (q,	  J	  =	  7.1	  Hz,	  2H),	  2.36	  (s,	  3H),	  
1.98	  (s,	  3H),	  1.31	  (t,	  J	  =	  7.1	  Hz,	  3H)	  ppm.	  
	  
(Z)-­‐ethyl	  3-­‐(4-­‐chlorophenylamino)but-­‐2-­‐enoate	  (207):	  
Prepared	   from	   4-­‐chloroaniline	   (0.383	   g,	   3	  mmol)	   and	   ethyl	  
acetoacetate	  (0.390	  g,	  3	  mmol);	  yield:	  79%;	  black	  oil.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  10.37	  (br	  s,	  1H),	  7.31	  (d,	  J	  =	  8.9	  
Hz,	  2H),	  7.03	  (d,	  J	  =	  8.7	  Hz,	  2H),	  4.74	  (s,	  1H),	  4.17	  (q,	  J	  =	  7.2	  Hz,	  2H),	  2.00	  (s,	  3H),	  
1.31	  (t,	  J	  =	  7.1	  Hz,	  3H)	  ppm.	  
	  
(Z)-­‐ethyl	  3-­‐(4-­‐methoxyphenylamino)but-­‐2-­‐enoate	  (208):	  
Prepared	   from	   p-­‐anisidine	   (0.370	   g,	   3	   mmol)	   and	   ethyl	  
acetoacetate	  (0.390	  g,	  3	  mmol);	  yield:	  75%;	  black	  oil.	  
1H	  NMR	   (250	  MHz,	  CDCl3)	  δ	  10.17	   (br	   s,	  1H),	  7.04	   (d,	   J	   =	  
8.8	  Hz,	  2H),	  6.87	  (d,	  J	  =	  8.8	  Hz,	  2H),	  4.67	  (s,	  1H),	  4.16	  (q,	  J	  =	  7.1	  Hz,	  2H),	  3.82	  (s,	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  9.	  Experimental	  section	  
9.5.4.2.	  General	  procedure	  for	  preparing	  quinolone	  compounds	  	  
Diphenyl	   ether	   (30	  ml)	   was	   stirred	   and	   heated	   at	   reflux	   while	   a	  β-­‐enaminone	  
compound	  (209-­‐210)	  was	  added	  rapidly.	  Stirring	  and	  refluxing	  continued	  for	  10-­‐
15	  until	  no	  more	  ethanol	  is	  separated	  by	  using	  the	  Dean-­‐Stark	  trap.	  The	  mixture	  
was	  allowed	  to	  cool	  down	  to	  r.t.	  while	  precipitation	  arises.	  The	  solid	  was	  filtered	  
off	  and	  washed	  with	  hexane	  and	  acetone.	  No	  further	  purification	  was	  needed.	  
	  
Cmpd.	   R1	  
209	   H	  
210	   CH3	  
211	   Cl	  
212	   OCH3	  
	  
2-­‐methylquinolin-­‐4(1H)-­‐one	  (209):	  
Prepared	  from	  205	  (4.00	  g,	  19.5	  mmol);	  yield:	  57%;	  grey	  powder.	  
1H	  NMR	  (300	  MHz,	  DMSO)	  δ	  11.71	  (br	  s,	  1H),	  8.19	  (d,	  J	  =	  7.1	  Hz,	  
1H),	  7.80	  –	  7.74	  (m,	  1H),	  7.65	  (d,	  J	  =	  8.2	  Hz,	  1H),	  7.46	  –	  7.40	  (m,	  
1H),	  6.07	  (s,	  1H),	  2.50	  (s,	  3H)	  ppm.	  
13C	   NMR	   (63	  MHz,	   DMSO)	   δ	   177.1,	   150.0,	   140.5,	   131.80,	   125.2,	   124.9,	   123.1,	  
118.1,	  108.8,	  19.8	  ppm.	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2,6-­‐dimethylquinolin-­‐4(1H)-­‐one	  (210):	  
Prepared	   from	  206	   (4.275	   g,	   19.5	  mmol);	   yield:	   73%;	   pale	  
brown	  solid.	  
1H	  NMR	   (250	  MHz,	  DMSO)	  δ	  11.64	  (br	  s,	  1H),	  7.95	  (s,	  1H),	  
7.58	  –	  7.49	  (m,	  2H),	  5.99	  (s,	  1H),	  2.50	  (s,	  3H),	  2.44	  (s,	  3H)	  ppm.	  
	  
6-­‐chloro-­‐2-­‐methylquinolin-­‐4(1H)-­‐one	  (211):	  
Prepared	   from	   207	   (4.674	   g,	   19.5	   mmol);	   yield:	   65%;	   grey	  
solid.	  
1H	  NMR	   (250	  MHz,	  DMSO)	  δ	  11.87	  (br	  s,	  1H),	  8.08	  (d,	  J	  =	  2.5	  




Prepared	  from	  208	  (4.590	  g,	  19.5	  mmol);	  yield:	  60%;	  brown	  
solid.	  
1H	  NMR	   (250	  MHz,	  DMSO)	  δ	   11.57	   (br	   s,	   1H),	   7.48	   –	   7.45	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9.5.4.3.	  4-­‐chloro-­‐2-­‐methylquinoline	  (213):	  
	  
2-­‐methylquinolinone	   209	   (0.300	   g,	   1.88	   mmol)	   was	   added	   portionwise	   to	   a	  
solution	   of	   an	   excess	   of	   phosphorus	   oxychloride	   (30	   ml)	   at	   0	   oC.	   After	   being	  
stirred	  for	  30	  min	  at	  r.t.,	  the	  reaction	  mixture	  was	  heated	  at	  80	  °C	  for	  30	  min	  to	  1	  
h.	   The	   excess	   of	   phosphorus	   oxychloride	   was	   removed	   by	   vacuum	   distillation.	  
The	   residue	   was	   poured	   slowly	   onto	   a	   mixture	   of	   crushed	   ice	   and	   saturated	  
NaHCO3	  solution	  with	  vigorous	  stirring.	  The	  pH	  of	   the	  solution	  was	  adjusted	   to	  
about	   9.0	   by	   addition	   of	   ammonium	   hydroxide.	   The	   formed	   precipitate	   was	  
collected	  by	  filtration	  to	  afford	  compound	  213	  in	  81%	  yield	  as	  a	  white	  solid.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.20	  (dd,	  J	  =	  8.3,	  1.0	  Hz,	  1H),	  8.06	  (d,	  J	  =	  8.4	  Hz,	  1H),	  
7.76	  (ddd,	  J	  =	  8.4,	  7.0,	  1.4	  Hz,	  1H),	  7.65	  –	  7.54	  (m,	  1H),	  7.42	  (s,	  1H),	  2.75	  (s,	  3H)	  
ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  159.3,	  149.1,	  143.0,	  130.8,	  129.3,	  127.1,	  124.3,	  122.4,	  
122.4,	  25.6	  ppm.	  
	  
9.5.4.4.	  General	  procedure	  for	  the	  condensation	  between	  methylquinolinones	  
and	  benzaldehyde	  
The	   suitable	   2-­‐methyquinolinone	   compound	   (1	   mmol)	   (209-­‐212)	   and	  
benzaldehyde	   (1	   mmol)	   were	   suspended	   in	   Ac2O	   (0.5	   ml)	   in	   a	   pressure-­‐tight	  
microwave	   tube	   containing	   a	   stirring	   bar.	   The	   mixture	   was	   heated	   under	  
microwave	   irradiation	   for	   1	   h	   at	   150	   °C,	   with	   an	   irradiation	   power	   of	   200	  W,	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using	   a	   CEM	   Discover	   SP	  microwave	   reactor.	   The	   solvent	   was	   removed	   under	  
reduced	  pressure	   to	   give	   a	   black	   residue	   that	  was	  purified	  by	   chromatography	  
through	   a	   silica	   column	  using	   PE-­‐EtOAc	   (90:10,	   v/v)	   as	  mobile	   phase	   to	   obtain	  
compounds	  214-­‐217.	  
	  
Cmpd.	   R1	  
214	   H	  
215	   CH3	  
216	   Cl	  
217	   OCH3	  
	  
(E)-­‐2-­‐styrylquinolin-­‐4-­‐yl	  acetate	  (214):	  
Prepared	   from	   209	   (0.160	   g,	   1	   mmol)	   and	   benzaldehyde	  
(0.106	  g,	  1	  mmol);	  yield:	  60%;	  yellow	  solid.	  
1H	  NMR	  (250	  MHz,	  DMSO)	  δ	  8.08	  (d,	  J	  =	  8.4	  Hz,	  1H),	  8.01	  (d,	  
J	  =	  7.7	  Hz,	  1H),	  7.89	  –	  7.76	  (m,	  5H),	  7.66	  –	  7.61	  (m,	  1H),	  7.54	  
–	  7.39	  (m,	  4H),	  2.55	  (s,	  3H)	  ppm.	  
13C	   NMR	   (75	   MHz,	   DMSO)	   δ	   168.7,	   156.7,	   154.3,	   149.2,	   136.0,	   134.8,	   130.5,	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(E)-­‐6-­‐methyl-­‐2-­‐styrylquinolin-­‐4(1H)-­‐one	  (215):	  
Prepared	  from	  210	  (0.173	  g,	  1	  mmol)	  and	  benzaldehyde	  
(0.106	  g,	  1	  mmol);	  yield:	  56%;	  yellow	  solid.	  
1H	  NMR	   (250	  MHz,	  DMSO)	  δ	  11.51	   (br	   s,	   1H),	   7.86	   (s,	  
1H),	  7.69	  –	  7.57	  (m,	  4H),	  7.52	  –	  7.40	  (m,	  4H),	  7.13	  (d,	   J	  =	  16.6	  Hz,	  1H),	  6.33	  (s,	  
1H),	  2.41	  (s,	  3H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   DMSO)	   δ	   177.7,	   147.4,	   139.2,	   136.4,	   135.4,	   134.1,	   133.1,	  
130.1	  (2C),	  129.9	  (2C),	  128.1,	  126.0,	  124.9,	  123.2,	  119.0,	  108.2,	  21.6	  ppm.	  
	  
(E)-­‐6-­‐chloro-­‐2-­‐styrylquinolin-­‐4-­‐yl	  acetate	  (216):	  
Prepared	  from	  211	  (0.194	  g,	  1	  mmol)	  and	  benzaldehyde	  
(0.106	  g,	  1	  mmol);	  yield:	  49%;	  pale	  yellow	  solid.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.09	  (d,	  J	  =	  9.1	  Hz,	  1H),	  7.90	  
(d,	  J	  =	  2.2	  Hz,	  1H),	  7.71	  (d,	  J	  =	  2.4	  Hz,	  1H),	  7.68	  –	  7.64	  (m,	  4H),	  7.47	  –	  7.37	  (m,	  
4H),	  2.55	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  168.4,	  157.5,	  153.9,	  148.2,	  136.4,	  136.3,	  132.9,	  131.9,	  
130.9,	  129.5,	  129.3	  (2C),	  128.2,	  127.9	  (2C),	  122.4,	  120.69,	  111.9,	  21.7	  ppm.	  
	  
(E)-­‐6-­‐methoxy-­‐2-­‐styrylquinolin-­‐4-­‐ol	  (217):	  
Prepared	   from	   212	   (0.190	   g,	   1	   mmol)	   and	  
benzaldehyde	   (0.106	   g,	   1	   mmol);	   yield:	   69%;	   yellow	  
solid.	  
1H	  NMR	  (250	  MHz,	  DMSO)	  δ	  7.74	  –	  7.66	  (m,	  3H),	  7.50	  
–	  7.35	  (m,	  6H),	  7.18	  (d,	  J	  =	  16.6	  Hz,	  1H),	  6.49	  (s,	  1H),	  3.86	  (s,	  3H)	  ppm.	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13C	   NMR	   (63	   MHz,	   DMSO)	   δ	   168.7,	   156.2,	   147.0,	   135.8,	   135.5,	   135.3,	   129.7,	  
129.4	  (2C),	  127.7	  (2C),	  125.9,	  123.1,	  122.4,	  120.7,	  106.2,	  104.2,	  55.8	  ppm.	  
	  
9.5.4.5.	  General	  procedure	  for	  preparing	  4-­‐chlorostyrylquinolines	  
The	  suitable	  styrylquinoline	  compound	  (3.5	  mmol)	  (214-­‐217)	  was	  added	  portion-­‐
wise	  to	  a	  solution	  of	  excess	  phosphorus	  oxychloride	  at	  0	  oC.	  After	  being	  stirred	  
for	  30	  min	  at	  room	  temperature,	  the	  reaction	  mixture	  was	  heated	  at	  80	  °C	  for	  30	  
min	   to	   1h.	   The	   excess	   phosphorus	   oxychloride	   was	   removed	   by	   vacuum	  
distillation.	   The	   residue	  was	   poured	   slowly	   onto	   a	  mixture	   of	   crushed	   ice	   and	  
saturated	   NaHCO3	   solution	   with	   vigorous	   stirring.	   The	   pH	   of	   the	   solution	   was	  
adjusted	   to	   about	   9.0	   by	   addition	   of	   ammonium	   hydroxide.	   The	   solid	   product	  
separated	  out	  was	   collected	  by	   filtration,	   dried	   and	  used	   for	   the	  next	   reaction	  
without	  further	  purification.	  
 
Cmpd.	   R1	  
218	   H	  
219	   CH3	  
220	   Cl	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(E)-­‐4-­‐chloro-­‐2-­‐styrylquinoline	  (218):	  
Prepared	   from	   214	   (1.01	   g,	   3.5	  mmol);	   yield:	   90%;	   yellow	  
solid.	  
1H	  NMR	   (250	  MHz,	  CDCl3)	   δ	   8.21	   (dd,	   J	   =	   8.4,	   1.1	  Hz,	   1H),	  
8.12	  (d,	  J	  =	  8.2	  Hz,	  1H),	  7.82	  –	  7.75	  (m,	  2H),	  7.74	  –	  7.58	  (m,	  4H),	  7.48	  –	  7.33	  (m,	  
4H)	  ppm.	  	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.3,	  149.4,	  143.2,	  136.6,	  135.8,	  131.1,	  129.9,	  129.4,	  
129.3	  (2C),	  128.3,	  127.8	  (2C),	  127.5,	  125.9,	  124.4,	  119.7.	  
	  
(E)-­‐4-­‐chloro-­‐6-­‐methyl-­‐2-­‐styrylquinoline	  (219):	  
Prepared	   from	   215	   (0.915	   g,	   3.5	   mmol);	   yield:	   99%;	  
yellow	  solid.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.16	  (d,	  J	  =	  8.6	  Hz,	  1H),	  7.99	  
(s,	  1H),	  7.82	  (s,	  1H),	  7.75	  –	  7.64	  (m,	  4H),	  7.52	  –	  7.38	  (m,	  4H),	  2.62	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  154.7,	  149.1,	  146.1,	  143.8,	  138.5,	  136.9,	  136.2,	  134.1,	  
129.8,	  129.3	  (2C),	  128.3,	  128.0	  (2C),	  125.7,	  123.5,	  119.4,	  22.3	  ppm.	  
	  
(E)-­‐4,6-­‐dichloro-­‐2-­‐styrylquinoline	  (220):	  
Prepared	   from	   216	   (1.133	   g,	   3.5	   mmol);	   yield:	   85%;	  
yellow	  solid.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.20	  (d,	  J	  =	  2.3	  Hz,	  1H),	  8.04	  
(d,	  J	  =	  9.0	  Hz,	  1H),	  7.79	  (s,	  1H),	  7.76	  –	  7.65	  (m,	  4H),	  7.48	  –	  7.36	  (m,	  4H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.6,	  147.8,	  142.1,	  136.4,	  136.2,	  133.5,	  132.0,	  131.5,	  
129.5,	  129.3	  (2C),	  127.9,	  127.8	  (2C),	  126.5,	  123.5,	  120.6	  ppm.	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(E)-­‐4-­‐chloro-­‐6-­‐methoxy-­‐2-­‐styrylquinoline	  (221):	  
Prepared	   from	  217	   (0.970	  g,	  3.5	  mmol);	   yield:	  95%;	  
yellow	  solid.	  
1H	  NMR	   (250	  MHz,	  CDCl3)	  δ	  8.34	  (d,	  J	  =	  8.8	  Hz,	  1H),	  
7.93	  (s,	  1H),	  7.79	  –	  7.63	  (m,	  4H),	  7.55	  –	  7.38	  (m,	  5H),	  4.03	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  MeOD)	  δ	  162.5,	  152.0,	  150.3,	  145.2,	  136.3,	  132.8,	  130.7	  (2C),	  
130.6,	  130.6,	  130.0	  (2C),	  128.9,	  125.1,	  121.2,	  120.0,	  104.9,	  57.5	  ppm.	  
	  
9.5.4.6.	  General	  procedure	  for	  preparing	  4-­‐aminostyrylquinolines	  
A	  mixture	   of	   the	   suitable	   4-­‐chloro-­‐styrylquinoline	   (218-­‐221)	   and	   excess	   phenol	  
(200	  mg)	  was	  heated	  at	  180	  oC	   for	  1	  h.	  A	  slow	  stream	  of	  ammonia	  was	  passed	  
through	   the	   reaction	   mixture	   at	   180	   oC	   for	   2	   h.	   After	   cooling	   to	   room	  
temperature,	  the	  mixture	  was	  poured	  into	  10%	  KOH	  aqueous	  solution.	  The	  solid	  
separated	  was	   collected	  by	   filtration,	  washed	  with	  water	  and	  dried	   to	  give	   the	  
products	  (222-­‐225),	  which	  were	  purified	  through	  column	  on	  silica	  gel.	  
	  
Cmpd.	   R1	  
222	   H	  
223	   CH3	  
224	   Cl	  
225	   OCH3	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(E)-­‐2-­‐styrylquinolin-­‐4-­‐amine	  (222):	  
Prepared	   from	   218	   (100	   mg,	   0.38	   mmol);	   yield:	   35%;	  
brown	  solid.	  
Elemental	  analysis	  calcd	  (%)	  for	  C17H14N2:	  C	  82.90,	  H	  5.73,	  
N	  11.37;	  found:	  C	  82.50,	  H	  5.45,	  N	  11.02.	  
Mp:	  103	  	  106	  °C	  
IR	  (neat)	  ν:	  3350,	  3167,	  1615,	  1516,	  1439,	  1209,	  756	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.04	  (d,	  J	  =	  8.4	  Hz,	  1H),	  7.77	  (d,	  J	  =	  8.4	  Hz,	  1H),	  7.70	  –	  
7.59	  (m,	  4H),	  7.46	  –	  7.25	  (m,	  5H),	  6.91	  (s,	  1H),	  4.96	  (br	  s,	  2H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  MeOD)	  δ	  157.4,	  155.1,	  149.1,	  138.3,	  136.0,	  131.7,	  130.3	  (2C),	  
130.2,	  129.2,	  128.6	  (2C),	  128.2,	  125.8,	  123.3,	  119.7,	  100.9	  ppm.	  
	  
(E)-­‐6-­‐methyl-­‐2-­‐styrylquinolin-­‐4-­‐amine	  (223):	  
Prepared	   from	   219	   (100	   mg,	   0.36	   mmol);	   yield:	   37%;	  
pale	  brown	  solid.	  
Elemental	   analysis	   calcd	   (%)	   for	   C18H16N2:	   C	   83.04,	   H	  
6.19,	  N	  10.76;	  found:	  C	  83.39,	  H	  6.50,	  N	  10.51.	  
Mp:	  138	  	  141	  °C	  
IR	  (neat)	  ν:	  3325,	  3143,	  2918,	  1634,	  1594,	  1491,	  821	  cm-­‐1.	  
1H	  NMR	   (250	  MHz,	  MeOD)	  δ	  8.04	   (s,	  1H),	  7.81	  –	  7.69	   (m,	  5H),	  7.48	  –	  7.45	   (m,	  
3H),	  7.22	  (d,	  J	  =	  16.4	  Hz,	  1H),	  7.02	  (s,	  1H),	  2.57	  (s,	  3H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   MeOD)	   δ	   158.7,	   152.2,	   140.0,	   138.2,	   137.1,	   136.7,	   131.5,	  
130.6	  (2C),	  130.2,	  129.2	  (2C),	  123.4,	  122.7,	  122.5,	  118.1,	  100.6,	  21.9	  ppm.	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(E)-­‐6-­‐chloro-­‐2-­‐styrylquinolin-­‐4-­‐amine	  (224):	  
Prepared	   from	   220	   (100	   mg,	   0.33	   mmol);	   yield:	   26%;	  
grey	  solid.	  
Elemental	   analysis	   calcd	   (%)	   for	   C17H13ClN2:	   C	   72.73,	   H	  
4.67,	  N	  9.98;	  found:	  C	  72.39,	  H	  4.80,	  N	  9.61.	  
Mp:	  142	  	  145	  °C	  
IR	  (neat)	  ν:	  3342,	  3195,	  2925,	  1636,	  1584,	  753	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  7.87	  (s,	  1H),	  7.75	  (d,	  J	  =	  8.6	  Hz,	  1H),	  7.66	  –	  7.53	  (m,	  
4H),	  7.45	  –	  7.35	  (m,	  3H),	  7.21	  (d,	  J	  =	  16.4	  Hz,	  1H),	  6.98	  (s,	  1H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   MeOD)	   δ	   155.7,	   155.3,	   146.2,	   138.1,	   136.4,	   136.3,	   134.2,	  
130.4	  (broad	  signal,	  3C),	  128.7	  (2C),	  128.0,	  127.0,	  122.6,	  119.4,	  100.8	  ppm.	  
	  
(E)-­‐6-­‐methoxy-­‐2-­‐styrylquinolin-­‐4-­‐amine	  (225):	  
Prepared	   from	  221	   (100	  mg,	  0.34	  mmol);	   yield:	  32%;	  
dark	  solid.	  
Elemental	  analysis	   calcd	   (%)	   for	  C18H16N2:	  C	  78.24,	  H	  
5.84,	  N	  10.14;	  found:	  C	  78.39,	  H	  5.80,	  N	  10.51.	  
Mp:	  222	  	  225	  °C	  
IR	  (neat)	  ν:	  3309,	  3197,	  2924,	  1586,	  1513,	  1232,1030,	  831	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  7.97	  (d,	  J	  =	  9.3	  Hz,	  1H),	  7.64	  –	  7.54	  (m,	  3H),	  7.44	  –	  
7.25	  (m,	  5H),	  7.00	  –	  6.93	  (m,	  2H),	  4.64	  (br	  s,	  1H),	  3.97	  (s,	  3H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   MeOD)	   δ	   158.5,	   155.9,	   153.6,	   145.6,	   138.6,	   134.4,	   132.1,	  
130.5,	  130.3	  (2C),	  129.8,	  128.4	  (2C),	  123.3,	  120.6,	  101.9,	  101.1,	  56.5	  ppm.	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9.6.	  Synthesis	  of	  4-­‐aminostyrylquinolines	  against	  leishmaniasis	  
9.6.1.	  (E)-­‐N1-­‐(2-­‐styrylquinolin-­‐4-­‐yl)ethane-­‐1,2-­‐diamine	  (226):	  
	  
Ethylenediamine	   (1.130	   g,	   18.8	  mmol)	  was	   added	   to	   4-­‐chloro-­‐2-­‐styrylquinoline	  
218	  (0.250	  g,	  0.94	  mmol)	  in	  a	  pressure-­‐tight	  microwave	  tube	  containing	  a	  stirring	  
bar.	  The	  mixture	  was	  heated	  under	  microwave	  irradiation	  for	  1	  h	  at	  120	  °C,	  with	  
an	   irradiation	   power	   of	   200	   W,	   using	   a	   CEM	   Discover	   SP	   microwave	   reactor.	  
Thereafter,	  the	  reaction	  mixture	  was	  treated	  with	  aqueous	  solution	  of	  KOH	  10%,	  
extracted	  with	   CH2Cl2,	   dried	  with	   anhydrous	   Na2SO4	   and	   evaporated	   in	   vacuo.	  
The	  excess	  of	  ethylenediamine	  was	  removed	  by	  distillation	  in	  EtOH.	  The	  resulting	  
residue	  was	   subsequently	   crystallized	   in	  MeOH	   and	   hexane	   to	   give	   compound	  
226	  as	  a	  yellow	  solid	  in	  40%	  yield.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  8.11	  (d,	  J	  =	  8.3	  Hz,	  1H),	  7.87	  (d,	  J	  =	  8.4	  Hz,	  1H),	  7.70	  
–	  7.64	  (m,	  4H),	  7.47	  –	  7.29	  (m,	  5H),	  6.94	  (s,	  1H),	  3.58	  (t,	  J	  =	  6.3	  Hz,	  2H),	  3.06	  (t,	  J	  =	  
6.4	  Hz,	  2H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   DMSO)	   δ	   155.9,	   151.0,	   148.7,	   137.0,	   132.5,	   130.5,	   129.4,	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9.6.2.	  (E)-­‐2-­‐bromo-­‐N-­‐(2-­‐(2-­‐styrylquinolin-­‐4-­‐ylamino)ethyl)acetamide	  (227):	  
	  
A	   solution	  of	  227	   (0.250	  g,	   0.864	  mmol),	   bromoacetyl	   bromide	   (0.209	  g,	   1.037	  
mmol)	   and	  pyridine	   (0.079	  g,	   2.59	  mmol)	   in	  dry	  THF	   (10	  ml)	  was	   stirred	  under	  
argon	   for	  30	  minutes	  at	  0	   °C.	  When	  the	   reaction	  was	   finished,	   the	  solvent	  was	  
removed	  under	   vacuum,	   and	   the	   resulting	   residue	  was	  dissolved	   in	  CH2Cl2	   and	  
washed	  with	  acidic	  water	  (2N	  HCl)	  to	  remove	  the	  excess	  of	  pyridine.	  Compound	  
227	  was	  purified	  through	  silica	  gel	  column	  and	  was	  isolated	  as	  a	  red	  solid	  in	  46%	  
yield.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  8.27	  (d,	  J	  =	  8.4	  Hz,	  1H),	  8.11	  (d,	  J	  =	  16.5	  Hz,	  1H),	  7.92	  
–	  7.91	  (m,	  2H),	  7.79	  –	  7.64	  (m,	  3H),	  7.49	  –	  7.47	  (m,	  3H),	  7.34	  –	  7.27	  (m,	  2H),	  4.12	  
(s,	  1H),	  3.91	  (s,	  1H),	  3.83	  –	  3.80	  (m,	  2H),	  3.67	  –	  3.65	  (m,	  2H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   MeOD)	   δ	   171.0,	   157.6,	   152.3,	   142.7,	   139.8,	   136.7,	   135.2,	  
132.1,	  130.6	  (2C),	  129.6	  (2C),	  128.3,	  124.1,	  121.2,	  120.6,	  118.3,	  97.0,	  44.4,	  43.6,	  
29.3	  ppm.	  
	  
9.6.3.	  General	  procedure	  for	  the	  synthesis	  of	  4-­‐aminostyrylquinolines	  
227	  (80	  mg,	  0.195	  mmol),	  the	  suitable	  amine	  (1	  equiv)	  and	  Cs2CO3	  (0.127	  g,	  0.39	  
mmol,	   2	   equiv)	   were	   suspended	   in	   EtOH	   (1	  ml)	   in	   a	   pressure-­‐tight	  microwave	  
tube	   containing	   a	   stirring	   bar.	   The	   mixture	   was	   heated	   under	   microwave	  
irradiation	  for	  30	  minutes	  at	  120	  °C,	  with	  an	  irradiation	  power	  of	  200	  W,	  using	  a	  
CEM	   Discover	   SP	   microwave	   reactor.	   Thereafter,	   the	   reaction	   mixture	   was	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  9.	  Experimental	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dissolved	   in	  CH2Cl2	   and	  washed	  with	  water.	   The	   combined	  organic	   layers	  were	  
dried	  with	  anhydrous	  Na2SO4	  and	  evaporated	  in	  vacuo.	  The	  compounds	  obtained	  
were	  subsequently	  crystallized	  from	  MeOH-­‐hexane	  mixtures	  or	  purified	  through	  
neutral	  alumina	  column.	  
	  
Cmpd.	   R2NH	   	   Cmpd.	   R2NH	  
228	  
	  




















	   	   	  
	  
(E)-­‐2-­‐(Dimethylamino)-­‐N-­‐[2-­‐(2-­‐styrylquinolin-­‐4-­‐ylamino)ethyl]acetamide	  (228):	  
Prepared	   from	   227	   (80	   mg,	   0.195	   mmol)	   and	  
dimethylamine	   (0.02	  ml,	   0.195	  mmol);	   the	   compound	  
9.	  Experimental	  section	   	   371	   	   	  
was	   crystallized	   from	   MeOH-­‐hexane	   mixture	   to	   give	   228	   in	   72%	   yield	   as	   an	  
orange	  powder.	  
Elemental	   analysis	   (%)	   calcd	   for	  C23H26N4O:	  C	  73.77,	  H	  7.00,	  N	  14.96;	   found:	  C	  
73.61,	  H	  7.16,	  N	  14.40.	  
Mp	  57	  	  60	  oC	  
IR	  (neat)	  ν:	  3346,	  2923,	  2850,	  2780,	  1660,	  1588,	  1365,	  1044cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  7.99	  (d,	  J	  =	  8.4	  Hz,	  1H),	  7.85	  (d,	  J	  =	  8.3	  Hz,	  1H),	  7.76	  
(d,	  J	  =	  6.7	  Hz,	  1H),	  7.71	  –	  7.60	  (m,	  4H),	  7.47-­‐7.32	  (m,	  4H),	  6.62	  (s,	  1H),	  6.55	  (br	  s,	  
1H),	  3.86-­‐3.75	  (m,	  2H),	  3.60	  –	  3.47	  (m,	  2H),	  3.03	  (s,	  2H),	  2.30	  (s,	  6H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  174.0,	  156.7,	  150.7,	  137.3,	  133.7,	  133.5,	  130.5,	  129.8	  
(2C),	  129.1	  (2C),	  128.7,	  127.6	  (2C),	  125.0,	  120.6,	  118.7,	  96.3,	  63.3,	  46.5	  (2C),	  46.2,	  
38.9	  ppm.	  	  
	  
(E)-­‐2-­‐(Diethylamino)-­‐N-­‐[2-­‐(2-­‐styrylquinolin-­‐4-­‐ylamino)ethyl]acetamide	  (229):	  
Prepared	   from	   227	   (80	   mg,	   0.195	   mmol)	   and	  
diethylamine	   (14	  mg,	   0.195	  mmol);	   the	   compound	  was	  
crystallized	   from	   MeOH-­‐hexane	   mixture	   to	   give	   229	   in	  
71%	  yield	  as	  an	  orange	  powder.	  
Elemental	   analysis	   (%)	   calcd	   for	   C25H30N4O:	   C	   74.59,	   H	  
7.51,	  N	  13.92;	  found:	  C	  74.52,	  H	  7.10,	  N	  13.50.	  
Mp:	  54	  	  57	  oC	  
IR	  (neat)	  ν:	  3341,	  2959,	  2905,	  2850,	  1658,	  1588,	  1430,	  1367,	  756	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  7.99	  (d,	  J	  =	  8.4	  Hz,	  1H),	  7.86	  (d,	  J	  =	  7.6	  Hz,	  1H),	  7.71-­‐
7.59	  (m,	  4H),	  7.49	  –	  7.30	  (m,	  5H),	  6.62	  (s,	  1H),	  3.85	  –	  375	  (m,	  2H),	  3.60	  –	  3.46	  (m,	  
2H),	  3.12	  (s,	  2H),	  2.56	  (q,	  J	  =	  7.1	  Hz,	  4H),	  1.04	  –	  0.93	  (m,	  6H)	  ppm.	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  9.	  Experimental	  section	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  175.6,	  156.6,	  150.8,	  137.2,	  133.6,	  130.3,	  130.3,	  129.8,	  
129.6,	   129.1	   (2C),	   128.7,	   127.6	   (2C),	   125.1,	   120.6,	   118.7,	   96.2,	   57.8,	   49.2	   (2C),	  
46.2,	  38.9,	  12.7	  (2C)	  ppm.	  
	  
(E)-­‐2-­‐(pyrrolidin-­‐1-­‐yl)-­‐N-­‐(2-­‐(2-­‐styrylquinolin-­‐4-­‐ylamino)ethyl)acetamide	  (230):	  
Prepared	  from	  227	  (80	  mg,	  0.195	  mmol)	  and	  pyrrolidine	  
(14	   mg,	   0.195	   mmol);	   the	   compound	   was	   crystallized	  
from	  MeOH-­‐hexane	  mixture	  to	  give	  230	  in	  69%	  yield	  as	  
a	  red	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	  C25H28N4O:	  C	  74.97,	  H	  7.05,	  N	  13.99;	   found:	  C	  
74.04,	  H	  6.98,	  N	  13.83.	  
Mp:	  68	  	  71	  oC	  
IR	  (neat)	  ν:	  3346,	  2918,	  2848,	  2809,	  1655,	  1588,	  1539,	  1365	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  7.98	  (d,	  J	  =	  7.7	  Hz,	  1H),	  7.85	  (d,	  J	  =	  8.1	  Hz,	  1H),	  7.70	  –	  
7.60	  (m,	  4H),	  7.48-­‐7.32	  (m,	  5H),	  6.62	  (s,	  1H),	  6.59	  (br	  s,	  1H),	  3.85-­‐3-­‐78	  (m,	  2H),	  
3.60	  –	  3.46	  (m,	  2H),	  3.26	  (s,	  2H),	  2.67-­‐2.53	  (m,	  4H),1.85-­‐1.75	  (m,	  4H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  174.4,	  156.7,	  150.7,	  148.9,	  137.3,	  133.5,	  130.5,	  129.8	  
(2C),	  129.1	  (2C),	  128.7,	  127.6	  (2C),	  125.0,	  120.6,	  118.7,	  96.3,	  59.4,	  55.1	  (2C),	  46.2,	  
38.9,	  24.4	  (2C)	  ppm.	  
	  
(E)-­‐2-­‐(piperidin-­‐1-­‐yl)-­‐N-­‐(2-­‐(2-­‐styrylquinolin-­‐4-­‐ylamino)ethyl)acetamide	  (231):	  
Prepared	  from	  227	  (80	  mg,	  0.195	  mmol)	  and	  piperidine	  
(17	   mg,	   0.195	   mmol);	   the	   compound	   was	   crystallized	  
from	  MeOH-­‐hexane	  mixture	  to	  give	  231	  in	  70%	  yield	  as	  
9.	  Experimental	  section	   	   373	   	   	  
a	  yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	  C26H30N4O:	  C	  75.33,	  H	  7.29,	  N	  13.52;	   found:	  C	  
75.66,	  H	  7.05,	  N	  13.70.	  
Mp:	  71	  	  74	  oC	  	  
IR	  (neat)	  ν:	  3348,	  2936,	  2851,	  1659,	  1563,	  1538,	  1366,	  1129	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.10	  (d,	  J	  =	  8.3	  Hz,	  1H),	  7.97	  (d,	  J	  =	  8.1	  Hz,	  1H),	  7.8-­‐
7.72	  (m,	  4H),	  7.6-­‐7.4	  (m,	  5H),	  6.74	  (s,	  1H),	  3.99	  –	  3.84	  (m,	  2H),	  3.72-­‐3.58	  (m,	  2H),	  
3.14	  (s,	  2H),	  2.62-­‐2.48	  (m,	  4H),	  1.70	  –	  1.67	  (m,	  4H),	  1.57	  –	  1.55	  (m,	  2H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  174.2,	  156.6,	  150.8,	  137.2,	  133.6,	  130.3,	  130.3,	  129.8,	  
129.7,	   129.1	   (2C),	   128.7,	   127.6	   (2C),	   125.1,	   120.6,	   118.7,	   96.2,	   62.6,	   55.4	   (2C),	  
46.2,	  38.9,	  26.6	  (2C),	  24.0	  ppm.	  
	  
(E)-­‐2-­‐Morpholino-­‐N-­‐[2-­‐(2-­‐styrylquinolin-­‐4-­‐ylamino)ethyl]acetamide	  (232):	  
Prepared	   from	   227	   (80	   mg,	   0.195	   mmol)	   and	  
morpholine	   (17	   mg,	   0.195	   mmol);	   the	   compound	   was	  
crystallized	   from	  MeOH-­‐hexane	  mixture	   to	   give	  232	   in	  
59%	  yield	  as	  an	  orange	  powder.	  
Elemental	  analysis	   (%)	  calcd	  for	  C25H28N4O2:	  C	  72.09,	  H	  6.78,	  N	  13.45;	   found:	  C	  
71.73,	  H	  6.81,	  N	  13.24.	  
Mp:	  67	  	  70	  oC	  
IR	  (neat)	  ν:	  3297,	  2918,	  2850,	  1656,	  1599,	  1560,	  1538,	  1464	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.03	  (d,	  J	  =	  8.0	  Hz,	  1H),	  7.88	  (d,	  J	  =	  8.5	  Hz,	  1H),	  7.79	  
(s,	  1H),	  7.72	  (s,	  1H),	  7.68	  –	  7.57	  (m,	  3H),	  7.48	  –	  7.31	  (m,	  4H),	  6.59	  (s,	  1H),	  3.88	  	  
3.77	  (m,	  2H),	  3.77	  –	  3.65	  (m,	  4H),	  3.62	  	  3.45	  (m,	  2H),	  3.10	  (s,	  2H),	  2.60	  –	  2.49	  (m,	  
4H)	  ppm.	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13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  173.2,	  153.1,	  151.5,	  147.6,	  136.8,	  131.4,	  130.4,	  129.6,	  
129.2	   (2C),	   129.1,	   128,4,	   127.8	   (2C),	   125.4,	   120.9,	   118.3,	   95.8,	   67.3	   (2C),	   62.2,	  




Prepared	   from	   227	   (80	   mg,	   0.195	   mmol)	   and	   1-­‐
methylpiperazine	   (20	   mg,	   0.195	   mmol);	   the	  
compound	   was	   crystallized	   from	   MeOH-­‐hexane	  
mixture	   to	   give	   233	   in	   59%	   yield	   as	   an	   orange	  
powder.	  
Elemental	   analysis	   (%)	   calcd	   for	  C26H31N5O:	  C	  72.70,	  H	  7.27,	  N	  16.30;	   found:	  C	  
71.87,	  H	  7.86,	  N	  15.39.	  
Mp:	  64	  	  67	  oC	  	  
IR	  (neat)	  ν:	  3348,	  2923,	  2850,	  1666,	  1588,	  1537,	  1373,	  756	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  7.99	  (d,	  J	  =	  8.5	  Hz,	  1H),	  7.83	  (d,	  J	  =	  8.1	  Hz,	  1H),	  7.61-­‐
7.50	  (m,	  4H),	  7.38	  –	  7.20	  (m,	  5H),	  6.52	  (s,	  1H),	  6.05	  (br	  s,	  1H),	  3.75	  –	  3.64	  (m,	  2H),	  
3.48	  –	  3.38	  (m,	  2H),	  3.11	  (s,	  2H),	  2.52-­‐2.41	  (m,	  4H),	  2.37-­‐2.25	  (m,	  4H),	  2.28	  (s,	  3H)	  
ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  173.5,	  156.7,	  150.7,	  148.9,	  137.2,	  133.5,	  130.4,	  129.8	  
(2C),	  129.3	  (2C),	  128.7,	  127.6	  (2C),	  125.1,	  120.5,	  118.7,	  96.3,	  61.6,	  55.5	  (2C),	  53.9	  
(2C),	  46.4,	  46.0,	  38.9	  ppm.	  
	  
	  
9.	  Experimental	  section	   	   375	   	   	  
(E)-­‐2-­‐(4-­‐Phenylpiperazin-­‐1-­‐yl)-­‐N-­‐[2-­‐(2-­‐styrylquinolin-­‐4-­‐ylamino)ethyl]acetamide	  
(234):	  
Prepared	   from	   227	   (80	  mg,	   0.195	  mmol)	   and	   1-­‐
phenylpiperazine	   (32	   mg,	   0.195	   mmol);	   the	  
compound	   was	   purified	   by	   chromatography	  
through	   a	   neutral	   alumina	   column	   using	   DCM-­‐
MeOH	  (95:5,	  v/v)	  as	  mobile	  phase	  to	  give	  234	  in	  45%	  yield	  as	  an	  orange	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	  C31H33N5O:	  C	  75.73,	  H	  6.77,	  N	  14.25;	   found:	  C	  
75.01,	  H	  6.44,	  N	  13.92.	  
Mp:	  92	  	  95	  oC	  
IR	  (neat)	  ν:	  3352,	  2940,	  2825,	  1661,	  1588,	  1538,	  1435,	  969,	  757	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  8.04	  (dd,	  J	  =	  8.4,	  0.9	  Hz,	  1H),	  7.88	  (dd,	  J	  =	  8.5,	  0.7	  
Hz,	  1H),	  7.76	  –	  7.61	  (m,	  4H),	  7.47	  –	  7.31	  (m,	  5H),	  7.23	  	  7.15	  (m,	  2H),	  7.03	  (s,	  1H),	  
6.86	  –	  6.78	  (m,	  3H),	  3.35	  	  3.31	  (m,	  8H),	  3.05	  (s,	  2H),	  3.03	  –	  2.97	  (m,	  2H),	  2.59	  –	  
2.52	  (m,	  2H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   MeOD)	   δ	   174.2,	   158.3,	   153.2,	   153.0,	   149.6,	   138.5,	   135.9,	  
131.3,	  130.4	  (2C),	  130.3	  (2C),	  130.2,	  130.1,	  129.2,	  128.7	  (2C),	  126.0,	  122.4,	  121.5,	  




Prepared	  from	  227	  (80	  mg,	  0.195	  mmol)	  and	  N-­‐
(4-­‐aminophenyl)piperidine	   (34	   mg,	   0.195	  
mmol);	   the	   compound	   was	   purified	   by	  
chromatography	   through	   a	   neutral	   alumina	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  9.	  Experimental	  section	  
column	  using	  DCM-­‐MeOH	  (95:5,	  v/v)	  as	  mobile	  phase	  to	  give	  235	  in	  43%	  yield	  as	  
an	  orange	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	  C32H35N5O:	  C	  76.01,	  H	  6.98,	  N	  13.85;	   found:	  C	  
75.68,	  H	  6.84,	  N	  13.81.	  
Mp:	  69	  	  72	  oC	  
IR	  (neat)	  ν:	  3330,	  2918,	  2838,	  1585,	  1555,	  1228,	  1118,	  756	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  7.99	  (d,	  J	  =	  7.6	  Hz,	  1H),	  7.83	  (d,	  J	  =	  7.9	  Hz,	  1H),	  7.71-­‐
7.60	  (m,	  4H),	  7.48	  –	  7.30	  (m,	  5H),	  7.16	  (s,	  1H),	  6.97	  (d,	  J	  =	  4.6	  Hz,	  1H),	  6.89	  –	  6.81	  
(m,	  1H),	  6.71	  –	  6.60	  (m,	  2H),	  6.49	  (br	  s,	  1H),	  4.04	  (s,	  2H),	  3.88	  	  3.76	  (m,	  2H),	  3.66	  	  
3.48	  (m,	  2H),	  3.26	  –	  3.11	  (m,	  2H),	  3.04	  –	  2.96	  (m,	  2H),	  1.78	  	  1.69	  (m,	  4H),	  1.59	  	  
1.53	  (m,	  2H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  173.0,	  156.7,	  150.6,	  148.9,	  146.2,	  140.2,	  137.3,	  133.5,	  
130.4,	  129.8	  (2C),	  129.1	  (2C),	  128.7,	  127.6	  (2C),	  125.0,	  120.5,	  119.6	  (2C),	  118.7,	  
116.6	  (2C),	  96.4,	  53.0	  (2C),	  46.0,	  38.8,	  26.6	  (2C),	  24.6,	  15.5	  ppm.	  
	  
(E)-­‐2-­‐(Phenylamino)-­‐N-­‐[2-­‐(2-­‐styrylquinolin-­‐4-­‐ylamino)ethyl]acetamide	  (236):	  
Prepared	   from	  227	   (80	  mg,	  0.195	  mmol)	  and	  aniline	  
(18	  mg,	  0.195	  mmol);	  the	  compound	  was	  purified	  by	  
chromatography	   through	   a	   neutral	   alumina	   column	  
using	  DCM-­‐MeOH	  (95:5,	  v/v)	  as	  mobile	  phase	  to	  give	  
236	  in	  88%	  yield	  as	  a	  yellow	  solid.	  
Elemental	   analysis	   (%)	   calcd	   for	  C27H26N4O:	  C	  76.75,	  H	  6.20,	  N	  13.26;	   found:	  C	  
76.45,	  H	  6.17,	  N	  12.88.	  
Mp:	  71	  	  74	  oC	  
IR	  (neat)	  ν:	  3350,	  1655,	  1585,	  1560,	  1535,	  1434,	  1118,	  756	  cm-­‐1.	  
9.	  Experimental	  section	   	   377	   	   	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  8.03	  (d,	  J	  =	  8.3	  Hz,	  1H),	  7.87	  (d,	  J	  =	  8.5	  Hz,	  1H),	  7.77	  
–	  7.60	  (m,	  4H),	  7.49	  –	  7.24	  (m,	  6H),	  7.15	  –	  6.99	  (m,	  3H),	  6.76	  –	  6.66	  (m,	  2H),	  3.75	  
(s,	  2H),	  3.75	  –3.42	  (m,	  4H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  172.1,	  159.4,	  154.0,	  150.6,	  139.5,	  136.7,	  132.1,	  131.4	  
(2C),	   131.3	   (2C),	   131.0	   (2C),	   130.1,	   129.6	   (2C),	   126.9,	   123.4	   (2C),	   121.1,	   120.7,	  




Prepared	   from	  227	   (80	  mg,	   0.195	  mmol)	   and	   2,4-­‐
dichloroaniline	   (32	   mg,	   0.195	   mmol);	   the	  
compound	   was	   purified	   by	   chromatography	  
through	   a	   neutral	   alumina	   column	   using	   DCM-­‐
MeOH	  (95:5,	  v/v)	  as	  mobile	  phase	  to	  give	  237	  in	  42%	  yield	  as	  a	  yellow	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C27H24Cl2N4O:	  C	  65.99,	  H	  4.92,	  N	  11.40;	  found:	  C	  
65.58,	  H	  4.89,	  N	  11.31.	  
Mp:	  59	  	  62	  oC	  
IR	  (neat)	  ν:	  3326,	  2918,	  1660,	  1585,	  1536,	  1435,	  1112,	  754	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  7.99	  (d,	  J	  =	  7.6	  Hz,	  1H),	  7.83	  (d,	  J	  =	  7.6	  Hz,	  1H),	  7.65	  
(m,	  4H),	  7.40	  (m,	  6H),	  7.16	  (t,	  J	  =	  6.3	  Hz,	  1H),	  6.63	  (s,	  1H),	  6.49	  (s,	  1H),	  4.04	  (s,	  
2H),	  3.86	  	  3.79	  (m,	  2H),	  3.58	  –	  3.52	  (m,	  2H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  173.0,	  156.7,	  150.6,	  148.9,	  137.3,	  133.5,	  130.4,	  129.8,	  
129.7,	   129.2,	   129.1	   (2C),	   129.1,	   128.7,	   128.7,	   128.6,	   128.2,	   127.9,	   127.6	   (2C),	  
125.0,	  120.5,	  118.7,	  96.4,	  70.1,	  67.6,	  46.0	  ppm.	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  9.	  Experimental	  section	  
(E)-­‐2-­‐((diethylamino)methyl)-­‐4-­‐(2-­‐styrylquinolin-­‐4-­‐ylamino)phenol	  (238):	  
Prepared	   from	   227	   (80	   mg,	   0.195	   mmol)	   and	   4-­‐amino-­‐
alpha-­‐diethylamino-­‐o-­‐cresol	   (38	   mg,	   0.195	   mmol);	   the	  
compound	   was	   purified	   by	   chromatography	   through	   a	  
neutral	   alumina	   column	   using	   DCM-­‐MeOH	   (95:5,	   v/v)	   as	  
mobile	  phase	  to	  give	  238	  in	  54%	  yield	  as	  a	  green	  solid.	  
Elemental	  analysis	  (%)	  calcd	  for	  C28H29N3O:	  C	  79.40,	  H	  6.90,	  N	  9.92;	  found:	  C	  
78.91,	  H	  6.50,	  N	  9.39.	  
Mp:	  127	  	  130	  °C	  
IR	  (neat)	  ν:	  3176,	  3050,	  3026,	  1586,	  1552,	  1492,	  1439,	  1257,	  752	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  MeOD)	  δ	  8.38	  (d,	  J	  =	  8.4	  Hz,	  1H),	  7.96	  (d,	  J	  =	  8.3	  Hz,	  1H),	  7.86	  
(t,	  J	  =	  7.7	  Hz,	  1H),	  7.66	  	  7.54	  (m,	  3H),	  7.43	  	  7.35	  (m,	  3H),	  7.27	  	  7.14	  (m,	  2H),	  7.04	  
(d,	  J	  =	  9.3	  Hz,	  1H),	  6.97	  (s,	  1H),	  6.78	  (d,	  J	  =	  8.4	  Hz,	  2H),	  4.17	  (s,	  2H),	  3.03	  (q,	  J	  =	  7.1	  
Hz,	  4H),	  1.30	  (t,	  J	  =	  7.1	  Hz,	  6H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   MeOD)	   δ	   158.1,	   155.0,	   145.2,	   138.8,	   137.4,	   133.7,	   131.7,	  
131.1,	   130.5	   (2C),	   129.3,	   129.1	   (2C),	   128.9,	   127.5,	   125.5,	   125.2,	   123.5,	   122.6,	  








9.	  Experimental	  section	   	   379	   	   	  
9.6.4.	  (E)-­‐4-­‐(1H-­‐Indol-­‐3-­‐yl)-­‐2-­‐styrylquinoline	  (239):	  
	  
4-­‐Chlorostyrylquinoline	  218	  (0.100	  g,	  0.34	  mmol),	  indole	  (44	  mg,	  0.34	  mmol)	  and	  
10%	   mol	   of	   InCl3	   (8	   mg)	   were	   charged	   in	   a	   pressure-­‐tight	   microwave	   tube	  
containing	   2	   ml	   of	   acetonitrile	   and	   a	   stirring	   bar.	   The	   reaction	   mixture	   was	  
submitted	  to	  microwave	  irradiation	  for	  1	  h	  at	  150	  C°,	  with	  an	  irradiation	  power	  
of	   150	   W,	   using	   a	   CEM	   Discover	   SP	   focused	   microwave	   reactor.	   The	   crude	  
mixture	  was	  dissolved	   in	  CH2Cl2,	  washed	  with	  H2O,	  dried,	   and	  evaporated.	   The	  
pure	   compound	  was	   obtained	   by	   flash	   chromatography	   on	   silica	   gel	   as	   a	   pale	  
yellow	  solid	  in	  58%	  yield.	  
Elemental	  analysis	  (%)	  calcd	  for	  C	  86.68;	  H	  5.24;	  N	  8.09;	  found:	  C	  86.53,	  H	  5.44,	  
N	  7.76.	  
Mp:	  94	  97	  °C	  
IR(neat)	  ν:	  3408,	  3054,	  3028,	  1586,	  1500,	  1243,	  962,	  742	  cm-­‐1.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.79	  (br	  s,	  1H),	  8.22	  (d,	  J	  =	  8.4	  Hz,	  1H),	  8.14	  (d,	  J	  =	  8.4	  
Hz,	  1H),	  7.82	  (d,	  J	  =	  19.5	  Hz,	  1H),	  7.78	  –	  7.66	  (m,	  4H),	  7.59	  –	  7.54	  (m,	  3H),	  7.48	  –	  
7.33	  (m,	  6H),	  7.28	  –	  7.22	  (m,	  1H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  156.1,	  149.3,	  142.8,	  137.0,	  136.7,	  134.8,	  130.1,	  129.8,	  
129.5,	   129.2	   (2C),	   129.0,	   127.7	   (2C),	   127.3,	   127.2,	   126.7,	   126.4,	   125.0,	   123.4,	  
121.1,	  120.5,	  120.2,	  114.6,	  112.1	  ppm.	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  section	  
9.6.5.	  (E)-­‐4-­‐[2-­‐(4-­‐Acetoxyquinolin-­‐2-­‐yl)vinyl]-­‐1,2-­‐phenylene	  diacetate	  (240):	  
	  
Compound	  209	  (0.100	  g,	  0.628	  mmol)	  and	  3,4-­‐dihydroxybenzaldehyde	  (0.104	  g,	  
0.754	  mmol)	  were	  suspended	  in	  Ac2O	  (1	  ml)	  in	  a	  pressure-­‐tight	  microwave	  tube	  
containing	   a	   stirring	   bar.	   The	  mixture	  was	   heated	  under	  microwave	   irradiation	  
for	  1	  h	  at	  150	  °C,	  with	  an	  irradiation	  power	  of	  200	  W,	  using	  a	  CEM	  Discover	  SP	  
microwave	  reactor.	  The	  solvent	  was	  removed	  under	  reduced	  pressure	  to	  give	  a	  
black	  residue	  that	  was	  purified	  by	  chromatography	  through	  a	  silica	  column	  using	  
PE-­‐EtOAc	   (90:10,	   v/v)	   as	   the	  mobile	   phase.	   The	   product	  240	  was	   isolated	   as	   a	  
pale	  yellow	  solid	  in	  65%	  yield.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.04	  (d,	  J	  =	  8.4	  Hz,	  1H),	  7.82	  (d,	  J	  =	  8.3	  Hz,	  1H),	  7.70	  –	  
7.63	  (m,	  1H),	  7.54	  (d,	  J	  =	  16.3	  Hz,	  1H),	  7.49	  –	  7.38	  (m,	  4H),	  7.19	  –	  7.14	  (m,	  2H),	  
2.44	  (s,	  3H),	  2.26	  (s,	  3H),	  2.24	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  167.2	  (3C),	  155.3,	  153.3,	  148.8,	  141.3,	  141.2,	  134.3,	  
132.1,	  129.4,	  128.6,	  128.3,	  125.6,	  124.5,	  122.7,	  120.9,	  120.4,	  120.1,	  110.0,	  20.2,	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9.6.6.	  (E)-­‐4-­‐[2-­‐(4-­‐Chloroquinolin-­‐2-­‐yl)vinyl]-­‐1,2-­‐phenylene	  diacetate	  (241):	  
	  
Compound	   240	   (0.100	   g,	   0.25	   mmol)	   was	   added	   portionwise	   to	   a	   solution	   of	  
excess	  phosphorus	  oxychloride	  (15	  ml)	  at	  0	  oC.	  After	  being	  stirred	  for	  30	  min	  at	  
room	  temperature,	   the	  reaction	  mixture	  was	  heated	  at	  80	  °C	  for	  30	  min	  to	  1h.	  
The	   excess	   phosphorus	   oxychloride	   was	   removed	   by	   vacuum	   distillation.	   The	  
residue	  was	  poured	  slowly	  onto	  a	  mixture	  of	  crushed	  ice	  and	  saturated	  NaHCO3	  
solution	  with	  vigorous	  stirring.	  The	  pH	  of	  the	  solution	  was	  adjusted	  to	  about	  9.0	  
by	  addition	  of	  ammonium	  hydroxide.	  The	  solid	  product	  that	  separated	  out	  was	  
collected	   by	   filtration,	   dried	   and	   used	   for	   the	   next	   reaction	   without	   further	  
purification.	  The	  product	  was	  isolated	  in	  79%	  yield	  as	  a	  grey	  solid.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.24	  (d,	  J	  =	  8.2	  Hz,	  2H),	  7.87	  –	  7.64	  (m,	  4H),	  7.58	  –	  
7.52	  (m,	  2H),	  7.40	  (d,	  J	  =	  16.0	  Hz,	  1H),	  7.27	  (d,	  J	  =	  7.2	  Hz,	  1H),	  2.36	  (s,	  3H),	  2.34	  (s,	  
3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  168.6	  (2C),	  155.1,	  147.5,	  144.8,	  143.2,	  142.9,	  135.6,	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  9.	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9.6.7.	  3,4-­‐Di(methoxymethoxy)benzaldehyde	  (242):	  
	  
Washed	  NaH	  (60%	  w/w	  1.104	  g,	  46	  mmol)	  in	  THF	  (10	  ml)	  was	  added	  to	  a	  solution	  
of	  3,4-­‐dihydroxybenzaldehyde	  (2.05	  g,	  14.9	  mmol)	  in	  THF	  (5	  ml).	  The	  mixture	  was	  
stirred	   for	   1	   h	   at	   r.t.	   Then,	   chloromethyl	  methyl	   ether	   (3.38	   g,	   46	  mmol)	   was	  
added	  dropwise	  and	  after	  2	  h	  the	  reaction	  was	  quenched	  with	  H2O	  (20	  ml)	  and	  
extracted	  with	  ether	  (50	  ml).	  The	  mixture	  was	  washed	  with	  H2O	  (2	  x	  50	  ml),	  5%	  
NaOH	   solution	   (2	   x	   50	   ml),	   and	   brine	   (2	   x	   50	   ml).	   The	   organic	   layers	   were	  
collected	  and	  dried	  with	  anhydrous	  Na2SO4,	  and	  the	  solvent	  removed	  in	  vacuo	  to	  
achieve	  242	  as	  a	  white	  oil	  in	  18	  %	  yield.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  9.89	  (s,	  1H),	  7.71	  (d,	  J	  =	  1.9	  Hz,	  1H),	  7.54	  (dd,	  J	  =	  8.4,	  
1.9	  Hz,	  1H),	  7.31	  (d,	  J	  =	  8.6,	  1H),	  5.35	  (s,	  2H),	  5.33	  (s,	  2H),	  3.55	  (s,	  6H)	  ppm.	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9.7.	  Synthesis	  of	  8-­‐aminostyrylquinolines	  against	  Leishmaniasis	  
9.7.1.	  General	  procedure	  for	  nitration	  of	  2-­‐methylquinoline	  
2-­‐Methylquinoline	  161	  (2	  g,	  13.96	  mmol)	  was	  dissolved	  in	  cold	  H2SO4	  (7	  ml)	  at	  0	  
°C,	  then	  a	  cold	  mixture	  of	  H2SO4/HNO3	  (7	  ml/3.5	  ml)	  was	  added,	  and	  the	  mixture	  
was	  stirred	  for	  30	  min	  at	  0	  °C,	  then	  heated	  for	  30	  min	  at	  50	  °C.	  The	  solution	  was	  
neutralized	   by	   slow	   addition	   of	   a	   concentrated	   solution	   of	  NaOH,	   the	   resulted	  
precipitate	  was	  filtered	  and	  washed	  with	  water.	  The	  solid	  was	  dried	  overnight	  in	  
the	  presence	  of	  P2O5.	  The	  roughly	  1/1	  mixture	  of	  8-­‐nitro	  (41%)	  and	  5-­‐nitro	  (35%)	  
quinaldine	   isomers	   was	   separated	   by	   column	   on	   silica	   gel	   (petroleum	   ether/	  
ethyl	  acetate	  -­‐	  93/7).	  
	  
2-­‐methyl-­‐5-­‐nitroquinoline	  (243):	  
Yield:	  35%;	  white	  solid.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.91	  (d,	  J	  =	  9.0	  Hz,	  1H),	  8.38	  –	  8.30	  (m,	  2H),	  7.79	  (t,	  J	  
=	  8.1	  Hz,	  1H),	  7.55	  (d,	  J	  =	  9.0	  Hz,	  1H),	  2.82	  (s,	  3H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  161.1,	  148.5,	  145.9,	  136.2,	  132.3,	  127.9,	  125.5,	  124.2,	  
119.9,	  25.7	  ppm.	  
	  
2-­‐Methyl-­‐8-­‐nitroquinoline	  (244):	  
Yield:	  41%;	  white	  solid.	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  9.	  Experimental	  section	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.15	  (d,	  J	  =	  8.5	  Hz,	  1H),	  8.02	  –	  7.98	  (m,	  2H),	  7.58	  (d,	  J	  
=	  7.9	  Hz,	  1H),	  7.45	  (d,	  J	  =	  8.5	  Hz,	  1H),	  2.81	  (s,	  3H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   CDCl3)	   δ	   162.60,	   139.55,	   136.28,	   131.90,	   127.82,	   127.79,	  
124.68,	  124.23,	  123.73,	  26.26	  ppm.	  
	  
9.7.2.	  8-­‐Nitroquinoline-­‐2-­‐carbaldehyde	  (245):	  
	  
To	  a	  solution	  of	  selenious	  acid	  (0.05	  g,	  0.38	  mmol)	   in	  dioxane	  (1	  ml)	  and	  water	  
(0.1	  ml)	  was	  added	  8-­‐nitro-­‐quinaldine	  244	  (0.05	  g,	  0.26	  mmol)	  in	  dioxane	  (1	  ml)	  
and	   the	   reaction	   refluxed	   for	   1	   h.	   The	   hot	   solution	  was	   then	   filtered	   from	   the	  
selenium	  metal	   and	   cooled	   and	   the	   solvent	   removed	   under	   reduced	   pressure.	  
The	  residue	  oil	  was	  basified	  with	  saturated	  NaHCO3	  and	  the	  precipitate	  collected.	  
Purification	  of	  the	  crude	  solid	  by	  flash	  chromatography	  (petroleum	  ether/	  ethyl	  
acetate,	  90/10)	  yielded	  the	  aldehyde	  265	  as	  a	  white	  solid	  in	  65%.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  10.23	  (d,	  J	  =	  0.9	  Hz,	  1H),	  8.48	  (dd,	  J	  =	  8.5,	  0.7	  Hz,	  1H),	  
8.22	  –	  8.15	  (m,	  3H),	  7.81	  (dd,	  J	  =	  8.2,	  7.6	  Hz,	  1H)	  ppm.	  	  
13C	   NMR	   (63	   MHz,	   CDCl3)	   δ	   193.37,	   154.24,	   139.60,	   138.23,	   138.14,	   132.26,	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9.7.3.	  Benzyltriphenylphosphonium	  bromide	  (246):	  
	  
The	  benzylbromide	  (0.250	  g,	  1.46	  mmol)	  and	  triphenylphosphine	  (0.380	  g,	  1.46	  
mmol)	   was	   refluxed	   in	   10	   ml	   of	   toluene	   for	   1	   h.	   The	   formed	   precipitate	   was	  
filtered	   to	   obtain	   the	   product	   as	   a	   white	   solid	   in	   98%	   yield.	   No	   further	  
purification	  was	  needed.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  7.82	  –	  7.61	  (m,	  15H),	  7.27	  –	  7.12	  (m,	  5H),	  5.43	  (d,	  J	  =	  
14.4	  Hz,	  2H)	  ppm.	  
13C	  NMR	  (63	  MHz,	  CDCl3)	  δ	  135.42	  (d,	  J	  =	  3.0	  Hz,	  3C),	  134.80	  (d,	  J	  =	  9.8	  Hz,	  6C),	  
131.92	  (d,	  J	  =	  5.6	  Hz,	  3C),	  130.57	  (d,	  J	  =	  12.5	  Hz,	  3C),	  129.24	  (d,	  J	  =	  3.3	  Hz,	  3C),	  
128.81	  (d,	  J	  =	  3.9	  Hz,	  2C),	  127.48	  (d,	  J	  =	  8.6	  Hz,	  1C),	  118.16	  (d,	  J	  =	  85.7	  Hz,	  3C),	  
31.22	  (d,	  J	  =	  47.0	  Hz,	  1C)	  ppm.	  
	  
9.7.4.	  (E)-­‐8-­‐nitro-­‐2-­‐styrylquinoline	  (247):	  
	  
Compound	   245	   (0.200	   g,	   0.989	   mmol)	   and	   1	   equiv	   of	  
benzyltriphenylphosphonium	  bromide	  246	  (0.428	  g,	  0.989	  mmol)	  were	  stirred	  in	  
a	   biphasic	   solvent	   system	   consisting	   of	   3	   ml	   of	   CH2Cl2	   and	   3	   ml	   of	   sodium	  
hydroxide	  (50%)	  for	  2	  h.	  The	  aqueous	  layer	  was	  then	  extracted	  with	  CH2Cl2,	  the	  
resultant	   organic	   extract	   dried	   and	   filtered,	   and	   the	   solvent	   removed	   under	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reduced	   pressure.	   TLC	   indicated	   two	   products,	   presumably	   the	   cis	   and	   trans	  
adducts,	  which	  upon	  reflux	  for	  1	  h	  in	  ethanol	  and	  catalytic	  p-­‐toluenesulfonic	  acid	  
monohydrate	  (50	  mg,	  10%)	  were	  converted	  to	  one	  product.	  Removal	  of	  ethanol	  
under	   reduced	   pressure	   followed	   by	   purification	   using	   flash	   chromatography	  
(8:2,	  hexane/ethyl	  acetate)	  yielded	  the	  required	  compound	  247	   in	  80%	  yield	  as	  
yellow	  solid.	  
1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.22	  (d,	  J	  =	  8.7	  Hz,	  1H),	  8.04	  –	  7.97	  (m,	  2H),	  7.85	  (d,	  J	  
=	  16.2	  Hz,	  1H),	  7.75	  (d,	  J	  =	  8.7	  Hz,	  1H),	  7.67	  (dd,	  J	  =	  8.0,	  1.2	  Hz,	  2H),	  7.58	  –	  7.52	  
(m,	  1H),	  7.48	  –	  7.38	  (m,	  4H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   CDCl3)	   δ	   158.46,	   148.45,	   140.03,	   137.15,	   136.66,	   136.45,	  
131.94,	  129.57,	  129.25	  (2C),	  128.50,	  128.21,	  128.04	  (2C),	  124.85,	  124.30,	  121.94	  
ppm.	  
	  
9.7.5.	  (E)-­‐2-­‐styrylquinolin-­‐8-­‐amine	  (248):	  
	  
Compound	  247	  (0.06	  g,	  0.216	  mmol),	  iron	  powder	  (100	  mg,	  0.324	  mmol),	  glacial	  
acetic	   acid,	   ethanol,	  water	   (0.4	  ml/0.4	  ml/0.2	  ml)	   and	   2	   drops	   of	   aqueous	  HCl	  
were	   refluxed	   for	   24	   h.	   Water	   was	   added	   and	   the	   mixture	   extracted	   with	  
chloroform.	  The	  organic	  layer	  was	  washed	  with	  saturated	  NaHCO3	  solution,	  dried	  
and	   the	   solvent	   removed	  under	   reduced	  pressure.	  The	  compound	  was	  purified	  
by	  chromatography	  that	  yielded	  248	  in	  98	  %	  yield	  as	  a	  yellow	  solid.	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1H	  NMR	  (250	  MHz,	  CDCl3)	  δ	  8.07	  (d,	  J	  =	  8.6	  Hz,	  1H),	  7.75	  –	  7.62	  (m,	  4H),	  7.47	  –	  
7.32	  (m,	  5H),	  7.16	  (d,	  J	  =	  7.5	  Hz,	  1H),	  6.96	  (d,	  J	  =	  7.5	  Hz,	  1H),	  5.10	  (br	  s,	  2H)	  ppm.	  
13C	   NMR	   (63	   MHz,	   CDCl3)	   δ	   153.43,	   144.29,	   138.53,	   137.13,	   136.71,	   133.63,	  
129.54,	  129.20	  (2C),	  128.83,	  128.23,	  127.56	  (2C),	  127.48,	  120.14,	  116.29,	  110.74	  
ppm.	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9.8.	  Functionalization	  of	  nanoparticles	  
9.8.1.	  Spion	  coating	  	  
SPION	   nanoparticles	   dissolved	   in	   toluene	   were	   precipitated	   with	   ethanol	   and	  
separated	   by	   centrifugation	   (765	   rcf,	   20min).	   The	   pellet	   was	   dried	   and	  
resolubilized	   in	   chloroform.	   Poly(maleic	   anhydride-­‐alt-­‐1-­‐octadecene)	   in	   excess	  
was	  dissolved	  stirring	  for	  1	  hour	  in	  chloroform.	  The	  solutions	  were	  mixed	  and	  the	  
chloroform	   slowly	   evaporated	   under	   pressure	   control	   lowering	   it	   starting	   from	  
210	   mbar	   to	   70	   mbar	   step	   by	   step.	   To	   completely	   eliminate	   the	   solvent,	   the	  
obtained	  sample	  was	  put	  under	  gentle	  stream	  of	  nitrogen	  for	  1	  hour.	  An	  alkaline	  
solution	  of	  water	  and	  TMAH	  and	  0.1M	  NaOH	  were	  used	   to	  solubilize	   the	  dried	  
film	   and	   sonicated	   for	   15	  min	   and	   left	   overnight.	   The	   solution	  was	   filtered	   by	  
0.22μm	  pores	  syringe	  filter	  and	  concentrated	  by	  ultracentrifugation	  with	  Amicon	  
filter	  units	  50kDa	  at	  405	  rcf49.	  
	  
9.8.2.	  Functionalization	  of	  polystyrene	  NPs	  with	  PEG	  
Stock	   solution	   of	   Jeffamine	   PEG	   (M	   =	   0.02)	   and	   EDAC	   (M	   =	   0.15)	   in	   PBS	  were	  
prepared.	   50	  µl	   of	   20	   nm	   polystyrene	  NPs	   (M	   =	   0.02)	  were	   placed	   in	   a	   15	  ml	  
falcon	   tube	  with	  700	  µl	   of	   PEG	   solution	   and	  700	  µl	   of	   EDAC.	   The	   solution	  was	  
stirred	   overnight	   and	   then	   dialysed	   against	   PBS	   at	   pH	   7.4	   (10	   mM	   NaCl)	   to	  
eliminate	   the	   excess	   of	   PEG	  by	   using	   a	   dialysis	   tube	  of	  Mw	  100kDa	   cut-­‐off	   for	  
three	  days	  changing	  the	  solvent	  twice	  a	  day.	  The	  NPs	  were	  characterized	  by	  DLS	  
(Zeta	  potential	  =	   -­‐1.17	  ±	  1.75,	  average	  diameter	  =	  80.06	  ±	  0.075,	  PDI	  =	  0.139	  ±	  
0.14),	  FTRI-­‐ATR	  (Figure	  9.1)	  and	  TGA	  (Figure	  9.2)	  spectra.	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Fig.	  9.1	  FTRI	  spectra	  of	  polystyrene	  NPs	  (red	  line)	  and	  NPs-­‐PEG	  (blue	  line).	  
	  
Fig.	  9.2.	  TGA	  spectra	  of	  Polystyrene	  NPs	  (brown	  line),	  Jeffamine	  PEG	  M1000	  (purple	  
line),	  mixture	  of	  NPs	  and	  PEG	  (blue	   line)	  and	   functionalized	  NPs	  with	  PEG	  (green	   line).	  
We	   can	  observe	   how	   the	   slope	  of	   the	   curve	   related	   to	   the	   functionalized	  NPs	   change	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9.8.3.	  Synthesis	  of	  an	  analog	  of	  the	  MSH	  peptide	  
The	  partially	   protected	  NDP-­‐MSH	  peptide,	  H-­‐Ser-­‐Tyr-­‐Ser-­‐Nle-­‐Glu-­‐His-­‐d-­‐Phe-­‐Arg-­‐
Trp-­‐Gly-­‐Lys(Dde)-­‐Pro-­‐Val-­‐NH2,	   was	   synthesized	   manually	   using	   Nα-­‐Fmoc	  
chemistry.	   Briefly,	   Rink	   amide	   resin	   (4-­‐(2’,4’-­‐dimethoxyphenyl-­‐
Fmocaminomethyl)	   phenoxy	   resin,	   substitution	   0.6	   mmol/g)	   was	   swollen	   in	  
dichloromethane:DMF	  (1:1)	  for	  three	  hours.	  The	  resin	  was	  washed	  with	  DMF	  (3	  ×	  
10	  ml),	   and	   the	  Nα-­‐Fmoc	   protecting	   group	  was	   removed	   by	   25%	   piperidine	   in	  
DMF	  (1	  ×	  5	  min	  and	  1	  ×	  20	  min).	  The	  resin	  was	  washed	  with	  DMF	  (3	  ×	  5	  ml),	  and	  
the	  first	  Nα-­‐Fmoc	  amino	  acid	  was	  coupled	  adding	  preactivated	  ester	  (3	  equiv	  of	  
Nα-­‐Fmoc	  amino	  acid,	  3	  equiv	  of	  HOBt,	  and	  3	  equiv	  of	  HBTU)	  in	  DMF	  solution	  and	  
6	   equiv	   of	   DIEA.	   The	   mixture	   was	   incubated	   for	   40	   min.	   At	   the	   end	   of	   the	  
coupling,	  the	  resin	  was	  washed	  with	  DMF	  (3	  ×	  10	  ml)	  and	  a	  Kaiser	  ninhydrin	  test	  
was	   done	   to	   check	   the	   extent	   of	   coupling.	   If	   coupling	  was	   complete,	   the	   resin	  
was	   once	   again	   washed	   with	   DMF,	   and	   the	   same	   procedure	   was	   repeated	   to	  
couple	  the	  remaining	  amino	  acids.	  
The	   cleavage	   cocktail	   consisting	   of	   tifluoroacetic	   acid	   (TFA,	   7.8	   ml),	  
triethylsilane	   (0.7	  ml),	   1,2-­‐ethanedithiol	   (0.7	  ml)	  water	   (0.8	  ml)	  was	   chilled	   on	  
ice.	  The	  cold	  solution	  was	  then	  added	  to	  the	  resin-­‐bound	  protected	  peptide	  and	  
the	  reaction	  mixture	  incubated	  for	  2.5	  h	  at	  room	  temperature.	  The	  crude	  peptide	  
was	  precipitated	  out	  by	  pouring	  the	  mixture	  into	  a	  round	  bottom	  flask	  filled	  with	  
diethyl	   ether	   (40	  ml)	   to	   give	   a	  white	   solid.	   The	  organic	   layer	  was	  decanted	  off	  
after	  centrifugation	  of	  the	  peptide	  for	  5	  min	  at	  12,000	  rpm.	  The	  precipitate	  was	  
washed	  with	  diethyl	  ether	  (3	  ×	  40	  ml)	  and	  dried	  in	  vacuum	  overnight.	  The	  crude	  
peptide	  did	  not	  need	  further	  purification.	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9.8.4.	  Covalent	  coupling	  between	  the	  peptidic	  ligand	  and	  PEG	  
To	   a	   solution	   of	   5	  mg	   of	   peptide	   (scramble	   or	  MSH,	   0.003	  mmol)	   and	   0.0066	  
mmol	   of	   NHS-­‐PEG	   750	   dissolved	   in	   DMF	   were	   added	   30	   µl	   of	   DIPEA	   and	   the	  
reaction	   mixture	   was	   stirrer	   for	   24	   h	   at	   room	   temperature.	   The	   reaction	   was	  
monitored	  by	  the	  ninhydrin	  Kaiser	  test.	  When	  it	  resulted	  negative	  the	  DMF	  was	  
evaporated	  under	  vacuum.	  The	  white	  solid	  residue	  was	  dissolved	  in	  the	  0.5	  ml	  of	  
water	  and	  purified	  through	  semi-­‐prep	  HPLC.	  The	  sample	  was	  eluted	  with	  water	  
containing	   0.1%	   TFA	   and	   acetonitrile	   containing	   0.1%	   TFA	   varying	   from	   0%	   to	  
90%	   over	   25	   min	   at	   a	   flow	   rate	   of	   1	   ml/min.	   The	   conjugated	   products	   were	  
characterized	  by	  mass	  spectra	  (Figure	  9.3).	  
	  
Fig.	  9.3.	  MALDI-­‐TOF	  spectra	  of	  the	  conjugated	  product	  between	  MSH	  peptide	  and	  PEG	  
750	  
In	  the	  case	  of	  the	  bi-­‐dentate	  PEG,	  10	  mg	  of	  MSH	  peptide	  and	  25	  mg	  of	  NSH-­‐
PEG-­‐BOC	  were	  dissolved	   in	   1	  ml	   of	  DMF.	   To	   the	  mixture,	   45	  µl	   of	  DIPEA	  were	  
added	  and	  was	  stirred	  for	  3	  days	  at	  r.t.	  After	  removal	  of	  solvent,	  the	  residue	  was	  
dissolved	  in	  1	  ml	  of	  water	  and	  purified	  through	  a	  Sephadex	  G-­‐25	  (GE	  Healthcare)	  
gel	  permeation	  chromatography	  column	  using	  water	  as	  the	  eluting	  solvent.	  The	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were	   collected,	   and	   the	   product	   was	   dialyzed	   against	   water	   for	   three	   days	   to	  
eliminate	  residues	  of	  PEG	  by	  using	  a	  dialysis	  tube	  of	  Mw	  100kDa	  cut-­‐off	  for	  three	  









	  	   	  
10.	  Conclusions	   	   395	   	   	  
1. Focused	  MW	   irradiation	  of	  equimolecular	  mixtures	  of	  9-­‐chloroacridines,	  
4-­‐chloroquinolines	   and	   4-­‐	   chloroquinazolines	  with	   amines	   in	   the	   presence	  of	   2	  
equiv	   of	   phenol	   led	   to	   a	   general,	   fast	   and	   high-­‐yielding	   synthesis	   of	   aminated	  
heterocycles,	  with	  a	  very	  broad	  scope	  in	  terms	  of	  the	  types	  of	  amine	  that	  can	  be	  
employed.	  Furthermore,	  workup	  consisted	  of	  a	   simple	  washing	  with	  water	  and	  
purification	   could	  be	   achieved	  by	   crystallization	  of	   the	   crude	  product,	   avoiding	  
the	  use	  of	  organic	  solvents	  in	  extraction	  and	  chromatographic	  purification	  steps.	  
These	  features	  lead	  us	  to	  the	  conclusion	  that	  our	  protocol,	  besides	  constituting	  a	  
green	  approach,	  solves	  a	   long-­‐standing	  synthetic	  problem	  and	  will	   facilitate	  the	  
generation	  of	  libraries	  of	  a	  class	  of	  compounds	  of	  great	  significance	  in	  medicinal	  
chemistry	  and	  drug	  discovery.	  
 
	  
2. We	   have	   developed	   a	   simple,	   general,	   one-­‐pot	   coupling	   reaction	   that	  
allows	  the	  rapid	  and	  fully	  regioselective	  generation	  of	  both	  aromatic	  C-­‐C	  and	  C-­‐N	  
bonds	  on	  a	  variety	  of	  nitrogen	  heterocycles,	   focusing	  on	  quinoline	  and	  acridine	  
moiety	  due	  to	  their	  relevance	  in	  neurodegenerative	  and	  protozoan	  diseases.	  The	  
process	   is	   highly	   affordable,	   as	   it	   requires	   only	   an	   equimolecular	   mixture	   of	  
simple	   starting	   materials	   and	   a	   catalytic	   amount	   of	   the	   relatively	   inexpensive	  
Lewis	   acid	   InCl3.	   Furthermore,	   in	   most	   cases	   workup	   required	   only	   a	   simple	  
filtration	   and	   hence	   no	   organic	   solvents	   were	   needed	   for	   extraction	   and	  
chromatographic	   purification	   steps.	   Some	   noteworthy	   features	   of	   the	  method	  
include:	   (a)	   the	   high	   yields	   and	   relatively	   short	   reaction	   times	   compared	   with	  
those	  needed	  under	  conventional	  conditions;	  (b)	  the	  first	  use	  of	  a	  Lewis	  acid	  as	  a	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catalyst	   in	   heteroarylation,	   vinylation	   and	   amination	   reactions	   on	   π-­‐deficient	  
heterocyclic	  substrates;	  (c)	  the	  confirmation	  of	  the	  generality	  of	  the	  method	  by	  
its	  application	  to	  target-­‐oriented	  synthesis. 
 
 
3. We	   have	   identified	   DKP	   as	   a	   novel	   scaffold	   in	   antiprion	   drug	   design.	  
Compound	  83,	  thanks	  to	  its	  planar	  conformation,	  is	  able	  to	  perturb	  PrP	  amyloid	  
fibril	  formation	  by	  preventing	  the	  process	  in	  vitro.	  Moreover,	  it	  has	  been	  shown	  
to	  inhibit	  prion	  replication	  in	  the	  low	  micromolar	  range	  in	  a	  cellular	  context.	  For	  
these	   reasons,	   83	   is	   a	   lead	   candidate	   for	   further	   optimization	   studies.	   Even	   if	  
preliminary,	   these	   results	   represent	   a	   first	   step	   toward	   the	   discovery	   of	   novel	  
DKPs	  with	  potential	  towards	  PrDs.	  A	  second	  major	  outcome	  of	  this	  work	  was	  the	  
identification	   of	   the	   β-­‐carboline	   derivative	   104.	   Fluorescent	   probes	   that	  
specifically	   target	   amyloid	   aggregates	   are	   of	   great	   relevance	   to	   advance	   our	  
understanding	  of	  the	  molecular	  pathogenesis	  underlying	  cerebral	  amyloidosis.	  
 
4.	   We	   reported	   the	   synthesis	   of	   two	   small	   libraries	   of	   fluorene	   and	  
carbazole-­‐based	   analogues	   of	   GN8,	   the	   study	   of	   their	   native	   fluorescence,	   the	  
evaluation	  of	  their	  antiprion	  activity	  in	  infected	  cells,	  and	  the	  staining	  of	  fibrillar	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plaques.	  Preliminary	  results	  showed	  that	  some	  compounds	  (124	  and	  125)	  turned	  
out	  to	  be	  more	  active	  and	  less	  toxic	  that	  GN8.	  Furthermore,	  compound	  128	  has	  
been	  shown	  to	  be	  able	  to	  interact	  selectivity	  with	  PrPSc	  preventing	  partially	  prion	  
replication	  and,	  due	  to	  its	  fluorescence,	  can	  be	  regarded	  as	  potential	  diagnostic	  
tool	  for	  prion	  diseases.	  More	  importantly,	  we	  have	  demonstrated	  how	  modifying	  





5.	   We	  preliminary	  explored	  styrylquinolines	  137-­‐138	  as	  Aβ/PrPSc	  diagnostic	  
and	   therapeutic	   small	   molecules.	   Among	   them,	   139	   is	   potentially	   useful	   to	  
diagnose,	   treat	   and	   monitor	   response	   to	   therapy	   in	   PMD.	   Indeed,	   from	   a	  
medicinal	   chemistry	   perspective	   139	   offers	   peculiar	   advantages:	   (1)	   a	   low	  
molecular	  weight,	  (2)	  a	  small-­‐molecule	  scaffold	  that	  is	  easily	  amenable	  to	  further	  
manipulation	  to	  improve	  fluorescence	  response	  and	  amyloid-­‐binding	  properties.	  
Most	  importantly,	  with	  respect	  to	  the	  previously	  reported	  NIR	  amyloid	  tracers,	  it	  
offers	   the	  additional	  advantage	  of	  a	   concomitant	  promising	  anti-­‐fibrillar	  profile	  
(in	  vitro	  and	  in	  a	  cellular	  context),	  together	  with	  a	  low	  toxicity.	  If	  these	  peculiar	  
properties	   are	   confirmed	   in	   vivo,	   139	   is	   likely	   to	   become	   the	   first	   purposely-­‐
designed	  therapeutic	  and	  diagnostic	  tool	  (theranostic)	  for	  PrD	  and	  AD.	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6.	   Starting	   from	   compound	   139,	   which	   is	   endowed	   with	   therapeutic	   and	  
diagnostic	   features,	  we	  designed	  and	  generated	  a	  new	  series	  of	   styrylquinoline	  
derivatives	  with	  the	  purpose	  of	  improving	  such	  characteristics.	  The	  synthesis	  was	  
achieved	   via	   a	   vinylogous	   variation	   of	   the	   Povarov	   reaction	   to	   afford	   2-­‐styryl-­‐
1,2,3,4-­‐tetrahydroquinolines	  followed	  by	  their	  dehydrogenation	  or,	  alternatively,	  
by	  microwave-­‐assisted	  aldol	  condensation	  between	  substituted	  quinaldines	  and	  
aromatic	   aldehydes.	   As	   regard	   the	   the	   biological	   data,	   our	   preliminary	   results	  
showed	   that	   7	   molecules	   have	   higher	   antiprion	   activity	   that	   that	   of	   139	   and	  
further	   studies	   are	   being	   performed	   to	   explore	   the	   possibility	   of	   using	   these	  
compounds	  for	  treatment	  and	  diagnosis	  of	  PMD	  in	  vivo. 
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7.	   Considering	   the	   styrylquinoline	   fragment	   as	   a	   privileged	   structure,	   we	  
generated	   a	   small	   library	   of	   4-­‐aminostyryquinoline	   derivatives.	   The	   anti-­‐
leishmanial	   activity	   was	   preliminary	   evaluated	   in	   vitro	   in	   promastigote	   and	  
amastigote	   forms	   across	   all	   the	   library	   of	   synthesized	   compounds	   revealing	   a	  
very	  high	  efficacy.	   In	  addition,	   further	  experiments	   showed	   that	   the	  polyamine	  
chain	   is	   critical	   for	   the	   activity	   and	   the	   styrylquinolines	   could	   exert	   their	  
leishmanicidial	   action	   by	   interfering	   with	   the	   parasite	   mitochondrial	  
functionality.	  
	  
8.	   Based	   on	   the	   good	   results	   obtained	   from	   the	   4-­‐aminostyrylquinoline	  
derivatives,	   we	   planned	   to	   develop	   a	   new	   series	   of	   styrylquinolines	   endowed	  
with	  different	  polyanimo	  chains	  at	  the	  quinoline	  C-­‐8	  position	  that	  will	  be	  tested	  
against	  Leishmanasis	  at	  Luis	  Rivas’s	  lab	  at	  CIB.	  
	  
Ø The quinoline ring
has a high degree
of drug-likeness
Ø The polyamino side chain 
is considered critical for 
the biological activity
Ø 2-Substituted quinolines
and styrylquinolines have 
shown activity against 
leishmaniasis
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9.	   In	   order	   to	   explore	   nanomedicine	   as	   another	   facet	   of	   the	   theranostic	  
field,	   we	   investigated	   nanoparticle	   chemistry.	   We	   developed	   an	   efficient	  
protocol	   to	   synthetize	   conjugated	   product	   between	   NDP-­‐MSH	   peptide	   and	   its	  
scramble	   version	   with	   NHS-­‐PEG.	   Furthermore,	   we	   found	   a	   general	   method	   to	  
functionalize	  20	  nm	  NPs	  with	  PEG.	  With	   the	  preparation	  of	   coated	  SPIONs,	  we	  
paved	   the	   way	   to	   the	   final	   step	   of	   the	   synthesis	   combining	   them	   with	   the	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